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Abstract 
Background: Quality of care for people with dementia in care homes is of concern. 
Interventions that can improve care outcomes are required.  
Objective: To investigate the clinical and cost-effectiveness of Dementia Care MappingTM 
(DCM™) for reducing agitation, and improving care outcomes for people living with dementia 
in care homes, versus usual care.   
Design: A pragmatic, cluster randomised controlled trial with open-cohort design, follow-up 
at 6- and 16-months, integrated cost-effectiveness analysis and process evaluation. Clusters 
were not blinded to allocation. Primary endpoint was completed by staff-proxy and 
independent assessors.   
Setting: Stratified randomisation of 50 care homes to intervention/control on a 3:2 ratio by 
type, size, staff exposure to dementia training and recruiting hub. 
Participants: Fifty care homes were randomised (31 intervention, 19 control), with 726 
residents recruited at baseline and a further 261 at 16-months. Care homes were eligible if 
they recruited a minimum of 10 residents, were not subject to improvement notices, had not 
used DCM™ in the previous 18-months and were not participating in conflicting research. 
Residents were eligible if they lived there permanently, had a formal diagnosis of 
dementia/score of 4+ on the Functional Assessment Staging of Alzheimer’s Disease, were 
proficient in English, not at end-of-life/permanently cared for in bed.  All homes were audited 
on delivery of dementia and person-centred care awareness training. Those not reaching a 
minimum standard were provided training ahead of randomisation. Eighteen homes took part 
in the process evaluation. 
Intervention: Two staff from each intervention home were trained to use DCM™ and 
requested to carry out three DCM™ cycles; the first supported by an external expert.  
Main outcome measures: The primary outcome was agitation (Cohen-Mansfield Agitation 
Inventory) at 16-months. Secondary outcomes included resident behaviours and quality of 
life.  
Results: There were 675 residents in the final analysis (287 control, 388 intervention). There 
was no evidence of difference in agitation levels between arms. The adjusted mean 
difference in CMAI score was -2.11 points, lower in the intervention group than control (95% 
CI -4.66 to 0.44, p=0.104, adjusted ICC control=0, intervention 0.001). The sensitivity 
analyses results supported the primary analysis. No differences were detected in any of the 
secondary outcomes. The health economic analyses indicated DCM™ was not cost-
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effective. Intervention adherence was problematic; only 26% of homes completed more than 
their first DCM™ cycle. Impacts of and barriers and facilitators to DCM™ implementation 
were identified.  
Limitations: Primary completion of resident outcomes was by staff proxy due to self-report 
difficulties for residents with advanced dementia. Clusters were not blinded to allocation 
although supportive analyses suggested any reporting bias was not clinically important.  
Conclusions: There was no benefit of DCM™ over control on any outcomes. 
Implementation of DCM™ by care home staff was sub-optimal compared to protocol in the 
majority of homes.  
Future work: Alternative models of DCM™ implementation should be considered, which do 
not rely solely on leadership by care home staff. 
Trial registration: Current Controlled Trials ISRCTN82288852 
Funding: This project was funded by the National Institute for Health Research Health 
Technology Assessment programme (project number 11/15/13).  
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Glossary 
 
Agency staff: Temporary staff who are provided by an external organisation (Agency) to 
cover staff shortages/absences when these cannot be met by the care home’s own staff 
pool. 
Bank staff: A pool of staff employed by the care home on non- substantive contracts and 
who are drawn on when the care home is unable to cover absences or shortages with staff 
who have contracted hours. 
DCM™ intervention lead: Member of the trial team who is responsible for oversight and 
leadership of DCM™ implementation across the intervention care homes and co-ordination 
of the DCM™ expert mappers. 
DCM™ expert mapper: Experienced User of DCM™ appointed by the trial to support trial 
mappers in completing cycle 1 of DCM™ in each intervention home.  
Independent researcher: A member of the research team who is independent of the care 
home by virtue of not having previously collected any outcomes data there. 
Mapper: Member of care home staff trained to use DCM™. 
 
  
14 
 
List of abbreviations 
 
BSC: Behaviours staff may find challenging to support 
CACE: Complier-Average Causal Effect  
CCA: Complete Case Analysis 
CDR: Clinical Dementia Rating Scale 
CEAC: Cost Effectiveness Acceptability Curve 
CI: Confidence Interval 
CMAI: Cohen Mansfield Agitation Inventory 
CMAI-O: Cohen-Mansfield Agitation Inventory - Observational 
CQC: Care Quality Commission 
CRF: Case Report Form 
CTRU: Clinical Trials Research Unit 
DAT: Dementia Awareness Training 
DCM™: Dementia Care Mapping™ 
DEMQOL-proxy: Dementia Quality of Life measure – proxy version 
DMEC: Data Monitoring and Ethics Committee 
EAT: Environmental Audit Tool 
EPIC: Enhancing Person-centred care In Care homes 
FAST: Functional Assessment Staging of Alzheimer's Disease 
GHQ-12: General Health Questionnaire – 12 item 
GLHC: Group Living Home Characteristics 
ICC: Intracluster Correlation Coefficient 
ICER: Incremental cost-effectiveness ratio 
LAG: Lay Advisory Group 
MAR: Missing at Random 
15 
 
MICE: Multiple Imputations by Chained Equations 
MNAR: Missing Not at Random 
MMSE: Mini–Mental State Examination 
N: Number 
NICE: National Institute for Health and Care Excellence 
NMB: Net monetary benefit 
NPI: Neuropsychiatric Inventory 
PAS: Pittsburgh Agitation Scale 
PCCT: Person-centred Care Training 
PPI: Patient and Public Involvement  
QALY: Quality-adjusted life year 
QoL: Quality of life 
QOL-AD: Quality of Life in Alzheimer’s disease measure 
QUALID: Quality of Life in Late-Stage Dementia 
QUIS: Quality of Interactions Schedule 
RCT: Randomised controlled trial 
RUSAE: Related Unexpected Serious Adverse Event 
SD: Standard Deviation 
SAE: Serious Adverse Event 
SCIDS: Sense of Competence in Dementia Care Staff Scale 
SCIE: Social Care Institute for Excellence 
UC: Usual Care 
All abbreviations that have been used in this report are listed here unless the abbreviation is 
well known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation 
used only in figures/tables/appendices, in which case the abbreviation is defined in the figure 
legend or in the notes at the end of the table 
 
16 
 
Plain English Summary 
 
Agitation is common in care home residents and may result from care that does not meet 
individual needs. Dementia Care Mapping (DCM™) is a tool used within care homes to 
improve the delivery of person-centred care, which may help reduce agitation. This 
randomised controlled trial aimed to understand whether DCM™ is better than usual care at 
reducing resident agitation, behaviours staff may find difficult to support, anti-psychotic 
medicines use and for improving their quality of life and staff communication. It also 
assessed its value for money. 
We recruited 726 residents with dementia from 50 care homes. After initial data collection, 
care homes were randomly assigned to DCM™ (31/50) or continue with usual care (19/50), 
and data were collected again after 6- and 16-months. A further 261 residents were recruited 
at 16-months. We also interviewed staff, relatives and residents about use of DCM™ after 
final data collection had taken place. 
Two staff in each DCM™ home were trained to use DCM™ and were helped by an expert to 
use it for the first time. They were asked to use it again a further twice without support.  
Results showed that DCM™ was no better than usual care on any of the outcomes. It was 
also not shown to be value for money. Only one-quarter of care homes used DCM™ more 
than once. Care staff interviewed said benefits of using DCM™ included, reduced resident 
boredom and increased staff confidence. There were also many challenges, including the 
time needed to complete DCM™, lack of managerial support and problems with staffing 
levels.  
Putting DCM™ into practice in care homes was difficult, even with expert support, and most 
care homes did not complete 3 DCM™ cycles. Future research should explore models of 
implementing DCM™ that do not rely on care home staff to lead them. 
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Scientific Summary 
Background 
At least 80% of people living in care homes have dementia. Concerns have consistently 
been raised about care home quality and improvement in this area has been a UK wide 
government research and practice development priority for over a decade. Poor quality care 
is associated with poor outcomes for people with dementia including an increase in 
behaviours staff may find challenging to support (BSC) (with the most common of these 
being agitation) reduced resident quality of life and increased prescribing and administration 
of anti-psychotic and other tranquillising medications. Person-centred care is a 
recommended approach to delivery of good quality care. 
Dementia Care Mapping™ (DCM™) is a whole home, practice development intervention, 
that has been widely used in health and social care settings nationally and internationally, to 
support the embedding of person-centred care in practice. There is good evidence of its use 
in practice settings as a quality audit and improvement tool. This trial was designed to 
provide robust evidence on the clinical and cost effectiveness of DCM™ as an intervention 
to support care homes to sustainably transfer learning from person-centred care training 
(PCCT) into care practice. The trial aimed to determine whether DCM™ could provide a 
solution for achieving widespread implementation of an approach to training and practice 
development, which is practical for use in routine health and social care and which improves 
care quality and outcomes for people living with dementia. 
Objectives 
The primary objective of the DCM™ EPIC (Enhancing Person-centred care In Care homes) 
trial was to determine whether the intervention is more effective in reducing agitation in 
residents with dementia as measured by the total Cohen-Mansfield Agitation Inventory 
(CMAI) score, and more cost-effective than the control (usual care) at 16-months post-
randomisation. The secondary objectives were to determine whether the intervention is more 
effective at reducing behaviours that staff my find challenging to support (BSC), use of 
antipsychotic and other psychotropic drugs, and improving mood and quality of life of 
residents with dementia, care home staff well-being and role efficacy, and the quality of 
staff/resident interactions at 6- and 16-months.  
Other questions the trial sought to explore included the safety profile of the intervention, any 
differential predictors of the effects of the intervention, and the process, challenges, benefits 
and impact of implementing the intervention. 
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Methods 
Design 
The DCM™ EPIC trial was a pragmatic, multicentre, cluster randomised controlled trial 
utilising an open-cohort design with embedded cost-effectiveness and process evaluation 
analyses. 
Setting 
Fifty residential, nursing and dementia care homes across West Yorkshire, Oxfordshire and 
South London, providing care for people with dementia, were recruited using a random 
sampling method. Homes were eligible if they could recruit a minimum of 10 residents, had 
no improvement notices and were not taking part in any conflicting research.  
Participants 
Residents recruited at baseline were registered after care home recruitment, confirmation of 
eligibility, informed consent and collection of baseline data, but prior to care home 
randomisation. At baseline residents were eligible for the trial if they were a permanent 
resident in the care home, had a formal diagnosis of dementia or a score of 4+ on the 
Functional Assessment Staging of Alzheimer’s Disease (FAST) and had sufficient 
proficiency in English to understand what the research involved, if able to do so. Residents 
were not eligible if they were known to be terminally ill, permanently bed-bound/cared for in 
bed or were taking part in other conflicting research.  
Following a design-change to an open-cohort design, due to greater than expected loss to 
follow up amongst residents, further residents were recruited at 16-months. In addition to the 
baseline eligibility criteria, residents recruited at 16-months were not eligible if they had 
declined trial participation at baseline or moved into the home or participating unit less than 
three-months prior to screening.  
Randomisation 
Care homes were randomised on a ratio of 3:2 to intervention or control. Treatment arms 
were balanced for home/unit type (general residential/nursing, specialist dementia care), 
size (large≥40 beds, medium/small<40 beds), provision of dementia awareness training by 
research team (yes, no) and recruiting hub (West Yorkshire, London, Oxford). 
Intervention 
The intervention followed standard procedures as set out in the DCM™ manual and 
guidance. Two staff members from each intervention care home were trained to use DCM™, 
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followed by implementation of three standard DCM™ cycles (each comprising of briefing; 
observation; data analysis, reporting and feedback; and action planning). The first cycle was 
supported by an external DCM™ expert mapper provided by the research team, who 
attended the first cycle and provide additional support remotely. This is a higher degree of 
support that mappers would usually receive post-training, but was required to support 
standardised intervention implementation across all intervention care homes. To support 
intervention fidelity and its measurement, care homes were provided with guidelines which 
included standardised templates for recording attendance at briefing and feedback sessions 
and for DCM™ reporting and action planning. Additional mechanisms for supporting 
intervention adherence included sending SMS reminders and hard copies of all paperwork to 
mappers ahead of each cycle, and provision of telephone support from the DCM™ 
intervention lead. Intervention homes were asked to complete DCM™ alongside usual care. 
Control 
Control homes were asked to continue with usual care. 
Outcome measures 
The primary outcome was agitation at 16-months measured by the Cohen-Mansfield 
Agitation Inventory. Other resident outcomes included: BSC and mood measured by the 
Neuropsychiatric Inventory (NPI); quality of life measured by the QUALID, QoL-AD, 
DEMQOL, DEMQOL-proxy, the ED-5D-5L and ED-5D-5L-proxy; prescribed and 
administered medications and safety data (e.g. hospitalisations, deaths). Staff outcomes 
were sense of competence in caring for people with dementia using the Sense of 
Competence in Dementia Care Staff (SCIDS) Scale. Care home outcomes were the quality 
of staff interactions with residents measured using the Quality of Interactions Schedule 
(QUIS). 
Sample size 
The sample size was calculated to detect a moderate standardised effect size of 0.4 on the 
primary outcome: the between-arm difference in mean CMAI scores at 16-months. Fifty care 
homes, each recruiting 15 participants provided 90% power at a 5% significance level to 
detect a clinically important difference of 3-points (standard deviation (SD) 7.5 points), 
assuming 25% loss to follow-up and an inflation factor of 2.0 (i.e. cluster size of 11 
participants available for analysis after loss to follow-up) and an intracluster correlation 
coefficient (ICC) no greater than 0.1. As the ICC was anticipated to be higher in the 
intervention arm, an allocation ratio of 3:2 was used, giving 30 (450) and 20 (300) care 
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homes (residents) in the intervention and control arms respectively, equating to 50 care 
homes (750) overall. 
During the trial loss to follow-up was higher than the anticipated maximum of 25%, mainly 
due to death rates. In order to preserve statistical power close to 90%, and our ability to 
detect a moderate standardised effect size of 0.4, maintain validity and increase the 
generalisability of the trial, we recruited additional, newly-eligible, consenting residents from 
the randomised care homes at 16-months post randomisation and performed a cross-
sectional analysis of the data. 
Results 
Out of 335 screened care homes, 241 randomly sampled care homes were approached, 94 
formally expressed interest and were assessed for eligibility. Of the 63 eligible care homes, 
50 consented to take part, were able to recruit a minimum of ten resident participants and 
were randomised into the trial; 19 to control and 31 to intervention.  
At baseline, a total of 1564 residents were screened for eligibility, 1069 were eligible, 781 
consented, 743 registered and 726 residents were registered at the point of care home 
randomisation. Following the approved design change, a further 1444 residents were 
screened from 48 care homes at 16-months post-randomisation. Of those, 421 were eligible, 
266 consented and 261 residents were subsequently registered (99 residents in control 
homes and 162 in intervention homes). 
Overall at 16-months, a total of 675 residents were included in the cross-sectional sample: 
414 residents from the original cohort who reached 16-months and 261 additionally-recruited 
residents. 
Primary analysis was conducted on the cross-sectional sample. All 675 residents in the 
cross-sectional sample at 16-months were included in the primary analysis, 666 of which 
had complete data. No evidence of a clinical or statistical difference was found between 
treatment arms in the primary outcome of agitation at 16-months. The mean adjusted 
difference in total CMAI score was -2.11 points lower in the intervention arm, than in the 
control (adjusted means 45.47 points in control; 43.35 points in intervention, 95% confidence 
interval (CI) -4.66 to 0.44, p=0.104). The adjusted ICC was zero in the control and 0.001 in 
the intervention arm.  
A complier average causal effect (CACE) analysis of the cross-sectional sample, comparing 
care homes in the intervention arm that completed at least one cycle to an acceptable level, 
with care homes that would have completed at least one cycle to an acceptable level had the 
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intervention been offered to them, gave a mean difference in CMAI score at 16-months of -
2.5 points (95% CI -5.4 to 0.4, p=0.089) lower in ‘compliers’ compared to ‘non-compliers’.  
The sensitivity analyses and the CACE analysis supported the results found in the primary 
analysis that the intervention is not superior to the control. 
Analyses of BSC, mood, quality of life, PRN prescription medications and quality of staff 
interactions were conducted on closed-cohort at 6-months and on the cross-sectional 
sample (primary) and the closed-cohort (supportive) at 16-months. No statistically significant 
differences were found in the closed-cohort between arms on any resident-level or care-
home level secondary outcome at 6-months. Although no statistically significant differences 
were found between arms in the primary cross-sectional sample at 16-months, trends in 
favour of the intervention in behaviours staff find challenging and mood were found in the 
closed-cohort at 16-months. 
There were no reported unexpected serious adverse events (RUSAE). 
In the health economic base case cost-utility analysis, the intervention was more costly (by 
£1,479) and more effective (.024 QALYs) than control. This yielded an ICER of £60,627; well 
above the £20,000 NICE threshold, indicating that DCM™ is not cost-effective. The cost-
effectiveness analyses based on improvement in CMAI indicate that while the intervention 
was more costly, it was also more effective. Incremental cost per unit improvement in CMAI 
was £289 for intervention versus £67 for control, for the imputed and complete case 
samples, respectively. However, all cost-effectiveness plane simulations lie above the 
willingness to pay threshold suggesting that, using the base case analysis, DCM™ is 
unlikely to be cost-effective. The CEAC confirmed this and indicated that, where λ= £20,000, 
there is a very low probability that the intervention will be cost-effective. 
The process evaluation identified that DCM™ implementation was poorer than expected, 
with 22.6% (n=7) of care homes not completing one full cycle, 51.6% (n=16) of homes 
completing only their first expert mapper supported cycle, 12.9% (n=4) completing two full 
cycles and only 12.9% (n=4) completing the three full, per protocol, cycles to an acceptable 
level. Mappers, managers, residents, relatives and staff interviewed were able to identify a 
range of benefits of using DCM™ for residents, staff and for care home practices including 
improved communication, staff being abler to identify resident needs and provision of more 
activities. A range of care home level (context, manager support, staff motivation and 
engagement, mapper skills and qualities), intervention level (understanding of tool and 
process, complexity and time demands) and trial level (expectations of DCM™ and trial, 
expert mapper support) barriers and facilitators to implementation were also identified.   
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Conclusions 
This trial indicates that as a care home staff led intervention, DCM™ is not effective or cost 
effective at reducing agitation or improving quality of life and other care outcomes for 
residents with dementia living in care home settings. This outcome may be associated with 
the poor intervention fidelity we experienced during the trial, despite efforts to support 
implementation, which went beyond standard DCM practice/implementation structures. This 
suggests the majority of care homes may not provide the right setting conditions for a costly 
intervention like DCM™ and that externally led models may provide a more practical and 
resource effective method of implementation. However, further research is needed to 
evaluate this. Future research should more carefully consider the setting conditions needed 
for effective psychosocial intervention implementation and appropriate models for delivering 
interventions, given the available resources and cultural and organisational challenges of 
implementing complex interventions in care home settings. 
Trial registration 
This trial is registered as ISRCTN82288852 
Funding 
This project was funded by the National Institute for Health Research Health Technology 
Assessment programme (project number 11/15/13). The views and opinions expressed 
therein are those of the authors and do not necessarily reflect those of the HTA, NIHR, NHS 
or the Department of Health and Social Care. 
 
  
23 
 
Chapter 1: Introduction  
1.1. Scientific background  
Of those living with dementia in the UK, 38% reside in a care home 1 and at least 80% of 
people living in care homes have dementia. 2 In 2017 there were over 16000 care homes 
registered in England, including around 11,900 residential homes, 4500 nursing homes and 
3, the majority of which provide care for older people. Concerns have consistently been 
raised about care home quality. 4, 5 Improvement in care quality and staff knowledge and 
skills has been a consistent UK government research and practice development priority for 
nearly a decade 6-9 . Poor quality care is associated with poor outcomes for people with 
dementia including an increase in behaviours staff find challenging (BSC).10, 11 Developing 
an informed and effective care homes workforce is a strategic component of improving care 
quality, 6, 12 however, there remains limited robust evidence regarding effective evidence-
based staff training and practice development interventions for care homes providing care 
for people with dementia. 13, 14 Furthermore, it is often difficult to achieve the widespread 
implementation into real-world practice, of evidence-based training interventions developed 
in the context of research. 14, 15  
Dementia Care Mapping™  (DCM™) 16, 17 is a whole home, practice development 
intervention, that has been widely used in health and social care settings nationally 18 and 
internationally, 19 to support the embedding of person-centred care in practice. There is good 
evidence of its use in practice settings as a quality audit and improvement tool. 20-29 This trial 
was designed to provide robust evidence, on the effectiveness and cost effectiveness of 
DCM™ as an intervention to support care homes to sustainably transfer learning from 
person-centred care training (PCCT) into care practice. The outcomes of the trial aimed to 
determine whether DCM™ could provide a solution for achieving widespread implementation 
of an approach to training and practice development, which is practical for use in routine 
health and social care. 
1.1.1 Behaviours staff may find challenging (BSC) 
The behaviours that may be expressed by people with dementia in care home settings such 
as agitation, aggression, restlessness, hallucinations, delusions, depression, anxiety and 
apathy, may be experienced by staff as challenging to support. 30 These BSC are also 
known as ‘neuropsychiatric’ or ‘behavioural and psychological symptoms of dementia’ 
(BPSD). We have chosen to use the term BSC rather than BPSD as it reflects a more 
person-centred terminology that better emphasises the bio-psycho-social causes of such 
behaviours. It also represents the terminology used by relatives and staff in care home 
settings. Up to 90% of people living with dementia experience one or more of these 
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behaviours during the course of their condition 30 and BSC are reported in up to 79% of care 
home residents at any one time. 31 BSC also cause distress to the people with dementia 
experiencing them, 32 are associated with reduced quality of life 33, 34 and have a negative 
impact on the well-being of other residents. 35 BSC also have significant associated costs 36, 
37 including increased risk of hospitalisation, 38, 39 Accident and Emergency use 37 and 
production of excess disability; meaning functional abilities of people decline more quickly 
than is otherwise expected. 37 Therefore, reducing BSC has the potential to improve the 
quality of life of people with dementia living in care homes as well as reduce costs of 
providing care to this group. 
Agitation is the most common, 31, 40 distressing to the person with dementia 32 and the most 
difficult to manage 41 BSC in care home settings. Agitation includes aggressive behaviours, 
physically non-aggressive behaviours and verbal agitation, 42 including  pacing, spitting, 
verbal aggression, constant requests for attention, hitting, kicking, pushing, throwing things, 
screaming, biting, scratching, intentional falling, hurting self and others, making sexual 
advances and restlessness. 43 The presence of these behaviours puts the person who is 
agitated at risk of triggering aggressive responses from other residents 44 and causes 
distress for other residents, the person’s family and staff. Rates of over 60% of nursing home 
residents with dementia displaying agitation are reported, 45, 46  making it an extremely 
common as well as potentially harmful BSC for the people experiencing it, other residents 
and staff.  
The presence of agitation is reported as highly challenging, compared to other BSC, in terms 
of clinical management.41 Agitation places increased burden on care staff 47, 48 who feel less 
confident in dealing with situations where residents are agitated than in their management of 
other BSC. 49 There is an association between a person with dementia experiencing 
agitation and fewer visits from relatives, experiencing social isolation 48 and poorer quality of 
life. 33 The frequency of agitated behaviours, the difficulties staff have in their management 
and the potential risks they pose to the person, other residents and staff, means that drug 
treatments such as antipsychotics and other psychotropic medications may frequently be 
prescribed as a first line management approach. However, links of antipsychotics to stroke 
and excess deaths 50 mean their reduced use is an ongoing priority. 4, 9 There is a concern 
that the mandated reduction in antipsychotic prescribing may in turn lead to the prescription 
of other psychotropic drugs as an alternative. 51, 52 despite lack of evidence of efficacy. 
Investigating psychosocial approaches to reduce the incidence of agitation and to support 
staff with BSC is therefore a research priority. 5 
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Agitation and other BSC are not an inevitable consequence of dementia. Agitation is often 
exacerbated by the poor care practices and environment surrounding the person with 
dementia 53 as well as by poorly managed physical health and pain. 41, 54 They often reflect 
an expression of unmet needs by a person with dementia in response to inadequate 
understanding of a person’s needs or poor quality care. 4, 54, 55 This is often related to lack of 
stimulation and engagement for the person with dementia. 56 For example, Brodaty et al 57 
found significant variability between care homes in terms of the proportions of residents 
within each setting who displayed BSC, indicating a care home level effect that may include 
both admissions criteria and care practices. Likewise, Weber et al 58 report a significant 
reduction in BSC when people with dementia attended a therapeutic day hospital 
programme compared to when at home, again indicating the impact of the psychosocial 
environment. The presence of agitation within individuals with dementia in care home 
settings is, therefore, likely to be associated with organisational aspects of care and the care 
culture. 54 Therefore, the use of psychosocial interventions that address the quality of care 
practice 4, 59-61 are recommended, with agitation being a key treatment target area for people 
with dementia in care homes. 62  
 
1.1.2 Person-centred care 
Person-centred care is an effective psychosocial approach in dementia care, 63 considered a 
best practice approach to reducing agitation and other BSC. 59 Person-centred care means 
providing a supportive social environment within a care setting where people with dementia 
are valued, treated as individuals, and staff are encouraged to see the world from their 
perspective. 59, 64 Person-centred care, therefore, involves evaluating and responding to the 
unique needs of each person with dementia and offering an individualised approach. The 
National Institute for Health and Care Excellence and Social Care Institute for Excellence 
(NICE/SCIE) dementia guideline 59 recommends individualised, holistic or person-centred 
assessment and care planning, with regular review and individually tailored and monitored 
psychosocial interventions for BSC. Delivery of care that is person-centred is associated with 
a reduction in agitated behaviours 65 and BSC more generally 61 and reduced use of anti-
psychotics. 63, 66, 67 Bird et al 68 found that multifaceted, individualised interventions lead to 
significant reductions in BSC. Therefore, the most useful interventions to effect change 
identify individual causes of BSC and suggest appropriate person-centred solutions. 68-70 
This approach is reliant on staff having the required knowledge, skills and confidence in 
delivery of person-centred care. Provision of person-centred support is an element of the 
common induction standards 71 for all social care workers in England. Provision of at least 
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basic training to staff on person-centred care is expected within all care homes in England 59 
and is a regulatory requirement. 72 Currently, there are no widely implemented, quality 
criteria for person-centred care training (PCCT) and content, approaches, quality and 
efficacy of PCCT vary considerably across the sector. 73 Effective PCCT can produce 
immediate practice benefits, 65, 67 however due to the variability of the amount, content and 
quality of PCCT staff receive across the sector, knowledge, skills and staff confidence levels 
in relation to delivery of person-centred care remain a concern. 49, 74 Research indicates 
standardising PCCT is unlikely to address these issues 14 and therefore, evidence-based 
approaches to help staff sustainably embed PCCT into practice are required. 15  
Whilst effective PCCT can produce immediate practice benefits, evidence suggests, that 
PCCT alone might not sustain change over time 13, 65, 67, 75 and that PCCT needs to be 
accompanied by an additional intervention to support ongoing change. 66, 76 For example, 
Fossey et al 66 employed PCCT alongside a comprehensive 10-month focussed intervention 
for training staff (FITS) including ongoing staff training and support. At post-test antipsychotic 
medication use had decreased by over 40% in the intervention group. Chenoweth et al 63 
provided PCCT to two staff members who then disseminated person-centred care practice 
across the site. Researchers provided additional individualised care planning and ongoing 
telephone support during a 4-month intervention period. At 10-months post-randomisation, 
agitation levels were significantly lower than in the usual care control sites. A limitation of 
both of these studies is that it is unclear whether PCCT, additional support or both caused 
the effect. Evidence of efficacy of PCCT after a longer follow-up period is limited, 13 however, 
Moniz-Cook et al. 67 found the benefits of PCCT alone were not sustained at one-year. The 
PCCT programmes evaluated thus far indicate that embedding additional support alongside 
the training intervention is required to produce sustained benefits. 15, 77, 78 Implementing 
evidence-based health care interventions in real world practice is a recognised challenge, 
with barriers to implementation of research-designed interventions reported across all areas 
of practice. 79-81 Current successful interventions that combine staff training with ongoing 
support, such as the FITS, 66 are resource intensive requiring regular ongoing input from a 
specialist practitioner and have not yet been possible to implement widely in everyday 
practice. 82 Interventions that provide staff with knowledge to support BSC that are cost-
effective and feasible to implement are required. Any such intervention will need to 
accommodate the varying amounts, content and quality of PCCT that is a feature of the 
sector. DCM™ is an intervention that may address this issue. 
 
1.1.3 Dementia Care Mapping™ (DCM™) 
27 
 
DCM™ 16, 17 is an established, routine care home/NHS practice development intervention, 
recommended in the NICE/SCIE dementia guideline 59 that is regularly used for ensuring a 
systematic approach to providing individualised person-centred care. DCM™ is an 
observational tool, set within a practice development cycle used to support the sustained 
implementation of PCCT in dementia care practice. 83 Following initial formal training of care 
staff to use the tool, application includes five phases: briefing, observation, data analysis and 
reporting, feedback and action planning. A detailed overview of the DCM™ intervention is 
provided in section 2.5.2. This cycle is repeated every 4-6 months to monitor and revise 
action plans. DCM™ implementation therefore, requires no external input over the long term 
and is thus potentially less resource intensive and more closely aligned with real world 
dementia practice than other interventions aiming to address BSC. 66  
Whilst DCM™ has been used in dementia care for nearly 20 years including in care home 
settings, 25, 84-87 and has strong face validity within the practice field, 88 there is limited robust 
evidence of its effectiveness in relation to clinical outcomes such as reduction of BSC. 
Reported benefits of DCM™ include the improvement of well-being in people with dementia, 
22, 27, 89 helping staff consider care delivery from the point of view of the person with 
dementia, the production of evidence to underpin action planning that in turn motivates staff 
and increases their confidence to deliver person-centred care. 87, 88  
 
1.2 Evidence of the effects of Dementia Care MappingTM 
There are only six published studies, which have examined the benefits of using DCM™ for 
improving clinical outcomes in care homes; two pilot studies employing a pre-test/post-test 
design, 90, 91 one quasi-experimental controlled trial 92 and three cluster RCTs. 63, 93, 94 None 
were carried out in the UK. At the time of submission of the grant application for this trial only 
the two pilot studies 90, 91 and one of the RCTs had been published. 63   
A pilot study conducted in the Netherlands 91 utilising a One-Group Pre-test/Post-test design 
found DCM™, used alone, reduced verbal agitation and anxiety in people with dementia. It 
also improved care staff feelings of connection with clients. A pre-test/post-test design pilot 
study 90 conducted in three Australian care homes, found DCM™ led to improvements in the 
quality of staff interactions and reductions in agitation and depression, compared with three 
control homes. A quasi-experimental controlled trial conducted in Germany, 92 compared 
outcomes at 6- and 16-months to baseline. Nine nursing homes units, located in nine 
nursing homes owned by the same group were allocated not at random to one of three arms; 
no intervention control group (n=3), DCM™ experienced intervention group (n=3) and 
DCM™ intervention group (n=3). The DCM™ experienced group had been exposed to two 
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externally delivered DCM™ cycles annually over a number of years. The DCM™ 
intervention group had no previous exposure to DCM™, but had expressed an interest in 
undertaking the method. Two staff members from both intervention groups received DCM™ 
training and were requested to implement three DCM™ cycles over 18-months. The control 
group received an intervention based on training staff about quality of life, followed by QoL 
assessment using a standardised tool, of all care home residents at least every 6-months. 
The study found no significant differences between the two intervention groups and control, 
or the two intervention groups on QoL or BSC.  
The first cluster RCT evaluating the efficacy of DCM™ was conducted in Australia 63 in 15 
care homes randomised equally between three arms (usual care (control), person-centred 
care training (PCCT), DCM™) and included 289 people with dementia (18% loss to follow up 
at 10-months). The trial found that at 10-months post randomisation, DCM™, when used 
alone, was associated with significantly reduced agitation and falls in people with dementia 
compared to control and PCCT and reduced staff feelings of burnout. 95 A three-arm cluster 
RCT 93 was also conducted in 15 care homes in Norway, randomising equally between 
control group, person-centred care framework implementation and DCM™. The study 
recruited 446 people with dementia (29% loss to follow up at 10-months). It found significant 
reductions in overall neuropsychiatric symptoms as measured by the Neuropsychiatric 
Inventory (NPI), in agitation and psychosis as measured by the NPI sub-scales and a 
significant improvement in quality of life compared to the usual care control. Both trials had 
explanatory designs involving researcher-led cycles of DCM™ with variable degrees of input 
from trained care home staff, restricting generalisability of the results, since usual 
implementation of DCM™ is practitioner-led. A Dutch cluster RCT conducted in 34 units, 
across 11 care homes compared DCM™ to usual care control. 94 It recruited 434 residents 
(35% loss to follow up at 12-months) and found no difference in residents’ agitation between 
the DCM™ intervention and control homes. Positive staff outcomes were found in the 
intervention group including significantly fewer reported negative emotional reactions and 
significantly more positive reactions towards people with dementia. The trial authors 
identified potential DCM™ intervention fidelity issues, indicating less than desirable 
implementation in some clusters. All three RCTs were exploratory and each only included 
two full cycles of DCM™ before final follow-up, with follow-up periods of only 10-12 months 
post-randomisation, reducing the time for potential change and impact to be realised.  
Results of these existing studies are mixed in terms of reported efficacy of DCM™. The 
studies that included researcher-led cycles of DCM™ (Australia, Norway) showed efficacy 
for some outcomes, whereas studies with care home staff led cycles of DCM™ have shown 
no benefits of DCM™ (Netherlands, Germany). A recent systematic review of DCM™ 
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implementation 96 found limited research in this area, with implementation found to be 
challenging across a number of the published studies. There was some consensus that 
appropriate mapper selection, preparation and ongoing support during DCM™ 
implementation, alongside effective leadership for DCM™ within an organisational context of 
commitment to delivery of person-centred care, could support better implementation.    
In summary limitations of existing studies include:  
 Relatively small number of clusters (Australia, Germany) or small numbers of care 
homes containing multiple clusters (Netherlands, Norway); 
 Use of DCM™ alone rather than alongside PCCT in accordance with UK best 
practice guidelines 83 (Australia, Netherlands), reflecting the context within each 
country at the time of the trial, for example in Australia where PCCT was the 
exception rather than assumed good practice; 
 Only two full cycles of DCM™ before final follow up limiting the potential for impact, 
based on the length of time that changes within care home practice can take to 
implement and thus demonstrate potential resident benefits (Australia, Norway, 
Netherlands); 
 Follow up period of no more than 12-months post randomisation, reducing the time 
for potential change and impact to be realised (Australia, Norway);  
 Explanatory trial design (Australia, Norway) involving researcher-led cycles of 
DCM™ with variable degrees of input from trained care home staff, potentially 
limiting staff ownership of the DCM™ process, implementation of any action plans 
and longer-term sustainability of DCM™ use. This also restricts generalisability of the 
results to usual implementation of DCM™ in care practice, which is practitioner-led; 
 No formal, published process evaluation (Australia, Norway); 
 Studies conducted in Australia, Norway, Germany and the Netherlands where care-
funding, policy, context, regulations and processes are different to the UK.  
 
Despite promising results on the potential efficacy of DCM™ in care home settings, the 
conduct of these trials in countries where usual care practices, funding and systems are 
different and where DCM™ was implemented differently to its use in the UK, means their 
results cannot be directly transferred. A definitive RCT evaluating the effectiveness and cost 
effectiveness of DCM™ for helping staff to implement person-centred care in UK care home 
settings, building on this previous work, was needed to inform future UK care home practice.  
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1.3 Rationale for the research 
The knowledge intended to be gained from this trial, beyond that within existing RCTs was: 
 Utilisation of a pragmatic trial design reflecting the conditions of DCM™ 
implementation in usual practice in UK care home settings, compared to the 
explanatory designs of the previous trials. In particular, trained care home staff rather 
than researcher-led cycles of DCM™ implementation were utilised. The trial design, 
size and statistical power allowed definitive conclusions to be drawn regarding 
effectiveness of DCM™ as an intervention in usual practice within UK care home 
settings. 
 Previous RCTs had conducted only one or two DCM™ cycles with a follow-up period 
of a maximum of 12-months. In this trial it was intended that care homes implement 
three cycles of the DCM™ intervention with follow-up over a period of 16-months. 
This is beneficial since some anticipated practice changes, for example to underlying 
care culture, are likely to require time to implement. Also given annual staff turnover 
rates of around 30% 97 in care homes potentially leading to longer term 
implementation challenges, a longer follow-up period was necessary to investigate 
whether longer term effects and sustainability could be achieved within this context.  
 A full economic evaluation within this pragmatic trial design was included, offering a 
definitive position on cost-effectiveness. Only one of the previous trials conducted an 
economic evaluation and given its explanatory design and conduct in a funding 
system different to the UK, the findings cannot be confidently generalised. 
The design of this trial built on existing explanatory trials, to offer a definitive assessment of 
the effectiveness and cost-effectiveness of DCM™ as a standard clinical intervention in care 
home settings. 
 
1.4 Aims and Objectives 
The aim of the DCM™ EPIC cluster-randomised controlled trial was to evaluate the clinical 
and cost-effectiveness of DCM™ implemented in addition to usual care (intervention) 
compared to usual care (control) for people with dementia living in care homes in the UK.  
It aimed to answer the following primary and secondary research questions: 
1.4.1 Primary research question: 
Is the intervention:  
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(i) more effective in reducing agitation in residents with dementia as measured by 
the total Cohen-Mansfield Agitation Inventory (CMAI) score and  
(ii) more cost-effective than the control,  
16-months following randomisation of care homes? 
1.4.2 Secondary research questions: 
Is the intervention more effective than control, at 6 and 16-months post-randomisation at:  
(i) reducing BSC in people with dementia over time?  
(ii) reducing the use of antipsychotic and other psychotropic drugs in residents with 
dementia?  
(iii) improving mood and quality of life in residents with dementia?   
(iv) improving care home staff well-being and role efficacy?  
(v) improving the quality of staff/resident interactions over time?  
Other questions the trial sought to explore related to:  
(vi) the safety profile of the intervention as assessed by the number and types of 
adverse events;  
(vii) any differential predictors of the effects of the intervention, and  
(viii) the process, challenges, benefits and impact of implementing the intervention. 
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Chapter 2: Trial design and methods  
 
2.1 Trial design 
This section reports the trial design and procedures at the commencement of trial 
recruitment. The original trial protocol is published elsewhere. 98 Subsequent amendments to 
the original trial protocol, after trial commencement, are highlighted throughout this section 
and then reported in detail in section 2.10.  
This trial was a pragmatic, multi-centre, cluster-randomised controlled trial of Dementia Care 
Mapping™ plus usual care (intervention) versus usual care alone (control) in residential, 
nursing and dementia care homes across West Yorkshire, Oxfordshire and South London, 
for people with dementia.  
Due to greater than expected loss to follow-up during the trial, a design change was 
approved to move from a closed-cohort to an open-cohort design, with additional residents 
recruited at 16-month follow-up and the cross-sectional sample of residents used within the 
primary analysis (see section 2.10). The cross-sectional sample of residents was used in the 
primary statistical analysis (and a secondary health economic analysis), defined at baseline 
and 16-months respectively as all residents registered at care home randomisation and at 
16-months. The closed-cohort sample of residents was used in the primary health economic 
analysis (a supportive statistical analysis and all analyses of 6-month outcomes), defined 
simply as all residents registered at care home randomisation. 
Since DCM™ is aimed at changing practice across the whole care home setting and it is not 
possible to limit the potential effects to the care provided to only a sample of people with 
dementia living in the home, a cluster design was justified. This influenced the decision to 
consider two important sources of clustering: cluster-randomisation and DCM™ treatment 
provision, with care homes nested within treatment arms. Due to this we anticipated that the 
clustering effect would vary across arms, with a higher ICC in the intervention arm. 
Therefore, an unequal allocation of care homes on a ratio of 3:2 to intervention and control 
respectively was implemented. An integral cost-effectiveness analysis and a nested 
qualitative process evaluation were included.  
 
2.2 Ethical approval, research governance and study oversight 
Ethical approval for the study was granted by NRES Committee Yorkshire & The Humber - 
Bradford Leeds on 14th February 2013, REC ref 13/YH/0016. Care home insurance and 
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indemnity applied to trained mappers who implemented the intervention within the care 
home setting. Appropriate site-specific approvals were obtained from the three participating 
hubs; Yorkshire (Bradford Teaching Hospitals NHS Foundation Trust), Oxford (Oxford 
Health NHS Foundation Trust) and London (Guy’s and St Thomas NHS Foundation Trust). 
The trial was registered with the International Standard Randomised Controlled Trial 
Register (ISRCTN) reference 82288852. Day to day management of the trial was 
undertaken by a Trial Management Group (TMG) comprised of the co-applicants, trials 
researchers and staff and a patient and public involvement representative. This group met 
twice before the official start of the project, monthly during trial set-up and then bi-monthly or 
quarterly subsequently. Updates on trial progress were provided by e-mail between 
meetings. A Lay Advisory Group was established and contributed to TMG decisions (see 
section 2.13). 
Trial steering committee 
The trial was overseen by a Trial Steering Committee (TSC), comprised of five independent 
members (three academic members, one patient and public representative and one care 
home representative). The TSC monitored trial recruitment, retention, timelines, intervention 
adherence, data return and quality and considered new issues. It also provided advice and 
approval for changes to the protocol or trial procedures. It met approximately 6-monthly 
throughout the trial. 
Data Monitoring and Ethics Committee 
An independent Data Monitoring and Ethics Committee (DMEC), comprised of four 
academic members met approximately 6-monthly during the trial. They reviewed unblinded 
data, recruitment, retention, intervention implementation and safety by group. The DMEC 
also undertook annual review of any Serious Adverse Events (SAEs).  
 
2.3 Participants  
It was intended that 750 residents with dementia from a random sample of 50 care homes 
would be recruited as well as participants’ relatives and care home staff.  
 
2.3.1 Care Home eligibility, recruitment and consent 
2.3.1.1 Care home eligibility 
To be eligible for the trial a care home was required to: 
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1) Have a sufficient number of permanent residents with dementia (based on a formal 
diagnosis or Functional Assessment Staging of Alzheimer’s Disease (FAST) score of 
4+) eligible to participate, in order to achieve a minimum of 10 residents registered to 
the trial prior to care home randomisation; 
2) Have a manager or nominated person agreeing to sign up to the trial protocol as 
research lead for the duration of the project; 
3) Have agreed to release staff for DCM™ training and subsequent mapping processes; 
4) Be within the trial catchment area. 
 
Care homes were not eligible for the trial if: 
1) They were subject to Care Quality Commission (CQC) enforcement notices, 
admission bans or relevant moderate or major CQC compliance breaches; 
2) They were receiving other special support for specific quality concerns, such as 
being currently subject to, or had pending, any serious safeguarding investigations, 
or receiving voluntary or compulsory admissions bans, or local commissioning 
special support due to quality concerns; 
3) They had used DCM™ as a practice development tool within the 18-months prior to 
randomisation or were planning to use DCM™ over the course of trial involvement; 
4) They were currently, recently or were planning to take part, in another trial that 
conflicted with DCM™ or data collection. 
 
Where a care home was a large multi-site or multi-floor establishment, one or two 
units with the largest percentage of residents with dementia, or where the manager 
felt DCM™ implementation would be most beneficial, were selected to participate as 
one home.  
 
2.3.1.2 Care home recruitment 
Catchment areas for each recruitment hub (Leeds Beckett University, Kings College London, 
Oxfordshire Health NHS Trust) were established based on post-code districts/boroughs in 
West Yorkshire, South London and Oxfordshire respectively. All care homes in the 
catchment areas were identified and screened for initial eligibility via publicly available 
information (home type, number of beds, CQC status). Care homes deemed eligible were 
randomly ordered within catchment areas and divided into batches. The first batch of homes 
from each hub were sent the Care Home Information Sheet (see Supplementary Material) by 
post. A researcher then contacted the care homes by telephone within one to three weeks to 
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determine interest in taking part. If a care home expressed interest in taking part, the 
Researcher conducted initial eligibility screening ahead of visiting to determine full eligibility 
and to initiate care home consent and management permissions (see Supplementary 
Material). If the researcher was unable to make contact with the care home following several 
attempts, a decision was made to cease attempting to contact. Once all care homes within a 
batch had been contacted, or deemed uncontactable, the next batch was approached until 
sufficient homes were recruited.  
2.3.1.3 Dementia training audit and provision of dementia awareness training 
As person-centred care is considered best practice within UK care homes 59 it was expected 
that homes would have routinely provided staff with appropriate PCCT.  72 As the quality of 
PCCT is variable across the sector in the UK, to ensure that each care home met at least 
minimum dementia awareness training standards, a training audit was developed by the 
research team and its content and minimum standards required in the trial are reported 
elsewhere. 99 The training audit was completed in each care home prior to baseline data 
collection. The researcher completed this via review of training records and discussions with 
the home manager and/or other relevant staff (e.g. training lead). Where homes fell below 
the minimum standard they received a half-day dementia awareness course modified in 
consultation with service users, from an existing resource developed by Bupa Care Services 
and the University of Bradford. 100 The course was delivered by an experienced 
trainer/mentor who coached a member of the care home staff to be able to onward deliver to 
additional staff. Care homes were expected to deliver the training to at least 20% of 
permanent direct care staff prior to baseline data collection and to complete paperwork 
detailing how many staff members received the training and when. Based on CQC data, 101 
we expected up to 20% of homes to require this dementia awareness package. 
2.3.2 Resident eligibility, recruitment and consent 
Residents were recruited to the trial at baseline, prior to care home randomisation. Further 
residents were recruited at 16-months following a design change to the study, due to larger 
than anticipated loss to follow-up (see section 2.10.2). 
2.3.2.1 Resident eligibility  
At baseline residents were eligible for the trial if they: 
1) Were a permanent resident in the care home and not present for receipt of respite or 
day-care; 
2) Had a formal diagnosis of dementia or a score of 4 or higher on the Functional 
Assessment Staging of Alzheimer’s Disease (FAST) 102 (indicating mild to severe 
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dementia) as rated by the home manager or another experienced member of staff; 
3) Were appropriately consented (in accordance with Mental Capacity Act 2005 103 and 
clinical trials guidance on informed consent 104, 105); 
4) Had an allocated member of staff willing to provide proxy data; 
5) Had sufficient proficiency in English to contribute to the data collection required for 
the research. 
At baseline residents were not eligible for the trial if: 
1)  They were known by the care home manager and/or relevant senior staff member to 
be terminally ill, e.g. formally admitted to an end of life care pathway; 
2)  They were permanently bed-bound/cared for in bed; 
3)  They were currently in, or had recently taken part in, or were planning to take part in, 
another trial that conflicted with DCM™ or with the data collected in the trial. 
2.3.2.3 Resident screening  
The researcher with the care home manager and/or a relevant member of senior staff, 
screened all care home residents to identify eligible people with dementia to be approached 
to take part in the trial. The basic demographics of all residents and their eligibility or reasons 
for ineligibility at screening were recorded, using only the screening number, 
2.3.2.4 Resident informed consent 
In accordance with the Mental Capacity Act 2005, 103 all eligible residents were assumed to 
have capacity to consent unless assessed otherwise. The manager/senior staff member 
approached each eligible resident and sought their permission for the researcher to speak 
with them. If the resident had capacity and gave verbal consent to speak to the researcher, 
this was documented and the researcher approached them to discuss the study. If the 
resident was deemed to lack capacity to make this decision, then the process for appointing 
a consultee was followed (see section 2.3.2.4.2).  
The researcher approached each resident who had capacity and agreed to speak to them, to 
explain the trial using the appropriate documentation and to undertake a further documented 
assessment of capacity to give informed consent. The resident was provided with the 
Resident Information Sheet (see Supplementary Material) and at least 24-hours later, they 
were given the opportunity to ask any further questions and then, for those with capacity, 
formal consent to participate in the trial was sought. If the resident was deemed by the 
Researcher at any point to lack capacity to consent, the process for appointing a consultee 
was followed (see section 2.3.2.4.2). 
2.3.2.4.1 Consent for those with capacity 
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Residents who were able to give informed consent were asked to sign, or make a mark on, 
the trial consent form (see Supplementary Material). For those who were not able to sign, a 
witness confirmed that informed consent had been given. Given the progressive nature of 
dementia, a further capacity assessment was conducted at each data collection point by the 
researcher to assess continued capacity. In the case of residents who lost capacity during 
the trial, appropriate guidance on consent in the light of changed capacity was followed 106, 
involving appointment of a consultee (see section 2.3.2.4.2). Where a resident had capacity 
and consented to taking part in the trial, consent to approach his/her main carer 
(relative/friend) was sought, regarding their participation as a proxy informant.  
2.3.2.4.2 Consent for those without capacity 
Where a resident was assessed to lack capacity to give informed consent a ‘Personal 
Consultee’ was appointed to give advice on the resident’s wishes. This was usually a relative 
or close friend. Where the resident had no close family or friend able or willing to act as 
Personal Consultee, a member of staff in the care home who knew them well but who was 
not actively involved in any elements of the research process (e.g. as a mapper or in giving 
proxy data on the resident), was appointed as a ‘Nominated Consultee’.  
If the proposed Personal Consultee was present in the care home, they were approached by 
the researcher and given all the appropriate documentation (see Supplementary Material) in 
person and asked for written consent to hold their personal details to enable the researcher 
to directly contact them thereafter. The proposed Personal Consultee was given at least 24- 
hours to talk to the resident and other relatives/friends about the resident’s wishes. The 
personal consultee was then asked to return the declaration form by post, within a week, 
expressing their advice on the resident’s wishes regarding taking part in the trial. If the 
Personal Consultee was not present in the care home, the documentation was sent to them 
by post, via the care home, on the researcher’s behalf. Details of how to contact the 
researcher should they wish to discuss the role were provided. For both methods of 
approach, if the declaration form had not been returned after a week, a follow up reminder 
was sent by post by the researcher informing the Personal Consultee that a Nominated 
Consultee would be identified if no response was received within a week. If after a further 
week the declaration form had not been returned the process of appointing a Nominated 
Consultee was followed. 
A Nominated Consultee identified by the manager was approached using the appropriate 
documentation (see Supplementary Material) to discuss the resident’s potential involvement 
in the trial with the resident, other staff members who knew them well and any 
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relatives/friends. The Nominated Consultee was then asked to complete the declaration form 
providing advice on the resident’s wishes. 
Personal and Nominated Consultees were advised that they could approach the researchers 
at any time to indicate if they felt the person they were representing had changed their mind 
about participating in the trial, and to withdraw them from participation. Given the frailty of 
the population who may be serving as Personal Consultees, a review of Personal 
Consultees’ capacity was undertaken by the researcher via the care home manager at 6- 
and 16-month follow-up, where feasible.  
 
2.3.3 Staff roles, eligibility, recruitment and consent 
2.3.3.1 Staff roles 
There were five staff roles within the trial, some which were mutually exclusive (Table 1): 
i) To act as a Nominated Consultee for residents (see section 2.3.2.4.2); 
ii) To provide data on standardised measures relating to their role (see section 2.3.3.2); 
iii) To provide proxy informant data on residents they know well (see section 2.3.3.3); 
iv) To become a trained DCM™ mapper (see section 2.5.2.1); 
v) To participate in the trial’s process evaluation (see section 2.9). 
 
Table 1: Role Summary 
  Nominated Consultee DCM™ mapper Proxy informant 
Nominated Consultee  X X 
Staff measures X   
Proxy informant X X  
DCM™ mapper X  X 
Process evaluation  X   
 
2.3.3.2 Staff measures 
To be eligible to complete a staff measures booklet, staff were required to be a permanent, 
contracted, agency or bank member of staff at the time of data collection and have sufficient 
proficiency in English. Consent to participate in this role was assumed through staff return of 
the booklet. The staff measures booklets and accompanying information sheets (see 
Supplementary Material) were distributed to all eligible staff members at each data collection 
visit by the researcher, or care home manager. Booklets were returned anonymously by the 
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staff member either via a sealed envelope to a locked box located within the care home or 
posted directly to the research office in the stamped return envelope provided.  
2.3.3.3 Proxy informant eligibility, recruitment and consent 
To be eligible to act as a proxy informant and provide proxy data on a resident, staff had to 
be a permanent or contracted member of staff who knew the resident well. Bank or agency 
staff were not eligible for this role. Potential proxy informants were identified by the care 
home manager/senior member of staff using the appropriate trial documentation (see 
Supplementary Material). Where possible the same proxy informant was used for each 
resident throughout the trial, although this was not always possible due to staff turnover, 
annual leave and shift patterns.  
 
2.3.4 Relative/friend eligibility, recruitment and consent 
Where possible a relative or friend who visited the care home regularly was identified for 
each participating resident, to provide proxy data. The relative/friend proxy was identified 
either in discussion with the resident or the care home manager/senior member of staff. 
They could also act in the role of Personal Consultee. To be eligible to provide proxy data, 
relatives/friends were required to visit the resident at least once per week over the last 
month, be willing to provide data either by telephone or post during the data collection week 
and to have sufficient proficiency in English to contribute to the data collection required. 
Relatives/friends were approached either in person by the care home manger or researcher 
or by post, depending on visiting patterns and times using the appropriate trial 
documentation (see Supplementary Material). 
Relative/friend recruitment took place at baseline and continued at 6-month follow-up in 
some homes until December 2015 when the decision to cease further recruitment was 
made, due to low overall relative/friend recruitment. Data continued to be collected from 
consented relatives/friends throughout the trial. Their continuing eligibility for participation 
was reassessed at each subsequent data collection point because of changing patterns of 
visiting over time. Where relative/friend proxies withdrew from the trial, additional participant 
relatives/friends were not recruited. 
 
2.4 Registration, Randomisation and Blinding 
2.4.1 Registration of residents 
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Residents recruited at baseline were registered with the Clinical Trials Research Unit 
(CTRU) University of Leeds following care home recruitment, training review (see section 
2.3.1.3) eligibility confirmation, obtaining informed consent and resident-level baseline data 
collection, but prior to care home randomisation. Following a design change (see section 
2.10) additional residents were recruited at 16-months and were registered with the CTRU 
after confirmation of eligibility, informed consent and collection of their resident-level data. 
 
2.4.2 Randomisation, stratification and blinding 
Immediately following baseline, once all residents, staff and relatives/friends were recruited 
and registration complete, care homes were randomised using the 24-hour automated 
randomisation system at the CTRU. Care homes fulfilling eligibility criteria were randomised 
on a 3:2 basis, to receive either intervention or control. A  computer generated minimisation 
programme was used, 107 incorporating a random element to ensure arms were balanced for 
the following care home characteristics: 
 Home/unit type (general residential/nursing, specialist dementia care);  
 Size (large>=40 beds, medium/small<40 beds);  
 Provision of dementia awareness training by research team (yes, no); 
 Recruiting hub (West Yorkshire, London, Oxford) 
 
To maintain blinding of trial researchers collecting data within care homes, randomisation 
was performed by CTRU Data Management, who were therefore not blind to treatment 
allocation. Following randomisation, the CTRU informed the care home manager of the 
treatment allocation, by phone call or e-mail. The Intervention Lead was notified of homes 
allocated to intervention, so that arrangements could be confirmed for training with 
consented mappers and contact with the DCM™ expert mapper initiated.  Researchers were 
not informed of treatment allocation and agreed procedures were applied to maintain 
blinding throughout the trial. Other CTRU staff were only informed of treatment allocation if 
this was required to undertake their role. All occurrences of unblinding and the reasons 
for/method of unblinding were recorded.  
As researchers were blinded they were unaware of the identity of trained mappers. 
Therefore, a text message was sent to mappers in the intervention homes by CTRU trial 
management staff, ahead of data collection at 6- and 16-months, to remind them not to 
provide proxy informant data if requested to do so.  
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2.5 Procedure 
2.5.1 Usual care (both arms) 
Usual care was defined as care routinely delivered within the setting, and was continued in 
all participating care homes with no restrictions imposed on current practices or on homes 
undertaking additional development or training. The exception was that control arm homes 
were required not to implement DCM™ during the trial period. Details regarding any 
changes in usual care practice during the course of the trial (e.g. new staff roles, change of 
ownership, new practice initiatives or training programmes) were documented by the 
researcher at follow-up visits. 
To facilitate a person-centred primary care response to BSC should care homes seek 
support, all General Practitioners (GPs) who served each care home were provided with 
generic best practice guidance about the implementation of person-centred care and 
managing BSC, irrespective of whether the residents they provided services to were 
participating in the trial. We did not inform individual GPs about which residents were 
participating in the trial.  
 
2.5.2 Dementia Care Mapping™ (intervention arm) 
The intervention followed standard procedures as set out in the DCM™ manual and 
guidance. 17, 108 Two staff members from each intervention care home were trained to use 
DCM™, followed by implementation of (ideally) three standard DCM™ cycles (each 
comprising of briefing; observation; data analysis, reporting and feedback; and action 
planning), in accordance with the British Standard best practice guideline. 83 In addition, care 
homes were provided with fidelity guidelines which included standardised templates for 
recording attendance at briefing and feedback sessions and for DCM™ reporting and action 
planning. Other mechanisms for ensuring adherence to intervention and supporting mapper 
engagement were implemented including, support from a DCM™ expert mapper during 
cycle one (see section 2.5.2.5) and sending SMS reminders to mappers ahead of each 
cycle. 
2.5.2.1 Mapper identification, eligibility and consent 
Two staff in each home were identified by the manager as suitable to be trained in use of 
DCM™ (mappers). To ensure timely progression from care home randomisation to DCM™ 
training, and to avoid selection bias, two mappers were identified in every consenting home 
at care home recruitment and their informed consent to undertake the mapper role was 
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gained. To be eligible staff had to be a permanent or contracted staff member, have the right 
skills and qualities as assessed by the home manager against a mapper role descriptor 
provided by the research team (see Supplementary Material), agree to implement DCM™ 
per protocol and to take part in the process evaluation, if required. 
Potential mappers were initially approached by the manager with reference to the written 
mapper role description. Once verbal consent was obtained, the researcher discussed the 
role and responsibilities of mappers again with reference to the role descriptor and mapper 
information sheet, before gaining their written informed consent (see Supplementary 
Material). If a mapper withdrew or left the care home before the end of the trial, where 
feasible, another suitable member of staff was identified, consented and trained using a 
similar procedure, to ensure continuity of DCM™ implementation in the home. 
2.5.2.2 Training 
Following randomisation, care homes allocated to intervention received DCM™ training as 
soon as their mappers were able, depending in part upon the course schedule.  
All trial mappers attended a standard four-day DCM™ training course held in Bradford or 
London and provided by the University of Bradford. It included an assessment of 
competency in use of DCM™. One further attempt at the assessment for attendees failing to 
achieve a pass mark at the first attempt, was permitted. The course trainers were informed 
which attendees were EPIC trial mappers in advance. They provided data as to which 
mappers had successfully completed and passed the course. 
2.5.2.3 Implementation 
Following completion of the formal, assessed training course, implementation of DCM™ 
commenced, comprising a practice development cycle of: briefing the staff team; observation 
over a number of hours; data analysis, reporting and feedback to the staff team; and action 
planning. Re-mapping at regular intervals forms part of the standard process, to monitor 
progress and set new action plans. Intervention homes were scheduled to complete their 
first cycle at 3-months post randomisation (or as soon as practicable), their second cycle at 
8-months and their final cycle at 13-months. Ahead of each mapping cycle the trial manager 
at CTRU contacted mappers individually via SMS to remind them of the upcoming cycle. 
Paper documents were posted to them to prompt completion of the cycle. 
2.5.2.3.1 Briefing 
Mappers were asked to run at least one briefing session 1-2 weeks prior to undertaking the 
mapping observations. Briefing sessions informed the care home staff about DCM™ and the 
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process of implementation and provided an opportunity for staff to ask questions and for 
mappers to address any staff concerns. 
2.5.2.3.2 Observation 
Mappers used the standard DCM™ procedure.  They were asked to observe as many 
individuals, up to a total of five, as they felt confident to, for up to six consecutive hours on a 
single day if possible. Alternatively, they could observe for as long as possible on 
consecutive days up to a total of six-hours. A detailed description of the DCM™ tool is 
published elsewhere 83, 109 and summarised here: every 5-minutes the mapper records two 
pieces of information about each person they are observing, a Behaviour Category Code 
(BCC) and a Mood/Engagement (ME) Value. There are 23 possible BCCs for the mapper to 
choose from, and they capture what the person with dementia is doing within that 5-minute 
period. The ME Value encapsulates the associated mood and engagement level of the 
person with dementia and is chosen from a 6-point scale (+5, +3, +1, -1, -3, -5). A set of 
rules is used to determine which BCC and ME to code. The mapper also records instances 
when a person with dementia is ‘put down’ by a care worker, known as personal detractions 
(PDs), and examples of excellent care, called personal enhancers (PEs). These are 
recorded as and when they occur. Since DCM™ is grounded in person-centred care, for 
reasons of privacy and dignity, observations only take place in communal living areas, such 
as the lounge, dining room and corridors. Mappers do not observe in bedrooms or 
bathrooms.  
2.5.2.3.3 Data analysis, reporting and feedback 
For the purposes of trial data analysis, reporting and feedback were considered as a single 
phase, rather than the two separate phases of implementation described in the DCM™ 
literature. Once the data had been collected they were analysed by the mappers and 
presented in a standardised report format for the purposes of feedback to the care team. In 
the trial a standard template for DCM™ reporting was given to the mappers by the research 
team (see Supplementary Material). DCM™ feedback sessions provide an opportunity for 
mappers to share their observations with the staff team and for collective discussion about 
good care practices and areas for improvement. In the trial mappers were requested to run 
one or more feedback sessions with as many of the staff team as possible, within one-month 
of conducting the observations.  
2.5.2.3.4 Action planning  
Action plans of ways to improve care were then produced. As part of the feedback session, 
or in a subsequent meeting, staff and mappers were asked to jointly develop agreed, 
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achievable group (care home level) and individual resident level action plans containing 
short, medium and longer term goals they wished to implement. Mappers were asked to 
monitor progress on these actions during the next mapping cycle. 
2.5.2.4 Resident consent for mapping 
Prior to mapping, residents were selected to be mapped through discussions between the 
care team and mappers, during the briefing session or on the day of mapping. Mappers 
followed DCM™ guidance, which states that residents may be selected for observation due 
to reflecting a range of abilities or having particular care needs staff members have 
difficulties meeting or understanding. Residents selected for mapping observations did not 
need to be consenting trial participants, since DCM™ was implemented as a whole home 
intervention. Consent was gained verbally by the mappers, from the resident or in discussion 
with their relative prior to observations taking place, in accordance with the usual consent 
process utilised in DCM™. Any resident data collected as part of the DCM™ process, 
subsequently used for monitoring intervention fidelity, or for any other purposes in the trial, 
was anonymised by the mappers before being sent to the research team. 
2.5.2.5 DCM™ Expert mapper support for cycle one 
This pragmatic trial aimed to ensure that DCM™ implementation reflected what is possible in 
a typical UK care home, maximising relevance to practice. However, the first cycle of 
mapping was supported by an expert in use of DCM™ (DCM™ expert mapper), provided by 
the research team. This is not standard practice as trained mappers would usually engage in 
DCM™ without further support following training completion. However, it was implemented in 
the trial to support implementation fidelity across clusters (see also section 2.9), provide 
coaching for care home mappers, to encourage implementation and to support 
establishment of inter-rater reliability of DCM™ coding between trained mappers in each 
care home. The DCM™ expert mapper worked alongside the mappers during their first 
DCMTM cycle, spending three days in the care home supporting establishment of inter-rater 
reliability on DCM™ coding frames, briefing, mapping observations and delivery of the 
feedback and action planning session. Two additional days of desk-based support were 
provided on preparation of briefing documentation, the feedback report and action plans. 
Telephone and e-mail support for DCM™ implementation, from the DCM™ Intervention 
Lead was available to all intervention homes thereafter, if required. 
 
2.6 Outcomes 
2.6.1 Primary endpoint 
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The primary endpoint was agitation at 16-months following randomisation measured by the 
Cohen-Mansfield Agitation Inventory (CMAI), as rated by staff proxy. The Pittsburgh 
Agitation Scale (PAS) and a modified observational CMAI (CMAI-O), rated by independent 
researchers provided a means of assessing concurrent validity, addressing the issue of 
potential detection bias, based on the inability to blind staff to intervention allocation status. 
 
2.6.2 Health economic endpoints 
The primary health economic endpoint was cost per quality-adjusted life year (QALY) at 16-
months. A secondary endpoint was cost per unit of improvement in CMAI at 16-months. Both 
of these adopted the health and personal social service provider perspective. 
2.6.3 Secondary endpoints  
Secondary endpoints relating to residents were: 
 Behaviours Staff find Challenging (NPI); 
 Mood (NPI); 
 Quality of Life (QUALID, QOL-AD, DEMQOL, EQ-5D-5L); 
 Prescribed Medication; 
 Safety (SAEs, Safeguarding). 
Secondary endpoints relating to staff were: 
 Sense of Competence in Dementia Care Staff (SCIDS) Scale. 
Secondary endpoints relating to homes were: 
 Quality of Interactions Schedule (QUIS). 
Furthermore, intervention fidelity was assessed. All other data are potential mediators or 
moderators of the treatment effect. Measures, collection time-points and method of 
completion are summarised in Table 2. 
 
To ensure a consistent data set was available for each resident at each time-point, the main 
informant for the primary outcome and for proxy completed secondary outcomes was a staff 
proxy informant. These data were supplemented, where possible, by information provided by 
the resident (where able) and their relative/friend (where available). 
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Table 2: Summary of data collected 
Assessment 
Method of Completion 
(completed with/on) 
 
Purpose 
 
Level 
Timeline 
Screening Baseline 6- months 16- months 
Resident Demographics Researcher Assessment (CM, CR)  Individual  X X X 
Cohen Mansfield Agitation 
Inventory (CMAI) 
Researcher Interview (SP) 
Primary endpoint Individual 
 X X X 
Cohen Mansfield Agitation 
Inventory Observational 
(CMAI-O) 
Independent Researcher 
Observations (R) 
Independent assessment of concurrent 
validity of CMAI for detection of potential 
bias 
Individual 
 X X X 
Pittsburgh Agitation Scale 
(PAS) 
Independent Researcher 
Observations (R) 
Independent assessment of concurrent 
validity of CMAI for detection of potential 
bias 
Individual 
 X X X 
Neuropsychiatric Inventory 
(NPI-NH) 
Researcher Interview (SP) 
Secondary endpoint Individual 
 X X X 
DEMQOL Proxy Researcher Interview (SP and RF) Health economics endpoint Individual  X X X 
EQ 5D 5L/EQ 5D 5L-proxy 
Researcher Interview (R and RF 
and SP) 
Health economics endpoint Individual 
 X X X 
QUALID Researcher Interview (SP and RF) Secondary endpoint Individual  X X X 
QOL-AD (care home) Researcher Interview (R) Secondary endpoint Individual  X X X 
Healthcare Resource Use Researcher Assessment (CR) Health economics endpoint Individual  X X X 
Prescription Medications Researcher Assessment (CR) Secondary endpoint Individual  X X X 
Resident Comorbidities Researcher Assessment (CR)  Individual  X X X 
Clinical Dementia Rating 
(CDR) 
Researcher Interview (SP) 
Process measure Individual 
 X X X 
Functional Assessment 
Staging (FAST) 
Researcher Interview (SP) 
 Individual 
 X X X 
General Health Questionnaire 
(GHQ-12)* 
Self-Completed (S) 
Secondary endpoint  
 X X  
Sense of Competence in 
Dementia care Staff (SCIDS) 
Self-Completed (S) 
Secondary endpoint  
 X X X 
Quality of Interactions 
Schedule (QUIS) 
Researcher Observations (R,S) 
Process measure Cluster 
 X X X 
Care Home Demographics Researcher Interview (CM)  Cluster  X X X 
Environmental Audit Tool 
(EAT) 
Researcher Observations (CH) 
Process measure Cluster 
 X X X 
Group Living Home 
Characteristics (GLHC) 
Researcher Assessment (CH) 
Secondary endpoint Cluster 
 X X X 
Assessment of Dementia 
Awareness and Person-
Centred Care Training 
(ADAPT) audit 
Researcher Assessment (CM, CR) 
Pre-baseline benchmarking for provision of 
additional person-centred dementia 
awareness training and usual care 
monitoring 
Cluster 
X  X X 
Safety Reporting Researcher Assessment (CM) Safety   Monthly following Randomisation 
RUSAE Report Researcher Assessment (CM) Safety   As highlighted. 
Key: CM – Care Home Manager, CH – Care Home Observations, CR – Care Home Records, R – Resident, S – Staff, SP – Staff Proxy Informant, RF – Relative/Friend Proxy Informant 
Note* Collection of GHQ data from staff was ceased during trial – see section 2.10
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2.6.4 Resident Measures  
2.6.4.1: Primary Outcome Measure:  
Cohen Mansfield Agitation Inventory (CMAI) 42, 43 
The CMAI measures 29 agitated or aggressive behaviours. 110 The frequency of each 
symptom is rated on a seven-point scale (1-7) ranging from “never” to “several times an 
hour”, based upon observations over the previous two-weeks. A total score is obtained by 
summing the individual frequency scores, yielding a total score ranging from 29 to 203. The 
CMAI has good psychometric properties 111 when used in a care home setting. Data from 
previous similar studies provides expected points change to inform the sample size 
calculation. The CMAI was completed via researcher interview with the staff proxy informant, 
in accordance with the CMAI Manual. 43 
Since blinding staff to intervention allocation was not possible, two independent 
observational measures of agitation were collected to assess potential bias in staff proxy 
informant completion of the CMAI (see section 2.6.4.2). Observation scales have been 
shown to have good convergence with informant measures of agitation 112. Observations 
were completed by an independent blinded researcher who was not involved in any other 
data collection in the care home. 
 
2.6.4.2 Agitation measures (supportive outcomes)  
Cohen Mansfield Agitation Inventory - Observation (CMAI-O) 113  
The CMAI-O was developed by the trial team, with the permission of the CMAI’s author, to 
provide an observational measure of agitation. It is rated on a four-point scale (1-4) ranging 
from “never” to “several times an hour”, based upon observations over one day. The CMAI-O 
data collection was completed on participating trial residents in communal areas between 
approximately 10:00- 12:00 and 14:00-17:00 (dependent on meal times in each care home). 
A copy is available from the authors on request.  
Pittsburgh Agitation Scale (PAS) 114 
The PAS is an established observational rating of agitation. The scale has good reported 
reliability and validity. 114  Observations are conducted for between 1 and 8 hours. PAS data 
were collected on participating trial residents in communal areas between 10:00-12:00 and 
14:00-17:00.  
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Neuropsychiatric Inventory Nursing Home (NPI-NH) 115 
The NPI-NH records a broader range of BSC including delusions, hallucinations, 
agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, 
disinhibition, irritability/lability, aberrant motor behaviour, sleep and night-time behaviour 
disorders and appetite/eating disorders. The NPI-NH is a 12-item version designed for use 
with nursing home/care home populations, and has good reported reliability and validity. 115 
 
2.6.4.3 Quality of life  
DEMQoL-Proxy 116 
The DEMQoL-proxy is a quality of life (QoL) questionnaire designed specifically for use in 
people with dementia. It has 32 items, covering mood, behavioural symptoms, cognition and 
memory, physical and social functioning and general health. It is administered by interview 
with a carer (formal or family) of the person with dementia. The DEMQoL-proxy has 
acceptable psychometric properties for measuring QoL in dementia 117 and is modelled to 
enable the derivation of preference-based indices (utility values), the latter of which were 
employed in the secondary cost-utility analyses. 118 
EQ-5D-5L/EQ-5D-5L Proxy 119 
EQ-5D is an accepted standardised, five-item measure of health outcome that provides a 
single index value for health status 120 covering: usual activities, self-care, mobility, pain and 
anxiety/depression, each with five response options (no problems, slight problems, moderate 
problems, severe problems and unable to do task). Both the self-report and proxy versions 
were used in the trial. 
Quality of Life in Late Stage Dementia (QUALID) 121 
The QUALID is an 11-item scale that rates the presence and frequency of QoL indicators 
over the previous seven days using proxy report. It is a reliable and valid scale for rating 
quality of life in people with moderate to severe dementia and has good internal consistency, 
test-retest reliability and inter-rater reliability. 121  
QOL-AD (care home) 122 
The QOL-AD is a 13-item self-report measure of quality of life with good reported internal 
reliability, test-retest reliability and convergent validity. 122 It is reported to be reliable in use 
with people with mild to severe dementia. 123-125 The adapted version of the QOL-AD 126 is a 
15-item questionnaire developed for use in care homes and uses simple language and a 
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four-response answer which is consistent across all questions (poor, fair, good, excellent). It 
includes minor changes to the standard QOL-AD scale to ensure relevance to those living in 
long-term care (e.g. amendment of wording of existing items, removal of questions on 
management of money and marriage status and addition of questions relating to 
relationships with staff, ability to take care of oneself, ability to live with others and ability to 
make choices). It has good reported internal consistency. 126  
2.6.4.4 Demographics, health and healthcare resource use  
Resident demographics 
Standardised demographic information (sex, date of birth etc) was collected by the 
researcher via interview with the care home manager or other senior member of staff and 
review of the resident’s care records. 
Healthcare resource use 
This measure was adapted from one developed for a care home feasibility trial. 127 The 
measure captured use of primary and secondary care including hospital-based care (e.g. 
hospital and A&E visits and stays), community-based care (e.g. GP visits and contact with 
other healthcare professionals such as physiotherapists and psychiatrists) and other costs 
(e.g. adapted beds and other aids) incurred during the previous three-months.  
Prescription medications 
Prescription of medications within categories of interest (e.g. antipsychotic, benzodiazepine, 
non-benzodiazepine anxiolytic, non-benzodiazepine anti-psychotic, memantine, 
antidepressant, cholinesterase inhibitor, anti-convulsant, mood stabiliser, pain relief) and 
administration of these if prescribed on an as required (PRN) basis, was recorded on a 
standardised CRF. This was completed by the researcher through review of residents’ 
medication records for the previous month.   
Resident comorbidities 
These were collected using a standardised CRF through researcher review of residents’ 
care records. 
2.6.4.5 Dementia severity 
Clinical Dementia Rating Scale (CDR) 128 
The CDR is a well utilised, standardised scale for rating the severity of dementia from no 
cognitive impairment to severe or advanced dementia. 129 Impairment on six cognitive 
categories is rated and an algorithm is used to calculate the overall severity rating. Severity 
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is rated by a trained assessor via informal interview/conversation with the person, or with a 
proxy who knows the person well. In this study the CDR was completed by the researcher 
through interview with a staff proxy who knew the resident well. 
Functional Assessment Staging (FAST) 102  
The FAST is a scale designed to record the functional severity of dementia. Scores range 
from 1 (no dementia) to 7 (severe dementia) with levels 6 and 7 each having five sub-levels. 
It is particularly designed for use in more moderate to severe dementia. It is completed by 
proxy report from a caregiver. 102 
 
2.6.5 Staff Measures 
2.6.5.1 Staff work stress  
General Health Questionnaire (12-item) (GHQ-12) 130 
This is a measure of stress/psychological well-being used in the general population. It has 
good reported psychometric properties. 131 It contains 12-items related to mental health, 
each scored on a four-point scale of frequency of symptoms or behaviours (‘less than usual’ 
to ‘much more than usual’). Due to poor return rates collection of GHQ-12 data was ceased 
during the trial (see section 2.10 for further details). 
2.6.5.2 Job or role efficacy  
Sense of Competence in Dementia Care Staff (SCIDS) 132  
The SCIDS is a user-friendly, self-complete, 17-item scale measuring staff members’ 
competence in caring for people with dementia, across four sub-scales (Professionalism, 
Building Relationships, Care Challenges, Sustaining Personhood). Each item is rated on a 
four-point scale of confidence (‘Not at all’ to ‘Very Much’). It has acceptable internal 
consistency and test-retest reliability. 132 
 
2.6.6 Organisational Measures 
 2.6.6.1 Care quality  
Quality of Interactions Schedule (QUIS) 133 
The QUIS is an observational measure of the quality and quantity of staff interactions with 
residents during care delivery, at a care home level. It records five types of interactions 
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(positive social, positive care, neutral, negative protective, negative restrictive) and has 
reported adequate inter-rater reliability and sensitivity. 134 The QUIS was completed via 
researcher observation, using a time-sampling technique in each setting. In accordance with 
QUIS guidelines 133, 135 observations of interactions at 5-minute intervals, were conducted in 
communal areas in the care home and recorded summarised into 15-minute intervals. One-
hour observations were completed at two time-points (AM and PM) over two days within the 
same week (7-day period) in accordance with Care Home activity (i.e. morning coffee break) 
in the most populated communal area in the home. For the purposes of analysis in this trial, 
the proportion of interactions that were positive (positive social and positive care) was used. 
2.6.6.2 Care home environment and characteristics 
Care Home Demographics Questionnaire 
This questionnaire, designed by the study team, collected organisational data regarding 
each care home (size, type, ownership, geography, staff turnover, staff ratios, resident 
demographics, etc.) and its manager (qualifications, length of time in post, leadership style 
etc.). 
Environmental Audit Tool (EAT) 136 
The EAT is an instrument with reported adequate reliability and validity used to differentiate 
between the quality of the physical environment in various types of dementia care facilities. 
136 It was completed by the researcher with the assistance of a staff member if required. 
Group Living Home Characteristics Questionnaire (GLHC) 137 
This is a measure of the style of care being delivered in the home. It examines how ‘home-
like’ care delivered is. It includes four-subscales (physical environment, residents, 
relatives/other visitors, staff) each containing at least three related statements answered 
according to a five-point scale (‘Never’ to ‘Always’). It was completed by the researcher. 
Assessment of Dementia Awareness and Person-Centred Care Training (ADAPT) audit 99 
See section 2.3.1.3. 
Safety and RUSAE reporting 
See section 2.11. 
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2.7 Sample size 
The sample size was calculated to detect a moderate standardised effect size of 0.4 on the 
primary outcome: the between-group difference in mean CMAI scores at 16-months. We 
assumed the standard deviation (SD) would be similar to that observed in a recently 
completed trial in UK care homes (7.5 points). 66 The moderate effect size translated to a 
minimum difference of 3 points. If greater variation in CMAI scores was observed, (SDs 
ranging from 15 to 20 points as reported by Zuidema et al 138), then for the same effect size 
a difference of 6 to 8 points could be detected, respectively. A difference of 8 points on the 
CMAI is seen as indicative of real behavioural change. 138 Fifty care homes, each recruiting 
15 participants provide 90% power at a 5% significance level to detect a clinically important 
difference of 3 points (SD 7.5 points), assuming 25% loss to follow-up (as seen in 
Chenoweth et al. 63) and an inflation factor of 2.0 (i.e. cluster size of 11 participants available 
for analysis after loss to follow-up and an intracluster correlation coefficient (ICC) no greater 
than 0.1 66).  
As provision of care is a further source of clustering, and the ICC was anticipated to be 
higher in the intervention arm (based on clinical opinion), an allocation ratio of 3:2 was used, 
giving 30 (450) and 20 (300) care homes (residents) in the intervention and control arms 
respectively, 50 (750) overall. 
During the trial, the TMG, DMEC and TSC monitored loss to follow-up. This was higher than 
the anticipated maximum of 25%, mainly due to death rates. In order to preserve statistical 
power close to 90%, and our ability to detect effect size of 0.4 SDs, maintain validity and 
increase the generalisability of the trial, we recruited additional, newly-eligible, consenting 
residents from the randomised care homes at 16-months post randomisation and performed 
a cross-sectional analysis of the data (see section 2.10). 
 
2.8 Statistical and health economic methods 
A comprehensive Statistical and Health Economic Analysis Plan was developed and 
approved following the approval of the design change. All analyses were performed once, at 
final analysis in SAS v9.4 or Stata v14.  
A CONSORT (Consolidated Standards of Reporting Trials) flow diagram has been used to 
display care home and resident pathway from registration to final follow-up (see section 3.1). 
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2.8.1 Analysis populations 
The principal analyses were intention-to-treat, including all randomised care homes and all 
registered residents, regardless of whether they received or adhered to their allocated 
intervention. A further supportive analysis was planned of ‘compliers’, defined as care homes 
that would have received at least one cycle of DCM™ to an acceptable level (all components 
of the cycle are completed) had it been offered to them. Other thresholds of compliance we 
considered were exploratory. Safety was summarised on the closed-cohort sample of 
residents since we were unable to obtain timely NHS Digital data on the cross-sectional 
sample. The samples of staff and relative/friends providing data (other than staff proxy data) 
were so small that analyses based on them are descriptive and provided in the Appendix 
only (see Appendix 1, Table 31). 
 
2.8.2 Missing data 
In general, if there were no instructions in the manual on how to handle missing items (for 
PAS, NPI-NH, QUALID, SCIDS and EAT), prorating was used if fewer than 25% of items 
were missing, (based on adopting a more conservative approach than that proposed by 
Staquet et al 139), otherwise the score was assigned as missing. As the proportion of 
residents with notable missing primary outcomes was low, we prorated for simplicity despite 
assumptions underlying prorating not always being met.  
The primary intended method for handling missing scale data in the cross-sectional analyses 
was to analyse complete cases, under the assumption that data are missing completely at 
random (MCAR). For completeness, we also report a sensitivity analysis using multiple 
imputation, under the assumption that cross-sectional data are missing at random (MAR). If 
the MCAR assumption was found not to hold true, then the primary analysis would use the 
multiple-imputed data, assuming data are missing at random (MAR).The proportion of 
residents missing in analyses of the closed-cohort sample was sizeable at 6-months and 
substantial at 16-months. As death and moving care home were expected to be the most 
important predictors of missing closed-cohort data, we expected this data would be missing 
not at random (MNAR). We considered a range of approaches to handling missing closed-
cohort data (see Table 10 and Tables 47 and 48), but report a tipping point analysis 140 for 
the primary analysis, which indicates the assumptions that would be required about the 
missing data to change the conclusions.  
For completeness, we also report an analysis using multiple imputation, under the 
assumption that closed-cohort data are missing at random (MAR), which assumes residents 
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registered at care home randomisation do not die during the duration of the trial. The same 
variables were included in the imputation models, apart from the baseline questionnaire 
scores; baseline questionnaire score used in the imputation model was always the same as 
the outcome questionnaire. The imputation model was done separately for different analysis 
population, in the cross-sectional, baseline variables were care home summaries, whereas 
in the closed-cohort, individual level baseline information was used. 
 
2.8.3 Screening, baseline, treatment and outcome summaries 
The numbers of care homes approached, screened, eligible, consenting and participating, 
along with the numbers of residents in the closed-cohort sample and the cross-sectional 
sample were summarised in a CONSORT flow diagram. Reasons for exclusion and the 
characteristics of screened residents were also presented overall and across samples. 
Baseline characteristics of care homes, care home managers and residents (closed-cohort 
and cross-sectional samples) were summarised overall and for intervention and control. In 
accordance with the TIDieR checklist, 141 summaries of treatment receipt were given by 
intervention component for DCM™ and by parallel-group for usual care.  
Baseline, 6- and 16-months outcomes were summarised for the intervention and control and 
additionally for residents in the closed-cohort and cross-sectional samples at 16-months.   
 
2.8.4 Primary effectiveness analysis 
The continuous primary outcome of agitation (CMAI score) was analysed on the cross-
sectional sample of residents using a linear two-level heteroscedastic regression model that 
allowed the cluster and resident-level random effects to vary by arm. The model adjusted for 
minimisation factors (care home type, size, provision of dementia awareness training and 
recruiting hub) and average care home-level baseline characteristics (dementia severity via 
CDR, age and CMAI score) as fixed effects. These variables were pre-specified in the 
protocol, age was added as an additional covariate. Unadjusted and adjusted ICCs, 
estimates and corresponding 95% confidence intervals were presented, by arm. A negative 
mean difference in outcome favours the intervention. The primary analysis model was 
decided a priori in the Statistical Analysis Plan before the data were un-blinded and without 
reference to the data. It was consistent with/followed on from the trial design.  
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2.8.5 Sensitivity effectiveness analyses 
The robustness of the conclusions of the primary effectiveness analysis was assessed via a 
number of sensitivity analyses. The primary effectiveness analysis was repeated: 
 With an additional covariate categorising care homes by whether they were recruited 
pre or post eligibility criteria change; 
 Including care home size as a continuous covariate; 
 Assuming clustering is homogeneous across arms; 
 Using the observational CMAI (CMAI-O) and PAS scores in place of the CMAI; 
 Using the closed-cohort sample in place of the cross-sectional sample, allowing 
dementia severity, age and CMAI score to be included as covariates at the resident-
level. 
 
2.8.6 Supportive effectiveness analyses 
The treatment effect among ‘compliers’ was estimated using a series of complier average 
causal effect (CACE) models. Our main supportive analysis defined ‘compliers’ as care 
homes that would have received at least one cycle of DCM™ to an acceptable level if it had 
been offered. Other thresholds were exploratory. CACE treatment estimates were obtained 
from two-stage least square instrumental variable regressions (using Stata command ivreg), 
using robust standard errors to allow for clustering effects. The model adjusted for the same 
baseline variables as the primary analysis model with the addition of binary variable 
‘treatment received’ (number of DCM cycles received to pre-specified level). 
For our mediation analysis, we used a parametric causal mediation approach to allow for 
interactions between mediators and treatments, which the typical Baron and Kenny 142 
approach does not. We reported the natural indirect effect, which is the effect on outcomes 
of having the mediator present compared to it not being present, for a number of pre-
specified intermediate variables (potential mediators). Analysis was done on an ITT basis on 
cross-sectional cohort. Each mediator was analysed separately assuming there was no 
unobserved confounding in treatment-outcome, mediator-outcome and treatment-mediator 
relationships and that any mediator-outcome relationship confounders were not affected by 
treatment allocation. We used parametric regression models using Stata the paramed 
command. A linear regression model was fitted for the outcome variable. Logistic regression 
was used for the mediator variable. In the multiple imputation we additionally included the 
potential mediators. 
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In our moderator analyses, we explored whether the treatment effect differed depending on 
pre-specified baseline characteristics of either the care home or the resident. The primary 
analysis was repeated, including each potential moderator, alongside the interaction 
between treatment and the potential moderator. Analyses was performed on the ITT cross-
sectional sample, subject to the availability of data for each potential moderator. 
 
2.8.7 Secondary effectiveness analyses 
Secondary analyses were undertaken using the same principles as the analysis of the 
primary outcome. For secondary outcomes (behaviours staff find challenging, use of 
antipsychotic drugs and other psychotropic drugs, mood, resident quality of life, staff role 
efficacy, care quality and the quality of staff/resident interactions), three analyses were 
performed: 
1. Cross-sectional at 16-months;  
2. Closed-cohort at 6-months;  
3. Closed-cohort at 16-months.   
The same covariates were included as for the primary analysis (for closed-cohort analyses, 
individual resident-level covariates were used as appropriate). Cluster-specific linear two-
level heteroscedastic regressions were fitted where outcomes were continuous (resident 
quality of life). Population-average logistic regressions were fitted, using generalised 
estimating equations (GEE), where outcomes were binary (behaviours staff find challenging, 
use of antipsychotic drugs, mood).  
 
2.8.8 Safety analysis 
The number and proportion of residents in the closed-cohort who died from any cause 
between randomisation and 16-months was summarised by arm. The cause and place of 
death was also reported. The number of hospital admissions per resident, mean number of 
hospital admissions per resident, average length of hospital admission, overall number of 
hospital admissions reported and admissions by ward type was summarised by arm and 
overall. No formal statistical comparison was undertaken between arms.  
 
2.8.9 Health Economic analysis 
The economic evaluation was a within-trial analysis. We chose not to develop a decision-
analytic model for the evaluation. While a model may have been useful in extrapolating any 
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costs and health benefits beyond the end of the trial, we felt that the measure of future 
effectiveness would be highly uncertain and would require additional assumptions (e.g. 
about the duration of effect). The analysis followed the reference case guidance for 
technology appraisals set out by the National Institute for Health and Care Excellence 
(NICE). 143 The primary analysis was a cost-utility analysis and presents outcomes as 
quality-adjusted life years (QALYs) using a health and personal social service provider 
perspective (whilst some of these costs might in practice be paid for by residents 
themselves, this was not accounted for in the analysis because it was deeded not to have 
any impact on the incremental costs of the DCM intervention). A secondary cost-
effectiveness analysis based on cost per unit of improvement in CMAI was also conducted.  
2.8.9.1 Deviations from the SAP 
The following deviations from the SAP were decided upon during data analysis. The primary 
health economic analysis assumed that the local authority pays for the provision of care for 
residents (NHS and social care perspective). We had planned to conduct an analysis where 
we assumed that some proportion of residents paid for their own care home stay. Following 
further discussions with the research team it was decided to remove this element. The 
justification for this was that care homes are paid even when residents are hospitalised and 
hence the source of payments for residency would not impact results.  
In the SAP we stated that: “The validity of reports will be assessed by correlating scores 
between EQ-5D and those on the alternative measures (QUALID, QoL-AD) and by exploring 
the ability of the measure to distinguish between known groups (for example, based on 
CDR).” This was not included as part of the required analysis within the original grant 
application. This analysis is still planned as additional methodological research. For the trial 
analysis we took the pragmatic approach and based the primary analysis on staff proxy 
measures since this was by some margin the most complete data. 
2.8.9.2 Resource Use and Costs 
Unit costs for health service staff and resources were obtained from national sources such 
as the Personal Social Services Research Unit (PSSRU), 144 the eMIT national database 145 
and NHS reference cost database 146 (see Appendix 1 Table 66 for a summary of unit costs).  
2.8.9.3 Cost of DCM™ intervention 
The DCM™ intervention consisted of two components: i) delivery and receipt of DCM™ 
training; and ii) implementation of the DCM™ process in care homes. 
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It was assumed that both components would require DCM™ mappers in the trial (two per 
intervention site) to take dedicated time away from their usual care duties during the working 
day. The amount of time required for the DCM™ training course was four days.  The 
estimated amount of time required for the DCM™ process is reported in existing DCM™ 
guidelines 83, based on the experiences of experts using DCM™ in practice settings.  Data 
were also collected during the trial in order to assess the validity of these estimates and, 
where this was shown to exceed the assumed average, the impact of any additional staff 
time was assessed in sensitivity analyses.  It was assumed that additional time was not 
required for other care home staff to attend DCM™ briefing and feedback sessions, but that 
these were arranged at handover and other convenient times for staff to attend as part of 
their usual duties. 
In order to calculate the total cost of staff time, an hourly wage was estimated for a typical 
DCM™ Mapper.  This incorporated data from the trial on the proportion of DCM™ Mappers 
in particular roles (e.g. a home care worker and a care home manager) and data published 
by the PSSRU on the hourly wages (or annual salaries converted to hourly wages using 
standard methods) of workers in these roles.  Where relevant wage data was not available 
from PSSRU, we reviewed alternative sources, including recent job advertisements.  
Additional costs of the delivery and receipt of DCM™ training included the course fees, 
training materials, accommodation, meals, subsistence and travel. These were estimated 
using information from the DCM™ course provider and data on the costs incurred in running 
the trial. A further additional cost of implementing the DCM™ process in care homes was the 
consultancy fees, travel and subsistence expenses incurred through employment of external 
DCM™ expert mappers to support the intervention implementation and fidelity during the 
first DCM™ mapping cycle in each of the intervention sites. The primary analysis assumed 
that the intervention was delivered as planned and all cycles were implemented and costed. 
A sensitivity analysis costed only the cycles that had been partially or fully implemented. 
The primary analysis assumed that the Local Authority payed for the provision of care home 
care for residents. As such these costs were included in the healthcare provider (NHS) and 
social care cost perspective.  
 
2.8.9.4 Healthcare resource use 
Data on healthcare resource use incurred during the previous 3-months were collected for 
each resident at baseline, 6- and 16-months. Medication use during the past month was 
captured at the same time points (see section 2.6.4.4). 
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2.8.9.5 Quality of Life/Utility 
Quality of Life was measured in the trial at baseline, 6- and 16-months using the EQ-5D-5L, 
completed by care home residents, and the EQ-5D-5L-Proxy, completed by staff and 
relatives. 120 A recently-generated UK general population tariff 147 was used to calculate the 
utility scores and a (5L to 3L) mapping algorithm was used as a sensitivity analysis. 148 
Utility values were also calculated using the DEMQOL-Proxy tool (DEMQOL-PROXY-U), 
which was completed by staff and relatives.  A UK population tariff was used to calculate 
utility scores. 118 The main cost-utility analyses were based on the EQ-5D-5L utility, but 
sensitivity analyses were conducted based on DEMQOL-Proxy-U.  
Taking a pragmatic approach, we elected to base the primary analysis on EQ-5D-5L data 
from the staff proxy at all three time-points as this represented the most complete set of 
responses. However, we conducted a sensitivity analysis employing resident completed EQ-
5D-5L data where it was available at all three time-points. Where this was not available we 
used data from relative proxies (if available at all three time-points) and, finally, when this 
was unavailable, from staff proxies.   
2.8.9.6 Analysis 
The primary economic analysis was a cost-utility analysis over 16-months presenting 
incremental cost-effectiveness ratios (ICER) for intervention versus control, with effects 
expressed in terms of QALYs. As the clinical efficacy analyses used agitation as the primary 
endpoint, a secondary cost-effectiveness analysis based on change in CMAI over 16-months 
was also conducted.  
Total QALYs were calculated using an area under the curve approach between adjacent 
utility measure completions using EQ-5D-5L and DEMQoL-Proxy utilities captured at 
baseline, 6- and 16-months. If residents died their utility value was assumed to be zero and 
their data were retained in the analyses. Quality of life was assumed to change from last 
completion value to zero in a linear fashion.   
Total costs were estimated using the resource use questionnaires at 6- and 16-months.  It 
was assumed that reported resource use during a 1-month (for medications) or 3-month 
(other costs) period remained constant between time points in the trial (e.g. the 10-month 
period between follow-up at 6- and 16-months). To capture the costs incurred prior to death, 
a daily cost was estimated based on each resident’s previous resource consumption (at 
baseline or 6-months) and applied until the date of death.   
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Incremental costs and QALYs (or CMAI) were estimated using a Seemingly Unrelated 
Regression (SUR) approach which consisted of a system of regression equations that can 
recognise the correlation between individual costs and outcomes:   
Model 1 (cost): 
𝑇𝑜𝑡𝑎𝑙𝐶𝑜𝑠𝑡𝑖 =  𝛼𝑖 +  𝛽 𝑅𝑎𝑛𝑑𝑇𝑟𝑡𝑐ℎ + 𝜀𝑖  
Model 1A (cost sensitivity analysis):  
𝑇𝑜𝑡𝑎𝑙𝐶𝑜𝑠𝑡𝑖 =  𝛼𝑖 + 𝛽1 𝑅𝑎𝑛𝑑𝑇𝑟𝑡𝑐ℎ +   𝛽2 𝑇0_𝐶𝑜𝑠𝑡𝑠𝑖 +  𝛽3 𝑇0_𝐶𝐷𝑅𝑖 +   𝛽4 𝑇0_𝐴𝑔𝑒𝑖 + 𝜀𝑖 
Model 2 (qalys): 
 𝑇𝑜𝑡𝑎𝑙𝑄𝐴𝐿𝑌𝑖 =  𝛼𝑖 +  𝛽1 𝑅𝑎𝑛𝑑𝑇𝑟𝑡𝑐ℎ +  𝛽2 𝑇0_𝑄𝐴𝐿𝑌𝑖 +   𝛽3 𝑇0_𝐶𝐷𝑅𝑖 +   𝛽4 𝑇0_𝐴𝑔𝑒𝑖 + 𝜀𝑖 
Where T0 = baseline, CDR = CDR score 
In addition to controlling for baseline QALYs, which differed at baseline, for consistency, with 
the statistical analysis age and baseline CDR score were also included (Model 2 above).  
Although costs were not significantly different at baseline, these same baseline 
characteristics were included in the SUR for costs in a sensitivity analysis. 
Incremental cost-effectiveness ratios (ICERs) were calculated both for cost per QALY gain 
and cost per unit improvement in CMAI score. We used the NICE willingness to pay per 
incremental QALY threshold (£20,000 = Lambda [λ]) to determine whether the intervention 
was cost-effective. Interventions with an ICER under £20,000 per QALY are generally 
considered cost-effective. There is no such willingness to pay threshold to aid the 
interpretation of changes in CMAI but we framed this in the context of other study results. 
Discounting at the NICE preferred rate of 3.5% per annum for costs and effects were 
conducted for values post 12-months (i.e. for the final 4-months of the trial). 
 
2.8.9.7 Net benefit analysis 
A net benefit regression framework was also employed to allow parametric analysis of the 
incremental costs and benefits of the intervention.  Net monetary benefit is calculated using 
individual-level total costs, total QALYs and the cost-effectiveness threshold (λ=£20,000): 
   NMB = (λ*QALYs) – Costs 
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Linear regression models were used to regress treatment allocation on individual-level (i for I 
individuals in the trial) estimates of NMB, whilst controlling for other observable trial arm 
imbalances (e.g. dementia severity, agitation levels or socio-demographics): 
   𝑁𝑀𝐵𝑖 =  𝛼𝑖 +  𝛽 𝑅𝑎𝑛𝑑𝑇𝑟𝑡𝑐ℎ + 𝛿 𝑿𝑖 +  𝜀𝑖  
Where RandTrt is the treatment allocation and X is a vector of observable characteristics. 
We also examined heterogeneity in the treatment effect by compliance at the care home 
level in a multi-level model accounting for clustering at the care home level: 
   𝑁𝑀𝐵𝑖 =  𝛼𝑖 +  𝛽 𝑪𝑯𝑐ℎ +  𝛿 𝑿𝑖 + 𝜀𝑖  
Where CH is a vector of three groups of intervention arm care homes, grouped according to 
the number of cycles in which the care home had completed all four components of the 
intervention (this is defined as an ‘acceptable’ level in the statistical analysis see section 
2.9.7): 
 
= 0 if care home had completed no cycles to an acceptable level 
= 1 if care home had completed one cycles to an acceptable level 
 = 2 if care home had completed two or three cycles to an acceptable level 
 
Control arm care homes were in the reference category and the coefficient (𝛽) is a measure 
of incremental net benefit associated with a particular group of care homes. 
To be consistent with the statistical analysis, we also conducted a CACE analysis on net 
monetary benefit which is designed to account for the potential endogeneity of compliance 
using a two staged least squares instrumental variables approach.  
 
2.8.9.8 Missing data 
We ran the resident-level analysis on complete cases (CCA) initially which required data on 
total QALYs (based on various EQ-5D-5L or DEMQOL measures, depending on the 
analysis) and total costs. However, due to the extent of missing data, the primary analysis 
was based on data where missing values were imputed using multiple imputation (MI).  This 
assumed that the data were missing at random. The first stage of the imputation process 
used mean imputations to estimate the baseline values of each EQ5D5L, DEMQOL-Proxy 
measures, CMAI score and time-invariant characteristics (age/date of birth at baseline), 
following guidance in a paper by Faria et al. 149   
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Second, Multiple Imputations by Chained Equations (MICE) was used to impute missing 
EQ5D-5L, DEMQOL-Proxy measures (index values rather than individual items) and CMAI 
score at 6-months and 16-months and individual components of total costs at all three time-
points. The number of individual components of total costs (n=15) used in the imputation 
process was decided, taking a pragmatic approach.  As a general rule, at each time-point, 
high cost and common resource items (e.g. hospital visits and stays) were imputed 
individually and less common items were imputed on a bundled basis.  
The number of imputations (n=48) reflected the ratio of missing: complete data. We 
accounted for clustering within care homes. Rubin’s 150 rules were used to combine 
parameter estimates of the multiple imputations   
 
2.8.9.9 Cross sectional cohort analysis 
The change in the trial to an open-cohort design meant that additional data for some 
residents were available at 16-months, despite them not being in the trial at baseline or 6-
month follow-up. For the primary analysis, we only used data from those residents 
consented into the trial at baseline (the original-cohort). However, in order to be consistent 
with the statistical analysis, an additional analysis was conducted incorporating the costs 
and QALYs for those residents providing data only at 16-months (the cross sectional-cohort). 
Where data on both costs and EQ-5D was only available at 16-months in the cross-sectional 
cohort, we imputed the total cumulative costs and total QALYs for the whole trial period 
using a two-stage imputation process.  First, mean values of the total costs and total QALYs 
generated in the imputations described above (n=48) were used to replace the missing data 
on total costs and total QALYs in the closed cohort. Second, data on total costs and total 
QALYs for each individual in the closed cohort (n=726) (including the values that had been 
imputed in the first stage) were used to impute the total costs and QALY data for all 
individuals in the cross-sectional cohort, using the MICE method and Rubin’s rules described 
above, accounting for recorded data at 16-months, including costs and quality of life. This 
enabled calculation of an ICER for the cross-sectional cohort.  Since this approach relied on 
an unusual two stage imputation process for individuals who had no recorded data at 
baseline, the results should be considered illustrative only and treated with due caution.  
This approach also relied on an assumption that survival was independent of the intervention 
and time spent in the care home since residents providing data at 16-months only would 
have survived until 16-months had they been in the care home for that duration.  
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2.8.9.10 Sensitivity analyses 
Deterministic sensitivity analysis of the ICER was undertaken to test the robustness of the 
results to changes in the analytical approach and to assumptions made. For example, we re-
ran analyses exploring the impact on results of different approaches to costing, handling 
missing data and of employing alternative utility capture methods. 
A non-parametric bootstrapping analysis was also conducted to determine the level of 
sampling uncertainty around the ICER estimates by generating 10,000 estimates of 
incremental costs and benefits, using the combined estimates of the multiple imputed 
datasets (n=48) using Rubin’s 150 rules, and accounting for clustering in care homes. The 
bootstrapped estimates were used to generate the cost-effectiveness plane and the cost 
effectiveness acceptability curve (CEAC). 151   
 
2.9 Process evaluation and assessment of treatment implementation 
2.9.1 Aims and research questions 
The process evaluation was designed to examine the process, challenges, benefits and 
impacts of the trial, in order to identify the processes and factors associated with degrees of 
successful and unsuccessful intervention implementation.  
The aims of the process evaluation included: 
 Describing adherence to the required components of the intervention and the quality 
(or fidelity) of intervention delivery.  
 Understanding staff, residents’ and relatives’ perceptions of the impacts of the 
intervention 
 Understanding the barriers and facilitators to implementing DCM™ in practice 
The process evaluation answered research questions aligned to the Medical Research 
Council guidelines on process evaluations 152 and included implementation, mechanisms of 
impact and context. 
1. What was implemented? 
a. What was the process of setting up the intervention in each care home? 
b. If, and how, did this differ from the intended process as outlined in the 
protocol? 
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c. How many cycles of DCM™ were delivered in each care home? (Dose + 
Reach) 
d. To what extent did each cycle in each care home meet the planned delivery 
as set out in the protocol? (Fidelity + Reach) 
e. If and how did care homes deviate from delivery of the intervention as set out 
in the protocol? 
2. How did participants react to the intervention? 
a. What were mappers’, managers’, residents’, relatives’ and staffs’ experiences 
of the intervention and its implementation? 
b. What were mappers’, managers’, residents’, relatives’ and staffs’ perceptions 
of the impact of the intervention? 
c. Did the intervention have any perceived, unexpected impacts or 
consequences?  
d. For perceived impacts, through what mediators/processes did each group 
perceive the intervention to have operated? 
e. Did the intervention or its mechanisms of impact operate in any unexpected 
ways? 
3. What contextual factors shaped if, and how, the intervention was implemented or 
worked? 
a. What were the perceived barriers and facilitators to intervention 
implementation, mechanisms of impact and perceived impact from the 
perspective of mappers, DCM™ expert mappers, managers, staff, residents 
and relatives? 
b. How did care homes that demonstrated different degrees of intervention 
implementation manage and address barriers and facilitators to intervention 
implementation? 
The process evaluation and implementation assessment was intended to support refining 
and improving of intervention efficacy and the sustainable implementation of the intervention 
over time, if the intervention was found to be effective. 153  
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2.9.2 Design of the process evaluation 
A mixed methods approach to data collection was used involving quantitative and qualitative 
components to embed the process evaluation as part of the main trial dataset.  
The quantitative data included assessment of levels of adherence and fidelity in each home 
utilising data provided by the mappers from each care home at each cycle. These data 
included details on the ‘dose’ and quality of DCM™ use in relation to briefing (number of 
briefing sessions held and proportion of care home staff receiving briefing), mapping cycles 
(number of mapping sessions, numbers of residents observed, length of mapping period and 
number of mappers taking part) feedback sessions (number of feedback sessions held and 
proportion of care home staff receiving feedback) and DCM™ and action planning 
documentation (successful completion of standard mapping documents during each cycle 
using the standard templates provided, and the number of action plans developed per 
resident and at home level).  
The qualitative data were collected from a subset of 18 intervention homes using semi-
structured interviews with residents, the care home manager, mappers, staff, relatives and 
residents. Homes that had achieved varying degrees of success with DCM™ implementation 
(no full cycles, at least one full cycle, two or more full cycles) were purposefully selected in 
order to explore the factors associated with successful and unsuccessful implementation. 
Although selection of care homes took place before the final follow-up data collection point, 
the process evaluation interviews took place after all outcome data had been collected in 
each home (i.e. at the end of the 16-month follow-up data collection). Semi-structured 
interviews were also conducted with the DCM™ expert mappers, to explore their experience 
of supporting the implementation of DCM™ within the intervention homes. To enable links 
between the qualitative and quantitative data, researchers undertaking the qualitative data 
collection were provided with implementation data by the CTRU from the first two cycles in 
the home prior to the interviews.  
 
2.9.3 Sampling for the quantitative and qualitative data collection 
For the quantitative data analysis, frequency data from the mapping cycles in all intervention 
homes were used to assess dose, adherence and fidelity, and to understand variation in levels 
of DCM™ implementation across the homes. 
For the qualitative data collection, purposive sampling was used to select a sub-set of 18 
homes, which had achieved varying degrees of success with DCM™ implementation to 
explore factors associated with this in greater detail. Due to the staggered recruitment of care 
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homes and the need to set up the process evaluation data collection dates with home 
managers ahead of time, participating homes had to be identified before all three cycles of 
mapping were due to have been completed. These homes were stratified into three equal 
groups (6 per group) according to whether they were deemed to be likely to be ‘successful 
implementers’ (more than two cycles completed), ‘partial implementers’ (1-2 cycles 
completed) or unsuccessful implementers’ (less than one cycle completed) of DCM™. 
Homes that differed according to key characteristics with the potential to affect DCM™ 
implementation, including location of homes (6 from each hub), size (large >=40 vs 
medium/small <40), and type of home (nursing, dementia, general residential), were also 
accounted for in the sampling.  
 
2.9.4 Participant eligibility 
Residents from homes taking part in the process evaluation were eligible if they were 
deemed to have capacity to consent and were able to take part in a brief interview. Staff 
were eligible to take part if they were a permanent or contracted member of staff. 
Relatives/friends were eligible if they had visited the home at least once a month during the 
trial.  
Identifying staff and relatives/friends to approach was undertaken in conjunction with the 
home manager and included identification of the staff who had played a key role in 
intervention delivery. All potential participants were provided with verbal and written 
information about the interview, were given time to consider taking part, and signed a 
consent form if willing to participate (see Supplementary Material). Mappers had already 
provided consent to take part in the process evaluation as part of their initial consent to 
become mappers.  
 
2.9.5 Data collection, transcription and storage 
All researchers were trained in qualitative interviewing ahead of data collection to ensure 
consistency of approach. Resident interviews were brief, using a conversational style 
informed by a flexible interview schedule. Staff and relative/friend interviews were conducted 
using a semi-structured format informed by a topic guide. The interviews focused on 
experiences of DCM™ implementation, with prompts to encourage interviewees to discuss 
the various stages of DCM™ implementation, the successes, challenges and impacts of 
implementation, and any changes required to improve DCM™ implementation or impact in 
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the care home, as well as future plans for DCM™ within the care home. Mappers who had 
left the home during the trial were not interviewed. Relatives/friends of resident participants 
who had died during the trial were not contacted regarding the process evaluation 
interviews. Interviews were conducted within the care homes, in a private room with no other 
individuals present and an alternative method of telephone interviews was offered to all 
relatives/friends (see Supplementary Materials for copies of interview topic guides). 
The interviews were audio recorded using a digital audio recording device and were 
professionally transcribed by a researcher independent to the study. Any potentially 
identifying information about the participants was anonymised or removed during 
transcription. Audio files were securely transferred in encrypted format and stored securely 
on computers in University offices. 
 
2.9.6 Data analysis 
Data analysis utilised a Framework Analysis approach. 154 Initial data analysis by all 
researchers involved in data collection informed the development of a coding matrix which 
guided and created a structure for further data analysis. The focus of the coding matrix (and 
therefore the data analysis) was on experiences of utilising and implementing DCM™, with a 
focus on identifying patterns and variations in implementation, barriers and facilitators to 
implementation, and the impacts of DCM™ implementation. The coding matrix helped to 
assimilate the development of coding categories between the team of researchers who 
undertook the analysis. Each transcript was independently analysed by two researchers to 
ensure key themes were identified. Development of the coding categories continued 
throughout data analysis, informed by the emerging themes and analytic thoughts of the 
researchers. Codes and themes were compared and contrasted across homes and between 
different types of respondents to develop an in-depth, nuanced and contextualised 
understanding of the implementation and impacts of DCM™. 
The quantitative data that informed the process evaluation (measures of adherence and 
fidelity in each home) were collected and analysed as part of the main trial dataset (as 
described in section 2.8.3). Findings from the quantitative data were integrated with the 
qualitative data to provide an in-depth understanding of DCM™ implementation, and the 
issues surrounding implementation. 
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2.9.7 Measurement of adherence  
Adherence to the prescribed processes for intervention delivery was monitored from 
randomisation to check that both mappers attended DCM™ training on time and passed the 
assessment. At each expected round of mapping, adherence to the processes was 
monitored to check that mappers delivered all components of the DCM™ cycle as intended 
and to the required quality (fidelity) and three full cycles (dose). Anonymised copies of all 
observation data collection sheets, feedback reports and action plans were collected to 
assess fidelity. Data was also collected from the DCM™ expert mapper about cycle one 
completion, following their support of mappers through their first cycle of mapping.  For the 
purposes of the trial DCM™ was considered as comprised of four required components: 1) 
briefing, 2) observation, 3) data analysis, reporting writing and feedback, 4) action planning. 
Care homes were classified according to their compliance with the intervention at each cycle 
as ‘Acceptable’, ‘Partial’ or ‘None’ compliance. 
For a cycle to be classified as: 
i) Acceptable, the care home must have completed all four components;  
ii) Partial, the care home had completed one to three components;  
iii) None, the care home had completed none of the components. 
If paperwork was not received for specific components and the researchers had been unable 
to ascertain verbally from mappers whether particular cycle components had been 
completed, the following rules were used to determine whether a component had been 
completed: 
• If there was paper documentation for observation, it was assumed that briefing also 
took place (at least 2 components were completed); 
• If there was paper documentation for feedback, it was assumed briefing and 
observation took place (at least 3 components were completed);  
• If there was paper documentation for action planning, it was assumed that briefing, 
observation and feedback took place (all components were completed). 
Assessment of the quality of each component was also conducted where paperwork had 
been returned including: whether all the required DCM™ coding frames and accompanying 
qualitative notes had been used during mapping; if the standard feedback report format had 
been used and all parts of this completed (group data summary and individual data summary 
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for each resident); and whether the standard action planning template had been used and if 
there were action plans developed at a care home level and for each resident mapped. 
 
2.10 Summary of changes to project protocol 
Ten substantial amendments to the protocol and associated trial documentation were made 
during the trial.  
2.10.1 Internal pilot  
An initial two homes were recruited to the study early to permit internal piloting and review of 
trial processes, procedures, measure and tools ahead of recruitment of further care homes. 
Data from these homes were included in the trial. Changes to the original project protocol, 
implemented following this pilot are reported in detail in the published protocol 98, in Table 3 
and the Appendix (see Appendix 2).  
2.10.2 Design change 
Our original sample size estimation, to detect a clinically important difference of 3 points (SD 
7.5) in the primary endpoint of agitation using the CMAI questionnaire assumed a 25% loss 
to follow-up at 16-months after care home randomisation. If loss to follow-up was higher than 
anticipated (but no greater than 35%), our intended sample size of 750 residents still 
provided more than 85% power at a 2-sided 5% significance level to detect a moderate 
effect size, equating to 0.4 SDs. 
Through monitoring loss to follow-up within the trial, we determined by November 2015 that 
the rate would exceed our lower limit of 25%. Using data from care homes randomised into 
the trial up to the 27th November 2015, we predicted that loss to follow-up at 16-months 
would be in the range of 32% to 48%, see Appendix 3, Figures 10 and 11. As such, 
continuing the trial as planned would not provide sufficient power for statistical analysis of 
the primary endpoint. An amendment to the trial design was required to ensure the results of 
trial were robust and generalizable. Based on consideration of all the available options, we 
proposed recruiting additional residents at follow-up (i.e. move to an “open cohort” design) 
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Table 3: Summary of substantial amendments to the protocol as associated trial documentation 
Amendment 
number 
Date Summary of amendment 
SA1 10/1/2014 Modification to method and content of health resource data to be collected including from medical records and 
NHS Digital (previously Health and Social Care Information Centre)  
SA2 22/4/2014 Modifications to care home information sheet to improve clarity and provide additional information following 
review by the PPI panel 
SA3 26/6/2014 Modifications to: care home recruitment process; resident, staff and relative eligibility criteria; screening of proxy 
informants; clarification of mutually exclusive staff roles; translation of trial documentation; amendment of 
assessment measures to be used; process for completion of independent assessments; monitoring of DCM™ 
implementation; relative/friend withdrawal; resident safety monitoring; establishment of a DMEC; information 
included on participant information sheets and consent (mapper, staff proxy and resident including consultees) 
documents; and development of a short form of the resident information sheet.  
SA4 10/9/2014 Personal Consultee introductory letter and reminder; and relative/friend proxy informant introductory letter 
approved. 
SA5 15/1/2015 GP letter to accompany guidance on antipsychotic prescribing approved 
SA6 15/1/2015 Change of sponsor; modification to care home eligibility criteria; modification to resident eligibility criteria; 
modification to randomisation stratification criteria. 
SA7 22/10/2015 Modification to requirements for witnessing resident consent; addition of text message reminders for mappers; 
and modifications to participant information sheets and consent forms  
SA8 4/2/2016 Detail added to the protocol on conduct of the process evaluation; modifications to staff measures booklet; 
modification to continued attempts to recruit relative/friend proxy informants post-baseline; and modifications to 
participant information sheets.  
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SA9 15/4/2016 Change to open cohort design, additional recruitment of resident participants at 16-month follow up and 
associated changes to trial documentation approved; modification to staff proxy informant consent processes; 
modification regarding requirements to check care home indemnity insurance; introduction/modification of 
documents to support process evaluation and to proposed process evaluation methods and processes; and 
modification to process for assessing ongoing capacity of Personal Consultees. 
SA10 25/7/2016 Modification to data collected during process evaluation; additional text messages to remind mappers about 
mutually exclusive staff roles.  
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(See Appendix 3). All those consenting to take part (residents already participating in the trial 
and consented at baseline, as well as additional residents consenting at 16-months), 
provided data at 16-months.  
The key impact of this design change was to increase the size of the cohort at follow-up to 
maintain the power of the trial and its ability to detect the effect size of 0.4 with 90% power, 
see Appendix 3, Table 67.  
2.10.2.1 Sample size calculations 
With an estimated 48% loss to follow up, we expected to lose 360 residents before 16-month 
follow-up, resulting in data at all three time-points from 388 residents. All the other 
parameters – significance level, 2-sided test, ICC of 0.1 remained the same. Consideration 
was given to recruiting only a proportion of eligible residents at each home at 16-months).  
Three possible scenarios of additional recruitment were considered (an average of 3 
additional residents per care home; recruiting 35% of residents lost at follow up in each care 
home; replacing only 25% of residents lost to follow up in each care home) and all provided 
sufficient power to detect the effect size of 0.4 (89%, 91%, 90% power respectively). The 
TMG, oversight committees (TSC and DMEC) and funder agreed that imposing a 
recruitment ceiling at 16-months would be open to selection bias, and that statistical power 
and the ability to generalise could be limited. Recruitment processes could also be 
protracted due to allowing time for decision-making via personal consultee i.e. should this be 
a refusal to take part, further resident-consultee dyads would then need to be approached, 
so considerably lengthening the recruitment process, researcher workload and thus cost. 
Researchers were therefore, instructed to recruit as many residents as possible in order to 
minimise bias. Numbers were monitored to ensure at least three extra residents from each 
remaining care home were recruited.  
Benefits of the design change were:  
a) ability to detect intervention effects at the care home level (as the intervention is aimed at 
the whole care home);  
b) conclusions could be generalised to a broader population of residents (i.e. not just to 
those still residing in the care home 16-months following randomisation);  
c) we would be able to analyse the data for a cross-sectional (i.e. open cohort) and closed 
cohort (longitudinal) design;  
73 
 
d) we minimised selection bias by providing an objective criterion for inclusion (all eligible 
consenting residents);  
e) recruitment processes were resource-efficient since all eligible residents were approached 
to participate at a single time-point; and 
f) we would be less reliant on assumptions around imputation for missing data. 
As well as maintaining power and increasing generalisability, the agreed design change 
incurred minimal additional cost.  
Three of the authors (RW, AF, CS) have since secured additional funding from the Medical 
Research Council 155 to conduct a methodology ‘bolt on’ to EPIC around the use of open-
cohort designs in clinical trials. This recognises the importance of considering alternative trial 
designs for the conduct of studies in populations with potential large loss to follow-up rates. 
 
2.10.2.2 Resident eligibility (16-months post randomisation) 
The following inclusion criteria were applied for additional residents recruited at 16-month 
follow-up: a permanent resident within the care home or unit(s) taking part in the trial; had a 
formal diagnosis of dementia or scored 4+ on FAST 102 rated by the home manager or 
another experienced member of staff; and had sufficient proficiency in English to contribute 
to the data collection required for the research. Residents were not eligible if they: were 
already a DCM™ EPIC Trial participant; declined (personally or via Personal or Nominated 
Consultee) trial participation at baseline; moved to the care home (or participating EPIC unit) 
less than three-months prior to screening; were known by the care home manager and/or 
relevant senior staff member to be terminally ill, e.g. formally admitted to an end of life care 
pathway; were permanently bed-bound/cared for in bed; and were taking part in or had 
recently taken part in another trial that conflicted with the DCM™ intervention or with data 
collection for the DCM™ EPIC trial. 
 
2.11 Resident safety 
Given the intervention was at the care home level, was very low risk and non-invasive, and 
that trial consent was for data collection, minimal reporting of safety data was required. 
Given the trial population was care home residents with dementia, adverse events (AEs) 
were expected as part of usual care and therefore, only data on adverse events serious in 
nature (SAEs) were collected on consented trial residents.  
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A serious adverse event (SAE) was defined as an untoward event which resulted in death, 
was life threatening, required or prolonged existing hospitalisation, was significantly or 
permanently disabling or incapacitating, or was otherwise considered medically significant by 
a clinician. It was expected that residents would be admitted to hospital in the event of an 
SAE, therefore the safety reporting form collected information on hospitalisation, including 
reason, duration, and outcome. All deaths occurring from the date of consent up to the last 
data collection visit were recorded on a trial death form and reported electronically to CTRU 
within one working day of becoming aware. These data were collected by the researcher, 
monthly via a phone call to the care home manager/research lead from point of 
randomisation to completion of 16-month follow-up. Summaries of SAEs were reviewed 
annually by the trial DMEC.  
Any SAE occurring to a resident which, in the opinion of the care home manager/lead and 
Chief Investigator, was related to research procedures and was unexpected, required 
reporting to the main Research Ethics Committee (main REC). 
 
2.12 Safeguarding  
It was possible the researchers might observe poor or potentially abusive practice while 
visiting care homes participating in the trial. The definition of abuse detailed in the 
Department of Health 156 guidance was utilised. In the case of observing suspected abuse 
the relevant Local Authority Safeguarding Adults processes were followed following 
discussion of the incident between the researcher and the recruitment centre lead/Chief 
Investigator. 
 
2.13 Patient and Public Involvement 
Patient and Public Involvement (PPI) was embedded in both the design and conduct of the 
trial, through both lay advisors on the investigator team and a Lay Advisory Group (LAG). 
The main focus was ensuring that PPI input was meaningful and a PPI strategy was written 
at the beginning of the trial to outline how their contribution was envisaged. 
 
2.13.1 Lay advisors  
Three dedicated lay advisors were part of the investigator team, one individual as a member 
of the TSC and two as members of the TMG (one of whom was also a co-applicant). These 
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individuals provided a user perspective on the design and conduct of the trial. They attended 
regular meetings throughout the trial and ensured that the TMG considered issues of 
importance to people living with dementia, their families and people working in care homes. 
Examples of advice included simplification of participant information and provision of 
assistance to the researchers to do this, and suggestion that a short, pictorial version of the 
resident information sheet was developed. These individuals also reviewed newsletters 
before they were circulated, making suggestions such as increased font size to improve 
accessibility of these to families of people living in care homes. The lay advisors collaborated 
on the development and writing of a trial summary which was prepared for care home 
managers. They also supported preparation of this section on PPI involvement. 
 
2.13.2 Lay Advisory Group 
The LAG was recruited through a partnership agreement with the Alzheimer’s Society, who 
hosted the LAG meetings. The LAG consisted of eight members comprising a person living 
with dementia, relatives of people living with dementia, the Manager of a care home, a 
person working for a Care Organisation and a representative from the Alzheimer’s Society. 
The LAG met three times during the process of the trial to discuss progress, initial results 
and dissemination strategies. A fourth meeting was held to discuss final trial outputs in 
February 2018, following completion of the trial in December 2017.  
Alongside attendance at LAG meetings, individuals provided review of trial documents such 
as information sheets and consent forms prior to ethical approval being sought. Individuals 
from the group also reviewed the intervention protocols. All trial newsletters were reviewed 
by the LAG prior to distribution. Members of the LAG had the opportunity to review the 
publication plan and be involved with all publications arising from the study. The decision on 
whether to be involved in each publication was based on if, as a group, members considered 
that it would be beneficial for a PPI representative to be involved and if it was relevant for 
them to provide input.  
The LAG was responsible for devising the non-academic dissemination strategy for the trial. 
Such avenues for dissemination included practitioner articles, a lay article for the Alzheimer’s 
Society magazine, infographics and radio interviews as well as dissemination on social 
media. The LAG will continue to be involved in the design and dissemination of these 
publications including the design of the trial results summaries and posters for care home 
and individual trial participants (i.e. residents, relatives/friends, staff members etc.).   
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Chapter 3: Results  
 
3.1 Recruitment and randomisation 
3.1.1 Cluster recruitment 
The number of care homes randomised, and residents registered, are summarised in Figure 
1 by treatment arm, at baseline, 6- and 16-months following randomisation for the original 
cohort and the cross-sectional sample.  
A total of 335 care homes were screened for entry into the trial. Of these, 241 randomly 
sampled care homes were approached and 94 homes expressing interest were formally 
assessed using the eligibility criteria. Of the 63 eligible care homes, 51 consented to take 
part and, following one consent withdrawal, 50 care homes were randomised into the trial 
(21 from Yorkshire, 15 from London and 14 from Oxford, see Appendix 1, Table 26). 
Nineteen care homes (38.0%) were randomised to control and 31 (62.0%) to intervention. 
Care homes were randomised over 16-months from October 2014 until January 2016.  
 
3.1.2 Resident participant flow and recruitment 
3.1.2.1 Original cohort 
A total of 1564 residents were screened for eligibility from consenting care homes, 1069 
(68.4%) were eligible, 781 (73.1%) were consented, 743 (95.1%) were registered, and 726 
(97.7%) were consented and registered at the point of care home randomisation. The 
reasons for exclusion from the trial are summarised overall and by hub in the Appendix 1, 
Table 27. Residents in the original cohort were registered over 15-months from October 
2014 until December 2015. 
3.1.2.2 Additional resident recruitment at 16-months 
Following the approved design change, a further 1444 residents were screened from 48 care 
homes at 16-months post-randomisation (see Appendix 1, Table 27). This included all 
already participating residents and those who had declined to take part when approached at 
baseline, who were then recorded as ineligible, alongside participants failing to meet other 
eligibility criteria. The first two care homes randomised did not screen additional residents as 
agreement for the design change was received after these care homes had completed 16-
month follow-up. Of the 1444 residents, 421 were eligible, 266 consented and 261 residents 
were subsequently registered (99 residents in control homes and 162 in intervention homes). 
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A lower proportion of residents in London were ineligible due to being permanently bed-
bound or terminally ill.  
There was a higher proportion of ineligible residents of those screened (due to not having a 
formal diagnosis of dementia), and consent refusals in the intervention compared to control 
arm (see Appendix 1, Table 28). The additional residents were screened over 11-months 
from June 2016 until May 2017.  
 
3.1.2.3 Cross-sectional sample 
Overall at 16-months, a total of 675 residents were included in the cross-sectional sample: 
414 residents from the original cohort who reached 16-months and 261 additionally-recruited 
residents. There were regional differences between hubs in resident ethnicity and funding 
type, with London reporting the lowest proportion of white residents and Oxford reporting the 
highest proportion of Local Authority funding (see Appendix 1, Table 29). 
 
3.1.2.4 Investigation into potential recruitment bias of additional residents 
As the additional residents for the cross-sectional sample were recruited following care 
home randomisation, age, gender, ethnicity, length of stay in care home and funding type 
were compared for all screened and registered residents (see Table 4). Overall, there was a 
shorter length of stay in the additional cohort compared to the original cohort, as was 
expected. Of the 726 residents included in the original cohort, 145 (20.0%) consented 
themselves; 263 (36.2%) were consented by a Personal Consultee and 318 (43.8%) by a 
Nominated Consultee (see Appendix 1, Table 30). In contrast, of the 261 residents recruited 
at 16-months, 58 (22.2%) consented themselves, 73 (28.0%) were consented by a Personal 
Consultee and 130 (59.8%) by a Nominated Consultee. There was no difference by arm in 
the proportion of residents who consented for themselves, but a higher proportion were 
consented by Nominated Consultees in the intervention arm (87, 53.7%) relative to the 
control arm (43, 43.4%). 
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Figure 1 Care Home and Resident CONSORT Diagram 
BASELINE 
Residents died, n=55 
Residents withdrawn, n=0 
Residents moved out, n=7 
No CMAI score at 6-months, n=2  
 
CARE HOMES 
Screened 335 CHs not approached, as sufficient 
number reached in area – 37 (11.0% 
of screened)  
Approached  
241/335 (71.9%) 
 
No response – 40 (16.6% of approached) 
(Several attempts at contact failed) 
Not interested – 107 (44.4% of 
approached) 
29 (27.1%) Not interested in research 
27 (25.2%) Organisation declined 
11 (10.3%) No/New manager 
10   (9.3%) Too busy 
  6   (5.6%) Care home closed 
  4   (3.7%) Taking part in other research 
  4   (3.7%) Ineligible 
  4   (3.7%) Not interested in intervention     
  2   (1.9%) Other 
Interested  
94/241 (39.0%) 
Not eligible – 31 (33.0% of interested) 
22 (71.0%) Insufficient n of dementia 
residents  
  5 (16.1%) Has used DCMTM in last 18 
months  
  2 (6.5%) Not suitable for participation (i.e. 
CQC status, admissions ban) 
1 (3.2%) Staff unavailable to attend DCM                       
training   
1 (3.2%) Involved in conflicting research 
 
Eligible  
63/94 (67.0%) 
Not consented - 12 (19.0% of eligible) 
4 (33.3%) Staffing issues 
3 (25.0%) Declined 
1   (8.3%) Care home being sold 
1   (8.3%) Care home under 
administration 
1   (8.3%) No response from care home 
1   (8.3%) Care home not required, 
sufficient number reached in area 
1   (8.3%) Could not recruit minimum 
number of residents 
 
Consented  
51/63 (80.9%) 
Randomised  
50 CARE HOMES and 
726 RESIDENTS 
registered  
at randomisation  
Withdrawn prior to randomisation – 1 
(2.0%) 
1 (100%) Staffing issues 
No longer eligible – 57 (17.1% of Screened) 
36 (63.2%)   CQC Status 
14 (24.6%)   Insufficient n residents with 
dementia  
 2 (3.5%)   Insufficient n permanent residents 
 1 (1.8%)   Participating in conflicting trial 
 4 (7.0%)   Other 
RESIDENTS 
Screened 1564 
Eligible    1069/1564 (68.4%) 
Consented 781/1069 (73.1%) 
Registered 743/781 (95.1%) 
CONTROL 
Care Homes, n=19 
Assessed, n=308 residents 
Median (min, max) = 14 (9, 36) 
residents/home 
INTERVENTION 
Care Homes, n=31 
Assessed, n=418 residents 
Median (min, max) = 13 (8, 21) 
residents/home 
Residents died, n=65 
Residents withdrawn, n=1 
Residents moved out, n=16 
No CMAI score at 6-months, 
n=2  
Care Homes, n=19 
Assessed, n=244residents (closed-cohort) 
Median (min, max) = 11 (5, 25) 
residents/home 
Care Homes, n=31 
Assessed, n=334 residents (closed-cohort) 
Median (min, max) = 10 (5, 19) 
residents/home  
6 MONTHS 
FOLLOW-UP 
16 MONTHS 
FOLLOW-UP 
(PRIMARY) 
 
Care homes withdrawn from intervention, n=0 
Residents died, n=54 
Residents withdrawn, n=1 
Residents moved out, n=6 
No CMAI score at 16months, n=0  
  
Care homes withdrawn from intervention, n=2 
Residents died, n=92 
Residents withdrawn, n=0 
Residents moved out, n=22 
No CMAI score at 16-months, n=2  
  
Care Homes, n=31 
Registered, n=226 residents and 
Assessed, n=220 residents (closed-cohort) 
Median (min, max) =7 (1,12)   
   residents/home 
Registered, n=162 residents (additional) and 
n=388 residents (cross-section) 
Median (min, max) = 12 (5, 24)  
   residents/home 
Assessed, n=382 residents (cross-section)  
  
Care Homes, n=19 
Registered, n=188 residents and 
Assessed, n=185 residents (closed-cohort) 
Median (min, max) = 9  (4, 19)   
   residents/home 
Registered, n=99 residents (additional) and 
n=287 residents (cross-section) 
Median (min, max) = 12 (4, 34)    
   residents/home 
Assessed, n=284 residents (cross-section)  
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Table 4 Characteristics of Screened Residents Overall and by Arm 
 
Original Cohort           Additional 
Screened Registered Screened* Registered 
Total 
(n=1564) 
Control 
(n=308)  
Interventio
n (n=418) 
Total 
(n=726) 
Control 
(n=275) 
Interventio
n (n=602) 
Total 
(n=877) 
Control 
(n=99) 
Interventio
n (n=162) 
Total 
(n=261) 
Age at 
registration 
(years) Mean (SD) 
85.1 (8.18) 85.2 (7.37) 85.9 (7.83) 85.6 (7.64) 85.1 (7.51) 85.1 (8.36) 85.1 (8.10) 84.6 (7.69) 85.9 (8.09) 85.4 (7.95) 
Length of stay in 
care home 
(years)  
Mean (SD) 
2.3 (2.48) 2.3 (2.14) 2.4 (2.47) 2.3 (2.34) 1.3 (1.84) 1.7 (2.29) 1.6 (2.17) 1.2 (1.01) 1.5 (1.72) 1.4 (1.50) 
Sex Female N (%)  1140 
(72.9%) 
244 (79.2%) 292 (69.9%) 536 (73.8%) 202 (73.5%) 423 (70.3%) 625 (71.3%) 68 (68.7%) 118 (72.8%) 186 (71.3%) 
Ethnicity N (%) Missing 
White 1483 
(94.8%) 26 
302 (98.1%) 400 (95.7%) 702 (96.7%) 271 (98.5%) 
2 
575 (95.5%) 
4 
846 (96.5%) 
6 
99 (100.0%) 158 (97.5%) 257 (98.5%) 
Other 55 (3.5%) 6 (1.9%) 18 (4.3%) 24 (3.3%) 2 (0.7%) 23 (3.8%) 25 (2.9%) 0 (0.0%) 4 (2.5%) 4 (1.5%) 
Funding type N (%)  
Local Authority 741 (47.4%) 128 (41.6%) 224 (53.6%) 352 (48.5%) 113 (41.1%) 291 (48.3%) 404 (46.1%) 52 (52.5%) 74 (45.7%) 126 (48.3%) 
Continuing 
Healthcare 
115 (7.4%) 28 (9.1%) 20 (4.8%) 48 (6.6%) 5 (1.8%) 16 (2.7%) 21 (2.4%) 1 (1.0%) 1 (0.6%) 2 (0.8%) 
Self-funded 555 (35.5%) 133 (43.2%) 156 (37.3%) 289 (39.8%) 94 (34.2%) 224 (37.2%) 318 (36.3%) 33 (33.3%) 75 (46.3%) 108 (41.4%) 
Local Authority 
and self-funded 
69 (4.4%) 17 (5.5%) 17 (4.1%) 34 (4.7%) 26 (9.5%) 42 (7.0%) 68 (7.8%) 13 (13.1%) 12 (7.4%) 25 (9.6%) 
Missing 84 (5.4%) 2 (0.6%) 1 (0.2%) 3 (0.4%) 37 (13.5%) 29 (4.8%) 66 (7.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
*Excluding those already participating in EPIC or those that were screened at baseline but refused consent. 
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3.1.3 Staff recruitment 
There was a very poor return rate of staff questionnaire booklets (see Appendix 1, Table 31) 
despite the changes made to encourage return rates i.e. removal of the GHQ12 and 
personal data (see section 2.10). Following consultation with oversight committees, it was 
agreed that persistence with obtaining staff data was important as the intervention was 
designed to effect a ‘whole-home’ change. However, due to low return rates, planned 
statistical analyses could not be conducted.  
3.1.4 Relative/friend recruitment 
At baseline, 197 relatives/friends were registered to the trial with 96 in the control arm and 
101 in the intervention arm. This reflects a larger proportion in the control arm given the 2:3 
randomisation allocation. The total number of relatives/friends registered to the trial reduced 
at 6-months (n=170, control=85, intervention=85) and 16-months (n=118, control=63, 
intervention=55) (see Appendix 1, Table 32) as might be expected with the high loss to 
follow-up rates. It was agreed by the oversight committees that, given the low percentage of 
data received, these data would not be useful when undertaking statistical analyses, with the 
exception of some of the health economic analyses (see section 2.8.9). New relative/friend 
informants were therefore not identified at follow-up. Where relatives/friends agreed to take 
part at baseline, we continued to request their follow-up data.  
 
3.2 Baseline data 
3.2.1 Care Home characteristics 
At baseline, on average the intervention arm homes were larger than control. However, the 
average proportion of permanent residents with dementia was higher in the control arm.  
Care home managers had similar work experience and training across both arms (Table 5) 
A slightly higher than anticipated number of care homes (n=13, 26%) 99 needed PCCT 
training ahead of baseline data collection due to not meeting minimum criteria on the ADAPT 
audit tool.   
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Table 5 Baseline care home and care home manager characteristics 
 Control (n = 19) Intervention (n = 31) Total (n = 50) 
Unit type (N (%) missing)   - General residential/nursing home 11 (57.9%) 0 20 (64.5%) 0 31 (62%) 0 
                                              - Specialist dementia care home/unit 8 (42.1%) 0 11 (35.5%) 0 19 (38%) 0 
More than one unit (N (%) missing) 3 (15.8%) 0 3 (9.7%) 0 6 (12%) 0 
DCM™ was used between 18-months to 5 years (N (%) missing) 11 (57.9%) 0 20 (64.5%) 0 31 (62%) 0 
Residents' meeting held within the last 6-months (N (%) missing) 17 (89.5%) 0 30 (100%) 1 47 (95.9%) 1 
Relatives' meeting held within the last 6-months (N (%) missing) 18 (94.7%) 0 29 (96.7%) 1 47 (95.9%) 1 
Number of beds in the care home (Mean (SD) missing) 28.8 (8.97) 2 36.8 (14.28) 1 33.9 (13.1) 3 
Number of permanent residents (Mean (SD) missing) 30 (11.27) 0 32.9 (14.02) 1 31.8 (12.98) 1 
Percentage of permanent residents with dementia (Mean (SD) missing) 83.1 (21.21) 0 74.2 (22.48) 1 77.7 (22.21) 1 
Percentage of self-funded residents (Mean (SD) missing) 52.8 (28.12) 0 37.9 (21.12) 1 43.7 (24.89) 1 
Cost of a self-funded place per year (£) (Mean (SD) missing) 44553 (13291) 0 41638 (13003) 1 42768 (13056) 1 
Average resident:staff ratio daytime (Median (Range) Missing) 5.2 (3.0, 8.8) 0 4.7 (2.5, 10.5) 1 4.8 (2.5, 10.5) 1 
Average resident:staff ratio night time (Median (Range) Missing) 9.5 (3.3, 17.5) 0 9.7 (2.9, 15.3) 1 9.7 (2.9, 17.5) 1 
Care Home manager    
Time in current role (Median (Range)) 2.5 (0.3, 37.0) 2.9 (0.3, 25.0) 2.6 (0.3, 37.0) 
Length of time worked in care homes (N (%))    
Up to 10 years 3 (15.8%) 7 (22.6%) 10 (20.0%) 
More than 10 years 16 (84.2%) 24 (77.4%) 40 (80.0%) 
Length of time in a manager role (N (%))    
- Up to 2 years 3 (15.8%) 7 (22.6%) 10 (20.0%) 
- Up to 5 years 5 (26.3%) 4 (12.9%) 9 (18.0%) 
- Up to 10 years 2 (10.5%) 5 (16.1%) 7 (14.0%) 
- More than 10 years 9 (47.4%) 15 (48.4%) 24 (48.0%) 
Manager dementia training/education    
Previously trained as a dementia care mapper by UoB 3 (15.8%) 4 (12.9%) 7 (14.0%) 
Dementia specific qualification 4 (21.1%) 10 (32.3%) 14 (28.0%) 
Dementia covered in one part of a qualification 10 (52.6%) 18 (58.1%) 28 (56.0%) 
Attended a dementia specific training course 19 (100.0%) 31 (100.0%) 50 (100.0%) 
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Table 6 Resident characteristics 
Original cohort at baseline 
Control              
(n = 308) 
Intervention           
(n = 418) 
Total             
(n = 726) 
Age at randomisation Years (Mean 
(SD) missing) 
85.3 (7.38) 0 86 (7.83) 0 85.7 (7.64) 0 
Gender Male (%) 64 (20.8%) 126 (30.1%) 190 (26.2%) 
Number of comorbidities per 
resident (Median (Range))  
2 (0, 10) 2 (0, 14) 2 (0, 14) 
Selected comorbidities*Anxiety 34 (11.0%) 23 (5.5%) 57 (7.9%) 
                                        Depression 62 (20.1%) 55 (13.2%) 117 (16.1%) 
                                        Psychosis 16 (5.2%) 24 (5.7%) 40 (5.5%) 
                                        Sleep      
                                        disturbance 
6 (1.9%) 7 (1.7%) 13 (1.8%) 
                                        Delirium 3 (1.0%) 2 (0.5%) 5 (0.7%) 
FAST stage (out of completed 
scores) 
(n=306) (n=391) (n=697) 
1 2 (0.7%) 0 (0.0%) 2 (0.3%) 
2 2 (0.7%) 0 (0.0%) 2 (0.3%) 
3 1 (0.3%) 1 (0.3%) 2 (0.3%) 
4 39 (12.7%) 56 (14.3%) 95 (13.6%) 
5 26 (8.5%) 48 (12.3%) 74 (10.6%) 
6 166 (54.2%) 214 (54.7%) 380 (54.5%) 
7 70 (22.9%) 72 (18.4%) 142 (20.4%) 
Cross-section at 16-months 
Control            
(n = 287) 
Intervention          
(n = 388) 
Total             
(n = 675) 
Age at randomisation Years (Mean 
(SD) missing) 
83.7 (7.77) 0 85.2 (7.79) 0 84.6 (7.81) 0 
Gender Male (%) 71 (24.7%) 110 (28.4%) 181 (26.8%) 
Number of comorbidities per 
resident (Median (Range)) 
2 (0, 7) 3 (0, 12) 2 (0, 12) 
Selected comorbidities*Anxiety 26 (9.1%) 27 (7.0%) 53 (7.9%) 
                                        Depression 64 (22.3%) 66 (17.0%) 130 (19.3%) 
                                        Psychosis 11 (3.8%) 21 (5.4%) 32 (4.7%) 
                                        Sleep  
                                        disturbance 
2 (0.7%) 5 (1.3%) 7 (1.0%) 
                                        Delirium 2 (0.7%) 2 (0.5%) 4 (0.6%) 
FAST stage (out of completed 
scores) 
(n=284) (n=384) (n=668) 
4 22 (7.7%) 35 (9.1%) 57 (8.5%) 
5 20 (7.0%) 21 (5.5%) 41 (6.1%) 
6 168 (59.2%) 238 (62.0%) 406 (60.8%) 
7 74 (26.1%) 90 (23.4%) 164 (24.6%) 
*not mutually exclusive 
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3.2.2 Resident characteristics 
In the closed-cohort, the mean resident age at randomisation was similar between 
intervention and control arms (85.3 years in control, 86.0 years in intervention) (Table 6). A 
higher proportion of residents in the intervention were male (126, 30.1%) compared to 
control (64, 20.8%) and the median number of comorbidities was two in both arms, with the 
proportion of residents with no comorbidities similar across arms.  
In the cross-sectional sample, control residents were slightly younger compared to 
intervention residents (83.7 versus 85.2 years respectively). There was a higher proportion 
of residents with no reported comorbidities in control compared to intervention. Similar levels 
of dementia severity were observed in both arms, as measured by the FAST, although a 
lower proportion of residents had moderately severe to severe dementia (FAST stage 6-7) in 
the closed-cohort (74.9%) compared to the cross-sectional sample (85.4%) due to 
worsening of dementia of residents in the closed-cohort over time. 
 
3.3 Treatment summaries 
3.3.1 Control  
Organisational and staff changes reflecting usual care at a care home level are summarised 
in Table 7 for both arms, each compared to the previous time point. A higher proportion of 
care homes had experienced management changes in the intervention arm at 6-months, and 
a higher proportion of care homes had new staff roles introduced in the unit in the 
intervention arm. At both follow-up points, a higher proportion of intervention care homes 
achieved or completed standard quality assessments (e.g. ISA). Compared with control 
homes a smaller proportion of intervention care homes reported having staff with higher-
level dementia-specific qualifications at 6-months, but by 16-months a higher proportion of 
intervention homes reported staff with higher-level dementia-specific qualifications. 
3.3.2 Intervention 
Adherence to the intervention is reported by cycle and number of components completed 
(i.e. briefing; observation; analysis, reporting and feedback; and action planning) in Figure 2 
(see Appendix 1, Table 33 for further detail on adherence by care home), with the furthest 
reported component through the DCM™ cycle presented. Based on documented evidence, 
16 (51.6%) of care homes in the intervention arm completed only one cycle to an acceptable 
level, 4 (12.9%) completed two cycles to an acceptable level and 4 (12.9%) completed all 
three cycles to an acceptable level. Seven care homes (22.6%) did not complete a full 
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intervention cycle, with three (9.7%) of these not completing any of the intervention 
components. Further intervention component summaries are in Appendix 1 (see Tables 34-
40 and Figure 7). Due to challenges in getting return full adherence data from care homes, it 
was not possible to ascertain how many care home staff had engaged with the DCM process 
during each cycle and thus to assess intervention ‘dose’ in terms of reach. 
 
Table 7 Summary of changes in usual care  
 At 6-months (from baseline) At 16-months (from 6-months) 
N (%) Unknown 
Control      
(n=19) 
Interventio
n (n=31) 
Total          
(n=50) 
Control      
(n=19) 
Intervention 
(n=31) 
Total          
(n=50) 
Any organisational changes 4 (21.1%) 6 (19.4%) 10 (20.0%) 4 (21.1%) 6 (19.4%) 10 (20.0%) 
Any care home 
management changes 
5 (26.3%) 12 (38.7%) 17 (34.0%) 8 (42.1%) 13 (41.9%) 21 (42.0%) 
Any new staff roles 1 (5.3%) 6 (19.4%) 7 (14.0%) 3 (15.8%) 7 (22.6%) 10 (20.0%) 
Any new projects or 
initiatives 
5 (26.3%) 9 (29.0%) 14 (28.0%) 6 (31.6%) 12 (38.7%) 18 (36.0%) 
Any new voluntary 
measures to improve 
standards 
1 (5.3%) 3 (9.7%) 4 (8.0%) 0 (0.0%) 3 (9.7%) 3 (6.0%) 
Any standard quality 
assessments achieved 
3 (15.8%) 9 (29.0%) 12 (24.0%) 2 (10.5%) 6 (19.4%) 8 (16.0%) 
Currently subject to any 
CQC notifications 
2 (10.5%) 6 (19.4%) 8 (16.0%) 1 (5.3%) 1 (3.2%) 2 (4.0%) 
PCC training available in 
unit 
18 (94.7%) 29 (93.5%) 47 (94.0%) 16 (84.2%) 
1 
31 (100.0%) 47 (94.0%)  1 
Staff with higher level 
dementia-specific 
qualification 
10 (52.6%) 12 (38.7%) 
1 
22 (44.0%) 
1 
10 (52.6%) 20 (64.5%) 30 (60.0%) 
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Figure 2: Completion of intervention components by cycle 
3.4 Losses and exclusions after randomisation  
3.4.1 Withdrawals 
Two care homes in the intervention arm withdrew from further trial treatment but not from 
further data collection in months 11 and 12, respectively. One resident from the closed-
cohort withdrew consent for all data collection in the intervention arm (withdrawn by personal 
consultee in month 2). There were four staff-proxy withdrawals, one in each arm at 6- and 
16-months follow-up. There were four relative/friend withdrawals, one in the control arm (at 
16-months follow-up) and three in the intervention arm (one at 6-months and two following 
16-months follow-up). 
3.4.2 Protocol violations 
There were two care home eligibility violations identified and reported in first two-months 
following randomisation (one in each arm). Both related to changed CQC status, between 
recruitment and randomisation. In both cases, the chief investigator agreed to the care 
homes continuing in the trial and were included in the ITT analysis. Five staff eligibility 
violations were reported in the intervention arm, involving individuals who undertook both 
mapper and staff-proxy roles.  
3.4.3 Resident deaths in closed cohort 
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Seventeen resident deaths occurred between care home registration and randomisation 
(See Appendix 1, Table 41); the remaining 726 residents constitute the original cohort. 
Overall, there were 272 (37.5%) deaths reported between randomisation and the end of 16-
month follow-up in the original cohort, 111 (36.0%) in the control arm and 161 (38.5%) in the 
intervention arm (however, of these, primary outcome data was available for 2 (1.8%) in the 
control arm and 4 (2.5%) in the intervention arm). The majority of residents died in the care 
home (224/272, 82%), 89/308 (80.2%) in the control and 135/418 (83.9%) in the intervention 
arm. The mean proportion of deaths per care home in the control was 0.36 (SD=0.12) and 
0.39 (SD=0.14) in the intervention arm. 
 
3.5 Clinical effectiveness of the intervention 
3.5.1 Analyses of the primary outcome 
Analyses were conducted on the cross-sectional sample (primary) and the closed-cohort. 
Unadjusted scores are presented in Table 8 for the primary outcome (staff-proxy completed 
CMAI) and change in unadjusted scores from baseline is presented graphically in Appendix 
1, Figures 8 and 9. At baseline, the mean CMAI total score was higher in control (48.4 
points) compared to intervention (45.4 points) homes. In the closed-cohort at 6-months, the 
gap had closed, with means being 44.9 points and 43.6 points respectively in control and 
intervention homes (148/726 (20.4%) residents were lost to follow-up however). By 16-
months, the gap had widened again in the closed-cohort (although by this time 321/726 
(44.2%) residents were lost to follow-up), with means of 46.4 points and 41.4 points 
respectively in control and intervention care homes. The gap was slightly narrower in the 
cross-sectional sample (9/675 (1.3% lost to follow-up), with means of 46.1 points and 42.8 
points in the control and intervention homes respectively. Differences in means between the 
control and intervention homes are therefore small in both resident samples, largely arising 
from changes carried through from baseline.  
All 675 residents in the cross-sectional sample at 16-months were included in the primary 
analysis, 666 of which had complete data. There was no evidence of a difference in agitation 
levels between arms. The mean difference in total CMAI score from the two-level 
heteroscedastic linear regression model fitted to the multiply-imputed data (assuming data 
were MAR) was -2.11 points, lower in the intervention arm than in the control (adjusted 
means 45.47 points in control; 43.35 points in intervention, 95% CI -4.66 to 0.44, p=0.104). 
The unadjusted ICC was zero in the control and 0.058 in the intervention arm, but the 
adjusted ICC was zero in the control and 0.001 in the intervention arm, indicating that 
between-cluster heterogeneity in the intervention arm was explained by the covariates in the 
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model. Using the complete cases, the mean difference was -2.19 points lower for 
intervention compared to control homes (95% CI -4.81 to 0.43), the adjusted ICC was zero in 
both treatment arms, indicating that the treatment effect was neither clinically meaningful or 
statistically significant at the 5% level (p=0.099) (see Appendix 1, Table 45). The primary 
analysis is summarised in Table 10.  
 
3.5.1.1 Supportive and sensitivity analyses 
Unadjusted scores for the observational CMAI (CMAI-O) and PAS scores outcomes using in 
place of the CMAI by resident sample and time-point are presented in Table 9 (cross-
section) and Appendix 1, Tables 42 (closed cohort), 43 and 46-47 (complete cases). A 
similar pattern of differences was found for these supportive outcomes completed by the 
blinded independent researcher. The mean CMAI-O scores were consistently very slightly 
higher in the afternoon than in the morning. The same is the case for PAS scores. Loss to 
follow-up was higher for these supportive outcomes (about 276/726=38.0% at baseline, 
358/726=49.3% at 6-months, and 495/726=68.2% and 310/675=45.9% at 16-months in the 
closed-cohort and cross-section respectively) than for the primary outcome. 
The sensitivity and supportive analyses are summarised in Table 10 and Appendix 1, Table 
44, respectively. The key sensitivity analysis simplified the model fitted to ensure complete 
convergence and was added post-hoc. Sensitivity analyses on the CMAI for the subset of 
residents included in the analyses of the CMAI-O and PAS were also added post-hoc. The 
equivalent analyses on the complete cases are provided in Appendix 1, Tables 18 to 20. The 
key sensitivity analysis and the first three planned sensitivity analyses supported the results 
found in the primary analysis.  
Sensitivity analyses of the CMAI-O and the PAS indicated a potential over-estimation of the 
treatment effect from the primary analysis, as the mean differences are reduced when a 
blinded independent observation is made (analyses in rows 4a and 4c Table 10). However, 
we would expect the CMAI-O and PAS to potentially under-estimate agitation levels since 
they are conducted over only two observations periods in a single week, in public areas of 
the home during restricted daytime hours. The staff-proxy rating is made over two weeks 
and includes consideration of agitation during personal care, evening and the night-time. The 
sensitivity analysis conducted on the closed-cohort gave a mean difference of -3.25 (95% CI 
-6.13 to -0.37, p=0.027), apparently contradicting the conclusion of the primary analysis. 
However, the sensitivity analysis is not robust, as it relies on multiply imputing data for 45% 
of the sample. It has a different interpretation too, as this is the treatment effect estimated for 
residents who remain the in the care home from baseline to 16-months. A sensitivity analysis  
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Table 8 Unadjusted CMAI scores by resident sample and time-point 
Unadjusted CMAI scoresa by resident sample and time-point 
  Closed-cohort  
Mean (SD) Missing 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n = 726) 
Baseline Total score                           48.4 (19.53) 2 45.4 (15.95) 2 46.7 (17.6)   4 
Subscales:    
Aggressive behaviour 14.3 (8.10) 2 12.6 (6.28)   2 13.3 (7.16)   4 
Physically non-
aggressive 
11.6 (6.47) 8 11.3 (6.08) 10 11.4 (6.25) 18 
Verbally agitated 10.4 (6.23) 5 9.9 (5.94)   2 10.1 (6.06)   7 
Other 12 (4.58) 0 11.5 (3.73)   2 11.7 (4.12)   2 
6-months Total score                           44.9 (16.75) 64 43.6 (14.32) 84 44.2 (15.39) 
148 
Subscales:    
Aggressive behaviour 13.3 (7.21) 64 12.4 (6.14)   84 12.8 (6.62) 148 
Physically non-
aggressive 
10.5 (5.88) 68 10.6 (5.28) 100 10.6 (5.54) 168 
Verbally agitated 9.4 (5.42) 64 9.6 (5.42)   87 9.5 (5.42) 151 
Other 11.7 (3.95) 64 11 (3.26)   84 11.3 (3.58) 148 
16-months Total score                           46.4 (16.54) 
123 
41.4 (14.73) 
198 
43.7 (15.76) 
321 
Subscales:    
Aggressive behaviour 14 (7.66) 123 12.3 (5.9) 196 13 (6.8) 319 
Physically non-
aggressive 
11 (5.82) 124 9.2 (4.85) 205 10 (5.38) 329 
Verbally agitated 9.7 (5.55) 123 9 (5.63) 197 9.3 (5.60) 320 
Other 11.8 (4.05) 123 10.8 (3.08) 199 11.3 (3.59) 322 
  Cross-section  
Mean (SD) Missing 
Control 
(n = 287) 
Intervention 
(n = 388) 
Total 
(n = 675) 
16-months Total score                           46.1 (16.78) 3 42.8 (15.79) 6 44.2 (16.29)   9 
Subscales:    
Aggressive behaviour 13.7 (7.93) 3 12.2 (5.87)   4 12.9 (6.86)   7 
Physically non-
aggressive 
11 (6.01) 4 9.9 (5.36) 15 10.4 (5.67) 19 
Verbally agitated 9.8 (5.79) 3 9.7 (6.16)   5 9.7 (6.00)   8 
Other 11.5 (3.73) 3 11 (3.49)   7 11.2 (3.60)   0 
a
CMAI overall, range 29-203, higher score indicates higher frequency of agitated behaviour. CMAI subscales: Aggressive 
behaviour (range 9-63), Physically non-aggressive behaviour (range 6-42), Verbally agitated behaviour (range 5-35) and Other 
behaviour (range 9-63). 
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Table 9 Unadjusted observational CMAI and PAS scores for by time-point - cross-sectional cohort  
Unadjusted CMAI-Oa and PASb scores by time-point - cross-section 
 AM PM 
 
Mean (SD) N completed 
Control 
(n = 287) 
Intervention 
(n = 388) 
Total 
(n = 675) 
Control 
(n = 287) 
Intervention 
(n = 388) 
Total 
(n = 675) 
16-months CMAI-O Total Score                           31.1 (3.8)  156 30.5 (3.3)  209 30.8 (3.5)  365 31.4 (3.8)  148 31.1 (3.9)  206 31.2 (3.9)  354 
Subscales: Aggressive behaviour 9.3 (0.9)  156 9.3 (1.0)  209 9.3 (1.0)  365 9.3 (1.1)  148 9.3 (1.2)  206 9.3 (1.1)  354 
                   Physically non-
aggressive 
6.7 (1.4)  156 6.5 (1.5)  209 6.6 (1.4)  365 6.9 (1.5)  148 6.8 (1.9)  206 6.9 (1.8)  354 
                   Verbally agitated 5.8 (2.2)  156 5.5 (1.5)  209 5.6 (1.8)  365 5.8 (1.9)  148 5.7 (1.7)  206 5.7 (1.8)  354 
                   Other 9.3 (1.0)  156 9.2 (0.7)  209 9.2 (0.8)  365 9.3 (0.9)  148 9.3 (0.9)  206 9.3 (0.9)  354 
16-months PAS score 1.1 (1.9)  156 0.8 (1.7)  209 0.9 (1.8)  365 1.2 (1.9)  148 0.9 (1.8)  205 1.0 (1.8)  353 
aCMAI-O: scores 29-116, higher score indicates more frequent agitated behaviour, bPAS: range of 0-16, with higher scores representing higher levels of agitation 
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on the closed-cohort assumed data are missing not at random (MNAR). This explores the 
impact of assumptions about the missing data, looking at a range of plausible and potentially 
implausible scenarios in which there was a shift in the CMAI at 16-months of up to 40 points 
either way for residents that died, withdrew or moved away. This assumes that the scores for 
all residents with missing data would have shifted by the same number of points. The 
conclusions of the closed-cohort analysis remain unchanged for shifts of -40 to 5 points from 
the average CMAI at 16-months for those who died and any shift for those who withdrew 
(see Appendix 1, Table 48).  
Supportive analyses of the closed-cohort at 6- and 16-months (see Appendix 1 Table 44) 
indicate that there were no differences in CMAI, CMAI-O or PAS scores at 6-months, and no 
differences in CMAI-O and PAS scores at 16-months. Overall, these analyses confirm that 
the intervention is not superior to the control. 
A complier average causal effect (CACE) analysis of the cross-sectional sample, comparing 
care homes in the intervention arm that completed at least one cycle to an acceptable level 
with care homes that would have completed at least one cycle had the intervention been 
offered to them, gave a mean difference in CMAI score at 16-months of -2.5 points (95% CI   
-5.4 to 0.4, p=0.089). This indicates that the ITT estimate from the primary analysis is not 
dissimilar to the effect of completing at least one cycle to an acceptable level. The 95% 
confidence intervals are wider compared to the primary analysis and the CACE estimate is 
not statistically significant at the 5% level (p=0.089) (Table 11). The exploratory CACE 
analyses using other definitions of adherence indicate that the treatment effect may increase 
if care homes complete at least two DCM™ cycles to an acceptable level compared to 
completing only one cycle. While these analyses are suggestive of a dose-response 
relationship in which supporting adherence to the second and third cycle might result in a 
clinically meaningful effect, this would need to be confirmed by further research. 
The change in unadjusted CMAI scores for the care homes between baseline and 16-
months is presented by intervention adherence (the number of cycles completed to an 
acceptable level) in Figure 3. There was considerable variation in CMAI score changes 
between care homes completing zero, one, two and three acceptable cycles.   
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Table 10: Primary and sensitivity analyses assuming missing data are MAR – cross-sectional sample 
Analysis 
Adjusted 
Mean in 
Control  
Adjusted 
Mean in 
Intervention 
Estimated 
Mean 
Difference 
Lower 95% 
Confidence 
Limit 
Upper 95% 
Confidence 
Limit p-value 
Adjusted 
ICC for 
Intervention  
Adjusted 
ICC for 
Control  N 
Primary analysis 45.47                 43.35 -2.11 -4.66 0.44 0.104 0.001            0.000 675 
Sensitivity analyses (cross-sectional 
sample) 
        
Key sensitivity analysis (hub omitted from 
the model) 
46.02 43.78 -2.24 -4.91 0.42 0.099            0.010 675 
1. Adjusting for before-after eligibility 
change* 
44.82 42.69 -2.13 -4.71 0.45 0.105 0.002 0.000 675 
2. Care home size as a continuous variable  45.59 43.21 -2.38 -5.00 0.25 0.076 0.000 0.000 675 
3. Homogeneous clustering across arms 45.41 43.32 -2.09 -4.61 0.44 0.105           0.001 675 
4a. CMAI-O (AM) 31.00 30.41 -0.58 -1.62 0.45 0.269 0.215 0.006 675 
4b. CMAI on subset with CMAI-O (AM) 47.49 43.43 -4.06 -7.55 -0.57 0.023 0.016 0.001 365 
4c. CMAI-O (PM) 31.34 31.11 -0.22 -1.52 1.08 0.737 0.220 0.013 675 
4d. CMAI on subset with CMAI-O (PM) 47.49 43.43 -4.06 -7.55 -0.57 0.023 0.016 0.001 365 
4e. PAS (AM) 0.93 0.73 -0.20 -0.67 0.27 0.402 0.166 0.011 675 
4f. CMAI on subset with PAS (AM) 47.49 43.43 -4.06 -7.55 -0.57 0.023 0.016 0.001 365 
4g. PAS (PM) 1.17 0.89 -0.28 -0.96 0.41 0.429 0.299 0.018 675 
4h. CMAI on subset with PAS (PM) 47.49 43.43 -4.06 -7.55 -0.57 0.023 0.016 0.001 365 
5. CMAI at 16-months (closed-cohort) 46.4 43.16 -3.25 -6.13 -0.37 0.027 0.013 0.001 726 
*eligibility changed in December 2014 after first two care homes randomised 
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 Table 11: CACE analysis using various scenarios 
 Model Treatment 
Effect 
(SE) 
95%  
Confidence 
Interval 
p-
value 
CACE Analyses 
(documented and 
expert evidence), 
multiple imputation 
At least one cycle to an acceptable 
level 
-2.5 (1.5) -5.4 to 0.4 0.089 
At least one cycle to a partial level  -2.2 (1.3) -4.8 to 0.3 0.087 
One cycle only to an acceptable 
level 
-3.6 (2.2) -7.9 to 0.8  0.106 
At least two cycles to an acceptable 
level 
-8.5 (5.3) -18.9 to 2.0 0.112 
Complete Case CACE 
Analyses, sensitivity 
analyses 
At least one cycle to an acceptable 
level 
   
At least two cycles to an acceptable 
level 
-2.6 (1.4) -5.4 to 0.2 0.068 
At least one cycle to a partial level -2.2 (1.3) -4.8 to 0.3 0.087 
 
 
 
Figure 3 Change in CMAI score between baseline and 16-months by adherence to the 
intervention 
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3.5.2 Analyses of the secondary outcomes 
Analyses of the NPI-NH, PRN prescription medications, quality of life and quality of staff 
interactions were conducted on closed-cohort at 6-months and on the cross-sectional 
sample (primary) and the closed-cohort (supportive) at 16-months. Unadjusted scores are 
presented in Tables 12, 13, 14 and 15 by resident sample and time-point and Appendix 1, 
Tables 49-60.  
As can be seen in Table 12, at baseline, the proportions of residents experiencing behaviour 
staff may find challenging to support (BSC) (defined as presence of the following behaviours 
in the NPI-NH: agitation/aggression, depression/dysphoria, anxiety, apathy/indifference, 
disinhibition or irritability/lability) were similar across the intervention and control arm. 
However, the average NPI-NH score was higher in the control than intervention arm. 
Agitation/aggression was experienced by the highest proportion of residents across all time-
points and in both samples. At 16-months, the proportion of residents experiencing BSC was 
smaller in the intervention arm compared to control for both the cross-sectional and closed-
cohort samples. The average NPI-NH score was similar in both arms for both samples, 
having reduced more in the control arm from baseline. 
The percentage of residents prescribed antipsychotics on a PRN basis was low across time-
points at less than 1.6% (see Table 13), making it difficult to detect any differences between 
the arms. Quality of life was primarily measured using the QUALID staff-proxy. Data is 
presented on the resident-rated QOL-AD and the relative-proxy QUALID, however, this is for 
comparison only, due to the poor completion rates (see Table 14). There are no notable 
differences in the QUALID scores provided by staff-proxies at baseline, 6- or 16-months in 
either resident sample. This pattern is supported by the resident-rated QOL-AD and relative-
proxy QUALID.  
The proportion of positive interactions as measured by the QUIS (see Table 15) differed 
between arms at baseline and at 6-months, with a higher proportion of interactions 
experienced in the intervention; this difference in proportions was not evident at 16-months.   
 
 
94 
 
Table 12 Unadjusted NPI-NH scores and behaviours staff find challenging by resident sample and time-point 
 Scores Mean (SD) Missing 
Number experiencing the behaviour staff find challenging        N (%) 
completed 
CLOSED-COHORT 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n = 726) 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n = 726) 
Baseline Total NPIa score                           13 (13.95) 0 11.7 (12.35) 0 12.2 (13.06) 0    
Subscales*:    236 (76.6%) 308 325 (77.8%) 418 561 (77.3%) 726 
Agitation/Aggression 5.0 (2.85) 2 4.7 (2.86) 0 4.8 (2.85) 2 145 (47.1%) 308 192 (46.0%) 417 337 (46.5%) 725 
                  Depression/Dysphoria 4.1 (2.77) 0 3.6 (2.63) 2 3.8 (2.70) 2 92 (30.0%) 307 129 (30.9%) 418 221 (30.5%) 725 
                  Anxiety 5.2 (3.16) 2 3.9 (2.32) 3 4.5 (2.80) 5 80 (26.0%) 308 98 (23.5%) 417 178 (24.6%) 725 
                  Apathy/Indifference 5.4 (3.30) 1 5.2 (3.07) 1 5.3 (3.16) 2 91 (29.5%) 308 130 (31.2%) 417 221 (30.5%) 725 
                  Disinhibition 5.0 (3.29) 0 3.8 (2.62) 0 4.3 (2.97) 0 51 (16.6%) 308 65 (15.6%) 416 116 (16.0%) 724 
                  Irritability/Lability 5.3 (3.16) 3 4.4 (2.85) 0 4.8 (3.01) 3 117 (38.0%) 308 153 (36.7%) 417 270 (37.2%) 725 
6-months Total NPI score                           11.3 (12.35) 0 9.7 (10.14) 0 10.4 (11.17) 0    
Subscales*:    186 (76.2%) 244 238 (74.4%) 320 424 (75.2%) 564 
Agitation/Aggression 5.4 (3.24) 0 4.4 (2.62) 0 4.9 (2.98) 0 120 (49.0%) 245 125 (39.2%) 319 245 (43.4%) 564 
                  Depression/Dysphoria 3.7 (2.66) 0 3.5 (2.35) 1 3.6 (2.47) 1 63 (26.0%) 242 101 (31.6%) 320 164 (29.2%) 562 
                  Anxiety 4.6 (2.92) 2 4.0 (2.71) 1 4.3 (2.81) 3 47 (19.3%) 244 57 (17.9%) 319 104 (18.5%) 563 
                  Apathy/Indifference 5.7 (3.39) 1 4.3 (2.91) 1 4.9 (3.16) 2 73 (29.9%) 244 116 (36.3%) 320 189 (33.5%) 564 
                  Disinhibition 4.9 (3.08) 0 5.3 (3.44) 0 5.1 (3.23) 0 35 (14.3%) 244 30   (9.4%) 320 65 (11.5%) 564 
                  Irritability/Lability 4.5 (3.12) 0 4.4 (2.89) 0 4.5 (2.99) 0 83 (33.9%) 245 99 (30.9%) 320 182 (32.2%) 565 
16-months Total NPI score                           10.4 (9.25) 0 7.7 (9.36) 0 8.9 (9.4) 0    
Subscales*:    146 (78.9%) 185 154 (69.4%) 222 300 (73.7%) 407 
Agitation/Aggression 4.5 (2.30) 0 4.5 (3.00) 0 4.5 (2.65) 0 82 (44.3%) 185 76 (34.2%) 222 158 (38.8%) 407 
                  Depression/Dysphoria 3.5 (2.09) 1 3.1 (1.87) 1 3.3 (1.99) 2 63 (34.1%) 185 55 (24.8%) 222 118 (29.0%) 407 
                  Anxiety 4.5 (2.28) 0 4.4 (2.83) 1 4.4 (2.56) 1 29 (15.7%) 185 34 (15.3%) 222 63 (15.5%) 407 
                  Apathy/Indifference 5.5 (3.33) 0 5.2 (3.40) 0 5.3 (3.36) 0 73 (39.5%) 185 62 (27.9%) 222 135 (33.2%) 407 
                  Disinhibition 3.6 (2.43) 1 3.6 (2.59) 0 3.6 (2.48) 1 24 (13.0%) 185 24 (10.8%) 222 48 (11.8%) 407 
                  Irritability/Lability 4.5 (2.30) 0 4.0 (2.83) 0 4.2 (2.58) 0 65 (35.1%) 185 66 (29.7%) 222 131 (32.2%) 407 
CROSS-SECTION 
Control 
(n = 287) 
Intervention 
(n = 388) 
Total 
(n = 675) 
Control 
(n = 287) 
Intervention 
(n = 388) 
Total 
(n = 675) 
16-months Total NPI score                           10 (10.46) 0 8.4 (10.25) 0 9.1 (10.36) 0    
Subscales*:    219 (77.1%) 284 269 (70.1%) 384 488 (73.1%) 668 
 Agitation/Aggression 4.7 (2.48) 0 4.7 (2.67) 2 4.7 (2.58) 2 116 (40.8%) 284 141 (36.7%) 384 257 (38.5%) 668 
                  Depression/Dysphoria 3.5 (2.35) 2 3.2 (2.03) 1 3.3 (2.19) 3 95 (33.5%) 284 105 (27.3%) 384 200 (29.9%) 668 
                  Anxiety 4.0 (2.45) 0 4.0 (2.57) 2 4.0 (2.51) 2 48 (17.0%) 283 72 (18.8%) 384 120 (18.0%) 667 
                  Apathy/Indifference 5.5 (3.41) 0 4.6 (3.06) 0 5.0 (3.25) 0 95 (33.5%) 284 108 (28.1%) 384 203 (30.4%) 668 
                  Disinhibition 3.8 (2.70) 1 4.4 (3.22) 0 4.1 (2.99) 1 35 (12.3%) 284 42 (10.9%) 384 77 (11.5%) 668 
                  Irritability/Lability 4.5 (2.44) 0 4.0 (2.66) 1 4.2 (2.58) 1 94 (33.1%) 284 127 (33.1%) 384 221 (33.1%) 668 
aA total NPI score, calculated by summing the total score for the first 10 domains (excluding Sleep and Appetite domains) together giving the total NPI score a range of 0 to 120. Higher scores on 
the NPI are indicative of the resident exhibiting more behaviours that staff find challenging *Number experiencing the behaviour staff find challenging means experiencing any of the behaviours from 
the listed subscale 
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All 726 residents in the closed-cohort were included in analyses of the resident-level 
secondary outcomes at 6-months; all 49 care homes where the QUIS was completed were 
included in the analysis at 6-months (see Table 16). The odds ratio for the presence versus 
absence of one or more of the six domains of the NPI-NH describing behaviours that staff 
find challenging is 0.95 (95% CI 0.61 to 1.48), indicating that there was no difference in the 
odds of residents experiencing these domains across arms (at a population or cluster-
specific level). The odds of residents being prescribed antipsychotics on a PRN basis in the 
intervention arm was 0.46 times the odds in the control arm. However, the 95% confidence 
interval (0.09 to 2.24) was wide, which reflects uncertainty from the small number of 
prescriptions made. The odds of experiencing depression/dysphoria and apathy/indifference 
in the intervention arm were both approximately 1.32 times the odds in the control arm, 
however the 95% confidence intervals both overlapped one (0.87 to 2.0 and 0.85 to 2.07, 
respectively) so differences are not statistically significant. The odds ratio for presence or 
absence of anxiety was 1.01 (95% CI 0.62 to 1.66), indicating that there was no difference in 
the odds of residents experiencing anxiety across arms.  
The mean QUALID staff-proxy score was 0.74 points lower in the intervention compared to 
the control (95% CI -1.91 to 0.43), indicating no difference in quality of life between arms. As 
such, no statistically significant differences were found in the closed-cohort between arms on 
any resident-level secondary outcome at 6-months. Similarly, there was insufficient evidence 
that proportions of positive staff interactions with residents, observed using the QUIS, 
differed by treatment arm. 
All 675 residents in the cross-sectional sample were included in the primary analyses and all 
726 residents in the closed-cohort were included in the supportive analyses of the resident-
level secondary outcomes at 16-months. All 49 care homes where the QUIS was completed 
were included in its analysis at 16-months (see Table 17). In the cross-sectional sample, the 
odds of residents experiencing one or more of the six domains of the NPI-NH describing 
BSC in the intervention arm were 0.72 (95% CI 0.48 to 1.08) times the odds in control, 
indicating that, although there was no statistically significant difference in the odds of 
residents experiencing these domains across arms (at a population or cluster-specific level), 
the trend is in favour of the intervention. In the closed-cohort, the odds in the intervention 
arm were 0.57 (95% CI 0.34 to 0.95) times the odds in the control, a result that is statistically 
significant (at a population or cluster-specific level) at the 5% level.  
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Table 13 Unadjusted PRN prescription medications by resident sample and timepoint 
CLOSED-COHORT 
N prescribed (%)  
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n = 726) 
Baseline  
Antipsychotic                           5 (1.6%) 5 (1.2%) 10 (1.4%) 
Non-benzodiazepine hypnotic 2 (0.6%) 4 (1.0%) 6 (0.8%) 
    
Pain relief 109 (35.4%) 123 (29.4%)  232 (32.0%)  
6-months  
Antipsychotic                           4 (1.3%) 2 (0.5%) 6 (0.8%) 
Non-benzodiazepine hypnotic 1 (0.3%) 3 (0.7%) 4 (0.6%) 
    
    
Pain relief 89 (28.9%)  132 (31.6%)  221 (30.4%)  
16-months                  
Antipsychotic                           2 (0.6%) 2 (0.5%) 4 (0.6%) 
Non-benzodiazepine hypnotic 4 (1.3%) 3 (0.7%) 7 (1.0%) 
Pain relief 59 (19.2%) 83 (19.9%) 142 (19.6%) 
CROSS-SECTION 
N prescribed (%) N Completed 
Control 
(n = 287) 
Intervention 
(n = 388) 
Total 
(n = 675) 
16-months  
Antipsychotic                           2 (0.7%) 4 (1.0%) 6 (0.9%) 
Non-benzodiazepine hypnotic 6 (2.1%) 3 (0.8%) 9 (1.3%) 
Pain relief 90 (31.4%) 138 (35.6%)  228 (33.8%)  
Frequencies are given out of those in the respective samples, assuming the missing data reflects 
no prescriptions. No PRN anticonvulsants, no PRN mood stabilisers and no PRN non-
benzodiazepine anxiolytics were prescribed for any residents at any time-points. 
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Table 14 Unadjusted quality of life scores by resident sample and time-point 
CLOSED-COHORT 
Mean (SD) N 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n = 726) 
Baseline                      
QUALIDa Staff-proxy                           20.9 (7.19) 308 20.1 (6.76) 418 20.5 (6.95) 726 
QUALID Relative-proxy 22.5 (7.49)   82 21.6 (6.86)   81 22.0 (7.18) 163 
QOL-ADb Resident 42.7 (5.13) 155 41.7 (7.11) 189 42.1 (6.31) 344 
6-months                     
QUALID Staff-proxy                           20.7 (6.88) 245 19.3 (6.04) 319 19.9 (6.45) 564 
QUALID Relative-proxy 21.6 (7.18)   62 22.1 (8.89)   65 21.8 (8.07) 127 
QOL-AD Resident 43.0 (5.09)   92 41.3 (5.97) 137 42.0 (5.68) 229 
16-months                  
QUALID Staff-proxy                           19.9 (6.38) 185 19.5 (6.06) 222 19.7 (6.20) 407 
QUALID Relative-proxy 23.0 (6.24)   38 23.1 (8.41)   31 23.0 (7.24)   69 
QOL-AD Resident 43.2 (6.17)   65 42.8 (5.47)   81 43.0 (5.77) 146 
CROSS-SECTION 
Mean (SD) N 
Control 
(n = 287) 
Intervention 
(n = 388) 
Total 
(n = 675) 
16-months  
QUALID Staff-proxy                           19.5 (6.44) 284 19.5 (6.20) 384 19.5 (6.30) 668 
QUALID Relative-proxy 23.0 (6.15)   39 23.1 (8.41)   31 23.0 (7.18)   70 
QOL-AD Resident 43.4 (5.69) 113 42.2 (6.61) 156 42.7 (6.25) 269 
 
aQUALID: range 11 to 55, with 11 representing the highest quality of life; bQOL-AD: 13 to 52, with higher scores reflecting 
greater quality of life. 
 
 
 
Table 15 Unadjusted QUIS interactions by resident sample and timepoint 
Total interactions (% positive) Missing 
Control 
(n = 19) 
Intervention 
(n = 31) 
Total 
(n = 50) 
Baseline                       2065 (74.9%) 0 2405 (81.7%) 1 4470 (78.6%) 1 
6-months 1766 (81.7%) 0 2291 (88.6%) 0 4057 (85.6%) 0 
16-months 1578 (83.7%) 0 2320 (83.7%) 0 3898 (83.7%) 0 
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Table 16 Secondary outcomes at 6-months (closed-cohort) 
Secondary Outcome 
 
 
 
Analysis 
Treatment 
Effect 
(Interventio
n 
- Control) 
Lower 
95% 
Confidenc
e Limit 
Upper  
95% 
Confidenc
e Limit p-value N 
RESIDENT RELATED       
Behaviours staff find 
challenging  
 
Population-Average Logistic 
Model (GEE) 
0.950 0.612 1.476 0.820 726 
Cluster-Specific Logistic 
Model (REML) 
0.951 0.584 1.547 0.838 726 
Antipsychotic 
medication 
Population-Average Logistic 
Model (GEE) 
0.455 0.093 2.236 0.331 726 
Mood (NPI Domain)       
    Depression/Dysphoria Population-Average Logistic 
Model (GEE) 
1.320 0.872 1.999 0.190 726 
    Anxiety  
    Apathy/Indifference 
Population-Average Logistic 
Model (GEE) 
1.011 0.617 1.656 0.967 726 
Population-Average Logistic 
Model (GEE) 
1.330 0.853 2.073 0.208 726 
Quality of Life       
    QUALID (staff-proxy) Linear Model (REML) -0.740 -1.910 0.430 0.214 726 
CARE HOME RELATED       
Quality of Staff 
Interactions  
 
 
     
(QUIS): Proportion of 
positive interactions 
Linear regression 0.039 -0.023 0.101 0.210 49 
OR <1 favours intervention 
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Table 17 Secondary outcomes at 16-months by resident sample 
Secondary Outcome 
 
 
 
Analysis 
Treatment 
Effect 
(Intervention 
- Control) 
Lower 95% 
Confidence 
Limit 
Upper 95% 
Confidence 
Limit p-value N 
CROSS-SECTION – RESIDENT RELATED       
Behaviours staff find challenging  
 
Population-Average Logistic Model (GEE) 0.720 0.479 1.083 0.115 675 
Cluster-Specific Logistic Model (REML) 0.681 0.400 1.158 0.156 675 
Antipsychotic medication Population-Average Logistic Model (GEE) 1.191 0.216 6.559 0.841 675 
Mood (NPI Domain)       
    Depression/Dysphoria Population-Average Logistic Model (GEE) 0.757 0.511 1.123 0.167 675 
    Anxiety  
    Apathy/Indifference 
Population-Average Logistic Model (GEE) 1.133 0.670 1.916 0.642 675 
Population-Average Logistic Model (GEE) 0.810 0.525 1.249 0.340 675 
Quality of Life       
    QUALID (staff-proxy) Linear Model (REML) -0.050 -1.120 1.020 0.922 675 
CLOSED-COHORT – RESIDENT RELATED      
Behaviours staff find challenging  
 
 
Population-Average Logistic Model (GEE) 
 
0.570 
 
0.343 
 
0.948 
 
0.031 
 
726 
 Cluster-Specific Logistic Model (REML) 0.577 0.334 0.996 0.048 726 
Antipsychotic medication Population-Average Logistic Model (GEE)a 0.783 0.114 5.368 0.802 726 
Mood (NPI Domain)       
    Depression/Dysphoria Population-Average Logistic Model (GEE) 0.592 0.369 0.950 0.030 726 
    Anxiety  
    Apathy/Indifference 
Population-Average Logistic Model (GEE) 
Population-Average Logistic Model (GEE) 
1.037 
0.601 
0.588 
0.380 
1.830 
0.952 
0.900 
0.030 
726 
726 
Quality of Life       
    QUALID (staff-proxy) Linear Model (REML) -0.070 -1.260 1.110 0.902 726 
CLOSED-COHORT – CARE HOME RELATED       
Quality of Staff Interactions  
(QUIS): Proportion of positive interactions 
      
Linear regression -0.001 -0.081 0.078 0.972 49 
OR <1 favours intervention       
a Model fitted without adjusting for hub and stratification factors to ensure convergence. 
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In the individual domains, in the cross-sectional sample, the odds that residents experienced 
depression/dysphoria or apathy/indifference in the intervention arm were both around 0.76 
times the odds in the control arm (95% CI: 0.51 to 1.12 and 0.53 to 1.25, respectively) but 
this was not statistically significant. In the closed-cohort, however, the odds in the 
intervention were both around 0.59 times the odds in the control (95% CIs 0.37 to 0.95 and 
0.38 to 0.95, respectively) statistically significant at the 5% level in favour of the intervention. 
As at 6-months, the odds ratios for the presence or absence of anxiety were close to one in 
both the cross-sectional and the closed-cohort samples, indicating no difference across 
arms. Overall, although no statistically significant differences were found between arms in 
the primary cross-sectional sample at 16-months, trends in favour of the intervention in BSC 
and mood were found in the closed-cohort. 
On the staff-proxy completed QUALID there was no difference in mean scores between 
arms, indicating no difference in quality of life at 16-months. There was no evidence of a 
difference between treatment arms in the proportion of positive staff interactions with 
residents observed using the QUIS.  
The confidence intervals for residents being prescribed antipsychotics on a PRN basis in the 
cross-sectional and closed-cohort samples were wide making them difficult to interpret 
(Tables 16 and 17).  
Further summaries of secondary outcomes are in Appendix 1, Tables 49-52, Table 61 
(unadjusted scores), Tables 26-30 (output from additional models) and Tables 58-60 
(summary of medications). 
 
3.5.3 Analyses of safety 
There were no reported unexpected serious adverse events (RUSAE). The majority of care 
home residents in the closed-cohort did not have any hospital admissions; 231 (75.0%) in 
the control and 308 (73.7%) in the intervention (see Table 18). On average, hospital 
admissions lasted 3.7 days in the control and 2.9 days in the intervention arm. The majority 
of hospital admissions were to general wards.  
Deaths are reported in Section 3.4.3 and in Appendix 1, Table 41. 
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Table 18 Hospital admissions in the closed-cohort 
 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n = 726) 
Number of hospital admissions per resident - N (%):    
0 231 (75%) 308 (73.7%) 539 (74.2%) 
1 64 (20.8%) 77 (18.4%) 141 (19.4%) 
2 11 (3.6%) 25 (6%) 36 (5%) 
3 2 (0.6%) 7 (1.7%) 9 (1.2%) 
Number of hospital admissions per resident - Mean (SD) 0.3 (0.57) 0.4 (0.71) 0.3 (0.65) 
Length of hospital admission (days) - Mean (SD) 3.7 (12.33) 2.9 (9.65) 3.2 (10.86) 
Overall number of hospital admissions reported - N (%) 92 (25%) 153 (26.3%) 245 (25.8%) 
Admission ward type:    
General 77 132 209 
ICU 2 4 6 
HDU 0 0 0 
Other 9 11 20 
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4. Cost effectiveness 
4.1 Missing data 
Figure 4 outlines the data available for the economic evaluation and the level of multiple 
imputation conducted. Data from 389 (intervention = 214; control = 175) residents were 
available for the original cohort complete case analysis and 726 (intervention = 418; control 
= 308) were available for the imputed dataset (and the primary analysis sample).  
 
 
Figure 4: Data completion rates for the complete case sample* 
*Baseline resource use not required for complete case analysis 
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4.2 Costs 
The costs of the DCM™ intervention and the assumptions behind this are described in Table 
19. These were agreed with the research team and cover the DCM™ training and 
implementation. The total cost of the DCM™ intervention was estimated to be £421.07 per 
resident (£9,290.30 per care home). Control arm costs were assumed to be zero. 
Table 65 in Appendix 1 includes descriptive statistics on resource use across time-points 
and by trial arm based on data taken from resident care plans and care home records. Due 
to changes to the consent requirements to access NHS Digital data between baseline 
recruitment and the request for a data download at 16-months, we were unable to receive 
the data and thus were unable to use it to check the accuracy of data on hospital admissions 
obtained from the care home records. The costs of these are described in Table 20 below. 
Costs are presented in UK £ sterling (2017 prices). Total costs were £3,539.00 and 
£2,059.58 on average per resident in intervention and control arms, respectively. T-tests 
suggest these costs were significantly different for the imputed (p<0.001) and complete case 
(p<0.05) samples. 
Primary care costs were similar across arms while secondary care costs were noticeably 
higher in the intervention arm. The intervention arm included a few high cost individuals. 
There were six residents whose costs exceeded the maximum in the control with long 
periods of hospital stay or one-to-one care; these were excluded along with seven other high 
cost individuals (generated in the imputation) in a sensitivity analysis. 
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Table 19: Costs of DCM™ intervention 
Description of 
costs 
£ Key assumptions and sources 
 
Training course fee £975.00  DCM™ course booking form 157. Inclusive of lunch, 
refreshments and course materials. 
Accommodation 
(four nights) 
£300.00 Based on review of DCM™ EPIC trial records. 
Meals/other 
subsistence 
£70.00 Based on review of DCM™ EPIC trial records. 
Travel to/from the 
course 
£100.00 Based on review of DCM™ EPIC trial records. 
Staff time £434.77 Assumed there are four categories of care staff (hourly wage 
and proportion of staff in each category shown in brackets):  
home care worker (£7.38, 20%) and senior home care worker 
(£8.20, 25%) (hourly wages reported in PSSRU 2016 144), nurse 
(£12.45, 20%) (based on £25,902 annual salary for band 5 
nurse reported in PSSRU 2016 144 and converted to hourly rate) 
and care home manager (£21.63, 35%) (assumed median 
annual salary of £45,000, based on a review of recent job 
advertisements). 
The proportion of staff in each category was based on review of 
DCM™ EPIC trial records.  Assumed course participation 
required four full working days (eight hours per day). 
Delivery and 
receipt of training 
(for each DCM™ 
mapper) 
£1,879.77 Assumed two staff trained in each intervention home and that 
there were no staff in the trial who did not require training (e.g. 
because they had previously received it). 
Assumed that there were no last minute cancellations (which 
may have incurred additional costs if rebooking). 
Staff time per 
mapping cycle for 
DCM™ mapper 
£543.46 Using data on the cost of staff time listed above and assuming 
that each mapping cycle required five full working days (based 
on DCM™ Mapper Guidance document and some verification 
using DCM™ EPIC trial data). 
Implementation 
costs (for each 
DCM™ mapper) 
£1,630.38 Assumed there were three mapping cycles per DCM™ Mapper 
(conducted in accordance with DCM™ Mapper Guidance based 
on published standards 83).  Assumed that additional time was 
not be required for other staff to attend DCM™ briefing and 
feedback sessions, but that these are arranged at handover or 
other convenient times as part of usual duties (as per protocol). 
Consultancy fees 
for External DCM™ 
Expert 
£2,100.00 To support intervention implementation and fidelity in the first 
cycle of DCM™ mapping, assumed to be for five days (£420.00 
per day). 
Travel and 
subsistence 
expenses for 
DCM™ expert 
mapper 
£170.00 Based on review of DCM™ EPIC trial data. 
Implementation 
costs (for each 
DCM™ expert 
mapper) 
£2,270.00 Assumed each care home received one full cycle of DCM™ 
supported by the expert mapper. 
TOTAL COSTS 
Per care home 
 
£9,290.30 Assumed 2 DCM™ Mappers and 1 External DCM™ Expert per 
care home 
Per resident 
 
£421.07 Assumed 22.06 residents per care home (calculation based on 
DCM™ EPIC trial data) 
All costs are reported at 2016/17 prices 
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Table 20: Healthcare resource costs in base case analysis* 
Costs (£) Intervention 
(n=418) 
Control 
(n=308) 
 Mean Std Err Min Max Mean Std Err Min Max 
Intervention 
cost 
£421.07 N/A N/A N/A £0.00 N/A N/A N/A 
Primary 
care costs 
£1,522.32 £81.37 £0.00 £19,559.93 £1,568.13 £85.58 £0.00 £8,544.83 
Secondary 
care costs 
£1,547.34 £315.41 £0.00 £67,346.67 £436.96 £99.98 £0.00 £14,220.38 
Medication 
costs 
£46.40 £3.64 £0.00 £405.38 £53.67 £4.76 £0.00 £459.25 
Total cost £3,539.00 £337.00 £421.00 £73,944.00 £2,059.58 £146.71 £0.66 £18,032.06 
*Discounted, closed cohort, EQ-5D 5L, staff completed, with imputation. These values are unadjusted to reflect the true range 
of costs. 
 
4.3 Utility 
Staff proxies represented the greatest proportion of completed quality of life measures. (n = 
453; 62%). This was followed by relative/friend proxies (n = 176; 24%) and then resident 
self-report (n=168; 23%). Table 21 includes the utility values (with multiple imputation) for 
each trial arm across assessment mode and questionnaire.  
The primary analysis was based on the utility values reported in the top row i.e. the imputed 
EQ-5D-5L completed by staff proxies and scored using the standard UK tariff. Other 
analyses presented in this study used the alternative utility values reported in other rows of 
the table.  The first four rows show imputed utility scores for EQ5D5L (rows 1-3) and 
DEMQOL (row 4) whereas the final two rows report the utilities that were used in the 
complete case analysis (i.e. prior to multiple imputation). 
In the primary analysis there was a slight baseline imbalance with the control arm having 
marginally higher quality of life. As we might anticipate, mean EQ-5D scores declined during 
the trial over 16-months with resident longevity. There was a trend apparent in most of the 
approaches that the decline in quality of life was greater in the control arm than in 
intervention arm. Using all approaches, quality of life was higher in the intervention arm than 
control arm at 16-months. 
The baseline imbalance in quality of life was a relatively consistent finding across 
assessments and scoring methods. Adjustment for this was made in the calculation of 
QALYs.  
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Table 21: Utility values  
Assessment* Baseline 6-months 16-months 
Intervention Control Intervention Control Intervention Control 
N Mean Std 
Err 
N Mean Std 
Err 
N Mean Std 
Err 
N Mean Std 
Err 
N Mean Std 
Err 
N Mean Std 
Err 
EQ-5D-5L* – Staff 
MI; Primary 
analysis 
 
418 .663 .011 308 .676 .011 418 .573 .015 308 .569 .019 418 .421 .018 308 .395 .019 
EQ-5D-5L – Staff 
MI; Death not 
recoded 
 
418 .663 .011 308 .676 .011 366 .654 .013 261 .672 .015 277 .636 .017 204 .596 .017 
EQ-5D-5L* – Staff 
MI Mapped to 3L 
 
418 .435 .016 308 .469 .019 418 .363 .018 308 .374 .020 418 .262 .019 308 .229 .017 
DEMQoL* – Staff 
MI 
 
418 .759 .006 308 .746 .007 418 .669 .013 308 .623 .016 418 .746 .018 308 .736 .021 
EQ-5D-5L* – Staff 
CCA** 
 
214 .663 .016 175 .682 .018 214 .554 .021 175  .531 .025 214 .364 .025 175  .349 .025 
EQ-5D-5L* 
Patient/Relative or 
Staff (CCA) 
215 .702 .016 176 .716 .019 215 .596 .022 176 .555 .026 215 .383 .025 176 .370 .027 
*In these cases deaths were coded as zero; **Only those with completions at all 3 time-points
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4.3.1 Cost-effectiveness 
Table 22 includes the ICERs for the primary and secondary analyses and for the various 
sensitivity analyses. In the base case cost-utility analysis, intervention is more costly (by 
£1,479) and more effective (.024 QALYs) than control. This yielded an ICER of £60,627; well 
above the £20,000 NICE threshold, indicating that DCM™ is not cost-effective. The 
complete case analysis had similar costs to the imputed sample but higher incremental 
QALYs for the intervention. With the exception of the analyses which excluded high cost 
outliers, the ICERs from various sensitivity analyses (including those which restricted the 
intervention sample to intervention compliant care homes i.e. those completing at least one 
cycle) also all exceeded £20,000. These analyses included additional costs associated with 
the intervention of over £1,600 and an incremental benefit ranging .024 to .036. The cross-
sectional cohort analysis yielded lower incremental costs and higher incremental benefits for 
the intervention than found in the imputed sample. 
In the sensitivity analyses which excluded the high cost outliers in the intervention arm (n=6 
were excluded from the complete case analysis and prior to conducting MI for an analysis 
using MI data), incremental costs reduced dramatically and the ICER approached the cost-
effectiveness threshold (£36,371/QALY) in the base case and fell below it in the complete 
case scenario (£10,975/QALY). The ICER also decreased in line with greater intervention 
compliance. An analysis adjusting for baseline costs yielded an ICER below £25,000 but this 
was based on a dramatically reduced sample and cannot be considered a robust estimate. 
The cost-effectiveness analyses based on improvement in CMAI indicate that while the 
intervention was more costly, it was also more effective. Incremental cost per unit 
improvement in CMAI was £289 and £67 for intervention versus control for the imputed and 
complete case samples, respectively.  
Figures 5 and 6 are the cost-effectiveness plane and the CEAC, respectively, for the base 
case cost utility analysis. The plane indicates the greatest uncertainty lies in the benefits of 
the intervention. All of the simulations lie above the willingness to pay threshold suggesting 
that, using the base case analysis, DCM™ is unlikely to be cost-effective. The CEAC 
confirms this and indicates that, where λ= £20,000, there is a very low probability that the 
intervention will be cost-effective.   
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Table 22: Cost effectiveness  
Analysis* Costs QALYs/Benefits  
N Interventi
on 
N Contro
l 
Increment
al 
N Interventi
on 
N Contro
l 
Increme
ntal 
ICER 
Base case 
EQ-5D-5L – Staff MI 418 £3,539 308 £2,060 £1,479 418 .718 308 .708 .024 £60,627 
CMAI MI 219 £3,318 185 £2,345 £974 219 -1.767 185 -.557 -3.37 £288.88 
Sensitivity analyses 
EQ-5D-5L CCA*** 214 £3,380 175 £2,073 £1,307 214 .682 175 .665 .029 £45,674 
EQ-5D-5L – Staff MI, implemented cycle costs 418 £3,463 308 £2,060 £1,403 418 .718 308 .708 .024 £57,509 
EQ-5D-5L – Staff MI, excluding intervention cost 
outliers in the imputations 
412 £ 3,046 308 £2,060 £533 412 .722 308 .708 .027 £36,371 
EQ-5D-5L CCA excluding intervention cost outliers*** 208 £2,437 175 £2,073 £364 208 .688 175 .665 .033 £10,975 
EQ-5D-5L Staff MI Mapped to 3L 418 £3,539 308 £2,060 £1,479 418 .457 308 .459 .026 £57,208 
DEMQoL – Staff MI 
 
418 £3,539 308 £2,060 £1,479 418 .836 308 .799 .032 £45,918 
EQ-5D-5L – Staff MI Open cohort** 523 £2,830 394 £1,608 £1,222 523 .577 394 .548 .028 £42,953 
DEMQoL – Staff MI Open cohort** 523 £2,830 394 £1,608 £1,222 523 .665 394 .629 .036 £34,234 
EQ-5D-5L Staff MI (int arm = only those who completed 
at least two DCM™ cycles to an acceptable level 
100 £2,856 308 £2,060 £ 796 100 .734 308 .708 .026 £30,447 
EQ-5D-5L Staff MI (int arm = only those who completed 
at least one DCM™ cycle to an acceptable level**** 
328 £3,833 308 £2,060 £1,774 328 .744 308 .708 .044 £40,062 
CMAI CCA 129 £2,768 101 £2,424 £344 129 -1.78 101 1.06 -5.12 £67.201 
EQ-5D-5L – Staff MI, with adjustment for baseline costs 262 £3,366 225 £1,924 £1,464 262 .732 225 .692 .061 £24,139 
All costs and benefits (with the exception of CMAI) occurring in the final 4-months are discounted; **unadjusted as baseline data not collected; 1Cost per unit change in CMAI no adjustment for 
baseline costs except where shown; **** Residents residing in care homes in the intervention arm that did not complete any cycles to an acceptable level of compliance, were excluded from the 
analysis.  
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Figure 5: Cost-effectiveness plane 
 
Figure 6: Cost-effectiveness acceptability curve 
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Table 23 reports the outcomes from the net benefit regression model including the 
covariates employed in the main statistical model and an interaction between trial arm and 
compliance indicator variable. The only significant predictors of net benefit were baseline 
EQ-5D (higher QoL leads to higher net benefit) and CDR (lower values lead to higher net 
benefit).  In this model, neither the intervention nor the compliance*intervention interaction 
terms are statistically significant. The CACE analysis yielded similar results in that the active 
treatment variable including only intervention care homes who complied with the intervention 
(completed at least one acceptable cycle) was not statistically significant. 
Table 23: Net Benefit Regression 
 
   N =  726 
    Prob > F 0.0000 
 
Coefficient Robust SE P value Lower CI Upper CI 
Constant 5282.33 1726.75 0.004 1802.20 8762.46 
Treatment*Compliance      
0 -1617.88 840.149 0.061 -3311.72 75.96 
1 -1427.81 1159.62 0.225 -3762.80 907.18 
2 177.53 1139.85 0.88 -2117.28 2472.34 
Date of birth 0.16 0.09 0.115 -0.04 0.35 
Baseline EQ-5D 14628.21 1381.11 0.000 11847.35 17409.07 
Baseline CDR -807.31 389.57 0.044 -1592.07 -22.56 
Care home type -463.22 835.22 0.582 -2144.57 1218.125 
Care home size 856.64 1032.51 0.411 -1221.49 2934.77 
Care home training 353.93 1107.15 0.751 -1874.86 2582.727 
Care home hub       
2 23.62 1359.16 0.986 -2713.0556 2760.31 
3 -1152.31 1215.883 0.348 -3599.056 1294.44 
Within VCE adjusted for 50 clusters in site 
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5. Process evaluation 
5.1 Participants 
In total, 75 interviews were conducted. Of these interviews, 67 were with staff members who 
had undertaken various roles during the trial. Interviews took place with 17 managers, 25 
mappers (2 of which were also managers), and 27 ‘other’ members of staff who reflected a 
range of roles in the care home and varying degrees of involvement with the intervention. 
Due to the high losses to follow up and the requirement of having to be able to provide 
informed consent to participate in an interview, only two residents participated. Six relatives 
agreed to participate in interviews. Interviews ranged greatly in duration (from 3 - 38 
minutes) depending on the interviewee’s knowledge and awareness of the intervention. 
5.2 What was implemented? 
Each care home was requested to implement DCMTM as detailed in the protocol and 
described above (section 3.3.2). There was considerable variation of implementation across 
the 31 intervention homes, as well as variable compliance with return of required trial 
documentation to evidence DCMTM implementation. A range of approaches was used to 
increase return rates of trial documentation including multiple phone and e-mail remainders 
being sent by the Intervention Lead and CTRU staff and in some cases un-blinded 
researchers attending the care home to collect copies of documentation. In some care 
homes documented evidence of all components of intervention completion (e.g. attendance 
sheets for briefing and feedback sessions, mapping data, feedback reports, action plans) 
were not always available even though mappers or managers reported a cycle of mapping 
had occurred. We made the assumption that undocumented earlier phases of a DCMTM 
cycle (e.g. briefing session) had been completed if documentation for later phases was 
provided (e.g. mapping data or feedback report). We also only recorded a component of a 
cycle as complete if we had documentary evidence for completion of it or a later stage of the 
process. In some cases, mappers reported verbally to the intervention lead or CTRU staff 
that a DCMTM cycle or components of it had been completed, but failed to provide 
documentary evidence of this. Therefore, our final compliance data may be subject to 
inaccuracies of both under and over reporting of the components of each cycle that actually 
occurred.  
5.2.1 Mapper training and retention 
Mapper training was delivered per protocol (within 2-months of randomisation) in 21/31 
(68%) homes. There were delays in training mappers from 9 care homes (29%) and no 
mappers were trained in one home (3%). In two homes (6%) only one mapper was trained 
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compared to the stipulated two. Withdrawal of one or both of the mappers occurred in 17 
homes (55%). The reasons for withdrawal were resignation from the care home, ill-
health/long-term sickness, maternity leave, and in one home, both mappers withdrew due to 
lack of management support to map. At 16-month follow-up 14 homes (45%) had two trained 
mappers still in post, 7 had one mapper (23%) and 10 (32%) had no mappers. While there 
was funding to train additional mappers this only occurred in one home due to insufficient 
time before the end of the trial to train further mappers, being unable to identify a suitable 
replacement mapper or the consented mapper being unable to attend scheduled DCM™ 
training due to personal or organisational reasons. 
5.2.2 Mapping cycles 
As is reported in section 3.2.2 DCM™ implementation was considerably less than the per 
protocol three acceptable cycles, in the majority of the 31 intervention homes, with only four 
homes completing three full cycles. The first cycle of mapping was commenced per protocol 
(within 3-months of randomisation) in 22/31 homes (71%). The DCM™ expert mappers 
reported spending considerable time contacting care homes to rearrange mapping dates 
following cancellations by the care home and in prompting production of feedback reports 
and actions plans during the first supported cycle (see discussion below). 
 
5.3 How did participants react to the intervention? 
5.3.1 Experiences of the intervention  
As with implementation of the intervention, experiences of the intervention and its success 
varied between homes, and also between stakeholder groups (e.g. mappers, managers, 
staff, relatives and residents). Discussion around experiences of the intervention 
predominantly focused around the impacts of DCMTM and the challenging and facilitating 
factors experienced when implementing DCMTM. Experiences of the intervention are 
therefore explored under these two broad themes – Section 5.3.2 focuses on perceptions of 
DCMTM’s impact, and Section 5.4.1 focuses on barriers and facilitators to DCMTM 
implementation and impact. 
 
5.3.2 Perceptions of intervention impact 
In keeping with the findings of the statistical analyses (Section 3.5) which identified variability 
in impacts between care homes, the process evaluation identified variability in how much 
participants felt DCM TM had an impact within their care home. Examples of positive impacts 
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are considered below, before moving on to consider examples of when DCM TM was felt to 
have variable or little impact. 
 
5.3.2.1 Perceptions of impacts for people with dementia 
A range of impacts of DCM TM were identified for people with dementia at an individual and 
home level, as indicated in the key themes below.   
 
5.3.2.1.1 Improved responses to individuals’ needs, personalities and interests 
A repeated positive experience was the ability of DCM TM, and the observational element in 
particular, to help staff to identify, and so respond to, residents’ individual needs, 
personalities and interests:  
 “One of our gentleman that we did the observation on, we found that he made his 
own wellbeing by playing with food and chucking it. So then I could go to the chef 
and say… ‘This gentleman plays with his food, what can we do?’ We saw him doing 
it before but because of the mapping it makes you look into it a bit more… He was 
happier, he’d have a lot more things that he could play with.” (50028/10394) 
“When you’re mapping somebody and you see that they’re not joining the group 
activities you, we thought right let’s just try and see if we can do an activity that’s just 
for her.” (50069/10475) 
DCM TM was repeatedly cited as enabling individualised tailoring of care and activities which 
helped staff to better meet residents’ preferences, needs and interests. This ability to better 
identify individual needs extended to groups of residents that staff could find more difficult to 
care for, as discussed below.  
 
5.3.2.1.2 Improved anticipation, understanding and prevention of complex behaviours 
Examples of enhanced identification of individual needs were made in reference to 
‘behaviour that is challenging’, which included agitation (the primary trial outcome measure), 
aggression and distress:  
 “I’m finding this really interesting because we can just observe all of the behaves of 
our residents, and then we can just think about this, what can we change? How can 
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we make them more happy? …How can we reduce of their really low behaves, which 
make them distract or distressed?” (50028/10637) 
“In terms of challenging behaviours… it became predictable, but then it is 
preventable through your interventions. The mapping itself helped us identify the 
individual needs and once that is identified we tried to set up plans and how to deal 
with or approach the challenge, the behaviour that is challenging.” (50011/10160) 
Participants repeatedly described how mapping helped to identify, and so to anticipate, 
preventable patterns of challenging behaviour by recognising antecedents, warning signs 
and early points of intervention. This supports the trial’s hypothesis that DCM™ would have 
an impact on agitation, although the above quotes suggest that reducing agitation would 
only have been a focus for residents who were identified by staff or mappers as being 
agitated, rather than a blanket intervention for all residents. 
 
5.3.2.1.3 Increased quality and quantity of interactions 
Alongside impacts at an individual level, staff also spoke of impacts for all residents at a care 
home level. The impact most frequently referred to was improvements in the quantity and 
quality of staff-resident and resident-resident interactions: 
“You know, they [staff] try and engage with people more.” (50010/10095) 
“We’ve got another lady who’s end stage dementia who’s just been people chatting 
with her, she’s actually started speaking again! Now whether that would have 
happened anyway I don’t know, but she’s not spoken for ever such a long time but 
now odd words are coming out.” (Manager 58930) 
Increases in staff-resident interaction were repeatedly cited, as in the example above, as 
having a visual impact on the person’s mood: 
“Sometimes even one little smile to residents, one little joke, or one interaction can 
make a big change, for the rest of the day even... It’s like our lunchtimes there is 
around thirty something residents plus six carers in one room, and how someone can 
still feel lonely, and one interaction can change that.” (50028/10637) 
“One of our care staff, he just went to her [lady with dementia] with a bright smile and 
started joking and how that changed her mood! …She was much more brighter, she 
was much more involved in all the situation.” (50028/10637) 
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These, and other quotes included throughout the process evaluation results, suggest a 
potential link between increased interaction and activity, as a result of DCM™ 
implementation, and improved well-being for residents in intervention homes. 
 
5.3.2.1.4 Increased provision of activities and occupation 
Alongside improvements in resident interaction, increased provision of social and therapeutic 
activities and meaningful occupation was another common impact of the DCM™ process. 
These activities were typically instigated in response to recognition from mapping 
observations that residents were spending large proportions of their time without these types 
of stimuli: 
“My activities budget is off the scale! But at least I know if I do a map now on a 
particular day I know that there’s going to be stuff going on, and I now that if I’m sat 
there I’m not going to be bored silly.” (50069/10475) 
“Now we introduce lots of sensory activities… all the residents have got some sort of 
activities... because we’ve been observing … and we’ve been thinking that what 
could improve their well-being.” (Manager 50018)” (50018/10268/10277) 
“In the two years that we’ve been here… the level of stimulus, activities, has grown.” 
(Relative 58747/40007) 
DCM™ highlighted the importance of care provision that not only addressed the physical 
needs of residents, but also their social and emotional needs and well-being: 
“I have to say, that first map I was bored silly, and that made me think we are not 
doing anywhere near enough for these residents. Yes, we’re ticking all the boxes in 
terms of care, they’re well looked after, you know, everything is up to date in terms of 
that person, but what are we doing here to keep their well-being sort of on a good 
level?” (Manager 50069)  
This quote again suggests a link between increased occupation for residents as a result of 
DCM™ and improvements in well-being. 
 
5.3.2.1.5 Improved responses to the needs of particular groups of residents 
Some staff perceived that DCM™ had a greater impact on certain sub-groups of residents. 
Residents with more advanced dementia or with more limited verbal communication abilities 
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were considered, by some staff, to be more likely to benefit from DCM™, since it provided a 
useful method of identifying their unique needs:  
“Especially those with end stage dementia, I think they do tend to get more attention 
possibly than they did before. I think staff are more considerate towards them and 
give them a bit more empathy... A lot of the residents we have that can still interact… 
they seem to be already getting quite a lot of attention… I think it has had more 
impact on the residents that weren’t getting the attention, possibly.” (59830/40002) 
“So many of our residents have severe dementia and, you know, their 
comprehension is very limited so (Mapper X) helped us in there to make changes.” 
(Manager, 50065) 
Residents who were included in DCM™ mapping, were another group that staff considered 
to gain particular benefit from DCM™ participation, as their involvement in mapping provided 
a focus on identifying their care needs.  
 
5.3.2.1.6 Other impacts for people with dementia 
Other impacts for people with dementia that were reported by staff included giving people 
with dementia a voice, and enhancements to the environment and equipment that better met 
residents’ needs at an individual or a care home level: 
“As we observe them [people with dementia], it gives them a lot of chance and 
opportunity to express themselves.” (50011/10160) 
 “One lady she couldn’t lift up the cup and we decide to change from plastic beaker 
the two handle, which has helped her a lot.” (58747/10447)  
“We changed many things, even change the place where they sit. We try to make 
them comfortable, those who are watching TV, switch off the radio when TV, 
because the first time [first mapping] it was kind of noise. So we try to make it better.” 
(58747/10447) 
These examples collectively illustrate how DCM™ gave staff the ability to understand 
experiences of the care home from the perspective of residents with dementia, and so to 
identify how those experiences might be improved. The ability of DCM™ to uncover the 
‘emic’ perspective of residents is explored further in Section 5.3.2.2 below. 
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5.3.2.1.7 Summary 
As the above examples show, the impacts of DCM™ for people with dementia reported by 
staff at both an individual and care home level indicate that DCM™ could lead to an increase 
in staff-resident and resident-resident interaction, an increase in meaningful resident 
occupation, and an improvement in staff identification of individual residents’ needs. Some 
staff reported that impacts were more likely for particular groups of residents, namely those 
with more advanced dementia or communication difficulties, or residents who underwent 
DCM™ mapping. 
 
5.3.2.2 Perceptions of impacts for staff 
The perceived impacts of DCM™ for managers, mappers and other care home staff included 
increased awareness of residents’ needs, communication of these needs, and of care 
quality, and greater confidence among staff in caring for residents with dementia. 
 
5.3.2.2.1 Improved awareness and understanding of residents needs and care quality 
Impacts on staff predominantly related to improved understanding of the residents under 
their care and, as a result, improved awareness of the quality of care being provided in the 
home: 
 “You don’t realise what you’re doing sometimes and it makes you look at things to 
say I wouldn’t like that type of thing.” (Staff 40005) 
 “I think the benefits were just along the lines of highlighting to staff a little bit more 
about the needs of dementia clients.” (Manager, 50013) 
Numerous references were made to DCM™ helping staff to better understand and respond 
to the needs and behaviours of people with dementia, indicating that this was a key impact 
for staff. DCM™ also provided access to the perspectives and experiences of residents with 
dementia, and a powerful reminder of the importance of understanding these: 
“Sometimes you just forget about, you know, the actual person. And to sit in that 
lounge and that dining room for six hours, you go through what they go through every 
day. If that isn’t the message of Dementia Care Mapping, I don’t know what is.” 
(Manager 50069) 
“We were looking at it from the residents’ point of view, so we could see what they 
like, what they didn’t like.” 50031/10456) 
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Comments from other staff echo these suggestions that, prior to DCM™ implementation, 
staff were less cognisant of residents’ experiences of care in the home. 
 
5.3.2.2.2 Improved understanding of embodied communication 
Improved understanding of embodied communication was a repeatedly cited impact. Staff, 
managers and mappers all referred to an increased awareness of, and response to, non-
verbal cues and communication from residents with dementia as a result of DCM™: 
“We’re more attuned to looking for non-verbal cues and very small changes.” 
(Manager, 58930)  
“It’s like offering somebody a drink and then, when you are observing it, actually 
they’re wanting to do it for themselves. So it’s watch that hand movement isn’t it, and 
making carers aware.” (10181) 
“…by holding hands or by touch, there is, you can see the difference. The person will 
be quiet, or they needed that attention.” (50018/10268/10277) 
Staff recognition of non-verbal cues of residents’ needs was important, as they helped the 
staff to identify the resident’s unique personality, abilities, preferences and requirements. 
Improving embodied communication was therefore particularly important for residents who 
rarely or never communicated verbally.   
 
5.3.2.2.3 Increased confidence and positive feedback for staff 
Staff were often reported to feel more confident in their care practices as a result of DCM™ 
taking place in the home: 
“They’re more confident now than they were.” (Manager, 50019) 
“Care assistants are now confident about doing things with the residents in there… I 
think they’re enjoying their jobs more, I think they’re enjoying being in that unit more.” 
(Manager, 50167) 
Increases in confidence appeared to stem from several sources. These included feedback 
from the DCM™ process about the needs of residents, examples of the positive impact on 
residents when their needs where well met, and increases in confidence which came from 
DCM™ providing an opportunity to celebrate the sometimes overlooked positive actions of 
staff: 
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“Sometimes even though you’re seeing the staffs are doing very good things to the 
residents, sometimes you don’t appreciate… you don’t get the time to do that…but 
this was the time that we could be able to appreciate the staff.” (50018/10268/10277)  
Increases in staff confidence and knowledge could also result from having staff trained as 
mappers available in the home as a perceived source of expertise and support in relation to 
problems and approaches to caring for residents with dementia: 
“After talking with the mappers it presents a greater awareness of what you need to 
do with and for your clients.” (50010/40010).  
“She’s (Mapper) got that extra knowledge that she’ll go well it could be this, or it 
could be that.” (10666/40015) 
The potential increases in staff confidence and knowledge that could arise from having 
access to the expertise of a mapper within the home suggests that some impact may have 
been possible in intervention homes which did not actually implement any DCM™ cycles. 
However, this is not borne out in the main trial results. 
 
5.3.2.2.4 Summary 
The most commonly cited impacts of DCM™ on staff were increased awareness and 
understanding of the needs of residents with dementia, including the embodied 
communication of residents with limited verbal communication, and increased confidence for 
staff in providing care for people with dementia. 
 
5.3.2.3 Changes in Care Practices and Culture 
Related to impacts on staff, were wider changes in the practice and culture of care across 
the home. The magnitude of the changes referred to could vary greatly, from small changes 
to staff behaviours to more significant changes which could require managerial or financial 
support.  
 
5.3.2.3.1 Smaller, achievable changes to care practices and culture 
Relatively small, and thereby achievable, changes in staff behaviour were often considered 
by participants to make a big difference, despite the relatively little time, cost or effort they 
took to implement: 
 120 
 
“Just tiny little things, for instance, when a staff member walked through the foyer… 
and acknowledged the residents, their faces lit up. That split second, and even a 
smile, it made a lot of difference to the residents.” (50031/10456) 
 “Now if I’m dealing with anybody, I have a conversation while I’m washing and 
dressing them. And that way I’m finding out little bits about them… about their likes 
and dislikes, what they use to do in their past life.” (50015/60002) 
Examples of these small, achievable changes often involved staff making better use of the 
opportunities available to them to interact with residents - for example, as they undertook 
care tasks or were passing through the home. Despite these examples signifying relatively 
small changes to practice, they were felt by staff, especially if collectively adopted, to have a 
significant impact on residents: 
“It doesn’t have to be a major functional change of the home, these [changes spoken 
of] are all really, really small things but, holistically and collectively, they make a 
massive difference.” (Manager, 50011) 
 “The little things can make a big difference for someone who is just, who is not 
involved in the situation, even in the big group where they are sitting.” (50028/10637)  
The significance attached to such changes was also an example of the low levels of baseline 
interaction seen in some homes during the QUIS observations, where residents could spend 
long periods of time with no one to interact with.  
 
5.3.2.3.2 Larger, formal changes to care practices and culture 
Larger changes to more formal care practices and processes were also reported, such as 
staff inductions, ‘in-house’ training, and care planning approaches. These changes required 
more effort to implement and could necessitate support at a managerial level, or agreement 
across multiple care homes: 
“We have made it into a holistic type of care planning, where in again we have 
brought in person-centred care.” (50011/10160) 
 “The main difference that it’s had so far is altering our training, ‘X’ does our 
dementia training across both homes, and we also do dignity training between both 
homes. And we’ve changed those courses quite a lot, so that it delivers a lot more of 
the language we learnt across Dementia Care Mapping.” (50018/10268/10277) 
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Changes to care home culture requiring managerial support were also spoken about, for 
example in relation to shifting prior assumptions held at a home level about talking to 
residents not constituting ‘proper work’: 
“There’s this culture shift where it’s okay to sit down and have a chat with them 
[residents], it’s okay to be seen to do that... If she [care home owner] saw a carer 
sitting down [before DCM™] it would be like ‘What the hell are you doing? You’re 
being lazy!’. And actually there’s a massive shift now, if you walk in and see a carer 
sitting and joking around with residents, that’s a really good responsive service.” 
(Manager, 50011) 
This last example indicates the importance of having senior management understanding and 
support for the need to change care practices and culture in the home. 
 
5.3.2.3.3 A tool for identifying and evaluating changes to care practices and culture 
Many of the responses above indicate that DCM™ was used as a tool to identify areas for 
improvement across a range of care home practices and processes, including training 
needs, the quantity and quality of interactions with residents, and care planning. Managers 
were particularly aware of the potential benefits of DCM™ as a structured tool for identifying 
and evidencing practice improvements: 
“Whereas before we would try to improve but we didn’t really know how, so it was a 
bit like running around headless… I think one of the most positive things about 
mapping is that it gives you a structure to sort of put dementia and dementia care 
in… So before [DCM™], you sort of, you want to improve but it’s very difficult to know 
how to improve.” (Manager, 50018) 
“From the cycles that the girls have done, they’ve identified and can share 
information with the rest of the employees, to actually improve in any way we can the 
care that’s delivered.” (Manager 50031) 
DCM™ was also used as a means of providing evidence of the impact of improvements to 
care practices, and thus provided a means of both motivating and maintaining changes to 
the practice and culture of care:    
“Until you’ve sat there for a few hours and actually seen someone gain enjoyment 
from just holding something, it’s something that’s very easy to ignore because it’s 
very small. So it [DCM™] meant we could actually start making small changes, 
people could see the difference.” (50018/10268/10277) 
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“I’ve always said it’s [sitting and chatting with residents] a legitimate activity, but it is, 
now it’s been pointed out to them that it actually does have an impact on that 
person’s health and well-being, then, you know it’s done more.” (Manager 58930) 
Where managers were also mappers, this facilitated the process of getting senior staff to 
understand, and provide financial support for, any changes required to care practices in the 
home. In some instances, significant changes were made to care practices as a result of 
DCM™ implementation: 
“That whole unit is light years away from before it was before you started doing the 
mapping, before we started the project.” (Manager 50167) 
 
5.3.2.3.4 Summary 
DCM™ enabled care homes to achieve change in some of the daily care practices of their 
staff, most noticeably in relation to the level of interactions with residents. Changes were 
also noted to formal care practices such as approaches to care planning and staff induction 
and training. DCM™ was perceived to be a useful tool through which the need for these 
changes was identified, with managerial or across site support required for changes to be 
made at a care home level.  
 
5.3.2.4 Impacts on Relatives 
Some impacts from DCM™ were noted for relatives of residents in the home. The most 
common impacts cited for relatives were increased involvement in the home and better 
provision of information by staff to relatives about their family member’s care: 
“It has involved not just the home staff; it has involved families.” (Manager, 50010)  
“I found it really interesting for the residents that we mapped to let their families know 
what we’d noticed … This is what we found when we were going [DCM™], and this is 
what we’re going to do.” (Manager, 50069) 
There is a suggestion here that impacts may be greater for residents who were mapped, and 
also for their relatives. It should, however, be noted that these perceived impacts were 
reported by staff and not by relatives who, as discussed in Section 3.7.4.2.1, could struggle 
to identify the impacts of DCM™ on themselves: 
“I don’t know, it’s really hard to say… Overall I’m really happy so I can’t say there’s 
been anything specific that I’ve noticed that’s any different.” (50010/40009) 
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5.3.2.5 Examples of limited impacts  
Although many participants identified positive impacts resulting from the implementation of 
DCM™ within their home, they sometimes struggled to provide examples or identify specific 
ways in which change had occurred: 
“I do think there is an impact there generally yes.” (Manager 50010)  
Interviewer: “Can you give us any examples of specific action plans that came from 
the first cycle, which was a while ago?” Participant: “It was ages ago, erm… I can’t 
specifically.” (Manager 50011)  
In addition, some participants considered that DCM™ had asserted little influence over care 
practices in the home or over the experiences of residents: 
Interviewer: “Has there been any impact, there might not have been, on the residents 
do you think as the result of mapping?” Participant: “No. No I don’t think so.” 
(50010/10096)  
Interviewer: “Has there been anything for staff, have they changed kind of their 
routines at all?” Participant: “Erm, not as a whole, no.” (50069/10475)  
It might be expected that staff from homes who implemented less cycles of DCM™ would 
struggle to identify impacts as a result. This tendency is supported to a degree by the above 
quotes, all of which came from homes that experienced problems with DCM™ 
implementation and only completed 1 or 2 cycles of DCM™ as a result. However, 
participants from homes completing 3 cycles could still struggle to identify definitive impacts 
from the implementation of DCM™: 
“I must admit I have seen some improvement but I'm not here every day.” 
Interviewer: “Have you seen improvement for the residents’ quality of life as well, do 
you think?” Participant: “I think so, yeah. Especially those with end stage dementia, I 
think they do tend to get more attention possibly than they did before.” (Mapper 
58930) 
“We’ve got another lady who’s end stage dementia who’s just be people chatting with 
her, she’s actually started speaking again. Now whether that would have happened 
anyway I don’t know...” (Manager 58930) 
“I suppose I haven’t necessarily seen any real changes, but I was happy in the first 
place.” (Relative 50018-20107) 
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Collectively, and in line with the main trial results, the above quotes suggest that 
implementing DCM™ did not uniformly lead to positive impacts for care home residents or 
for staff. Issues were also experienced with unexpected, and sometimes negative, impacts 
and with maintaining positive impacts over time, as is explored next.  
 
5.3.2.5 Unexpected impacts or consequences 
A small number of potentially unexpected, and sometimes negative, impacts or inappropriate 
uses of DCM™ were identified during the interviews.  
 
5.3.2.5.1 Conflict amongst staff 
Disagreements over the findings of mapping sessions were reported to lead to conflict 
amongst staff in one home, although these differences were subsequently resolved: 
“There was arguments as well, because you know they say sometimes that you don’t 
see the residents and how they are being… and we cleared everything and they did 
take it in a positive way eventually!” (50018/10268/10277) 
Although this was the only reference made to arguments, some other homes also reported 
initially negative responses from staff to DCM™ feedback, highlighting the importance of 
ensuring that staff understand the DCM™ process and the importance of providing feedback 
which celebrates positive examples of care as well as highlighting areas for care 
improvement.  
 
5.3.2.5.2 Fear of scrutiny from past negative experiences  
As a result of a home beginning to use DCM™, some staff felt scrutinised and fearful, 
predominantly due to past negative experiences of other forms of care scrutiny, such as 
CQC inspections:  
“In most cases when it [feedback on care] happens it’s a negative experience 
because there’s inspectors from various organisations, so I think it wasn’t until we 
started giving feedback and there was quite a bit of positives in there that the staff 
really engaged with the process.” (50018/10268/10277) 
 “The staff… it didn’t matter how much time we spent explaining that it wasn’t about 
spying on them, that’s how they felt about it.” (10181) 
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 “It was like being spied on.” (50010/40010) 
These feelings appeared to be more common in staff members who did not fully understand 
the purposes or processes of DCM™. Such feelings typically, but not always, lessened or 
went away as the processes involved in implementing DCM™ became more familiar to staff 
and better understood. 
 
5.3.2.5.3 Inappropriate use of DCM™ 
Some misunderstandings about the purpose of DCM™ also appeared to lead to it being 
used in ways that appeared to be inappropriate or not in line with its recommended use. One 
home reported using evidence from DCM™ to assess potential new members of staff and as 
part of a fee review to provide evidence that a resident’s needs have changed and their fee 
should be increased:  
“We ask all new members of staff to come in for a train where we dementia map 
them… We also use it [DCM™] for fee review, so if we have someone whose needs 
have really drastically increased I can go to them and say she needs X amount of 
day care hours a week and there is the evidence.” (Manager 50011) 
And in another home DCM™ was perceived as a method for staff to highlight errors in each 
other’s care practices: 
“The idea is that if one carer’s working with another they can turn to them and say 
you shouldn’t have done that you should do this.” (Manager 50018) 
It is potentially relevant that both these examples came from managers who had not been 
trained in DCM™ and appeared, from the content of their interviews, not to fully appreciate 
the purpose of DCM™. This reconfirms the importance of ensuring that care home staff who 
hold key leadership roles, such as managers, have a clear understanding of DCM™ in order 
for it to be implemented appropriately and effectively.  
 
5.3.2.5.4 Summary 
In summary, some unexpected and negative consequences of DCM™ implementation were 
also identified, including conflict between staff over the results of mapping sessions, fear of 
being scrutinised, and inappropriate uses of DCM™. These undesirable consequences were 
noted more frequently amongst homes and staff (and particularly managers), where DCM™ 
was poorly understood. In addition, the impacts of DCM™ were not always easy to identify 
 126 
 
or uniformly positive. Some participants struggled to identify any impacts as a result of 
DCM™ implementation, or to definitively attribute any impacts they did identify to DCM™ 
implementation. Participants who could not identify or attribute impacts were often, but not 
always, from homes who had struggled or failed to implement the trial’s recommended dose 
of DCM™.  
 
5.4 What contextual factors shaped if and how the intervention was implemented or 
worked? 
5.4.1 What were the perceived barriers and facilitators to intervention implementation, 
mechanisms of impact and perceived impact from the perspective of mappers, DCM™ 
expert mappers, managers, staff, residents and relatives? 
 
The data indicated that implementing DCM™ in care homes is complex, and there are many 
factors that may facilitate or prevent successful implementation. Barriers and facilitators 
were identified by managers, mappers, expert mappers and staff members and related to 
three main themes; care home level barriers and facilitators, intervention barriers and 
facilitators, and trial barriers and facilitators. 158 
 
5.4.1.1 Care home level barriers and facilitators 
5.4.1.1.1 Care Home Context 
Contextual features of care homes affected the degree to which DCM™ was implemented 
within each care home. This included broad issues, such as the type of setting and staffing 
levels or losses, and more specific issues such as the availability of computers in the home 
and funds to support implementation. 
The type of care home may have influenced implementation, with additional complications 
present in nursing homes. However, the value of DCM™ in more complex settings was 
acknowledged. 
“I think it’s just the work load, really. The amount of work there is sometimes, and 
with it being a nursing home - the intensity of the workload. Obviously, we have a lot 
of very poorly people sometimes.” (58930 Mapper) 
Managers of residential homes felt they were disadvantaged by a lack of qualified staff 
members, who might hold expertise that would help to facilitate implementation. 
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“Because we are only a residential home, erm, y’know, we haven’t got nurses and 
stuff so my staff aren’t that confident anyway… I’m glad we got involved because we 
got a lot out of it, I’m just disappointed that we weren’t able to continue.” (10666 
Manager) 
Larger care homes that were well staffed were able to build time for DCM™ into their rotas, 
whereas smaller care homes with less staff could struggle to accommodate the cover 
required to facilitate DCM™. 
 
“That’s the reason we pulled out, is because they [mappers] couldn’t carry on doing 
their deputy manager role, or senior care role, and be a mapper with the amount of 
reports ... So I think it’s just a bit unrealistic.” (50011 Manager) 
Across all care home settings, high levels of staff turnover were an issue. Consistency of 
staff involvement is needed to understand change over time for residents and also to 
implement changes as a result of DCM™.  
“Care homes are really, really busy. Turnover of staff in care homes can be quite 
dramatic at times, and the realities are there’s other pressures on them isn’t there. 
But that’s, that’s it though isn’t it. That’s the reality of anywhere though I suppose.” 
(DCM™ expert 70005) 
Particularly important in relation to staffing of care homes, was the turnover of mappers. Not 
only did this lead to delays in implementing DCM™ whilst additional mappers were recruited 
and trained, but this also impacted on the confidence of remaining mappers, leaving some 
feeling overwhelmed by what was required of them.  
“I think where I struggled and like with the report and things was because I was the 
only mapper, they were like “I need you to map three people”. And it was like ‘ahh… 
my first map’. And I’m mapping three people whereas if there was somebody with 
me, then we could’ve both done that together.” (50028 Mapper) 
Care homes with limited access to computers experienced difficulties with completing the 
computer-based elements of DCM™. 
“We’re not always the most IT literate in care homes. Having access to computers 
and time to analyse can be quite difficult.” (50018 Manager) 
Some care homes also had high demand or competing priorities at the time, such as CQC 
reports or problems with staffing levels. 
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“It was mainly the home, the crisis that the home was in … Knowing the staff we had 
at the time and the difficulties we had… I struggled just to get them to do the health 
and safety training, the basics.” (50009 Manager) 
These findings suggest that DCM™ implementation may be easier in larger nursing or 
dementia-specific care homes with greater numbers of qualified staff, where there may be 
greater access to computers and to funds and larger staffing pools to provide cover for 
mappers to undertake DCM™. 
 
5.4.1.1.2 Manager 
The care home manager was a key individual in the success of DCM™. Whilst managers 
were not always involved in the implementation of DCM™, as they generally had 
responsibility for rotas, allocation of staff workload and supervision of the mappers, their 
engagement either ensured it ran efficiently or placed barriers for the mappers. 
“I think management support, you know, it can either be amazing when it’s amazing 
or it can be a real difficulty if the manger isn’t supportive.” (DCM™ expert 70006) 
Generally, there was thought to be a lack of support from managers. Managers needed to 
have awareness of the time required for their mappers to be involved and willing to support 
this process.  
“The managers delegated all aspects – all of it – to the mappers, and didn’t take any 
responsibility for ensuring the process. I think the odd manager was supportive, 
again from the office, but not really understanding about making time.” (DCM™ 
expert 70004) 
Where there were difficulties in the relationship between managers and mappers, issues 
arose for mappers, particularly at the feedback stage. The hierarchical nature of care homes 
sometimes acted as a barrier in the process, meaning that mappers were unwilling or felt 
unable to challenge the care home manager.  
“It’s mainly from a confidence perspective, [they] were clearly not confident to 
challenge a manager who was not supporting.” (DCM™ expert 70003) 
Conversely, where managers were engaged with DCM™, this facilitated the process and 
helped mappers to make changes based on what was observed during the cycles. 
Furthermore, where managers valued DCM™, they could see clear benefits from 
implementing it. For example, one manager believed that it was a key tool to help the CQC 
rating of the care home improve.  
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“They were very clear that they thought DCM™ was fantastic, because they saw it as 
a way of improving the quality of their care to take their home CQC rating from good 
to outstanding.” (DCM™ expert 70004) 
Managers referred to adaptations required to make DCM™ fit in their home. This included 
suggested or actual adaptations to the process of DCM™ itself, such as shorter maps, and 
hypothetical or actual adaptations to the work of staff, such as changes to rotas and over 
time. 
“We’re going to be having to change shifts so they can be on shift at the same time 
every month because we can do some mapping.” (Manager 50010) 
These findings suggest that managers are key in the implementation of DCM™, and can act 
as either a barrier or facilitator. A good relationship between the manager and mappers is 
crucial to successful implementation. 
 
5.4.1.1.3 Motivation and enthusiasm for DCM™ 
Motivation and enthusiasm was a key factor when implementing DCM™. Expert mappers 
emphasised that when managers and staff teams were motivated to be involved in the 
DCM™ process, mappers were more likely to implement DCM™ within the home. 
“The manager would come in and you know be really enthusiastic. They came to the 
briefing, everybody was at the briefing, the whole home, the manager of the home, 
do you know what I mean. The company really bought, really bought in to DCM™. 
And the two girls, the two mappers were just really enthusiastic about it, … and 
really, really tried their hardest.” (DCM™ expert 70005) 
Capitalising on this motivation and confidence by undertaking the first cycle of DCM™ soon 
after the training appeared to have benefits, with greater difficulties experienced if mapping 
was undertaken or attempted a while after attendance at the training session. 
“They went for that training down in London then there was a gap and I kind of think if 
they had just gone straight in and done the mapping, they might have done it. But I 
feel that when a few weeks passed, they were struggling to say how we do this… 
maybe they didn’t have the confidence, you know what, to roll it out.” (10666 
Manager) 
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The motivations of mappers were sometimes overshadowed by the time constraints within 
care homes, meaning that the mappers were able to complete the mapping hours, but often 
struggled to find the time to sit and discuss what had been observed. 
“When I was actually there we had lots of you know creative really, very inspiring 
conversations about care practice. But it’s trying to nab them, it’s almost like it’s 
impossible to nab, sit the person down and really discuss what’s going on.” (DCM™ 
expert 70002) 
In summary, having motivation and enthusiasm for making changes to practice was key in 
the success of DCM™. However, the challenges faced, such as time constraints, sometimes 
overshadowed the motivation of individuals. 
 
5.4.1.1.4 Staff engagement 
As DCM™ is a home level intervention, effective engagement with care home staff 
influenced the extent to which DCM™ was implemented. Particularly important was having 
staff who were open to feedback based on the observations, and willing to contribute 
towards formulating action plans. In some care homes, the mappers were able to engage a 
large proportion of staff in feedback sessions, which was seen as a positive by the DCM™ 
experts. Mappers who were in more senior roles may have found it easier to encourage staff 
to attend feedback sessions, due to their status within the home. 
“I was so impressed how they just gathered people up, at busy times as well. And 
they really saw the worth of that, and great discussion. I was, and that was the first 
home, so I thought wow this really works.” (DCM™ expert 70002) 
In order to implement a care home level intervention, the involvement of all staff roles was 
crucial. The importance of staff members in a range of roles attending feedback sessions 
was highlighted.  
“There was a really big crowd actually, and it did include lots of different disciplines of 
staff, including the painter and decorator and maintenance man, which was great.” 
(DCM™ expert 70002) 
The degree of engagement of the wider care home staff with DCM™ influenced the 
implementation of DCM™. High levels of engagement with staff led to more of a ‘whole 
home’ approach to considering DCM™ feedback and agreeing action plans. 
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“You really have to get quite a few people across the organisation thinking in the 
same way to sort of drive that change.” (50018 Manager) 
Staff engagement was achieved through multiple strategies. These included providing 
feedback in staff meetings to ensure good coverage, a focus on ensuring staff understood 
DCM™, its purpose and the outputs of the mapping, a focus on providing positive as well as 
negative feedback helped to ensure staff were engaged with, and demonstration of the 
benefits of DCM™. 
“We sort of ended up picking two or three very small examples of people who were 
very happy or very sad and just focusing on those, describing in laymen’s terms... 
They did take it in a positive way because they’d been, initially we said it’s for all our 
residents’ well-being.” (50018 Mapper) 
The selection of mappers influenced how engaged the staff team were. Where mappers 
were not seen to be popular staff members or people to be respected, it was difficult for 
them to engage with the staff team to implement change.  
“The second time around we held a meeting and nobody came … We did try like you 
know individual, a few minutes at a time, but I don’t think they took it seriously 
enough, do you know what I mean?” (50010 Mapper) 
However, where mappers were respected, engagement was facilitated by implementation 
and feedback being peer led as opposed to being conducted by an external person. 
“It’s people that you know and peer-led, it’s, you know, it’s not like somebody from 
outside coming and talking with them, it engages the staff.” (58930 Manager) 
 
In one home, there was a division in the work environment between staff who did and did not 
support the mapper, which made feedback sessions particularly difficult. This led to further 
difficulties in implementing DCM™, as staff were not willing to make changes to practice. 
This may have been reflective of the culture in the care home, highlighting underlying issues 
that existed prior to involvement in the trial. 
“I would say in that home there’s two very definite groups of staff, the ones who want 
to see progress, who would support the mapper, who would want to encourage her 
and make it work, and there was also a very strong group of people who say you 
know ‘what she thinks she’s telling us’.” (DCM™ expert 70001) 
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Negative attitudes towards DCM™ from both staff and managers also acted a barrier in the 
engagement with DCM™. If DCM™ was not perceived to be a priority, staff often did not 
take time to learn about and understand the process.  
“I felt that the ways that people had been working prior to that, the culture of the 
place, whilst there was a lot about it which I would really commend it for, there were 
definitely some things that needed to be looked at. And I felt that there was a 
reluctance to look at that. And there was quite a lot of defensive response.” (DCM™ 
expert 70001) 
Some staff questioned the validity of DCM™ when the presentation of residents was 
changeable or they considered that DCM™ did not suit the residents they provided care for. 
“…some of our residents are quite, quite poorly so it doesn’t work for them, it just     
depends how well they are.” (58747 Staff) 
 
However, gathering together to collectively reflect on DCM™ feedback sometimes made 
staff feel a part of the process and helped to break down potential barriers and mistrust, for 
example in relation to being observed and receiving feedback, which staff could have past 
negative experiences of. 
 
“In most cases when it happens, it’s a negative experience because there’s 
inspectors from various organisations, so I think it wasn’t until we started giving 
feedback and there was quite a bit of positives in there that the staff really got 
engaged with the process.” (50018 Manager) 
In summary, staff engagement was crucial to the implementation of DCM™. Without the 
support of the staff team, mappers struggled to make practice changes. The mappers 
needed to be respected by the staff team for DCM™ to have any influence in the care home. 
The importance of receiving feedback from peers rather than external individuals was 
highlighted.  
 
5.4.1.1.5 Mapper qualities 
Choice of mappers, including whether they had required qualities, were a key indicator of 
implementation success. The qualities valued in mappers, that were considered by 
Managers to facilitate DCM™ implementation, included confidence to undertake the 
mapping and feedback sessions, leadership skills to motivate and influence action planning 
in the home, pragmatism, dedication, an interest and enthusiasm for DCM™ and for 
 133 
 
improving the care of people with dementia, and a keenness to learn. Managers were asked 
to select mappers and those recruited were based on the skills required to become a 
mapper, but also the staff members that were available to choose from in each home, who 
were deemed likely to remain working at the home for the duration of the trial. 
“Two team leaders stuck out a being really passionate about people living with 
dementia.” (50019 Manager) 
Attending the training and implementing DCM™ improved the confidence of some mappers.  
“I never thought I’d be able to do it, but when we got back here, and after the training 
we actually put it into practice ... It all made sense.” (50031 Mapper) 
Mappers having motivation to improve the quality of care for people with dementia helped 
facilitate the implementation of DCM™. However, for one mapper, the challenges of 
implementing DCM™ overruled her motivation and she became disengaged with process. 
“I think it impacted on how they felt about it. It became a chore and one lady I can 
think of in particular was very excited and motivated about it, and became less so 
because of the challenges. And that’s really sad to see. Someone who had that real 
passion to just go “do you know it’s just too hard and”, and, but initially is like “I’m 
happy to come in on my day off because I think it’s marvellous”, but when you’re not 
then getting that support it you know wears you out really. Wears you down.” (DCM™ 
expert 70003) 
Certain skills and abilities were also perceived to be central to enabling mappers to 
undertake the various processes involved in implementing DCM™. These skills and abilities 
included computer literacy, writing high quality reports, fluency in English, and sufficient 
academic ability to undertake the more complex components. Conversely, mappers who did 
not possess some of the aforementioned qualities or skills, despite the trial processes used 
to identify and recruit mappers with the required skills, could struggle to implement DCM™. 
In particular, the lack of IT skills, confidence and insufficient fluency in English were cited as 
barriers to DCM™ implementation. 
“For me it was quite difficult because English is not my native language.” (58930 
Mapper) 
The utility of mappers in senior roles was perceived to have positive and negative impacts 
on DCM™ implementation. Whilst senior staff could possess academic, writing and 
leadership skills which facilitated DCM™ implementation, it was more difficult to free up staff 
 134 
 
in these roles to undertake mapping and they could be subject to multiple competing 
demands on their time which challenged their ability to implement DCM™. 
“[I chose] two quite strong team leaders that I knew would be able to get staff on their 
side and would be able to manage the feedback, because they can be quite difficult 
sometimes.” (50019-Manager) 
“I was disappointed that my staff couldn’t continue with the mapping, but I think I 
made the error in the staff I chose… their level of responsibility in the home was too 
high, so it didn’t enable them to have enough time.” (50167-Manager) 
Whilst the above qualities and skills were identified as important, in reality it could be difficult 
for Managers to identify staff members who possessed many or all of the skills required to 
implement DCM™ in a care home context. 
“If I look at the whole team there are few other people who would have been 
possible, academically capable of completing that project. And that’s a difficulty.” 
(50167-Manager) 
An important component of mapper choice was commitment from the potential mapper. 
Agreement was not, however, always forthcoming given the length of the DCM™ course and 
the often distant geographical locations in which the courses were held. These were 
logistical issues which were especially problematic for staff with caring or other 
commitments. 
“We need someone who would agree to do it, and promise that when they come 
back they’re going to get the job done.” (50021-11082-Manager) 
Furthermore, whilst managers recognised the qualities that were important for mappers to 
possess, in reality the choice of mapper often came down to who was willing and available to 
undertake the four-day course, particularly if this would involve staying in another area. 
“When we found out they would have to do four days training in London, [mapper 
initially chosen] wasn’t able to do that. And because we found out almost at the last 
minute, we just had to grab somebody else that was free really”. (10666 Manager) 
A further example of availability being prioritised above ability was seen in in another care 
home where, following a mapper leaving, the manager did not pick a staff member to attend 
DCM™ training based on their abilities. Instead, the new mapper was selected based on 
their availability to attend the course.  
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“I think when in one case where a manager … didn’t have a clue about who to 
nominate, she was just, she was looking at the off-duty and sort of picking names off 
the off-duty.” (DCM™ expert 70005) 
Mappers who were less qualified or experienced found it harder to implement DCM™. The 
DCM™ process asked mappers who were care assistants to develop and utilise skills that 
they were not familiar with using. Having the skills to ask questions as part of feedback 
sessions that allowed staff members to give opinions rather than yes or no responses was 
particularly challenging for some mappers. 
“It was about time, it was about access, it was about computer literacy. And the, for 
some of the care workers writing anything was a real challenge. You know they just 
not, not used to putting descriptions down, let alone sort of feedback type questions 
to ask.” (DCM™ expert 70002) 
There were many conflicting priorities placed on mappers, particularly if they were staff with 
additional responsibilities, such as completing the medication rounds or conducing 
assessments for potential new residents. This impacted on the time available to complete 
the stages of DCM™. 
 “Well it was all just such a squeeze in the day, you know, and I remember being at 
one home where one of the mappers was late, one of the other mappers was busy 
doing the drugs, you know, and that was quite a familiar scenario”. (DCM™ expert 
70004) 
In summary, selection of mappers had a significant impact on delivery of DCM™ as an 
intervention. Recruiting mappers with the appropriate skills facilitates the delivery of DCM™, 
as difficulties with stages of the mapping process such as analysis, and report writing, can 
result in much more time than anticipated needing to be dedicated to the completion of 
cycles. For mappers to undertake the DCM™ cycles a degree of effort, commitment and 
time was necessitated that some mappers had not anticipated or appreciated when agreeing 
to take on the role. The amount of time required to be away from their usual roles to 
undertake DCM™ meant that it was not viewed by some, in its current form, as a tenable 
intervention in a care home setting. Ensuring that Managers understood what skills are 
particularly important for mappers helps to reduce the likelihood of these acting as a barrier 
in the delivery of DCM™. 
 
5.4.1.2 Intervention barriers and facilitators 
A number of barriers and facilitators related to the DCM™ intervention itself were identified. 
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5.4.1.2.1 Understanding of DCM™ 
The extent to which mappers, managers and staff valued and understood the benefits of 
DCM™ influenced whether it was successfully implemented or facilitated. Where DCM™ 
was perceived as a tool and process that could improve the quality of care being delivered, 
managers and mappers were more engaged. In care homes where DCM™ was not 
understood, particularly in terms of the time commitments required, there were issues with 
completion of cycles. 
 “The manager that clearly didn’t get it, I think was just so busy with everything else. 
absolutely, you know, I did see her running around like this, yeah.” (DCM™ expert 
70003) 
An understanding of the DCM™ process and its potential for changing the care delivered in 
care homes is crucial to successful implementation. Where some of the trained mappers did 
not fully understand the process, they struggled to explain it to others. 
“The trouble is, when they came back [from the training], they weren’t able to explain 
properly what they had to do. So, you know, they were trying to explain it to us and 
we were finding difficulty understanding what was actually involved.” (10666 Staff). 
As a result of a lack of understanding of DCM™, managers and staff did not always engage 
with the process. 
“I still don’t understand it … no one has been able to understand it to me fully… 
Every time I asked them [the mappers] to explain they were struggling. So I never got 
a full grasp of what it was all about.” (10666 Manager) 
Where managers did not understand the process or value of DCM™, it was perceived as a 
distraction and it became particularly difficult for mappers to be released from their duties. 
“I would say the challenges outweigh everything else really.” (50009 Manager) 
However, for the majority of mappers, the value of DCM™ was clear and easily understood, 
even where this was not clear to the managers.  
“You can see a big difference. You can actually see what goes on through their [the 
residents] eyes. When you sit there and watch them for about three hours.” (10180 
Mapper) 
These findings indicate the importance of mappers, managers and staff having a clear 
understanding of the DCM™ process before attempting to implement it. Without this 
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understanding, mappers are unable to be released from their duties to complete mapping 
tasks, as it is not seen as a priority or a valuable tool within the care home. 
 
5.4.1.2.2 Complexity and time demands of DCM™ 
DCM™ was felt to be complex and time consuming by some participants, with the nature of 
DCM™ felt by these participants to be a barrier to its implementation in a care home context. 
Various aspects of DCM™ were felt to be too complex, including the observation phase and 
associated coding, the report writing, and the language used.  
“So the report writing, yeah, was horrific to be honest. Very time consuming. 
Obviously we both had different roles at that point so quite demanding, so getting 
time, and it’s not a very quick process. Like I say it took quite a lengthy period of 
time. So that were quite bad to be honest, it was very demanding.” (50069 Mapper) 
Particular components of the process were identified as time consuming or overly onerous, 
including the length of the training course, and the paperwork and report writing 
requirements.  
“Some of the things that certainly I picked up on, some of the things they found more 
difficult was around the kind of data analysis and report writing. That was the area 
that people seemed to find most difficult.” (DCM™ expert 70006) 
For some mappers, there were delays between them attending the training course and 
completing their first cycle of DCM™, which might have led to them forgetting some of the 
more detailed parts of the process, such as the observational coding framework. The DCM™ 
experts had to give additional time that was not expected to help mappers ‘revise’ some 
parts of their training before starting the mapping cycle. 
“I mean one person I worked with we did our first IRR, our first kind of check of her 
accuracy and I think we got, our agreement was kind of in the forties. Like it was 
very, very low. And that was mapping one person for an hour.” (DCM™ expert 
70006) 
The time required to undertake DCM™ meant that mappers had to be taken away from their 
usual roles and defined as ‘off the floor’, therefore removed from the core business of care 
delivery in the case of direct care staff. 
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“The mappers were also carers and nurses and had, you know, activities and tasks 
and jobs to do as well as the mapping. Yeah, I think they found it quite 
overwhelming.” (58930 Manager) 
In addition, some managers felt that once the training course was completed they were then 
left to implement DCM™ on their own, although in reality every home had access to a 
DCM™ expert for 5 days to support implementation of their first cycle. Such views raise 
questions about the fit of DCM™ for care homes and suggest the need to consider adapting 
standard DCM™ processes for care home staff in the future development of the tool. 
 
5.4.1.3 Trial barriers and facilitators 
5.4.1.3.1 Expectations of DCM™ and the trial  
Expectations of the trial and what was required to support the implementation of DCM™ did 
not meet the realities experienced by participants. In particular, the time and costs exceeded 
those expected by the managers and mappers. This impacted on the schedules in place for 
each care home and led to the expert mappers having to consistently renegotiate schedules. 
“But from start to finish, although we renegotiated kind of schedules for me going 
down there it was difficult, I think they would say that they weren’t aware of the time 
commitments to it.” (DCM™ expert 70005) 
Some managers were not aware that the mappers could not be included as members in the 
staff team and thus could not provide direct care on the days they were mapping. These 
managers did not appreciate that the mappers were unable to stop mapping to assist 
residents with any care needs they had during the mapping process. This led to tensions 
between some managers, mappers and expert mappers. 
“They were definitely not aware of that because they were not normally on the part of 
the numbers, so they didn’t realise that they would have to be off the numbers to do 
the you know, preparing the map, for the mapping, for the map itself and to do the 
rest of their work.” (DCM™ expert 70005) 
The range of processes and tasks involved in participation in the trial, as well as those 
involved in implementing DCM™, such as the completion of trial and DCM™ paperwork, 
seeking consents, undertaking interviews and identification of staff participants, were not 
anticipated by managers or mappers prior to taking part. 
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“They struggled with the copious amounts of paperwork, they told me that if they 
knew what was involved that wouldn’t have gone for it.” (50019 Manager) 
In summary, conduct of the trial may have negatively influenced perceptions of the tenability 
of implementing DCM™ in care home settings, with the combined burden of trial and DCM™ 
participation proving difficult for some care homes to manage. Mismatches occurred 
between expectations of what the DCM™ intervention entailed and the additional work that 
was required by managers and staff during the trial, despite having been provided with 
detailed written and verbal explanations of the processes and time involved by the research 
team. Care home managers and mappers were not fully aware of the expectations of them 
during the trial, particularly in relation to the time involved in each stage and component of 
the trial, and the requirement of mappers to focus on all aspects of the DCM™ intervention 
while in the mapper role, with the consequence of being unable to attend to usual care work 
at these times. This had a negative impact on the ability of mappers to implement DCM™, 
as they were frequently not released from the staff roster to complete the DCM™ 
procedures. 
 
 
5.4.1.3.2 DCM™ expert mapper support 
DCM™ expert mappers viewed themselves as incredibly valuable to the implementation of 
DCM™, suggesting that without their input and support, DCM™ would not have not been 
successfully implemented in the majority of care homes. 
“If the expectations had remained the same, I don’t think it would have worked  
without the expert mappers.” (DCM™ expert 70006)  
 
However, two DCM™ experts felt that the mappers would have completed the cycles 
regardless of whether they supported the mappers or not. They thought instead that the 
observation data or implementation process would have been of a lower quality without their 
support to the mappers. 
“I think some of the classic mistakes that can be made in DCM™ would’ve been 
made … and if they hadn’t been picked up and supported or changed, it can have a 
really devastating effect on DCM™.” (DCM™ expert 70002) 
Support provided by the expert mappers helped to clarify any uncertainties and alleviate 
mapper doubts. 
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“It is nice to have somebody sat with you whilst you’re actually doing it practically, to 
be able to say ‘Am I using this code or that code?’ ‘Am I observing this right?’” 
(58930 Mapper) 
When DCM™ expert mapper support was delivered flexibly and with a friendly manner, it 
was valued by care homes. There were, however, also times when support was perceived 
as problematic. 
“The expert mapper was a little full on. Knew her subject, very passionate, but very, 
erm, timescale orientated. Which kind of pushed, I think, added to the stress.” (58930 
Manager) 
The DCM™ expert mappers believed they went above on beyond their expected roles to 
provide support within care homes. They were allocated five days of time to support each 
care home, however they felt that much more time than this was required. Certain situations 
led to increased need for DCM™ expert mapper support, such as a care home having only 
one mapper, or tensions in the relationship between mappers. 
“I’ve tried to support her individually because the other mapper hasn’t supported her 
in the individual care summaries. So I’ve tried to support her extra by phone and do 
that, but I don’t think she was, she had the skills to do that by herself.” (DCM™ 
expert 70005) 
Despite support from the DCM™ expert mapper being provided to all homes during the first 
cycle of DCM™, not all homes felt supported. 
“I feel as if we were, had the training and then left to our own devices really.” (50024 
Manager) 
Conversely, some mappers felt that they did not need the support and that as they know the 
residents well, they had a better insight into the residents than the DCM™ expert. 
“When you learn anything really you just want to go and do it on your own don’t you. 
You don’t want someone looking over your shoulder going: yeah, yeah you’ve not 
done that right, or I didn’t get that or why did you put that … well I know that resident 
and I know.” (50069 Mapper) 
For other homes, the mappers benefitted from DCM™ expert mapper support during the first 
cycle but felt that they required more than was provided, to continue to undertake DCM™ 
cycles. 
“When she’d gone the support had gone” (50010 Mapper) 
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One DCM™ expert mapper suggested that for future DCM™ research, research assistants 
should support mappers to complete DCM™ paperwork. However, this does not represent 
the standard use of DCM™ within care homes and thus the pragmatic trial design employed 
in the present trial. 
 “I think you would’ve really struggled if they hadn’t had someone going in. Be that an 
expert mapper or be that a research assistant, to go in and support them with doing 
the paperwork and completing that, which obviously would un-blind the researchers. 
But they would need some kind of support to be able to engage with the research.” 
(DCM™ expert 70006) 
These findings suggest that DCM™ expert mappers felt that their influence had a positive 
impact on DCM™ delivery and resulted in substantially more cycles being completed than 
would have been without their input. However, this support was not always appreciated by 
the mappers. The implementation data, which shows only 26% of intervention homes 
completed further, acceptable DCMTM cycles after the expert supported first cycle, suggests 
the value of expert mapper input for supporting DCMTM implementation in care home 
settings.  
 
5.4.1.4 Summary 
There were many barriers and facilitators to implementing DCM™, due to the complex 
nature of both the intervention and care home settings. Selection of appropriate staff as 
mappers was key, ensuring that they had the necessary skills to implement all aspects of 
DCM™, including suitable language skills, the time to undertake all aspects of DCM™ within 
their day to day role, were well respected by the staff team, and had leadership capabilities 
and influence among staff. It was crucial that the expectations of DCM™ were understood by 
both care home managers and mappers before training was completed. Implementation was 
easier in larger care homes, where there was a larger staff budget to allow mappers to be 
released from their usual roles. The support of expert mappers was felt to be particularly 
important in the beginning to implement DCM™. While this is not a standard component of 
DCM™ unless purchased as an addition to standard training, it was a necessary feature of 
mapper support during the trial. These findings have implications for considering the way 
that mappers are currently trained and the support that may be required to implement 
DCM™ in practice (fully engage in the 4 phases of a DCM™ practice development cycle).   
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5.4.1.5 Specific barriers and facilitators to identifying, achieving or maintaining impact 
Alongside the barriers to intervention implementation (and so to impact) identified above, 
there were some specific barriers and facilitators to identifying, achieving or maintaining 
impacts from DCM™.  
 
5.4.1.5.1 Barriers to identifying impact 
Challenges to identifying impact arose primarily from perceived difficulties in accurately 
identifying the impacts of any care improvements on people with dementia. For example, 
some staff and relatives felt that people with dementia would not be able to recognise the 
impact of any changes made, and some relatives (who may have been involved in 
completing outcome measures) felt it was difficult for them to identify changes in their family 
member due to the infrequency of their contact with the resident: 
“They [people with dementia] will not acknowledge it [DCM™] as having an impact on 
them.” (50011/10160) 
“I think their life has perhaps been improved by it, but I don’t know whether they 
would be able to express that or realise that.” (Manager, 58930) 
“I think it’s amazing and probably essential, and you know, it’s hard to get data 
because… the residents themselves aren’t particularly reliable.” (Relative, 50016) 
 
5.4.1.5.2 Barriers to achieving positive impacts 
Interviewees spoke of multiple challenges to achieving positive impacts from DCM™. Some 
of the more predictable barriers included staffing, the costs of making changes, and 
competing priorities for staff such as high workloads or emergencies. For example, if 
competing priorities meant that action plans were not always carried out then potential 
impacts from DCM™ were not always realised: 
“You are trying to carry action plans out, but the day to day everything means that 
you can’t carry them out as much as you’d like to because, like I say, you end up with 
short staff, you end up with emergencies.” (59830/40002) 
Understanding and perceptions of DCM™ (e.g. of its purpose, quality and reliability) and 
perceptions of the current quality of care in the home appeared to shape the degree to which 
the outputs of mapping sessions were attended to or seen as indicating a need for change: 
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“They [staff] don’t understand what it is.” (50010/10095) 
“The main issues [with DCM™] are, some of the things we got on the feedback were 
well you were looking at so and so, they hadn’t slept last night so that’s why they’ve 
been nodding off the whole time. So even for that resident it sometimes doesn’t give 
you an accurate picture.” (50018/10268/10277) 
[Answering a question about whether changes to care have occurred] “No I don’t 
think so, because they’re all pretty good anyway. The staff here are pretty good. So 
we do sort of pride ourselves on person-centred care.” (50031/10456) 
Additional barriers to achieving positive impacts included staff who were not open to change, 
and a lack of managerial or financial support for changes proposed as a result of DCM™ 
cycles: 
“Obviously you always get a few who don’t want to take on board anything.” 
(59830/40002) 
“When we do the briefing we, let’s say, decided to do some things a different way, 
and they agree. But later on they found some difficulties, like I said, to change the 
chairs or something. And then maybe that’s cost then.” (58757/10446) 
 
5.4.1.5.3 Barriers to maintaining positive impacts 
Some care homes experienced challenges in maintaining positive impacts from DCM™ over 
time. These challenges included difficulties in maintaining staff engagement with the DCM™ 
process, in particular with the feedback and action planning sessions, and difficulties 
maintaining momentum as staffing teams changed over time: 
“People stopped turning up… The first time around… we had maybe eight or 
something in here, and they did, you know, we had a good meeting. But then the 
second time around we held a meeting and no one came… we put posters up all 
over and we let everyone know that we were doing these feedback sessions… and 
nobody turned up.” (50010/10095 & 10096) 
“I think sustained changes certainly from the staff who were here then, but the staff 
who haven’t actually had that form of training, the momentum has waned actually.” 
(Manager 50024) 
Of note in relation to achieving and maintaining positive impacts for care home residents 
generally, many examples of impacts for residents were specific to individuals who had been 
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mapped. These findings suggest that the impacts of DCM™ may be greater for mapped 
individuals, rather than residents who were not involved in mapping: 
“The ones that we mapped, I’d like to think are more gainfully employed with their 
time.” (50069/10475) 
“We have observed a resident then we have made a care plan specific to that 
resident’s needs.” (50011/10160) 
As mapped individuals were a small minority of the trial sample, producing and maintaining a 
positive effect on residents more generally may have been a difficulty for homes which 
focused predominantly on action planning for mapped individuals and focussed less on 
development of home level action plans. Given mappers could select any care home 
residents to be observed during DCM™ cycles, those mapped were not necessarily trial 
participants. In addition, a focus in some homes on addressing the needs of mapped 
individuals may have reduced the longer-term impact of DCM™ as the high rates of death 
and transfer to other care settings made it likely that many mapped individuals were no 
longer residing in the homes at follow up:  
“Even to be observed, for them [mapped individuals], was kind of benefitting… but 
unfortunately most of them are not here anymore… so we can’t say ‘oh it’s brilliant, 
working…’ (58787/10446) 
Action plans and impacts for mapped residents were not necessarily transferrable to other 
residents, or were not viewed as such by staff, which may have affected the degree to which 
positive impacts from DCM™ were able to be maintained over time. 
 
5.4.1.5.4 Facilitators to achieving and maintaining impact 
As well as identifying challenges to achieving positive outcomes from DCM™, interviewees 
also reported a number of factors that facilitated the achievement or maintenance of 
impacts. Changing staff perceptions of the quality of care they were providing, and/or their 
perceptions of people with dementia and their needs, was a key impact facilitator: 
“You don’t realise, when you’re walking through the room, that you’ve passed ten 
people and you haven’t even spoke to them.” (10095) 
 “It encourages the staff to think more of them as people… because obviously they 
[people with more advanced dementia] don’t respond as much… so it has helped in 
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that way, to make them more aware that they still have to have the same contact, the 
same explanations for them.” (59830/40002) 
As creating change in care practices was dependant on staff recognising the need for 
change, mappers needed to understandably demonstrate the issues with current care in 
order for these to be recognised and addressed by staff: 
“It’s really tempting to go in gung-ho and start talking about PEs and the different 
codes, and it’s like trying to sit the staff down and talk about trigonometry. It’s not 
something interesting that makes much sense to them… We sort of ended up picking 
two or three very small examples of people who were very happy or very sad and just 
focusing on those, describing it in layman’s terms.” (50018/10268/10277)  
“It was good and clear to see, you know, which areas we really needed to improve 
on.” (Manager 50069) 
Making DCM™ feedback accessible helped staff to understand the need for changes in their 
care practices, and the purpose and value of DCM™ - a lack of understanding of which was 
an identified a barrier to impact. Creating a shared understanding of the need for 
improvements was felt to be an important driver for change: 
“You really have to get quite a few people across the organisation thinking in the 
same way to sort of drive that change.” (50018/10268) 
“One thing I am more aware of is how staff, certain staff, sometimes talk to 
residents... in the inductions now that we do, we make it really clear about what we 
want a new member of staff, how we want them to interact, how we want them to 
speak… I go through how I would like people to speak to residents.” (50069/10475) 
Embedding DCM™ data, feedback and action plans into the work of the care home, through 
their inclusion in care plans, handovers and staff meetings, and engaging staff across the 
home in identifying care improvements, were strategies through which mappers tried to 
ensure a home-level approach to care improvement: 
“We implemented it in our handovers as well as through all the team leaders”. 
(10181) 
“Putting together a dementia group which has carers, cleaners, people across the 
organisation, and you talk to them and try and actually get them on board. You try 
and sort of instil in them what person-centred care looks like.” (50018/10268) 
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“So then I could …say to the chef ‘This gentleman plays with food, what can we do?” 
50028/10394) 
Some of these actions to embed DCM™ into usual care practice also helped to ensure 
changes were maintained. In addition, the identification of achievable changes, such as 
where staff were encouraged to interact more with residents on a routine basis, were 
considered by participants as a good strategy for facilitating impact. 
 
Summary 
Multiple barriers and facilitators to identifying, achieving and maintaining impact were 
identified by participants. These included difficulties in measuring impacts for people with 
dementia, competing care priorities, levels of managerial, financial and home-level support 
for change, and staff understanding and perceptions of DCM™, of current care quality and 
the need for change, and of people with dementia. A focus on care improvements for 
mapped individuals can limit impacts for other residents and the maintenance of impact over 
time. 
 
5.5 Mechanisms of action 
In this section we have drawn on the available evidence to assess if the anticipated 
mechanisms of action or logic model through which we expected DCM™ to have an impact 
on outcomes, were present.  
 
5.5.1 Ancillary analyses (moderator/mediator analyses) 
Complete cases of the cross-sectional sample were included in the analysis of care home 
level moderators identified a priori, see Table 24. Moderators were measured at baseline 
and assessed by including an interaction between treatment arm and the moderator variable 
in the primary analysis of CMAI one at a time. There was no evidence of moderation of any 
pre-specified baseline characteristics on CMAI at 16-months. The results are exploratory 
and should be treated with caution. 
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Table 24 Assessment of moderators of treatment effect at 16-months – cross-
sectional sample, complete cases – adjusted estimates 
 Unadjusted CMAI score at 16-months (95% CI)  
Moderator Control Intervention 
p-value for 
interactiona 
1. Care home size    0.7672 
       <40 residents 45.1 (42.54, 47.63) 42.8 (40.71, 44.98)  
       >= 40 residents 47.0 (44.06, 50.03) 42.9 (40.45, 45.26)  
2. Care home type    0.8713 
       Independent 46.9 (42.68, 51.20) 40.9 (38.67, 43.12)  
       Chain 45.8 (43.58, 48.01) 44.4 (42.16, 46.61)  
3. Agency staff use    0.1815 
       Below or equal to median 45.5 (42.15, 48.94) 42.2 (40.19, 44.16)  
       Above median 46.3 (43.89, 48.69) 43.7 (41.13, 46.34)  
4. Bank staff use   0.2249 
       Below or equal to median 48.3 (45.19, 51.38) 42.0 (40.01, 43.96)  
       Above median 44.3 (41.81, 46.83) 43.8 (41.25, 46.33)  
5. Self-funding (proportion of self-funded places) 
(continuous) 
  0.8230 
       Below or equal to mean 46.1 (43.52, 48.68) 42.6 (40.68, 44.51)  
       Above mean 46.1 (43.04, 49.05) 43.3 (40.42, 46.11)  
6. Care home facilities (EAT) (continuous)   0.4339 
       Below or equal to mean 45.0 (42.11, 47.92) 41.9 (39.80. 43.98)  
       Above mean 47.0 (44.29, 49.64) 44.0 (41.58, 46.47)  
7. Group living Home Characteristics (continuous)   0.9756 
       Below or equal to mean 45.3 (42.67, 47.87) 42.4 (40.38, 44.43)  
       Above mean 47.1 (44.09, 50.12) 43.4 (40.85, 45.93)  
8. Care home manager experience (length of time in 
care home) (continuous) 
  0.9961 
       Below or equal to mean 45.9 (43.79, 48.06) 44.2 (42.21, 46.18)  
       Above mean 46.8 (41.72, 51.78) 39.8 (37.22, 42.30)  
9. The Quality of Interactions Schedule (QUIS) 
(proportion positive) 
  0.0737 
       Below or equal to mean 46.8 (43.85, 49.81) 44.4 (41.67, 47.11)  
       Above mean 45.4 (42.79, 48.02) 41.7 (39.83, 43.65)  
10. Staff-resident ratio (continuous)   0.3592 
       Below or equal to mean 48.0 (45.03, 50.90) 44.5 (42.41, 46.48)  
       Above mean 44.2 (41.64, 46.85) 39.4 (37.07, 41.82)  
11. Average baseline CDR (continuous)   0.3601 
       Below or equal to mean 44.3 (41.58, 46.95) 39.9 (37.71, 42.12)  
       Above mean 47.8 (44.99, 50.69) 44.9 (42.69, 47.06)  
12. Average baseline CMAI (continuous)   0.7150 
       Below or equal to mean 42.8 (40.43, 45.07) 40.3 (38.21, 42.32)  
       Above mean 49.5 (46.40, 52.61) 45.8 (43.37, 48.19)  
athe same variables in the model as in the primary analysis with added moderator and interaction term moderator*treatment 
 
All 675 residents in the cross-sectional sample were included in the exploratory analyses of 
care-home level mediators of the randomised effect of intervention versus control on CMAI 
at 16-months. The ‘natural indirect’ or mediated effects of each potential mediator (and their 
95% confidence intervals) are given in Table 25 adjusted for all the covariates included in 
the primary analysis of CMAI. It can be seen that no potential mediator was found to 
dominate the mediation of the effect of randomised treatment on the primary outcome, and 
none of the mediated effects were statistically significant at the 5% level. Further analyses 
are planned (outside the scope of the final analyses reported) to explore whether our a priori 
potential mediators have a clearer role in mediating treatment received on the primary 
outcome. 
 148 
 
Unadjusted scores of predictive and process measures are in Appendix 1, Tables 62 to 64. 
Table 25 Causal Mediators Analyses based on Multiple Imputations 
 Adjusted Natural 
Indirect Effect  
(Standard Error) 
95%  
Confidence Interval 
Potential Care Home-Level Mediators (at 6-
months): 
  
Change in care home manager (yes/no) 0.27 (0.22) -0.16 to 0.70 
QUIS (proportion of positive interactions) 0.18 (0.34) -0.48 to 0.84 
EAT improvement in privacy and community (yes/no) 0.21 (0.39) -0.56 to 0.98 
EAT improvement in community links (yes/no) 0.00 (0.37) -0.72 to 0.73 
EAT improvement in domestic activity (yes/no) 0.39 (0.27) -0.13 to 0.91 
Improved Group Living Home Characteristics (yes/no) -0.67 (0.55) -1.75 to 0.41 
Potential Care-Home Level Mediators (at 16-
months): 
  
Change in care home manager (yes/no) -0.00 (0.11) -0.23 to 0.22 
QUIS (proportion of positive interactions) 0.00 (0.06) -0.11 to 0.11 
EAT improvement in privacy and community (yes/no) 0.12 (0.23) -0.34 to 0.58 
EAT improvement in community links (yes/no) - - 
EAT improvement in domestic activity (yes/no) 0.15 (0.17) -0.18 to 0.47 
Improved Group Living Home Characteristics (yes/no) -0.67 (0.42) -1.49 to 0.16 
Mediator analysis did not account for clustering  
5.5.2 Interview data 
Drawing on interviewees’ perceptions of the DCM™ implementation process and its impacts, 
alongside the quantitative trial data, we had intended to propose a model for the 
intervention’s mechanisms of impact. This model was intended to set out the processes 
through which the implementation of DCM™ may lead to change, and the barriers and 
facilitators which may enable or inhibit the achievement and maintenance of those changes. 
Whilst the above results set out some of the contextual features required to facilitate DCM™ 
implementation, and the challenges which need to be overcome in order to implement 
DCM™ effectively, given the negative trial result and the great variability in DCM™ 
implementation observed, we have been unable to come to any conclusions about potential 
mechanisms of action. Specific potential barriers to mechanisms of action were poor 
implementation of DCM™, particularly beyond the first supported mapping cycle, meaning 
exposure to DCM™ over the trial period was limited to one or fewer cycles over the 15-
month period for three-quarters of the intervention homes.    
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6. Discussion  
 
6.1 Key findings 
The DCM™ EPIC trial was a pragmatic, multi-centre cluster RCT of DCM™’s effectiveness 
and cost effectiveness compared to usual care control in UK care home settings. The trial 
evaluated whether DCM™ led to reductions in agitation, other BSC, PRN anti-psychotic and 
other tranquillizer use and improved quality of life for care home residents with dementia and 
improved quality of staff interactions with residents. It also sought to determine whether 
DCM™ was cost-effective. Thirty-one care homes were randomised to implement the 
DCM™ intervention and 19 to control. A total of 987 residents were recruited and registered; 
726 at baseline (308 in the control arm and 418 in intervention) and a further 261 at 16-
month follow-up (99 in the control arm and 162 intervention). A total of 675 residents were 
included in the final cross-sectional sample (287 in the control arm and 388 in intervention) 
used for the primary analysis; 414 from the original sample and 261 recruited at the 16-
month time-point. 
  
6.2 Primary outcomes 
Care home residents in intervention arm care homes did not demonstrate any clinically 
meaningful or statistically significant reduction in agitation compared to control arm 
residents.  
 
6.3 Secondary outcomes 
There were no clinically meaningful or statistically significant differences in BSC, quality of 
life, PRN use of prescription medications for care home residents with dementia at 6- or 16-
month follow-up. However, trends for BSC and mood (depression/apathy) were found in 
favour of the intervention at 16-months in the closed cohort. The prescription rates of PRN 
medications were low across both arms at all time-points and this alongside the wide 
confidence intervals within the secondary analyses makes the results difficult to interpret. 
The quality of staff interactions did not differ between arms at either time-point. 
Given the poor return rates for staff outcome measures we were unable to evaluate any 
potential impact of DCM™ on staff health related QoL (GHQ-12) or feelings of confidence in 
caring for people with dementia (SCIDS). 
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6.4 Economic evaluation 
We conducted an economic evaluation alongside a clinical trial adhering where possible to 
the NICE reference case for technology appraisals.  The primary analysis was a cost-utility 
(cost per QALY) evaluation, and a cost-effectiveness (cost per unit improvement in CMAI) 
evaluation was conducted as a secondary analysis. 
Costs for the intervention per person were £421.07. This depended on a number of 
assumptions including the number of staff involved, number of cycles implemented and the 
number of residents who might benefit. In general, our assumptions regarding these costs 
were conservative.  We also conducted a sensitivity analysis which accounted for different 
costs incurred by care homes dependent on their compliance with the intervention. 
Costs of resource use were substantially higher in the intervention arm and this was driven 
by higher secondary (hospital) care costs. This resulted from the presence of several high 
cost individuals in the intervention arm (n=6 in the intervention arm had higher costs than the 
highest cost individual in the control arm). We conducted sensitivity analyses where we 
removed these six individuals (in a complete case analysis and prior to conducting MI for an 
analysis using MI data) in order to examine the impact of these outliers on our cost-utility 
estimates. 
Regardless of the utility measure used and the analytical approach adopted, QoL appeared 
to be higher in the intervention than control arm at 16-months. Although QoL declined over 
16-months, in general this decline was lower in the active treatment arm.  
The base case ICER was £60,627 and, being substantially over the NICE threshold of 
£20,000, suggests DCM™ would not be an efficient use of health/social service resources. 
The sensitivity analyses were consistent in finding the intervention to be more costly but 
more effective than control. With the exception of analyses which excluded the high cost 
individuals, ICERs from the sensitivity analyses ranged from £24,139 to £57,509. 
Analyses which excluded high cost individuals in the intervention arm yielded ICERs that 
were below (£10,975/QALY for the CCA) or closer to (£36,371/QALY for the MI analysis) the 
NICE threshold. When we examined data on comorbidities and the reason for hospital 
admission for the six high cost individuals, it was not possible to conclude that these higher 
secondary care costs could have been the result of chance rather than attributable to the 
intervention.  Hence there was no reasonable justification for removing these individuals 
from the main analyses. ICERs from analyses adjusting for baseline costs or including more 
compliant care homes only also approached cost-effectiveness. However, these estimates 
were based on reduced samples and are considered less robust. 
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Consistent with the main cost-effectiveness analysis, the net benefit regression analyses 
indicated that DCM™ did not represent value for money when compared to usual care.  
Furthermore, the net benefit regression and CACE analyses also showed no indication that 
intervention compliance may have had a mediating effect.  This was despite the likelihood 
that these analyses were biased by the failure to control for (unobserved) factors related to 
potential differences in care home quality (which might be positively related to the likelihood 
of compliance as well as resident quality of life). 
We found the cost per unit improvement in CMAI to be between £67 and £289 depending on 
the analysis. This lower figure, although not our base case, is roughly in line with previously 
generated estimates of comparable interventions. 159, 160 
 
6.5 Safety 
Undertaking DCM™ was not detrimental to care home residents. No unexpected SAEs 
occurred in the trial and the majority of residents did not have any hospital admissions over 
the trial period, with admissions figures and length of stay similar across intervention and 
control arms. 
 
6.6 Comparison to other trials of DCM™ in care home settings 
The efficacy of DCM™ has been evaluated in three previous exploratory cluster RCTs 63, 93, 
94 and one quasi-experimental trial. 92 The RCT conducted by Chenoweth et al 63 found that 
researcher led cycles of DCM™ led to significant reductions in agitation and falls for care 
home residents with dementia compared to those in the usual care control. Likewise, the 
Norwegian study carried out by Rokstad et al 93 found a significant reduction in overall BSC, 
agitation and psychosis and a significant improvement in quality of life for care home 
residents with dementia in the DCM™ intervention arm, compared to usual care control. This 
study also used researcher-led cycles of DCM™ implementation. Conversely the cluster 
RCT conducted by van de Ven et al, 94 using care home staff led cycles of DCM™, found no 
significant difference in agitation between the DCM™ intervention arm and usual care 
control. This trial did find a significant improvement in staff emotional reactions towards 
people with dementia in the DCM™ intervention arm compared to control. The quasi-
experimental trial conducted by Dichter et al, 92 adopted care home staff led cycles of 
DCM™ and also found no significant benefits of the DCM™ intervention over control for 
resident QoL or BSC.  
 152 
 
The DCM™ EPIC trial is the only pragmatic, explanatory trial conducted on the effectiveness 
and cost effectiveness of DCM™ to date. It did not replicate the findings of the exploratory 
trials conducted by Chenoweth et al 63 or Rokstad et al 93, where significant benefits of 
DCM™ over usual care control for resident agitation, falls and QoL were indicated. It did 
support the findings of the exploratory trial by van de Ven 94 and the quasi-experimental trial 
of Dichter et al 92 where no significant benefits of DCM™ were found for agitation, BSC or 
QoL over control. Unlike the economic evaluation of DCM™ conducted by van de Ven et al, 
161 which found DCM™ to be cost neutral, the DCM™ EPIC trial found DCM™ not to be 
cost-effective. The costliness of DCM™ as an intervention was also identified by Chenoweth 
et al, 63 who found the costs of DCM™ per CMAI point averted over usual care, were 
markedly higher compared to person-centred care training. Due to poor return rates on staff 
measures, we were unable to assess any potential effects of DCM™ on staff outcomes in 
the DCM™ EPC trial.  
Comparison between the outcomes of the DCM™ EPIC trial and previous trials requires 
caution given the pragmatic, explanatory design of this trial compared to the exploratory 
designs of the previous studies. Likewise, this is the only trial to have been conducted in the 
UK and thus the care home resident population, care systems and costs differ from those of 
previous trials. Nevertheless, a common feature emerges in that all trials adopting care 
home staff led cycles of DCM™, even with support from a DCM™ expert or lead, recorded 
implementation challenges and no significant benefits of DCM™ over usual care control. In 
the two trials where significant benefits of DCM™ were reported over control, DCM™ was 
led by researchers and few implementation challenges were identified. This indicates that 
consideration needs to be given to the model of DCM™ implementation and leadership, with 
all trials to date adopting care home staff led cycles, failing to find effectiveness over control, 
in contrast to the trials where efficacy was found through external/research led cycles. 
The potential benefits of externally supported interventions is confirmed by other intervention 
trials in care home settings. The WHELD trial, 76 which combined staff training with support 
from a WHELD therapist who provided coaching, supervision and regular review over a 9-
month period, found statistically significant benefits for quality of life, agitation and 
neuropsychiatric symptoms and positive care interactions compared to treatment as usual. 
The benefits being greater for those with moderately severe dementia. 
This trial is the first randomised, controlled study of DCM™ in the UK and reflects the largely 
practice-led development and evolution of the method in the UK. While the current 8th edition 
of DCM™ was produced following a thorough review process, only the revised observational 
tool was evaluated using formal research methods, with the additional guidance on DCM™ 
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implementation developed through a series of working groups involving practitioners. 109 A 
recent systematic review 96 of the published research evidence on the process of DCM™ 
implementation, when used as a practice development methodology, found only twelve 
papers representing nine research studies that reported on this area. Only six papers used 
formal research methods to gather data and all were published from 2014 onwards, 
indicating the limited published research in this area to date, despite DCM™’s use in 
practice for over 20 years. The review concluded that more research is required.  
The formal process evaluation reported as part of this trial is the largest study of DCM™ 
implementation to be conducted to date internationally. Therefore, in addition to the process 
evaluation results reported above, a number of in-depth papers discussing DCM™ 
implementation from the perspective of mappers, care home staff, care home managers and 
expert mappers are being prepared in order to contribute to this body of evidence.  
 
6.7 Strengths and limitations of the study 
The DCM™ EPIC trial is the largest and only definitive trial of the effectiveness and cost 
effectiveness of DCM™ to date (worldwide). It successfully recruited on time and to target 
adding to the relatively limited body of research on conduct of pragmatic, cluster RCT 
studies in care home settings. Our use of random sampling to approach care homes within 
specific geographical regions permitted recruitment of a number of care homes who had not 
participated in research previously. This has increased the pool of care homes who have 
been exposed to research and in particular to clinical trials and thus the numbers of homes 
who may be considered ‘research ready’. The EPIC trial gave care home staff and managers 
an opportunity to participate in research and a number of staff trained as mappers discussed 
the value they placed on being able to access this training for their own professional 
development. Some of the care homes have expressed a desire to be involved in future 
research projects with the local recruitment hubs.  
The DCM™ EPIC trial has also provided a valuable opportunity to increase the number of 
researchers with expertise in conducting dementia research within care home settings, 
across a range of trial roles. Some research assistants employed on the trial have taken up 
permanent PhD or post-doctoral positions in dementia research or are commencing Clinical 
Psychology training, ensuring their expertise is retained within the field.    
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6.7.1 Study design  
The EPIC trial followed the Medical Research Council guidance on evaluation of a complex 
intervention. A cluster RCT design was utilised, appropriate outcome measures were selected, a 
full economic evaluation was conducted as well as a full, integrated process evaluation. 
However, loss to follow-up was larger than had been anticipated (close to 50% vs estimated 
25-30%) due mainly to resident deaths because of the frailty of this population and this 
resulted in the necessity to implement a design change and to adopt an open-cohort design 
mid-trial. This is not an established design for cluster RCT studies and three of the co-
applicants (Walwyn, Farrin and Surr) have been successful in gaining additional funding to 
conduct methodological research on the use of open-cohort designs.  
Cluster blinding to allocation was not feasible within the trial since care home staff were 
responsible for intervention delivery. Therefore, this could have led to reporting bias. 
Independent observational measures of agitation (PAS, CMAI-O) were therefore collected by 
an independent, blinded researcher to permit analysis of potential reporting bias by arm. 
However, observational measures do not capture agitation that may occur outside of public 
areas, for example during personal care and the set observation days and time meant 
agitation could not be assessed that occurred outside of the observational hours, for 
example evening and night-time and over more than two half- days during a week. 
Therefore, the comparison between observational and proxy reported measures must be 
considered with some caution.   
Researchers were all blinded to cluster allocation and were not permitted to collect data in 
homes to which they became unblinded. This required flexibility within the research teams 
and some cross working between research hubs to provide cover when researchers became 
unblinded. The independent researcher who collected observational PAS, CMAI-O and 
QUIS data was both blinded and independent and so had collected no other data in the care 
home apart from these observational measures. The maintenance of the independent 
researcher and researcher blinding to cluster allocation of homes in which they collected 
data was able to be maintained throughout the trial. 
Due to the variability in the ability of care home residents with dementia to self-report on 
measures of BSC and quality of life, the primary and secondary analyses were conducted 
using staff proxy completed measures. It was not possible to use relative/supporter proxy 
measures as many residents did not have a proxy informant recruited either due to visiting 
less frequently than was required for the measures used (at least once a fortnight) or 
because relatives/supporters did not wish to take part. Proxy completed measures are 
reported to have some but not full correlation with self-report 162 and therefore, it is a 
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limitation of this study that outcomes are reliant upon proxy views. Whilst we attempted to 
use the same staff proxy respondent at each time point, this was not always feasible due to 
staff turnover, sickness and annual leave. There is no reason, to conclude that these issues 
affected one arm of the trial more or differently to the other. However, the issues associated 
with use of staff proxy informants in both arms of the trial must be considered when 
interpreting the results. 
Poor intervention adherence beyond the first expert supported cycle of DCMTM is a further 
limitation. Given the pragmatic trial design, aiming to implement DCMTM in ‘real world’ 
conditions, the findings are important for highlighting implementation challenges and for 
informing future use in such settings. 
 
6.7.2 Health economic analysis 
The health economic analysis has a number of limitations. The level of missing data was 
high and evaluation heavily reliant on imputation. Given the difficulties in incorporating the 
cross-sectional cohort approach in the economic evaluation framework, in particular the 
requirement to have baseline data to calculate change in costs and QALYs, it was not 
possible to fully capitalise on the increased sample size in a robust way.  
The adoption of a health and social care perspective meant that some societal costs were 
not accounted for in the analysis (e.g. informal care), however it is highly unlikely these 
would have had a substantial impact on total costs and collecting such data would have 
presented significant challenges. 
Additional consideration is needed of how to deal with high cost outliers 163 and when it may 
be appropriate to exclude them from analyses. Research should identify the most 
appropriate way to measure and combine QoL estimates in this group.  
Finally, future research should explore the maintenance of the health benefits of the DCM™ 
intervention identified here.  
 
6.8 Generalisability and sources of bias 
Random selection of care homes from the large pool of eligible homes from three 
geographically wide recruitment hub areas ensured a good representation of different care 
home settings and thus generalisability of the trial across care home settings in England. 
This aided minimisation of selection bias. Our exclusion of care homes that were subject to 
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admissions bans, supportive input or other improvement measures, due issues or concerns 
around care quality, means a small proportion (c.3%) 164 of the care home sector were not 
represented in the trial. Following randomisation, the characteristics of the clusters were 
found to be balanced. No clusters were lost during the trial. There was a higher variation in 
cluster sizes in control compared to intervention, however the median cluster size was 
similar in both arms and in both cohorts.  
Recruitment of residents was carefully designed to minimise selection bias at various levels. 
Resident recruitment commenced following the recruitment of care homes but prior to their 
randomisation. All residents who were identified as eligible and who consented to take part 
in the trial were recruited. Following the change in design, recruitment at 16-months of all 
eligible residents with dementia who were not already participating in the trial or who had 
previously declined to take part, contributed to minimisation of selection bias. Researchers 
independent of the care home were involved in resident recruitment. Screened and 
registered residents’ characteristics were well balanced across arms and cohorts, 
demonstrating a lack of selection bias in resident recruitment.  
Allocation concealment during the researchers’ visits to care homes was not always 
successful, however every effort was made that researchers collected no further data in care 
homes to whose allocation they were unblinded. Research blinding to allocation of care 
homes in which they collected data, was able to be maintained throughout the trial. 
 
6.9 Implementation of a complex intervention 
As a pragmatic trial, the DCM™ intervention was implemented as it would usually be in UK 
care home settings, with some components enhanced from standard practice, but still within 
the scope of what would be feasible in usual practice. This included (1) selection of care 
homes on the basis of criteria that would ensure there were no setting conditions likely to 
reduce ability to engage with the trial e.g. quality concerns, competing research studies; (2) 
selection of mappers using criteria of required qualities and skills; (3) provision of a standard 
4-day DCM™ training course with assessment; (4) provision of support for the first cycle of 
DCM™ from an expert mapper; (5) provision of standardised documentation for DCM™ 
implementation e.g. report template, action plan template (6) ongoing telephone and e-mail 
support from the DCM™ intervention lead; (7) prompts to conduct mapping cycles at the 
required intervals sent to mappers by SMS and through the post.  
DCM™ training was provided at standard training locations (Bradford and London) for ‘open’ 
DCM™ courses (those open to any trainees and not purchased by a single provider 
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organisation for their own staff). However, evidence gathered during the mapper recruitment 
phase, subsequent efforts to recruit further mappers to replace those who had withdrawn 
and the process evaluation all indicated that this was difficult for many care home staff and 
thus restricted who could be recruited as a mapper. For the majority of those recruited as 
mappers, the four-day training course had to be completed on a residential basis, or required 
significant daily travel. Some of those identified as potential mappers indicated they would 
be unable to attend the training because of childcare or other responsibilities, whilst others 
did not wish to or were concerned about travelling and/or attending the training on a 
residential basis.  
While overall commencement of DCM™ training within the planned two-months of 
randomisation was adequate, 29% of homes (n=9) experienced delays in training mappers, 
and one home failed to train any mappers during the trial period. Mapper withdrawal was 
also high with over half of homes having one or more mappers withdraw during the trial 
period and a third of homes having no trained mappers in post by 16-month follow up. 
Reasons for withdrawal were mainly personal (leaving the organisation, ill-health, maternity 
leave, change of role within the home). Finding suitable replacement mappers who could be 
trained during the trial period was not possible in the majority of homes. These issues 
impacted on the ability to implement DCM™ over the trial period and raise questions 
regarding the long term sustainability of DCM™ as an intervention within care home settings. 
Given DCM™ is an established intervention, piloting of its implementation was not 
considered as a requirement within this trial. However, given the lack of robust evidence on 
implementation of DCMTM available at the time of trail design and the subsequent 
implementation challenges identified, undertaking some feasibility work to assess 
intervention adherence in care home settings and potential barriers and facilitators to this 
may have been beneficial. Published and practitioner evidence regarding best practice in 
DCM™ implementation was consulted in designing the study, and experts in use of DCM™ 
were involved in the trial design and delivery. DCM™ implementation within the trial included 
the range of supports and prompts for mapping described above, which are over and above 
what would normally be received by a mapper following completion of DCM™ training. 
Nevertheless, considerable DCM™ implementation difficulties and problems with 
compliance were still encountered.  
 
6.9.1 Intervention compliance 
DCM™ implementation was poorer than expected and even with DCM™ expert mapper 
support, 10% of intervention care homes failed to undertake any DCM™ activity and 23% 
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did not complete one full cycle. A further 52% of homes completed only their first expert 
mapper supported cycle, leaving just over a quarter (26%) who completed more than one 
cycle with only 13% (n=4) completing the three full, per protocol cycles to an acceptable 
level. This was despite a range of methods for tracking and supporting intervention 
compliance were implemented during the trial. Tracking intervention compliance was 
challenging and required considerable effort. Despite this there was missing documentation, 
particularly that associated with briefing and feedback sessions and assumptions had to be 
made that previous components of the cycle had been completed if documented evidence 
for later components was submitted e.g. assumption that a briefing session had occurred if 
there was documented evidence of mapping observations having taken place.  
Two homes withdrew from the DCM™ intervention during the trial period, one because they 
felt DCM™ was not of value and the other because they were unable to identify any suitable 
mappers following withdrawal of the trained mappers due to personal reasons. The poor 
intervention compliance was disappointing given our adoption of established DCM™ training 
and implementation processes and the introduction of enhanced support for the trained care 
home mappers above that which might be expected in usual DCM™ practice. This has 
implications for considering implementation of DCM™ in the future, in particular 
consideration of models of implementation that are not reliant on care home staff. 
 
6.9.2 Integral process evaluation (separate papers in preparation) 
An integral process evaluation was conducted within the DCM™ EPIC trial. It investigated 
the perceptions of DCM™ implementation and impact from the perspective of mappers, care 
home managers and staff, care home residents with dementia, their relatives/friends and the 
DCM™ expert mappers. The process evaluation results have provided a valuable context 
within which to understand and interpret the DCM™ EPIC trial findings and will be presented 
in detail in additional papers that are currently in preparation. 
 
6.10 Interpretation of results 
The results of this trial may potentially be attributed to poor intervention compliance. While 
DCM™ implementation was successful in a number of sites and the process evaluation was 
able to identify factors associated with successful implementation as well as barriers to this, 
the proportion of intervention homes who failed to complete any, or more than the initial 
expert supported cycle, was disappointing. This indicates that although DCM™ was a well-
used intervention within care homes prior to this trial and was assumed therefore, to be 
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acceptable and feasible to use in these settings, this may not be the case. While the 
exploratory CACE analyses indicated that the treatment effect may increase if care homes 
complete at least two DCM™ cycles to an acceptable level compared to completing only one 
cycle and are thus suggestive of a dose-response relationship, further research would need 
to be undertaken to explore this potential relationship.  
 
6.10.1 Economic evaluation 
We estimated the mean resident cost of DCM™ to be £421.07 and the most costly 
components of this attendance at DCM™ training and DCM™ expert mapper support. While 
there appeared to be incremental health (QALY) benefits for the intervention over control, 
these were relatively modest and out-weighed by the additional costs. As such, DCM™ did 
not appear to represent value for money in the cost-utility framework. Cost per reduction in 
CMAI cost-effectiveness values were generated and these should be interpreted alongside 
previous studies reporting the same metric.  
The results were largely driven by a small number of high cost outliers in the intervention 
arm and sensitivity analyses removing these reduced the ICER substantively. Since we 
cannot definitively state that these cost outliers were random and not associated with the 
intervention, they are retained in the main analysis. The conclusions were robust to 
sensitivity analyses. However, efforts to reduce the cost of the intervention and improve 
compliance may improve value for money estimates. However, given the DCM™ 
implementation challenges identified in this study it seems unlikely greater adherence would 
be feasible to achieve with DCM™ cycles led solely by care home staff. Therefore, the costs 
of potential alternative models of delivery would need to be considered carefully in future 
research. 
 
6.10.2 Overall evidence 
Systematic reviews have identified DCM™ as effective for reducing agitation immediately 
and at 6-months post-randomisation in care home residents with dementia 62 and in 
presenting benefits for care home staff. 165 However, the number of published studies is low, 
their outcomes varied and robust evidence to guide effective DCM™ implementation is 
extremely limited. 96 Trials demonstrating efficacy of DCM™ have to date included 
researcher led cycles of DCM™. The DCM™ EPIC trial sought to examine whether DCM™ 
implemented within care homes settings, following usual UK models of care home staff led 
cycles, was effective and cost effective. It is the largest and only explanatory trial of DCM™ 
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conducted internationally and the only UK-based trial. Recruiting 978 residents across 50 
care homes, and randomising 31 clusters to DCM™ intervention, DCM™ EPIC is the largest 
trial of DCM™ conducted to date (the previous largest trial 94 recruited 268 residents in 33 
units across 14 care home locations and randomised 13 units in 7 care homes to DCM™). 
The DCM™ EPIC trial has provided conclusive evidence that implementation of care home 
staff led cycles of DCM™ is not effective in reducing agitation, BSC, use of PRN anti-
psychotic or other tranquillising medications or improving QoL for care homes residents with 
dementia compared to control. Neither is it cost effective. 
The findings of the process evaluation indicate that despite a range of methods to support 
DCM™ implementation within the trial, care home staff led cycles of DCM™ result in poor 
intervention compliance, with the vast majority of care homes (74%) failing to complete more 
than the first DCM™ expert supported cycle. Barriers to DCM™ implementation were found 
at the individual mapper level, the DCM™ intervention level and the care home level. Further 
barriers caused by the burdens of trial participation were also identified. Considering these 
results alongside the findings from previous exploratory trials of DCM™, indicates that 
externally led or supported implementation of DCM™ may provide a more beneficial and 
sustainable format for DCM™ delivery. This aligns with the broader contextual challenges 
faced by care homes in implementing complex interventions that are staff led, these include 
but are not limited to high staff turnover rates; low staff literacy, numeracy, IT skills and 
confidence; and lack of time and resources. Future research will need to consider 
mechanisms for addressing these wider contextual issues within the context of intervention 
design and delivery. Utilising ‘bottom up’ approaches to intervention design, that involve care 
home staff, managers and providers may provide a mechanism to identify and address 
potential challenges within the development process.     
 
7. Conclusions  
This trial indicates that as a care home staff led intervention DCM™ is not effective or cost 
effective at reducing agitation or improving quality of life and care outcomes for residents 
with dementia living in care home settings. This outcome may be associated with the poor 
DCM™ implementation we experienced during the trial, despite efforts to support care home 
mappers to implement the intervention. Providing support for the first DCMTM cycle, in the 
form of an external expert mapper, enabled 77.4% of intervention homes to complete that 
cycle, however, DCMTM implementation reduced greatly after the first cycle when this 
support ended. Given the picture emerging from trials of DCM™ internationally, where care 
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home staff led cycles of DCM™ have consistently led to negative trials results and 
researcher led cycles have produced significant outcomes this indicates models of DCM™ 
implementation that do not rely solely on care home staff to implement them warrant further 
investigation. The process evaluation revealed the challenges care home staff faced when 
trying to implement DCM™ including: mappers not having the required skills and qualities to 
lead change, or feeling unconfident to do so; lack of time, resources and management 
support; and difficulties in engaging colleagues in supporting the change process. Staff 
turnover, sickness and other personal issues that impacted on mappers’ ability to continue in 
the role, were also challenging, with over half the homes having at least one mapper 
withdraw during the study period. Nevertheless, a quarter of intervention care homes did 
complete two or more DCM™ cycles and staff within the process evaluation reported a 
range of benefits they felt using the tool had for residents, staff and care practices more 
broadly. This trial suggests that the majority of care home settings may not provide the right 
setting conditions for a costly intervention like DCM™ and that externally led models may 
provide a more practical and resource effective method of implementation. However, further 
research is needed to evaluate this. Our findings have implications for future complex 
intervention trials in care home settings. Future research should more carefully consider the 
setting conditions needed for effective intervention implementation and thus the most 
appropriate models for delivering these interventions given the available resources and 
cultural and organisational contexts of care home settings. 
  
 162 
 
8. Acknowledgements 
This project was funded by the National Institute for Health Research Health Technology 
Assessment programme (project number 11/15/13). The views and opinions expressed 
therein are those of the authors and do not necessarily reflect those of the HTA, NIHR, NHS 
or the Department of Health. 
Contribution of authors 
Claire A Surr (Professor of Dementia Studies and Director of the Centre for Dementia 
Research): the conception and design of the study, analysis of the qualitative data, 
interpretation of data and drafting of this paper  
Ivana Holloway (Senior Medical Statistician): analysis of the statistical data, interpretation of 
data and drafting of this paper 
Rebecca EA Walwyn (Principal Statistician): the conception and design of the study, 
analysis of the statistical data, interpretation of data and drafting of this paper 
Alys W Griffiths (Research Fellow): acquisition of data, analysis of the qualitative data, 
interpretation of data and drafting of this paper  
David Meads (Associate Professor Health Economics): design of the study, analysis of the 
health economic data, interpretation of data and drafting of this paper 
Rachael Kelley (Research Fellow): design of the process evaluation, analysis of the 
qualitative data, interpretation of data and drafting of this paper  
Adam Martin (Senior Research Fellow in Health Economics): analysis of the health 
economic data, interpretation of data and drafting of this paper 
Vicki McLellan (Senior Trial Co-ordinator): data acquisition, management of the trial and 
drafting of this paper 
Clive Ballard (Pro-Vice-Chancellor Exeter Medical School): design of the study, data 
acquisition and commenting on the draft of this paper  
Jane Fossey (Associate Director of Psychological Services): design of the study, data 
acquisition and commenting on the draft of this paper 
Natasha Burnley (Research Assistant): data acquisition, qualitative data analysis and 
interpretation and commenting on the draft of this paper 
Lynn Chenoweth (Professor of Nursing): design of the study and commenting on the draft of 
this paper 
 163 
 
Byron Creese (Senior Research Fellow): data acquisition, qualitative data analysis and 
commenting on the draft of this paper 
Murna Downs (Professor of Dementia Studies): design of the study and commenting on the 
draft of this paper 
Lucy Garrod (Research Therapist): data acquisition, qualitative data analysis and 
commenting on the draft of this paper 
Elizabeth H Graham (Trial Manager): study design, data acquisition and commenting on the 
draft of this paper  
Amanda Lilley-Kelley (Trial Manager): study design, data acquisition and commenting on the 
draft of this paper  
Joanne McDermid (Research Therapist): data acquisition, qualitative data analysis and 
commenting on the draft of this paper 
Holly Millard (Assistant Psychologist): data acquisition, qualitative data analysis and 
commenting on the draft of this paper 
Devon Perfect (Senior Clinical Research Assistant): data acquisition, qualitative data 
analysis and commenting on the draft of this paper 
Louise Robinson (Director, Newcastle University Institute for Ageing and Professor of 
Primary Care): study design and commenting on the draft of this paper 
Olivia Robinson (Research Assistant): data acquisition, qualitative data analysis and 
commenting on the draft of this paper 
Emily Shoesmith (Research Assistant): data acquisition, qualitative data analysis and 
commenting on the draft of this paper 
Najma Siddiqi (Clinical Senior Lecturer in Psychiatry): study design and commenting on the 
draft of this paper 
Graham Stokes (Director of Memory Care Services): study design and commenting on the 
draft of this paper 
Daphne Wallace (Expert by Experience): study design and commenting on the draft of this 
paper 
Amanda J Farrin (Professor of Clinical Trials & Evaluation of Complex Interventions, Director 
of Complex Interventions Division): the conception and design of the study, interpretation of 
data and drafting of this paper 
 164 
 
 
Publications 
Surr, C., Walwyn, R., Lilley-Kelley, A., Cicero, R., Meads, D., Ballard, C., Burton, K., 
Chenoweth, L., Corbett, A., Creese, B., Downs, M., Farrin, A.J., Fossey, J., Garrod, L., 
Graham, E.H., Griffiths, A., Holloway, I., Jones, S., Malik, B., Siddiqi, N., Robinson, L. and 
Wallace, D. (2016) Evaluating the effectiveness and cost effectiveness of Dementia Care 
Mapping™ to enable person-centred care for people with dementia and their carers (DCM-
EPIC) in care homes: Study protocol for a randomised controlled trial. Trials. 17:300. DOI: 
10.1186/s13063-016-1416-z 
Griffiths, A. Creese, B., Garrod, L., Chenoweth, L. and Surr, C. (2018) The development and 
use of the Assessment of Dementia Awareness and Person-centred Care Training (ADAPT) 
tool in long-term care. Dementia: the International Journal of Social Research and Practice 
doi:10.1177/1471301218768165 
Griffiths, A., Kelley, R., Garrod, L., Perfect, D., Robinson, O., Shoesmith, E., McDermid, J., 
Burnley, N. and Surr, C. (2019) Barriers and facilitators to implementing Dementia Care 
Mapping in Care Homes: Results from the DCM EPIC Trial process evaluation. BMC 
Geriatrics. 19: 37. doi: 0.1186/s12877-019-1045-y 
Griffiths, A., Albertyn, C., Burnley, N., Creese, B., Walwyn, R., Holloway, I., Safarikova, and 
Surr, C. (in press) Development and validation of an observational version of the Cohen-
Mansfield Agitation Inventory. International Psychogeriatrics 
 
All data requests should be submitted to the corresponding author for consideration.  
Access to available anonymised data may be granted following review  Other 
acknowledgements  
We would like to thank all the care homes, individuals with dementia, their family members 
and care home staff for taking part in this study and giving freely of their time. 
We would like to thank the following people who have contributed to the successful 
completion of this trial. Chris Albertyn, Heather Blakey, Marie Crabbe, Elyse Couch, Cara 
Gates, Layla Hamadi, Stephanie Jones, Baber Malik, Harriet Maunsell,  Kirsty Nash, Sahdia 
Parveen, Luisa Rabanal, Bina Sharma, Victoria Simons, Emily Smeaton, Alyma Somani, 
Emily Standell, Rebecca Thomas, Ingelin Testad and Miguel Vasconcelos Da Silva, the 
researchers who collected the data; Robert Cicero who supported development of the 
statistical analysis plan; Kayleigh Burton who undertook trial management; Madeline Harms, 
 165 
 
Alison Fergusson and Laura Stubbs who undertook data management;  Benjamin Thorpe 
who assisted with statistical programming; Sharon Jones, Lisa Heller, Juniper West, Judith 
Farmer, Maria Scurfield and Lisa Breame who supported DCM™ intervention 
implementation activities; Jan Robins, Clare Mason and Lindsey Collins who delivered 
Dementia Awareness training; Barbara Carlton, Sandra Duggan, Jane Ward, Daniella 
Watson and Connie Williams who were members of the Lay Advisory Group and Sue 
Fortescue who sat on the Trial Management Group and Lay Advisory Group. Ian Wheeler 
who provided administrative support for the trial and Matt Murray from the Alzheimer’s 
Society who provided oversight for the Lay Advisory Group. GS would like to acknowledge 
Bupa UK, who were his employing organisation during the majority of the study period.  
  
 166 
 
9. References  
1. Prince M, Knapp M, Guerchet M, McCrone P, Prina M, Comas-Herrera A, et 
al. Dementia UK: update. London: Alzheimer's Society; 2014. 
2. Alzheimer's Society. Low expectations. Attitudes on choice, care and 
community for people with dementia in care homes. London: Alzheimer's Society; 
2013. 
3. Care Quality Commission. The state of adult social care services 2014 to 
2017. Newcastle: Care Quality Commission; 2017. 
4. All-Party Parliamentary Group on Dementia. Always a last resort. Inquiry into 
the prescription of antipsychotic drugs to people with dementia living in care homes. 
London: The Stationary Office; 2008. 
5. Department of Health. Quality outcomes for people with dementia: building on 
the work of the National Dementia Strategy. London: Department of Health; 2010. 
6. Department of Health. Living well with dementia: A National Dementia 
Strategy. London: Department of Health; 2009. 
7. Department of Health. Prime Minister's challenge on dementia. delivering 
major improvements in dementia care and research by 2015. London: Department of 
Health; 2012. 
8. Department of Health. Prime Minister's Challenge on Dementia 2020. London: 
Department of Health; 2015. 
9. Ministerial Advisory Group on Dementia Research. The Ministerial Advisory 
Group on Dementia Research. Headline report. London: Department of Health; 
2011. 
10. Bowie P, Mountain G. The relationship between patient behaviour and 
environmental quality for the dementing. Int J Geriatr Psychiatry 1997;12:718-23. 
11. Ballard C, O'Brien J, James I, Mynt P, Lana M, Potkins D, et al. Quality of life 
for people with dementia living in residential and nursing home care: The impact of 
performance on activities of daily living, behavioural and psychological symptoms, 
language skills and psychotropic drugs. Int Psychogeriatr 2001;13:93-106. 
12. All-Party Parliamentary Group on Dementia. Prepared to Care. Challenging 
the dementia skills gap. London: The Stationary Office; 2009. 
13. Kuske B, Hanns S, Luck T, Angermeyer MC, Behrens J, Riedel-Heller SG. 
Nursing home staff training in dementia care: a systematic review of evaluated 
programmes. International Psychogeriatrics 2007;19:818-41. 
14. Surr C, Gates C, Irving D, Oyebode J, Smith SJ, Parveen S, et al. Effective 
dementia education and training for the health and social care workforce: A 
systematic review of the literature. Review of Educational Research 2017;87:966-
1002. 
15. Fossey J, Masson S, Stafford J, Lawrence V, Corbett A, Ballard C. The 
disconnect between evidence and practice: a systematic review of person-centred 
interventions and training manuals for care home staff working with people with 
dementia. Int J Geriatr Psychiatry 2014;29:797-807. 
16. Bradford Dementia Group. Evaluating Dementia Care. The DCM Method. 7th 
Edition. Bradford: University of Bradford; 1997. 
17. Bradford Dementia Group. DCM 8 User's Manual. Bradford: University of 
Bradford; 2005. 
18. Cox S. Developing quality in services. In: Cantley C, editor. A Handbook of 
Dementia CareBuckinghamshire: Open University Press; 2001. 
 167 
 
19. Innes A. Dementia Care Mapping: Applications across cultures. Maryland: 
Health Professions Press; 2003. 
20. Bredin K, Kitwood T, Wattis J. Decline in quality of life for patients with severe 
dementia following a ward merger. Int J Geriatr Psychiatry 1995;10:967-73. 
21. Brooker D. Auditing Outcome of Care in in-patient and day patient settings 
using Dementia Care Mapping. Can it be done? PSIGE Newsletter 1994;51:18-22. 
22. Brooker D, Foster N, Banner A, Payne M, Jackson L. The efficacy of 
Dementia Care Mapping as an audit tool: report of a 3-year British NHS evaluation. 
Aging and Mental Health 1998;2:60-70. 
23. Clare M. Spreading DCM far and wide in Suffolk. Journal of Dementia Care 
2006:10-1. 
24. Edwards P, Brotherton S. DCM 8 in Cheshire. Journal of Dementia Care 
2006. 
25. Jacques I. Evaluating care services for people living with dementia. Elder 
Care 1996;8:10-3. 
26. Martin GW, Younger D. Anti oppressive practice: a route to the empowerment 
of people with dementia through communication and choice. J Psychiatr Ment Health 
Nurs 2000;7:59-67. 
27. Martin GW, Younger D. Person-centred care for people with dementia: A 
quality audit approach. J Psychiatr Ment Health Nurs 2001;8:443-48. 
28. Wilkinson AM. Dementia Care Mapping: A pilot study of its implementation in 
a psychogeriatric service. Int J Geriatr Psychiatry 1993;8:1027-9. 
29. Williams J, Rees J. The use of 'Dementia Care Mapping' as a method of 
evaluating care received by patients with dementia - an initiative to improve quality of 
life. J Adv Nurs 1997;25:316-23. 
30. Ballard C, Corbett A. Management of neuropsychiatric symptoms in people 
with dementia. CNS drugs 2010;24:729-39. 
31. Margallo-Lana M, Swann A, O'Brien J, Fairburn A, Reichelt K, Potkins D, et al. 
Prevalence and Pharmacological Management of Behavioural and Psychological 
Symptoms Amongst Dementia Sufferers Living in Care Environments. Int J Geriatr 
Psychiatry 2001;16:39-44. 
32. Davison TE, Hudgson C, McCabe MP, George K, Buchanan G. An 
individualised psychosocial approach for 'treatment resistent' behavioural symptoms 
of dementia among aged care residents. Int Psychogeriatr 2007;19:859-73. 
33. Banerjee S, Smith SC, Lamping DL, Harwood RH, Foley B, Smith P, et al. 
Quality of life in dementia: more than just cognition. An analysis of associations with 
quality of life in dementia. J Neurol Neurosurg Psychiatry 2006;77:146-48. 
34. Liperoti R, Pedone C, Corsonello A. Antipsychotics for the treatment of 
behavioural and psychological symptoms of dementia (BPSD). Curr Neuropharmacol 
2008;6:117-24. 
35. Deudon A, Maubourguet N, Gervais X, Leone E, Broker P, Carcaillon L, et al. 
Non-pharmacological management of behavioural symptoms in nursing homes. Int J 
Geriatr Psychiatry 2009;24:1386-95. 
36. Herrmann N, Lanctot KL, Sambrook R, Lesnikova N, Hebert R, McCracken P, 
et al. The contribution of neuropsychiatric symptoms to the cost of dementia care. Int 
J Geriatr Psychiatry 2006;21:972-6. 
37. Finkel S. Introduction to behavioural and psychological symptoms of dementia 
(BPSD). Int J Geriatr Psychiatry 2000;15:S2-S4. 
38. Majic T, Pluta JP, Mell T, Aichberger MC, Treusch Y, Gutzmann H, et al. The 
pharmacotherapy of neuropsychiatric symptoms of dementia. A cross-sectional 
 168 
 
study in 18 homes for the elderly in Berlin. Deutsches Arzteblatt International 
2010;107:320-7. 
39. Tunis SL, Edell WS, Adams BE, Kennedy JS. Characterizing behavioural and 
psychological symptoms of dementia (BPSD) among geropsychiatric inpatients. 
Journal of the American Medical Directos Association 2002;3:146-51. 
40. Ballard C, Margallo-Lana M, Fossey J, Reichelt K, Myint P, Potkins D, et al. A 
1-year follow-up study of Behavioral and psychological symptoms in dementia 
among people in care environments. J Clin Psychiatry 2001;62:631-6. 
41. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating 
pain to reduce behavioural disturbances in residents of nursing homes with 
dementia: cluster randomised clinical trial. BMJ 2011;343:193. 
42. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a 
nursing home. The Journal of Gerontology 1989;44:M77-M84. 
43. Cohen-Mansfield J. Instruction manual for the Cohen-Mansfield agitation 
inventory (CMAI). Maryland: The Research Institute of the Hebrew Home of Greater 
Washington; 1991. 
44. Hindley N, Gordon H. The elderly, dementia, aggression and risk assessment. 
Int J Geriatr Psychiatry 2000;15:254-59. 
45. Burgio LD, Butller FR, Roth DL, Hardin JM, Hsu C-C, Ung K. Agitation in 
nursing home residents: the role of gender and social context. Int Psychogeriatr 
2000;12:495-511. 
46. Zuidema S, Koopmans RTCM, Verhey F. Prevalence and predictors of 
neuropsychiatric symptoms in cognitively impaired nursign home patients. J Geriatr 
Psychiatry Neurol 2007;20:41-9. 
47. Miyamoto Y, Hisatenr T, Hiroto I. Formal caregiver burden in dementia: 
Impact of behavioral and psychological symptoms of dementia and activities of daily 
living. Geriatric Nursing 2010;31:246-53. 
48. Cohen-Mansfield J. Agitated behavior in persons with dementia: The 
relationship between type of behavior, its frequency, and its disruptiveness. J 
Psychiatr Res 2008;43:64-9. 
49. Hughes J, Bagley H, Reilly S, Burns A, Challis D. Care staff working with 
people with dementia. Training, knowledge and confidence. Dementia 2008;7:227-
38. 
50. Banerjee S. The use of antipsychotic medication for people with dementia: 
Time for action. London: Department of Health; 2009. 
51. Bishara D, Taylor D, Howard RJ, Abdel-Tawab R. Expert opinion on the 
management of behavioural and psychological symptoms of dementia (BPSD) and 
investigation into prescribing practices in the UK. Int J Geriatr Psychiatry 
2009;24:944-54. 
52. Raju J, Sikdar S, Krishna T. What happened to patients with behavioural and 
psychological symptoms of dementia (BPSD) after the committee on safety of 
medicines (CSM) guidelines? Int J Geriatr Psychiatry 2005;20:898-99. 
53. Cohen-Mansfield J, Werner P, Marx MS. The social environment of the 
agitated nursing home resident. Int J Geriatr Psychiatry 1992;7:789-98. 
54. Testad I, Auer S, Mittelman M, Ballard C, Fossey J, Donabauer Y, et al. 
Nursing home structure and association with agitation and use of psychotropic drugs 
in nursing home residents in three countries: Norway, Austria and England. Int J 
Geriatr Psychiatry 2010;25:725-31. 
55. Stokes G. Challenging behaviour: a psychological approach. In: Woods RT, 
editor. Handbook of the clinical psychology of ageingChichester: Wiley; 1996:601-28. 
 169 
 
56. Cohen-Mansfield J, Marx MS, Dakheel-Ali M, Regier NG, Thein K, Freedman 
L. Can agitated behavior of nursing home residents be prevented with the use of 
standardized stimuli? J Am Geriatr Soc 2010;58:1459-64. 
57. Brodaty H, Draper B, Saab D, Low LF, Richards V, Paton H, et al. Psychosis, 
depression and behavioural disturbances in Sydney nursing home residents: 
prevalence and predictors. Int J Geriatr Psychiatry 2001;16:504-12. 
58. Weber K, Meiler-Mititelu C, Herrmann FR, Dalaloye C, Giannakopoulos P, 
Canuto A. Longitudinal assessment of psychotherapeutic day hospital treatment for 
neuropsychiatric symptoms in dementia. Aging and Mental Health 2009;13:92-8. 
59. NICE/SCIE. Dementia. Supporting people with dementia and their carers in 
health and social care. NICE clinical guideline 42. London: British Psychological 
Society and Royal College of Psychiatrists; 2006. 
60. Salzman C, Jeste D, Meyer RE, Cohen-Mansfield J, Cummings JL, 
Grossberg G, et al. Elderly patients with dementia-related symptoms of severe 
agitation and aggression: consensus statement on treatment options, clinical trials 
methodology, and policy. J Clin Psychiatry 2008;69:889-98. 
61. Moniz-Cook E, Stokes G, Agar S. Difficult behaviour and dementia in nursing 
homes: five cases of psychosocial intervention. Clinical Psychology and 
Psychotherapy 2003;10:197-208. 
62. Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. Non-
pharmacological interventions for agitation in dementia: systematic review of 
randomised controlled trials. Br J Psychiatry 2014;205:436-42. 
63. Chenoweth L, King MT, Jeon YH, Brodaty H, Stein-Parbury J, Haas M, et al. 
Caring for Aged Dementia Care Resident Study (CADRES) of person-centred 
dementia care, dementia-care mapping, and usual care in dementia: a cluster-
randomised trial. The Lancet - Neurology 2009;8:317-25. 
64. Brooker D. What is Person Centred Care for people with Dementia? Rev Clin 
Gerontol 2004;13:215-22. 
65. Chrzescijanski C, Moyle W, Creedy D. Reducing dementia-related aggression 
through a staff education intervention. Dementia 2007;6:271-86. 
66. Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, et al. Effect of 
enhanced psychosocial care on antipsychotic use in nursing home residents with 
dementia: cluster randomised controlled trial. BMJ 2006;332:756-8. 
67. Moniz-Cook E, Agar S, Silver M, Woods RT, Wang M, Elston C, et al. Can 
staff training reduce behavioural problems in residential care for the elderly mentally 
ill? Int J Geriatr Psychiatry 1998;13:149-58. 
68. Bird M, Llewellyn-Jones RH, Korten A. An evaluation of the effectiveness of a 
case-specific approach to challenging behaviour associated with dementia. Aging 
and Mental Health 2009;13:73-83. 
69. Turner J, Snowdon J. An Innovative Approach to Behavioral Assessment and 
Intervention in Residential Care: A Service Evaluation. Clin Gerontol 2009;32:260-
75. 
70. Bird M, Jones RHL, Kortent A, Smithers H. A controlled trial of a 
predominantly psychosocial approach to BPSD: treating causality. Int Psychogeriatr 
2007;19:874-91. 
71. Skills for Care. Common induction standards (2010 'refreshed' edition). In. 
Leeds: Skills for Care; 2010. 
72. Care Quality Commission. Guidance about compliance. Essential standards 
of quality and safety. London: Care Quality Commission; 2010. 
 170 
 
73. CSCI. See me not just the dementia. Understanding people's experiences of 
living in a care home. London: CSCI; 2008. 
74. Furaker C, Nilsson A. The competence of certified nurse assistants caring for 
persons with dementia diseases in residential facilities. J Psychiatr Ment Health Nurs 
2009;16:146-52. 
75. Lintern T, Woods RT, Phair L. Training is not enough to change care practice. 
Journal of Dementia Care 2000:15-7. 
76. Ballard C, Corbett A, Orrell M, Williams G, Moniz-Cook E, Romeo R, et al. 
Impact of person-centred care training and person-centred activities on quality of life, 
agitation, and antipsychotic use in people with dementia living in nursing homes: A 
cluster-randomised controlled trial. PLoS Med 2018;15:e1002500. 
77. Visser SM, McCabe MP, Hudgson C, Buchanan G, Davison TE, George K. 
Managing behavioural symptoms of dementia: effectiveness of staff education and 
peer support. Aging and Mental Health 2008;12:47-55. 
78. Ballard C, Powell I, James I, Reichelt K, Myint P, Potkins D, et al. Can 
psychiatric liaison reduce neuroleptic use and reduce health service utilization for 
dementia patients residing in care facilities. Int J Geriatr Psychiatry 2002;17:140-5. 
79. Andrews S, McInerney F, Robinson A. Realizing a palliative approach in 
dementia care: strategies to facilitate aged care staff engagement in evidence-based 
practice. Int Psychogeriatr 2009;21:S64-S8. 
80. Brodribb W. Barriers to translating evidence-based breastfeeding information 
into practice. Acta Paediatr 2011;100:486-90. 
81. Godley S, Garner B, Smith J, Meyers R, Godley M. A Large-Scale 
Dissemination and Implementation Model for Evidence-Based Treatment and 
Continuing Care. Clinical Psychology - Science and Practice 2011;18:67-83. 
82. Brooker DJ, Latham I, Evands SC, Jacobson N, Perry W, Bray J, et al. FITS 
into practice: translating research into practice in reducing the use of anti-psychotic 
medication for people with dementia living in care homes. Aging & Mental Health 
2016;20:709-18. 
83. BSI. PAS 800:2010. Use of Dementia Care Mapping for improved person-
centred care in a care provider organization. Guide. In. London: BSI; 2010. 
84. Innes A. Changing the culture of dementia care. A systematic exploration of 
the process of culture change in three care settings. Bradford: University of Bradford; 
2000. 
85. Innes A, Surr C. Measuring the well-being of people with dementia living in 
formal care settings: the use of Dementia Care Mapping. Aging and Mental Health 
2001;5:258-68. 
86. Wylie K, Madjar I, Walton JA. Dementia Care Mapping. A person-centred, 
evidence-based approach to improving the quality of care in residential care settings. 
Geriaction 2002;20:5-9. 
87. Mansah M, Coulon L, Brown P. A mapper's reflection on Dementia Care 
Mapping with older residents living in a nursing home. Int J Older People Nurs 
2008;3:113-20. 
88. Beavis D, Simpson S, Graham I. A literature review of Dementia Care 
Mapping: methodological considerations and efficacy. J Psychiatr Ment Health Nurs 
2002;9:725-36. 
89. Brooker D. Dementia Care Mapping: A Review of the Research Literature. 
Gerontologist 2005;45:11-8. 
 171 
 
90. Chenoweth L, Jeon YH. Determining the efficacy of dementia Care Mapping 
as an outcome measure and process for change: A pilot study. Aging and Mental 
Health 2007;11:237-45. 
91. Kuiper D, Dijkstra GJ, Tuinstra J, Groothoff JW. The influence of Dementia 
Care Mapping (DCM) on behavioural problems of persons with dementia and the job 
satisfaction of caregivers: a pilot study. Tijdschr Gerontol Geriatr 2009;40:102-12. 
92. Dichter MN, Quasdorf T, Schwab CGG, Trutschel D, Haastert B, Riesner C, et 
al. Dementia care mapping: effects on residents’ quality of life and challenging 
behavior in German nursing homes. A quasi-experimental trial. Int Psychogeriatr 
2015;27:1875-92. 
93. Rokstad AM, Røsvik J, Kirkevold Ø, Selbæk G, Saltyte Benth J, Engedal K. 
The Effect of Person-Centred Dementia Care to Prevent Agitation and Other 
Neuropsychiatric Symptoms and Enhance Quality of Life in Nursing Home Patients: 
A 10-Month Randomized Controlled Trial. Dement Geriatr Cogn Disord 2013;36:340-
53. 
94. van de Ven G, Drasovic I, Adang EMM, Donders R, Zuidema S, Koopmans 
RTCM, et al. Effects of Dementia-Care Mapping on Residents and Staff of Care 
Homes: A Pragmatic Cluster-Randomised Controlled Trial. PLoS One 
2013;8:e67325. 
95. Jeon YH, Luscombe G, Chenoweth L, Stein-Parbury J, Brodaty H, King M, et 
al. Staff outcomes from the Caring for Aged Dementia Care REsident Study 
CADRES): A cluster randomised trial. International Journal Nursing Studies 
2012;49:508-18. 
96. Surr C, Griffiths AW, Kelley R. Implementing Dementia Care Mapping as a 
practice development tool in dementia care services: a systematic review. Clin Interv 
Aging 2018;13:165-77. 
97. Skills for Care. The state of the adult social care sector and workforce in 
England. Leeds: Skills for Care; 2017. 
98. Surr CA, Walwyn R, Lilley-Kelly A, Cicero R, Meads D, Ballard C, et al. 
Evaluating the effectiveness and cost effectiveness of Dementia Care Mapping™ to 
enable person-centred care for people with dementia and their carers (DCM-EPIC) in 
care homes: Study protocol for a randomised controlled trial. . Trials 2016;17:300. 
99. Griffiths AW, Creese B, Garrod L, Chenoweth L, Surr C. The development 
and use of the Assessment of Dementia Awareness and Person-centred Care 
Training (ADAPT) tool in long-term care Dementia: The international journal of social 
research and practice 2018; 10.1177/1471301218768165. 
https://doi.org/10.1177/1471301218768165 
100. Bupa. Person First ... dementia second The Essentials Workbooks. In. Leeds: 
Bupa; 2010. 
101. Care Quality Commission. The state of health care and adult social care in 
England. An overview of key themes in care 2009/10. . London The Stationary 
Office; 2010  
102. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 
1988;24:653-59. 
103. Mental Capacity Act. Place Published; 2005. 
104. Medical Research Council. MRC guidelines for good clinical practice in clinical 
trials. London: Medical Research Council; 1998. 
105. Department of Health, Welsh Assembly Government. Guidance on 
nominating a consultee for research involving adults who lack capacity to consent. 
London:: Department of Health; 2008. 
 172 
 
106. Medical Research Council. Medical research involving adults who cannot 
consent. London: Medical Research Council; 2007. 
107. Kuznetsova OM TY. Preserving the allocation ratio at every allocation with 
biased coin randomisation and minimisation in studies with unequal allocation. 
Statistics in Medicine (2012) 702-23. 
108. Brooker D, Surr C. Dementia Care Mapping: Principles and Practice. 
Bradford: University of Bradford; 2005. 
109. Brooker D, Surr C. Dementia Care Mapping (DCM): initial validation of DCM 8 
in UK field trials. Int J Geriatr Psychiatry 2006;21:1018-25. 
110. Cohen-Mansfield J, Billig N. Agitated behaviours in the elderly. I. A conceptual 
review. J Am Geriatr Soc 1986;34:711-21. 
111. Shah A, Evans H, Parkash N. Evaluation of three aggression/agitation 
behaviour rating scales for use on an acute admission and assessment 
psychogeriatric ward. Int J Geriatr Psychiatry 1998;13:415-20. 
112. Cohen-Mansfield J, Libin A. Assessment of agitation in elderly patients with 
dementia: correlations between informant rating and direct observation. Int J Geriatr 
Psychiatry 2004;19:881-91. 
113. Griffiths AW, Albertyn CP, Burnley NL, Creese B, Walwyn R, Holloway I, et al. 
Development and validation of an observational version of the Cohen-Mansfield 
Agitation Inventory. Int Psychogeriatr in press. 
114. Rosen J, Burgio LD, Kollar M, Cain M, Allison M, Fogleman M, et al. The 
Pittsburgh Agitation Scale: A user-friendly instrument for rating agitation in dementia 
patients. Am J Geriatr Psychiatry 1994;2:52-9. 
115. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, 
Gombein J. The Neuropsychiatric Inventory. Comprehensive assessment of 
psychopathology in dementia. Neurology 1994;44:2308. 
116. Smith SC, Lamping DL, Banerjee S, Harwood RH, Foley B, Smith P, et al. 
Development of a new measure of health-related quality of life for people with 
dementia: DEMQOL. Psychol Med 2007;37:737-46. 
117. Smith SC, Lamping DL, Banerjee S, Harwood RH, Foley B, Smith P, et al. 
Measurement of health-related quality of life for people with dementia: development 
of a new instrument (DEMQOL) and an evaluation of current methodology. Health 
Technol Assess 2005;9:1-93. 
118. Rowen D, Mulhern B, Banerjee S, Van Hout B, Young TA, Knapp M, et al. 
Estimating Preference-Based Single Index Measures for Dementia Using DEMQOL 
and DEMQOL-Proxy. Value Health 2012;15:346-56. 
119. EuroQol Group. EuroQol - a new facility for the measurement of health-related 
quality of life. Health Policy 1990;16:199-208. 
120. Herdman MGC, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, et al. 
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-
5L). Qual Life Res 2011;10:1727-36. 
121. Weiner MF, Martin-Cook K, Svetlik DA, Saine K, Foster BF, C.S. The Quality 
of Life in Late-Stage Dementia (QUALID) Scale. J Am Med Dir Assoc 2000;1:114-6. 
122. Logsdon RG, Albert SM. Assessing Quality of Life in Alzheimer's Disease: 
Conceptual and Methodological Issues. Journal of Mental Health and Aging 
1999;5:3-6. 
123. Hoe J, Katona C, Roch B, Livingston G. Use of the QOL-AD for measuring 
quality of life in people with severe dementia—the LASER-AD study. Age Ageing 
2005;34:130-35. 
 173 
 
124. Thorgrimsen L, Selwood A, Spector A, Royan L, de Madariaga Lopez M, 
Woods RT, et al. Whose quality of life is it anyway? The validity and reliability of the 
Quality of Life - Alzheimer’s Disease (QOL-AD) Scale. . Alzheimer Dis Assoc Disord 
2003;17:201-8. 
125. Logsdon RG, Gibbbons L, McCurry SM, Teri L. Assessing quality of life in 
older adults with cognitive impairment. Psychosom Med 2002;64:510-9. 
126. Edelman P, Fulton BR, Kuhn D, Chang C-H. A comparison of three methods 
of measuring dementia-specific quality of life: perspectives of residents, staff and 
observers. The Gerontologist 2005;45:27-36. 
127. Siddiqi N, Cheater F, Collinson M, Farrin A, Forster A, George D, et al. The 
PiTSTOP study: a feasibility cluster randomized trial of delirium prevention in care 
homes for older people. Age Ageing 2016;45:652-61. 
128. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale 
for the staging of dementia. The British Journal of Psychiatry 1982;140:566-72. 
129. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring 
rules. Neurology 1993;43:2412-4. 
130. Goldberg DP, Williams PA. User's guide to the General Health Questionnaire. 
Windsor: NFER-Nelson; 1988. 
131. Penninkilampi-Kerola V, Meiettunen J, Ebeling H. A comparative assessment 
of the factor structures and psychometric properties of the GHQ-12 and the GHQ-20 
based on data from a Finnish population-based sample. Scand J Psychol 
2006;47:431-40. 
132. Schepers AK, Orrell M, Shanahan N, Spector A. Sense of competence in 
Dementia Care Staff (SCIDS) scale: development, reliability and validity. Int 
Psychogeriatr 2012;24:1153-62. 
133. Dean R, Proudfoot R, Lindesay J. The Quality of Interactions Schedule 
(QUIS): development, reliability and use in the evaluation of two domus units. Int J 
Geriatr Psychiatry 1993;8:819-26. 
134. Coates CJ. The Caring Efficacy Scale: nurses' self-reports of caring in 
practice settings. Adv Pract Nurs Q 1997;3:53-9. 
135. Lindesay J, Skea D. Gender and interactions between care staff and elderly 
nursing home residents with dementia. Int J Geriatr Psychiatry 1997;12:344-48. 
136. Smith R, Fleming R, Chenoweth L, Jeon YH, Stein-Parbury J, Brodaty H. 
Validation of the Environmental Audit Tool in both purpose-built and non-purpose-
built dementia care settings. Australas J Ageing 2012;31:159-63. 
137. Te Boekhorst S, Depla MFIA, Pot AM, De Lange J, Eefsting JA. The ideals of 
group living homes for people with dementia: do they practice what they preach? 
International Psychogeriatrics 2011;23:1526-7. 
138. Zuidema S, Buursema AL, Gerritsen MGJM, Oosterwal KC, Smits MMM, 
Koopmans RTCM, et al. Assessing neuropsychiatric symptoms in nursing home 
patients with dementia: reliability and Reliable Change Index of the Neurpsychiatric 
Inventory and the Cohen-Mansfield Agitation Inventory. Int J Geriatr Psychiatry 
2011;26:127-34. 
139. Staquet MJ, Hays RD, Fayers PM. Quality of life assessment in clinical trials: 
Methods and practice. . Oxford: Oxford University Press; 1998. 
140. Yan X, Lee S, Li N. Missing Data Handling Methods in Medical Device Clinical 
Trials. J Biopharm Stat 2009;19:1085-98. 
141. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. 
Better reporting of interventions: template for intervention description and replication 
(TIDieR) checklist and guide. BMJ 2014;348:g1687. 
 174 
 
142. Baron RM, Kenny DA. The moderator–mediator variable distinction in social 
psychological research: Conceptual, strategic, and statistical considerations. J Pers 
Soc Psychol 1986;51:1173. 
143. NICE NIfHaCE. Guide to the methods of technology appraisal 2013. 2013. 
URL: https://www.nice.org.uk/process/pmg9/chapter/the-appraisal-of-the-evidence-
and-structured-decision-making# (accessed 2nd June 2017, 2017). 
144. Curtis L, Burns A. Units Costs of Health and Social Care 2016. Canterbury: 
PSSRU; 2016. 
145. Department of Health. Drugs and pharmaceutical electronic market 
information tool (eMIT). In; 2017. 
146. Department of Health. National Scedule of Reference Costs 2015-16. In; 
2017. 
147. Devlin N, Shah K, Feng Y, Mulhern B, van Hout B. Valuing Health-Related 
Quality of Life: An EQ-5D-5L Value Set for England. OHE Research Paper 16/01. 
London: Office of Health Economics; 2016. 
148. EuroQol Group. EQ-5D-5L Index Value Calculator Version 1.0. In; n/d. 
149. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in 
cost-effectiveness analysis conducted within randomised controlled trials. 
Pharmacoeconomics 2014;32:1157-70. 
150. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 
1987. 
151. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-
effectiveness acceptability curves. Health economics 2001;10:779-87. 
152. Moore G, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process 
evaluation of complex interventions: UK Medical Research Council (MRC) guidance: 
Medical Research Council; 2014. 
153. Linnan L, Steckler A. Process evaluation for public health interventions and 
research. San Francisco: Jossey-Bass; 2002. 
154. Smith J, Firth J. Qualitative data analysis: the framework approach. Nurse 
Res 2011;18:52-62. 
155. Walwyn R, Copas A, Farrin A, Surr C. Open cohort designs for cluster 
randomised trials in institutional settings: A methodology bolt on to DCM-EPIC. In: 
Medical Research Council; 2019-21. 
156. Department of Health. No secrets: Guidance on developing and implementing 
multi-agency policies and procedures to protect vulnerable adults from abuse. 
London: Department of Health; 2000. 
157. University of Bradford. DCM™ for Realising Person Centred Care Booking 
Form 2017-18. Bradford: University of Bradford; 2017. URL: 
http://www.bradford.ac.uk/health/dementia/training/training-courses/dementia-care-
mapping-for-realising-person-centred-care/ (accessed Sept 2017). 
158. Griffiths AW, Kelley R, Garrod L, Perfect D, Robinson O, Shoesmith E, et al. 
Barriers and facilitators to implementing Dementia Care Mapping in Care Homes: 
Results from the EPIC Trial process evaluation. BMC Geriatr 2019;19:37. 
https://doi.org/10.1186/s12877-019-1045-y 
159. Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. A 
systematic review of the clinical effectiveness and cost-effectiveness of sensory, 
psychological and behavioural interventions for managing agitation in older adults 
with dementia. Health Technol Assess 2014;18:1-226. 
160. Zwijsen SA, Bosmans JE, Gerritsen DL, Pot AM, Hertogh CM, Smalbrugge M. 
The cost-effectiveness of grip on challenging behaviour: an economic evaluation of a 
 175 
 
care programme for managing challenging behaviour. Int J Geriatr Psychiatry 
2016;31:567-74. 
161. van de Ven G, Drasovic I, van Herpen E, Koopmans RTCM, Donders R, 
Zuidema S, et al. The Economics of Dementia-Care Mapping in Nursing Homes: A 
Cluster-Randomised Controlled Trial. PLoS One 2014;19:e86662. 
162. Moyle W, Murfield JE, Griffiths SG, Venturato L. Assessing quality of life of 
older people with dementia: a comparison of quantitative self-report and proxy 
accounts. J Adv Nurs 2012;68:2237-46. 
163. Wen YW, Tsai YW, Wu DB, Chen PF. The Impact of Outliers on Net-Benefit 
Regression Model in Cost-Effectiveness Analysis. PLoS One 2013;19:e65930. 
164. Care Quality Commission. The state of health care and adult social care in 
England 2016/17. London: Care Quality Commission; 2017. 
165. Barbosa A, Lord K, Blighe A, Mountain G. Dementia Care Mapping in long-
term care settings: a systematic review of the evidence. Int Psychogeriatr 
2017;29:1609-18. 
 
 
 
  
 176 
 
10. Appendices 
Appendix 1: Supporting tables 
Screening  
Table 26 Resident original cohort CONSORT by hub 
Residents 
Hub 
Total 
50 CHs 
Yorkshire 
21 CHs 
London 
15 CHs 
Oxford 
14 CHs 
Screened 656 419 489 1564 
Eligible 451 (68.8%) 297 (70.9%) 321 (65.6%) 1069 (68.4%) 
Not eligible 205 (31.2%) 122 (29.0%) 168 (34.4%) 495 (31.6%) 
           Does not have formal diagnosis of 
dementia 133 (64.9%) 67 (54.9%) 98 (58.3%) 298 (60.2%) 
           Permanently bed-bound 27 (13.2%) 32 (26.2%) 30 (17.9%) 89 (18.0%) 
           Terminally ill 22 (10.7%) 18 (14.8%) 18 (10.7%) 58 (11.7%) 
           Not a permanent resident 38 (18.5%) 2 (1.6%) 21 (12.5%) 61 (12.3%) 
           Insufficient proficiency in English 2 (1.0%) 6 (4.9%) 4 (2.4%) 12 (2.4%) 
Consented (out of eligible) 366 (81.2%) 199 (67.0%) 216 (67.3%) 781 (73.1%) 
 Not consented (out of eligible) 85 (18.8%) 98 (33.0%) 105 (32.7%) 288 (26.9%) 
          Consent refused 69 (81.2%) 87 (88.8%) 82 (78.1%) 238 (82.6%) 
               By: Resident 24 (66.7%) 4 (11.1%) 8 (22.2%) 36 (15.1%) 
                      Personal consultee 33 (24.8%) 37 (27.8%) 63 (47.4%) 133 (55.9%) 
                      Nominated consultee 12 (17.4%) 46 (66.7%) 11 (15.9%) 69 (29.0%) 
          Resident died 5 (5.9%) 5 (5.1%) 8 (7.6%) 18 (6.3%) 
          Unwilling to engage with researcher 4 (4.7%) 2 (2.0%) 5 (4.8%) 11 (3.8%) 
          Resident transferred elsewhere 7 (8.2%) 2 (2.0%) 7 (6.7%) 16 (5.6%) 
          No consultee available to consent 0 (0.0%) 0 (0.0%) 2 (1.9%) 2 (0.7%) 
          Other 1 (1.2%) 2 (2.0%) 2 (1.9%) 5 (1.7%) 
Registered (out of consented) 339 (92.6%) 191 (96.0%) 213 (98.6%) 743 (95.1%) 
Not registered (out of consented) 27 (7.4%) 8 (4.0%) 3 (1.4%) 38 (4.9%) 
          Died 16 (59.3%) 7 (87.5%) 3 (100.0%) 26 (68.4%) 
          Withdrawn 1 (3.7%) 0 (0.0%) 0 (0.0%) 1 (2.6%) 
          No longer eligible 3 (11.1%) 0 (0.0%) 0 (0.0%) 3 (7.9%) 
          Moved out of care home 7 (25.9%) 0 (0.0%) 0 (0.0%) 7 (18.4%) 
          Other  1 (3.7%) 1 (12.5%) 0 (0.0%) 2 (5.3%) 
Registered at randomisation (out of 
registered) 
330 (97.3%) 185 (96.9%) 211 (99.1%) 726 (97.7%) 
         Died between registration and CH    
randomisation (out of   registered) 
9 (2.7%)    6 (3.1%) 2 (0.9%) 17 (2.3%) 
Percentages of reasons “Not eligible”, “Not consented” and “Not registered” are calculated out of 
number of “Not eligible”, “Not consented” and “Not registered” respectively.  
Reasons “Not eligible”, “Not consented” and “Not registered” are not mutually exclusive. 
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Table 27 Additional resident cohort screening by hub 
Residents 
Hub 
Total 
CHs 
Yorkshire 
CHs 
London 
 CHs 
Oxford 
 CHs 
Screened 569 396 479 1444 
    Currently participating in EPIC (out of 
screened) 
185 (32.5%) 109 (27.5%) 131 (27.3%) 425 (29.4%) 
    Screened and not participating in EPIC 
(out of screened) 
384 (67.5%) 287 (72.5%) 348 (72.7%) 1019 (70.6%) 
        Screened at baseline but consent 
refused (out of   screened and not 
participating in EPIC) 
43 (11.2%) 57 (19.9%) 42 (12.1%) 142 (13.9%) 
Eligible (out of screened) 189 (33.2%) 90 (22.7%) 142 (29.6%) 421 (29.2%) 
Not eligible (out of screened)* 152 (26.7%) 140 (35.4%) 164 (34.2%) 456 (31.6%) 
       Does not have formal diagnosis of 
dementia 
93 (61.2%) 57 (40.7%) 103 (62.8%) 253 (55.5%) 
       Permanently bed-bound 9 (5.9%) 38 (27.1%) 7 (4.3%) 54 (11.8%) 
       Terminally ill 6 (3.9%) 13 (9.3%) 2 (1.2%) 21 (4.6%) 
       Not a permanent resident 19 (12.5%) 1 (0.7%) 8 (4.9%) 28 (6.1%) 
       Insufficient proficiency in English 1 (0.7%) 4 (2.9%) 2 (1.2%) 7 (1.5%) 
       Moved to the unit <3-months ago 44 (28.9%) 42 (30.0%) 48 (29.3%) 134 (29.4%) 
       Missing information 1 (0.7%) 0 (0.0%) 0 (0.0%) 1 (0.2%) 
Consented (out of eligible) 120 (63.5%) 47 (52.2%) 99 (69.7%) 266 (63.2%) 
Not consented (out of eligible)*, Missing 
68 (36.0%), 
1 
42 (46.7%), 1 43 (30.3%),0 153 (36.3%), 
2 
       Consent refused by who 65 (95.6%) 36 (85.7%) 39 (90.7%) 140 (91.5%) 
                         Resident 14 (21.5%) 1 (2.8%) 13 (33.3%) 28 (20.0%) 
                         Personal consultee 19 (29.2%) 10 (27.8%) 14 (35.9%) 43 (30.7%) 
                         Nominated consultee 32 (49.2%) 25 (69.4%) 12 (30.8%) 69 (49.3%) 
       Resident died 1 (1.5%) 2 (4.8%) 2 (4.7%) 5 (3.3%) 
       Unwilling to engage with researcher 1 (1.5%) 1 (2.4%) 1 (2.3%) 3 (2.0%) 
       No response from personal consultee 0 (0.0%) 2 (4.8%) 0 (0.0%) 2 (1.3%) 
       Transferred elsewhere 1 (1.5%) 0 (0.0%) 0 (0.0%) 1 (0.7%) 
       Other 1 (1.5%) 1 (2.4%) 1 (2.3%) 3 (2.0%) 
Registered (out of consented) 119 (99.2%) 45 (95.7%) 97 (98.0%) 261 (98.1%) 
Not registered (out of consented), Missing 1 (0.8%) 2 (4.3%) 1 (1.0%), 1 4 (1.5%), 1 
      Does not have formal diagnosis of 
dementia 0 (0.0%) 1 (2.1%) 0 (0.0%) 1 (0.4%) 
      Moved out of care home 1 (0.8%)  0 (0.0%) 0 (0.0%) 1 (0.4%) 
      Died 0 (0.0%) 0 (0.0%) 1 (0.8%) 1 (0.4%) 
      In hospital 0 (0.0%) 1 (2.1%) 0 (0.0%) 1 (0.4%) 
*Categories are not mutually exclusive 
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Table 28 Residents screened in additional cohort by treatment arm 
 Control 
(CHs=19) 
Intervention 
(CHs=31) 
Total 
(CHs=48) 
Screened 494 950 1444 
Currently participating in EPIC (out of screened) 185 (37.4%) 240 (25.3%) 425 (29.4%) 
   Screened and not participating in EPIC (out of 
screened) 
309 (62.6%) 710 (74.7%) 1019 (70.6%) 
         Screened at baseline but consent refused (out    
         of screened and not participating in EPIC) 
34 (11.0%) 108 (15.2%) 142 (13.9%) 
Eligible 147 (29.8%) 274 (28.8%) 421 (29.2%) 
Not eligible* 128 (25.9%) 328 (34.5%) 456 (31.6%) 
Does not have formal diagnosis of dementia 61 (47.7%) 192 (58.5%) 253 (55.5%) 
Moved to the unit <3-months ago 15 (11.7%) 39 (11.9%) 54 (11.8%) 
Permanently bed-bound 6 (4.7%) 15 (4.6%) 21 (4.6%) 
Terminally ill 3 (2.3%) 25 (7.6%) 28 (6.1%) 
Not a permanent resident 3 (2.3%) 4 (1.2%) 7 (1.5%) 
Insufficient proficiency in English 51 (39.8%) 83 (25.3%) 134 (29.4%) 
Missing information 1 (0.8%) 0 (0.0%) 1 (0.2%) 
Consented (out of eligible) 100 (68.0%) 166 (60.6%) 266 (63.2%) 
Not consented (out of eligible)*, Missing 46 (31.3%), 1 107 (39.1%), 1 153 (36.3%), 2 
Consent refused by who: 40 (87.0%) 100 (93.5%) 140 (91.5%) 
                         Resident (% out of who) 9 (22.5%) 19 (19.0%) 28 (20.0%) 
                         Personal consultee 10 (25.0%) 33 (33.0%) 43 (30.7%) 
                         Nominated consultee 21 (52.5%) 48 (48.0%) 69 (49.3%) 
Resident died 2 (4.3%) 3 (2.8%) 5 (3.3%) 
Unwilling to engage with researcher 1 (2.2%) 2 (1.9%) 3 (2.0%) 
No response from personal consultee 2 (4.3%) 0 (0.0%) 2 (1.3%) 
Transferred elsewhere 1 (2.2%) 0 ( 0.0%) 1 (0.7%) 
Other 1 (2.2%) 2 (1.9%) 3 (2.0%) 
Registered (out of consented) 99 (99.0%) 162 (97.6%) 261 (98.1%) 
Not registered (out of consented), Missing 1 (1.0%) 3 (1.8%), 1 4 (1.5%), 1 
Does not have formal diagnosis of dementia 1 (1.0%) 0 (0.0%) 1 (0.4%) 
Moved out of care home 0 (0.0%) 1 (0.6%) 1 (0.4%) 
Died 0 (0.0%) 1 (0.6%) 1 (0.4%) 
In hospital 0 (0.0%) 1 (0.6%) 1 (0.4%) 
*Categories are not mutually exclusive. Percentages of reasons “Not eligible”, “Not consented” and 
“Not registered” are calculated out of number of “Not eligible”, “Not consented” and “Not registered” 
respectively. Percentages of who refused the consent are calculated out of “Consent refused”. Those 
categories are not mutually exclusive. 
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Table 29 Screening data – original and additional cohort by hub 
Screening data – recruited residents by cohorts 
 
Original           (n=1564) Additional (n=877)* 
Yorkshire 
(n=656) 
London 
(n=419) 
Oxford 
(n=489) Total (n=1564) 
Yorkshire 
(n=341) 
London 
(n=230) 
Oxford 
(n=306) Total (n=877) 
Age at registration (years) 
Mean (SD) 
85.3 (8.00) 84.7 (8.43) 85.1 (8.20) 85.1 (8.18) 85.0 (7.64) 84.2 (8.65) 86.0 (8.11) 85.1 (8.10) 
Length of stay (years) 
Mean (SD) 
2.1 (2.29) 2.4 (2.44) 2.5 (2.70) 2.3 (2.48) 1.4 (1.79) 1.7 (2.63) 1.7 (2.17) 1.6 (2.17) 
Sex Female N (%)  483 (73.6%) 301 (71.8%) 356 (72.8%) 1140 (72.9%) 248 (72.7%) 164 (71.3%) 213 (69.6%) 625 (71.3%) 
Ethnicity N (%) 
White 642 (97.9%) 367 (87.6%) 474 (96.9%) 1483 (94.8%) 338 (99.1%) 208 (90.4%) 300 (98.0%) 846 (96.5%) 
Other 7 (1.1%) 40 (9.5%) 8 (1.6%) 55 (3.5%) 0 (0.0%) 20 (8.7%) 5 (1.6%) 25 (2.9%) 
Missing 7 (1.1%) 12 (2.9%) 7 (1.4%) 26 (1.7%) 3 (0.9%) 2 (0.9%) 1 (0.3%) 6 (0.7%) 
Funding type 
Local Authority 297 (45.3%) 179 (42.7%) 265 (54.2%) 741 (47.4%) 145 (42.5%) 92 (40.0%) 167 (54.6%) 404 (46.1%) 
Continuing Healthcare 58 (8.8%) 35 (8.4%) 22 (4.5%) 115 (7.4%) 4 (1.2%) 16 (7.0%) 1 (0.3%) 21 (2.4%) 
Self-funded 226 (34.5%) 141 (33.7%) 188 (38.4%) 555 (35.5%) 116 (34.0%) 80 (34.8%) 122 (39.9%) 318 (36.3%) 
Local Authority and self-
funded 
59 (9.0%) 1 (0.2%) 9 (1.8%) 69 (4.4%) 57 (16.7%) 7 (3.0%) 4 (1.3%) 68 (7.8%) 
Missing 16 (2.4%) 63 (15.0%) 5 (1.0%) 84 (5.4%) 19 (5.6%) 35 (15.2%) 12 (3.9%) 66 (7.5%) 
*Excluding those already participating in the trial and those that were screened at baseline but refused consent. 
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Table 30 Type of consent of registered residents 
Type of consent of registered residents – original and additional cohort  
Original Additional 
 Total (n=726) 
Control  
(n=99) 
Intervention 
(n=162) Total (n=261) 
Consent by:     
Resident 145 (20.0%) 22 (22.2%) 36 (22.2%) 58 (22.2%) 
Personal consultee 263 (36.2%) 34 (34.3%) 39 (24.1%) 73 (28.0%) 
Nominated 
consultee 
318 (43.8%) 43 (43.4%) 87 (53.7%) 130 (49.8%) 
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Staff and relative/ friend 
Table 31 Staff measures – SCIDS (total number of staff that completed at least one SCIDS item) 
 SCIDS summaries 
 Baseline 6-months 16-months 
Mean (SD) missing 
Control 
(n = 86) 
Intervention 
(n = 260) 
Total 
(n = 346) 
Control 
(n = 84) 
Intervention 
(n = 112) 
Total 
(n = 196) 
Control 
(n = 50) 
Intervention 
(n = 132) 
Total 
(n = 182) 
Total SCIDS score 53.2 (8.96) 1 53.7 (9.24) 5 53.6 (9.16) 6 55 (8.64) 1 53.5 (8.56) 2 54.1 (8.6) 3 58.4 (7.97) 1 56.8 (8.3) 1 57.2 (8.22) 2 
Professionalism 16.7 (2.61) 0 17 (2.75) 4 16.9 (2.72) 4 17.2 (2.72) 3 16.8 (2.52) 2 17 (2.6) 5 18 (2.17) 1 17.6 (2.4) 2 17.7 (2.34) 3 
Building relationships 11.7 (2.37) 0 11.8 (2.36) 4 11.8 (2.36) 4 12.3 (2.24) 0 11.9 (2.18) 1 12.1 (2.21) 1 13 (2.39) 1 12.6 (2.24) 1 12.7 (2.28) 2 
Core challenges 11.9 (2.84) 1 11.9 (2.9) 6 11.9 (2.88) 7 12.2 (2.71) 1 12 (2.63) 3 12.1 (2.66) 4 13.6 (2.51) 1 12.9 (2.61) 1 13.1 (2.59) 2 
Sustaining personhood 12.9 (2.31) 0 13 (2.43) 5 13 (2.39) 5 13.4 (2.27) 2 12.8 (2.47) 1 13.1 (2.4) 3 13.8 (1.96) 1 13.6 (2.11) 2 13.6 (2.07) 3 
Booklets circulated 
to staff 525 1143 1668 546 848 1394 526 1108 1634 
Overall score ranging from 17-68 with higher scores indicative of more confidence in delivering care to those with dementia. 
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Table 32 QUALID – completed by relative/ friend (out of relatives that were registered at each timepoint) 
  QUALID summaries – completed by relative/ friend 
 Baseline 6-months 
16-months 
original cohort 
16-months 
cross-sectional cohort 
Mean (SD) 
missing 
Median (IQR) 
Control        
(n = 96) 
Intervention 
(n = 101) 
Total        
(n = 197) 
Control          
(n = 85) 
Intervention 
(n = 85) 
Total            
(n = 170) 
Control     
(n = 63) 
Intervention 
(n = 55) 
Total            
(n = 118) 
Control      
(n = 64) 
Intervention 
(n = 55) 
Total            
(n = 119) 
QUALID relative/  
proxy 
22.5 (7.49) 
14 
21.6 (6.86) 
20 
22 (7.18) 
34 
21.6 
(7.18) 23 
22.1 (8.89) 
20 
21.8 (8.07) 
43 
23 
(6.24) 
25 
23.1 (8.41) 
24 
23 (7.24) 
49 
23 
(6.15) 
25 
23.1 (8.41) 
24 
23 (7.18) 
49 
 21 (17, 28) 21 (17, 25) 21 (17, 
26) 
20.9 (15, 
25) 
20 (14.3, 30) 20.9 (15, 
27) 
23 (18, 
26) 
22 (16.5, 29) 22 (18, 28) 23 (18, 
26) 
22 (16.5, 29) 22.5 (18, 
28) 
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Intervention 
Table 33 Compliance with intervention by care home  
Compliance with intervention by CH  
(using documented evidence and expert opinion for cycle 1) 
CH hub CH CYCLE 1 CYCLE 2 CYCLE 3 
No of cycles 
to at least 
acceptable 
level 
No of cycles 
to at least 
partial level 
Yorkshire 1 Acceptable None None One cycle One cycle 
 2 None None None No cycles No cycles 
 3 Acceptable Acceptable None Two cycles Two cycles 
 8 None None None No cycles No cycles 
 9 Acceptable Partial None One cycle Two cycles 
 17 Acceptable Partial Partial One cycle Three cycles 
 24 Acceptable None None One cycle One cycle 
 32 Acceptable Acceptable None Two cycles Two cycles 
 33 Partial None None No cycles One cycle 
 34 None None None No cycles No cycles 
 38 Partial None None No cycles One cycle 
 44 Acceptable None None One cycle One cycle 
 48 Acceptable Acceptable Acceptable Three cycles Three cycles 
Oxford 4 Acceptable None None One cycle One cycle 
 5 Acceptable Partial None One cycle Two cycles 
 6 Acceptable None None One cycle One cycle 
 11 Acceptable None None One cycle One cycle 
 12 Partial None None No cycles One cycle 
 14 Partial None None No cycles One cycle 
 16 Acceptable Acceptable Acceptable Three cycles Three cycles 
 23 Acceptable Partial Partial One cycle One cycle 
 25 Acceptable Acceptable None Two cycles Two cycles 
London 10 Acceptable None None One cycle One cycle 
 19 Acceptable None None One cycle One cycle 
 20 Acceptable Partial Partial One cycle Three cycles 
 26 Acceptable None None One cycle One cycle 
 31 Acceptable Acceptable None Two cycles Two cycles 
 39 Acceptable None None One cycle One cycle 
 40 Acceptable Acceptable Acceptable Three cycles Three cycles 
 42 Acceptable None None One cycle One cycle 
 47 Acceptable Acceptable Acceptable Three cycles Three cycles 
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Briefing 
Table 34 Summary of briefing sessions as documented 
Summary of briefing sessions by cycle - by hub and overall 
 Cycle 1 (n=31) Cycle 2 (n=31) Cycle 3 (n=31) 
Number of formal sessions    
1 9 (29.0%) 7 (22.6%) 3 (9.7%) 
2 4 (12.9%) 1 (3.2%) 1 (3.2%) 
3 2 (6.5%) 1 (3.2%) 1 (3.2%) 
Missing 16 (51.6%) 22 (71.0%) 26 (83.9%) 
Length of formal sessions (mins)    
Mean (SD) Missing 71.7 (61.72) 16 66.9 (34.94) 23 93.8 (41.31) 27 
Median (Range) 40 (20, 240) 60 (30, 140) 97.5 (45, 135) 
Total number of staff attended    
Mean (SD) Missing 10.1 (4.52) 18 15.8 (7.44) 23 18.0 (8.19) 28 
Median (Range) 10 (3, 20) 14.5 (8, 28) 20 (9, 25) 
Number of direct staff attended    
Mean (SD) Missing 11.4 (6.23) 26 15.3 (6.08) 27 14.0 (5.29) 28 
Median (Range) 13.0 (3.0, 17.0) 13.5 (10.0, 24.0) 16.0 (8.0, 18.0) 
Timing of formal session from 
randomisation (months) 
   
Mean (SD) Missing 2.8 (0.98) 16 8.7 (2.79) 23 13.5 (1.19) 26 
Median (Range) 2.7 (1.0, 4.9) 8.1 (4.4, 13.0) 13.6 (12.4, 15.3) 
Informal briefing sessions held    
Yes N (%) Missing 15 (48.4%) 15 10 (32.3%) 20 3 (9.7%) 26 
No 1 (3.2%) 1 (3.2%) 2 (6.5%) 
Number of staff informally briefed    
Mean (SD) Missing 10.5 (7.51) 17 13.1 (10.89) 23 19.3 (1.15) 28 
Median (Range) 8.5 (2.0, 30.0) 7.0 (4.0, 31.0) 20.0 (18.0, 20.0) 
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Figure 7 Time between CH randomisation and briefing sessions 
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Observation 
Table 35 Summary of observation as documented 
Observations adherence by cycle 
 Cycle 1 (n=31) Cycle 2 (n=31) Cycle 3 (n=31) 
Number of mappers observed    
1 1 (3.2%) 1 (3.2%) 1 (3.2%) 
2 18 (58.1%) 10 (32.3%) 4 (12.9%) 
Missing 12 (38.7%) 20 (64.5%) 26 (83.9%) 
N of observation periods    
Mean (SD) Missing 4.3 (2.05) 16 3.9 (1.89) 23 2.0 (0.00) 28 
Median (Range) 4 (2, 8) 4 (2, 8) 2 (2, 2) 
N of days between first and last 
observation 
   
Mean (SD) Missing 3.0 (7.05) 13 4.5 (14.75) 20 0.0 (0.00) 26 
Median (Range) 0 (0, 29) 0 (0, 49) 0 (0, 0) 
Total mapping time (hours)    
Mean (SD) Missing 8.9 (2.76) 16 9.4 (2.30) 23 7.8 (0.43) 28 
Median (Range) 9.2 (4.0, 12.4) 9.9 (6.5, 12.3) 8.0 (7.3, 8.0) 
Using all codes Yes N (%) Missing 10 (32.3%) 13 7 (22.6%) 20 2 (6.5%) 26 
Total residents observed    
Mean (SD) Missing 5.4 (1.79) 13 5.7 (2.41) 20 5.2 (1.79) 26 
Median (Range) 5 (2, 8) 6 (2, 10) 4 (4, 8) 
Out of observed:    
N of residents with less than 3 hours of 
observation 
   
Mean (SD) Missing 2.2 (1.72) 13 1.1 (2.39) 20 1.0 (1.41) 26 
Median (Range) 2 (0, 5) 0 (0, 8) 0 (0, 3) 
N of residents with at least 3 hours of 
observation 
   
Mean (SD) Missing 3.3 (1.81) 13 4.6 (2.06) 20 4.2 (1.48) 26 
Median (Range) 3 (0, 6) 5 (2, 8) 4 (2, 6) 
% of observed residents with at least 3 
hours of observation 
   
Mean (SD) Missing 58.7 (33.75) 13 86.0 (25.13) 20 82.5 (24.37) 26 
Median (Range) 60 (0, 100) 100 (20, 100) 100 (50, 100) 
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Table 36 Observation quality by cycle 
Observation quality by cycle 
 
Cycle 1 
(n=31) 
Cycle 2 
(n=31) 
Cycle 3 
(n=31) 
Two mappers completed at least 4 hours of 
observations over a 1 week period 
   
Yes, completed fully 13 (41.9%) 7 (22.6%) 3 (9.7%) 
Completed partially 6 (19.4%) 4 (12.9%) 2 (6.5%) 
Not completed 12 (38.7%) 20 (64.5%) 26 (83.9%) 
At least 5 residents observed in total with at 
least 3 hours of available data on each resident 
   
Yes, completed fully 2 (6.5%) 4 (12.9%) 1 (3.2%) 
Completed partially 16 (51.6%) 7 (22.6%) 4 (12.9%) 
Not completed 13 (41.9%) 20 (64.5%) 26 (83.9%) 
Mappers using all 4 of the coding frames and 
making at least minimal qualitative notes 
   
Yes, completed fully 9 (29.0%) 5 (16.1%) 2 (6.5%) 
Completed partially 9 (29.0%) 6 (19.4%) 3 (9.7%) 
Not completed 13 (41.9%) 20 (64.5%) 26 (83.9%) 
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Feedback 
Table 37 Summary of feedback sessions as documented 
Summary of feedback sessions by cycle 
 Cycle 1 (n=31) Cycle 2 (n=31) Cycle 3 (n=31) 
Number of mappers participating in the 
feedback process 
   
1 1 (3.2%) 2 (6.5%)  
2 13 (41.9%) 7 (22.6%) 3 (9.7%) 
Missing 17 (54.8%) 22 (71.0%) 28 (90.3%) 
Formal feedback sessions held N (%) 
Missing 
   
Yes  12 (38.7%) 17 8 (25.8%) 21 3 (9.7%) 27 
No 2 (6.5%) 2 (6.5%) 1 (3.2%) 
Total number of formal feedback 
sessions 
   
Mean (SD) Missing 1.8 (0.83) 19  1.4 (0.79) 24 1.0 (0.00) 28 
Median (Range) 2 (1, 3) 1 (1, 3) 1 (1, 1) 
Total length of formal feedback 
sessions (hours) 
   
Mean (SD) Missing 2.0 (2.26) 20 1.2 (0.67) 25 0.8 (0.29) 28 
Median (Range) 1.2 (0.5, 8.4) 1.0 (0.5, 2.3) 1.0 (0.5, 1.0) 
N days between first and last feedback 
session (days) 
   
Mean (SD) Missing 2.8 (5.75) 19 1.3 (2.98) 24 0.0 (0.00) 28 
Median (Range) 0 (0, 20) 0 (0, 8) 0 (0, 0) 
Total number of staff attended formal 
feedback sessions 
   
Mean (SD) Missing 9.6 (4.56) 19 12.3 (4.46) 25 12.3 (4.51) 28 
Median (Range) 9.0 (2, 17) 11.5 (7, 18) 12.0 (8, 17) 
Total number of direct care staff 
attended formal feedback sessions 
   
Mean (SD) Missing 8.0 (2.65) 28 8.5 (2.12) 29 12.0 (.) 30 
Median (Range) 9 (5, 10) 8.5 (7, 10) 12 (12, 12) 
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Table 38 Care home and residents feedback points 
CH and residents feedback points by cycle 
 Cycle 1 (n=31) Cycle 2 (n=31) Cycle 3 (n=31) 
N of care home feedback points    
Mean (SD) Missing 5.0 (3.06) 21 3.7 (1.21) 25 6.0 (5.72) 27 
Median (Range) 4.5 (2, 13) 3 (3, 6) 5.5 (0, 13) 
Total number of residents with 
feedback points 
   
Mean (SD) Missing 4.4 (1.78) 19 4.2 (2.23) 25 3.5 (1.73) 27 
Median (Range) 4.5 (1, 7) 5 (1, 6) 4 (1, 5) 
Mean number of resident feedback 
points 
   
Mean (SD) Missing 3.2 (2.12) 20 2.5 (0.93) 25 2.3 (0.96) 27 
Median (Range) 2.8 (0.8, 7.8) 2.9 (1.0, 3.3) 2.4 (1.3, 3.3) 
% of achieved resident action 
plans set in previous cycle 
 Cycle 1 to cycle 2 Cycle 2 to cycle 3 
Mean (SD) Missing  51.6 (41.75) 22 73.8 (43.38) 26 
Median (Range)  64.7 (0, 100) 100.0 (0, 100) 
% of achieved CH action plans set 
in previous cycle 
   
Mean (SD) Missing  54.8 (44.72) 22 79.2 (25.00) 27 
Median (Range)  60.0 (0, 100) 83.3 (50, 100) 
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Action planning 
Table 39 Summary of action planning as documented 
Action planning by cycle 
 Cycle 1 (n=31) Cycle 2 (n=31) Cycle 3 (n=31) 
Care home action plan received N (%) 
Missing 
   
Yes 13 (41.9%) 12 6 (19.4%) 20 4 (12.9%) 26 
No 6 (19.4%) 5 (16.1%) 1 (3.2%) 
Number of care home action points    
Mean (SD) 4.9 (3.20) 18 5.2 (4.83) 25 5.0 (2.16) 27 
Median (Range) 4 (2, 14) 3 (3, 15) 4.5 (3, 8) 
Resident action plans received N (%) 
Missing 
   
Yes 13 (41.9%) 12 6 (19.4%) 20 3 (9.7%) 26 
No 6 (19.4%) 5 (16.1%) 2 (6.5%) 
Total number of residents with action 
points 
   
Mean (SD) 5.5 (1.85) 18 5.8 (2.86) 25 4.7 (1.15) 
Median (Range) 5 (3, 8) 5.5 (2, 10) 4 (4, 6) 
Mean number of resident action points    
Mean (SD) 2.0 (1.95) 18 2.0 (1.24) 25 1.8 (1.77) 28 
Median (Range) 1.6 (0.1, 7.8) 2.2 (0.1, 3.3) 1.3 (0.3, 3.8) 
 
Table 40 Action planning quality 
Action planning quality by cycle 
N (%) Missing Cycle 1 (n=31) 
Cycle 2 
(n=31) 
Cycle 3  
(n=31) 
Standard care home template used     
Yes 13 (41.9%) 18 6 (19.4%) 25 3 (9.7%) 27 
No   1 (3.2%) 
Standard resident template used     
Yes 12 (38.7%) 18 6 (19.4%) 25 2 (6.5%) 28 
No 1 (3.2%)  1 (3.2%) 
At least one action point per observed 
resident 
   
Yes 5 (16.1%) 18 4 (12.9%) 25 1 (3.2%) 28 
No 8 (25.8%) 2 (6.5%) 2 (6.5%) 
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Resident deaths 
Table 41 Residents deaths by treatment arm 
Residents deaths by treatment arm 
 Control (n=308) 
Intervention 
(n=418) Total (n=726) 
Died 111 (36.0%) 161 (38.5%) 272 (37.5%) 
Place of death    
Care home 89 (80.2%) 135 (83.9%) 224 (82.4%) 
Hospital 22 (19.8%) 26 (16.1%) 48 (17.6%) 
Average proportion of deaths per CH 
at 16-months 
   
Mean (SD) 0.36 (0.123) 0.39 (0.140) 0.37 (0.134) 
Median (Range) 0.41 (0.07, 0.60) 0.36 (0.10, 0.75) 0.36 (0.07, 0.75) 
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Outcomes 
Residents 
Table 42 Unadjusted observational CMAI and PAS summaries by time-point – closed cohort 
Unadjusted CMAI-O1 and PAS2 scores by time-point – closed cohort 
 AM  PM  
 Closed-cohort 
Mean (SD) N completed 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n = 726) 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n = 726) 
Baseline CMAI-O Total Score                           31.1 (3.1)  184 30.5 (2.7)  266 30.8 (2.9)  450 32.0 (3.7)  198 31.5 (3.8)  272 31.7 (3.8)  470 
Subscales: Aggressive behaviour 9.2 (0.6)  185 9.1 (0.5)  266 9.1 (0.6)  451 9.4 (1.1)  198 9.3 (1.0)  272 9.3 (1.1)  470 
                   Physically non-aggressive 7.2 (1.8)  184 6.9 (1.7)  265 7.0 (1.8)  449 7.6 (2.1)  198 7.3 (2.0)  272 7.4 (2.0)  470 
                   Verbally agitated 5.5 (1.3)  184 5.3 (0.9)  266 5.4 (1.1)  450 5.6 (1.4)  198 5.6 (1.6)  272 5.6 (1.6)  470 
                   Other 9.3 (0.9)  184 9.2 (0.7)  266 9.2 (0.8)  450 9.4 (1.1)  198 9.3 (0.8)  272 9.3 (0.9)  470 
6-months CMAI-O Total Score                           31.1 (4)  159 31.3 (3.6)  209 31.2 (3.8)  368 31.6 (3.6)  151 32.0 (3.9)  206 31.8 (3.8)  357 
Subscales: Aggressive behaviour 9.3 (1.0)  159 9.2 (0.6)  209 9.2 (0.8)  368 9.3 (0.9)  151 9.3 (0.8)  206 9.3 (0.9)  357 
                   Physically non-aggressive 6.8 (1.8)  159 6.9 (1.8)  209 6.9 (1.8)  368 7.1 (2.0)  151 7.4 (2.0)  206 7.3 (2.0)  357 
                   Verbally agitated 5.7 (1.7)  159 5.6 (1.7)  209 5.6 (1.7)  368 5.8 (1.7)  151 5.8 (1.9)  206 5.8 (1.8)  357 
                   Other 9.4 (1.0)  159 9.6 (1.2)  209 9.5 (1.1)  368 9.4 (1.0)  151 9.5 (1.1)  206 9.5 (1.1)  357 
16-months CMAI-O Total Score                           31.2 (3.8)  102 30.4 (3.2)  129 30.7 (3.5)  231 31.3 (4.1)  97 31 (3.9)  124 31.1 (4.0)  221 
Subscales: Aggressive behaviour 9.3 (1.1)  102 9.3 (1.0)  129 9.3 (1.0)  231 9.3 (1.2)  97 9.4 (1.3)  124 9.4 (1.3)  221 
                   Physically non-aggressive 6.7 (1.5)  102 6.5 (1.5)  129 6.6 (1.5)  231 6.8 (1.5)  97 6.7 (1.9)  124 6.8 (1.8)  221 
                   Verbally agitated 5.8 (2.2)  102 5.4 (1.4)  129 5.6 (1.8)  231 5.8 (2.0)  97 5.5 (1.5)  124 5.6 (1.7)  221 
                   Other 9.4 (1.0)  102 9.2 (0.7)  129 9.3 (0.8)  231 9.4 (1.0)  97 9.3 (1.0)  124 9.4 (1.0)  221 
Baseline PAS score 1.0 (1.5)  185 0.8 (1.5)  266 0.8 (1.5)  451 1.3 (1.6)  197 1.3 (2.2)  271 1.3 (2.0)  468 
6-months PAS score 0.9 (1.9)  159 0.9 (1.4)  209 0.9 (1.7)  368 1.1 (1.9)  151 1.2 (1.8)  204 1.2 (1.8)  355 
16-months PAS score 1.0 (1.8)  102 0.7 (1.6)  129 0.9 (1.7)  231 1.2 (2.1)    97 0.9 (1.9)  123 1.0 (2.0)  220 
1CMAI-O: scores 29-116, higher score indicates more frequent agitated behaviour, 2PAS: range of 0-16, with higher scores representing higher levels of agitation 
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Figure 8 Graphical depiction of change in average CMAI scores in care homes (cross-
sectional) by treatment arms (16 months-baseline)
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Figure 9 Graphical depiction of change in CMAI scores (closed-cohort) by treatment arms (16 months-baseline and 6 months-baseline) 
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Table 43 Observational CMAI (CMAI-O) and PAS summaries – unadjusted scores 
 CMAI-O and PAS summaries 
 Baseline 6-months 
16-months 
original cohort 
16-months 
cross-sectional cohort 
Mean (SD) N 
Control 
(n = 308) 
Interventio
n 
(n = 418) 
Total 
(n = 726) 
Control 
(n = 308) 
Interventio
n 
(n = 418) 
Total 
(n = 726) 
Control 
(n = 308) 
Interventio
n 
(n = 418) 
Total 
(n = 726) 
Control 
(n = 287) 
Interventio
n 
(n = 388) 
Total 
(n = 675) 
Total CMAI-O  
(10:00-12:00) 
31.1 (3.1) 
184 
30.5 (2.7) 
266 
30.8 (2.9) 
450 
31.1 (4)    
159 
31.3 (3.6) 
209 
31.2 (3.8) 
368 
31.2 (3.8) 
102 
30.4 (3.2) 
129 
30.7 (3.5) 
231 
31.1 (3.8) 
156 
30.5 (3.3) 
209 
30.8 (3.5) 
365 
CMAI-O subscales 
(10:00-12:00): 
            
Verbally agitated 5.5 (1.3)  
184 
5.3 (0.9)  
266 
5.4 (1.1)  
450 
5.7 (1.7)  
159 
5.6 (1.7)  
209 
5.6 (1.7)  
368 
5.8 (2.2)  
102 
5.4 (1.4)  
129 
5.6 (1.8)  
231 
5.8 (2.2)  
156 
5.5 (1.5)  
209 
5.6 (1.8)   
365 
Physically non-
aggressive 
7.2 (1.8)  
184 
6.9 (1.7)  
265 
7 (1.8)     
449 
6.8 (1.8)  
159 
6.9 (1.8)  
209 
6.9 (1.8)  
368 
6.7 (1.5)  
102 
6.5 (1.5)  
129 
6.6 (1.5)  
231 
6.7 (1.4)  
156 
6.5 (1.5)  
209 
6.6 (1.4)   
365 
Other 9.3 (0.9)  
184 
9.2 (0.7)  
266 
9.2 (0.8)  
450 
9.4 (1)     
159 
9.6 (1.2)   
209 
9.5 (1.1)  
368 
9.4 (1)     
102 
9.2 (0.7)  
129 
9.3 (0.8)  
231 
9.3 (1)     
156 
9.2 (0.7)  
209 
9.2 (0.8)   
365 
Aggressive behaviour 9.2 (0.6)  
185 
9.1 (0.5)  
266 
9.1 (0.6)  
451 
9.3 (1)     
159 
9.2 (0.6)  
209 
9.2 (0.8)  
368 
9.3 (1.1)  
102 
9.3 (1)     
129 
9.3 (1)     
231 
9.3 (0.9)   
156 
9.3 (1)     
209 
9.3 (1)      
365 
             
Total CMAI-O  
(12:00-17:00)  
32 (3.7)    
198 
31.5 (3.8) 
272 
31.7 (3.8) 
470 
31.6 (3.6) 
151 
32 (3.9)   
206 
31.8 (3.8) 
357 
31.3 (4.1)   
97 
31 (3.9)   
124 
31.1 (4)   
221 
31.4 (3.8) 
148 
31.1 (3.9) 
206 
31.2 (3.9) 
354 
Median (IQR) 31 (29, 34) 30 (29, 
32.6) 
30 (29, 33) 30 (29, 33) 30 (29, 34) 30 (29, 33) 29 (29, 32) 29 (29, 32) 29 (29, 32) 29 (29, 32) 29 (29, 32) 29 (29, 32) 
CMAI-O subscales 
(12:00-17:00): 
            
Verbally agitated 5.6 (1.4)  
198 
5.6 (1.6)   
272 
5.6 (1.6)   
470 
5.8 (1.7)   
151 
5.8 (1.9)  
206 
5.8 (1.8)  
357 
5.8 (2)        
97 
5.5 (1.5)  
124 
5.6 (1.7)  
221 
5.8 (1.9)   
148 
5.7 (1.7)   
206 
5.7 (1.8)    
354 
Physically non-
aggressive 
7.6 (2.1)   
198 
7.3 (2)      
272 
7.4 (2)      
470 
7.1 (2)     
151 
7.4 (2)     
206 
7.3 (2)     
357 
6.8 (1.5)    
97 
6.7 (1.9)   
124 
6.8 (1.8)   
221 
6.9 (1.5)   
148 
6.8 (1.9)   
206 
6.9 (1.8)    
354 
Other 9.4 (1.1)   
198 
9.3 (0.8)   
272 
9.3 (0.9)  
470 
9.4 (1)      
151 
9.5 (1.1)   
206 
9.5 (1.1)   
357 
9.4 (1)        
97 
9.3 (1)      
124 
9.4 (1)      
221 
9.3 (0.9)  
148 
9.3 (0.9)   
206 
9.3 (0.9)   
354 
Aggressive behaviour 9.4 (1.1)   
198 
9.3 (1)      
272 
9.3 (1.1)   
470 
9.3 (0.9)   
151 
9.3 (0.8)   
206 
9.3 (0.9)   
357 
9.3 (1.2)    
97 
9.4 (1.3)   
124 
9.4 (1.3)   
221 
9.3 (1.1)  
148 
9.3 (1.2)  
206 
9.3 (1.1)   
354 
             
Total PAS  
(10:00-12:00): 
1 (1.5)     
185 
0.8 (1.5)   
266 
0.8 (1.5)  
451 
0.9 (1.9)  
159 
0.9 (1.4)  
209 
0.9 (1.7)  
368 
1 (1.8)     
102 
0.7 (1.6)   
129 
0.9 (1.7)  
231 
1.1 (1.9)   
156 
0.8 (1.7)  
209 
0.9 (1.8)   
365 
Total PAS  
(12:00-17:00): 
1.3 (1.6)   
197 
1.3 (2.2)  
271 
1.3 (2)     
468 
1.1 (1.9)   
151 
1.2 (1.8)  
204 
1.2 (1.8)  
355 
1.2 (2.1)     
97 
0.9 (1.9)  
123 
1 (2)        
220 
1.2 (1.9)   
148 
0.9 (1.8)  
205 
1 (1.8)      
353 
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Sensitivity analyses 
Table 44 Supportive analysis assuming missing data are MAR – closed-cohort 
Analysis 
Adjusted 
Mean in 
Control  
Adjusted 
Mean in 
Intervention 
Estimated 
Mean 
Difference 
Lower 95% 
Confidence 
Limit 
Upper 95% 
Confidence 
Limit p-value 
Adjusted 
ICC for 
Intervention  
Adjusted 
ICC for 
Control  N 
Supportive analyses (closed-cohort)          
6-months          
CMAI 43.44 44.04 0.59 -1.98 3.17 0.653 0.049 0.001 726 
CMAI-O (AM) 31.40 31.86 0.46 -0.37 1.30 0.276 0.019 0.000 726 
CMAI-O (PM) 31.64 32.20 0.57 -0.27 1.40 0.182 0.023 0.001 726 
PAS (AM) 1.04 1.18 0.14 -0.24 0.52 0.473 0.022 0.001 726 
PAS (PM) 1.05 1.23 0.18 -0.20 0.57 0.350 0.021 0.001 726 
16-months          
CMAI-O (AM)  30.90 30.50 -0.40 -1.27 0.46 0.361 0.014 0.001 726 
CMAI-O (PM)  31.17 31.05 -0.13 -1.09 0.84 0.795 0.012 0.001 726 
PAS (AM)  0.91 0.79 -0.12 -0.52 0.28 0.547 0.008 0.001 726 
PAS (PM)  1.08 0.91 -0.17 -0.67 0.33 0.502 0.018 0.001 726 
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Table 45 Primary and sensitivity analyses – complete cases, cross-section 
Analysis 
Estimate
d mean in 
control 
Estimate
d mean 
in 
interventi
on 
Estimat
ed 
Mean 
Differen
ce 
Lower 
95% 
Confiden
ce Limit 
Upper 
95% 
Confide
nce 
Limit 
p-
value 
Unadjust
ed ICC 
for 
Interventi
on Arm 
Unadjust
ed ICC 
for 
Control 
Arm 
Adjusted 
ICC for 
Interventi
on Arm 
Adjust
ed ICC 
for 
Control 
Arm N 
Primary analysis  45.52 43.33 -2.19 -4.81 0.43 0.099 0.0546 0.0002 0 0 666 
Key sensitivity analysis   46.01 43.73 -2.28 -4.98 0.42 0.095 0.0497 0.007 666 
Sensitivity analysis (1) adjusting for before after  
                                eligibility change  
44.85 42.65 -2.2 -4.82 0.43 0.099 0.0546 0.0002 0 0 666 
                                (2) care home size as a  
                                continuous variable  
45.48 43.16 -2.32 -5.03 0.38 0.090 0.0546 0.0002 0 0 661 
                                (3) assuming homogeneous  
                                clustering across arms  
45.45 43.30 -2.16 -4.75 0.43 0.100 0.0497 0 666 
 
Table 46 Sensitivity analyses (4-5) CMAI, PAS and CMAI-O at 16-months – complete cases 
Closed-cohort analysis – PAS and CMAI-O at 16-months, complete cases 
Analysis 
Estimated 
mean in 
control 
Estimated 
mean in 
intervention 
Estimated 
Mean 
Difference 
Lower 95% 
Confidence 
Limit 
Upper 95% 
Confidence 
Limit p-value 
Unadjusted 
ICC for 
Intervention  
Unadjusted 
ICC for 
Control  
Adjusted 
ICC for 
Intervention  
Adjusted 
ICC for 
Control  N 
CMAI  46.00 42.44 -3.57 -6.65 -0.48 0.025 0.0779 0.0003 0.0261 0.002 400 
PAS (AM)  1.10 0.66 -0.44 -1.04 0.15 0.140 0.0882 0.0012 0.0031 0.0024 170 
PAS (PM)  1.40 0.75 -0.65 -1.4 0.09 0.084 0.2394 0.0108 0.2265 0.0151 174 
CMAI-O (AM)  31.08 30.04 -1.04 -2.25 0.17 0.089 0.1189 0.0009 0.0251 0.0079 169 
CMAI-O (PM)  31.42 30.71 -0.72 -2.12 0.69 0.310 0.0985 0.0003 0.0272 0.0018 176 
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Table 47 CMAI, observational CMAI and PAS at 6-months – complete cases 
Closed-cohort analysis – CMAI, PAS and CMAI-O at 6-months, complete cases 
Analysis  
Estimated 
mean in 
control 
Estimated 
mean in 
intervention 
Estimated 
Mean 
Difference 
Lower 95% 
Confidence 
Limit 
Upper 95% 
Confidence 
Limit p-value 
Unadjusted 
ICC for 
Intervention  
Unadjusted 
ICC for 
Control  
Adjusted 
ICC for 
Intervention  
Adjusted 
ICC for 
Control  N 
CMAI  43.32 43.73 0.41 -2.6 3.42 0.784 0.1356 0.011 0.0892 0 572 
CMAI-O (AM)  31.41 31.79 0.38 -0.66 1.42 0.468 0.09 0.0001 0.0418 0.0006 270 
CMAI-O (PM)  31.79 32.34 0.55 -0.73 1.83 0.393 0.121 0.0127 0.1445 0.0353 278 
PAS (AM)  0.90 1.08 0.18 -0.29 0.66 0.446 0.112 0.0018 0.0862 0.0022 268 
PAS (PM)  1.09 1.23 0.14 -0.42 0.7 0.621 0.1001 0 0.0779 0.0077 275 
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Table 48 Sensitivity analysis (5) - CMAI score at 16-months – closed-cohort - deaths and withdrawals assumed MNAR - two-way 
tipping point analysis 
 Deaths shifted by 
Treatment 
effect p-
values -40 -35 -30 -25 -20 -15 -10 -5 0 5 10 15 20 25 30 35 40 
Withdrawals and moves shifted by              
-40 0.028 0.025 0.023 0.022 0.02 0.019 0.019 0.018 0.018 0.018 0.018 0.019 0.02 0.021 0.023 0.025 0.028 
-35 0.029 0.027 0.025 0.023 0.021 0.02 0.02 0.019 0.019 0.019 0.019 0.02 0.021 0.022 0.024 0.026 0.029 
-30 0.03 0.028 0.026 0.024 0.023 0.022 0.021 0.02 0.02 0.02 0.021 0.021 0.022 0.024 0.026 0.028 0.03 
-25 0.032 0.03 0.027 0.026 0.024 0.023 0.022 0.022 0.021 0.021 0.022 0.023 0.024 0.025 0.027 0.029 0.032 
-20 0.034 0.031 0.029 0.027 0.026 0.024 0.024 0.023 0.023 0.023 0.023 0.024 0.025 0.027 0.029 0.031 0.034 
-15 0.036 0.033 0.031 0.029 0.027 0.026 0.025 0.025 0.025 0.025 0.025 0.026 0.027 0.029 0.031 0.033 0.036 
-10 0.038 0.036 0.033 0.031 0.03 0.028 0.027 0.027 0.027 0.027 0.027 0.028 0.029 0.031 0.033 0.036 0.039 
-5 0.041 0.038 0.036 0.034 0.032 0.031 0.03 0.029 0.029 0.029 0.029 0.03 0.032 0.033 0.036 0.038 0.041 
0 0.044 0.041 0.038 0.036 0.034 0.033 0.032 0.032 0.031 0.031 0.032 0.033 0.034 0.036 0.038 0.041 0.044 
5 0.047 0.044 0.041 0.039 0.037 0.036 0.035 0.034 0.034 0.034 0.035 0.036 0.037 0.039 0.041 0.044 0.048 
10 0.05 0.047 0.045 0.042 0.04 0.039 0.038 0.037 0.037 0.037 0.038 0.039 0.041 0.042 0.045 0.048 0.051 
15 0.054 0.051 0.048 0.046 0.044 0.042 0.041 0.041 0.041 0.041 0.041 0.043 0.044 0.046 0.049 0.052 0.055 
20 0.058 0.055 0.052 0.05 0.048 0.046 0.045 0.045 0.044 0.045 0.045 0.046 0.048 0.05 0.053 0.056 0.06 
25 0.062 0.059 0.056 0.054 0.052 0.05 0.049 0.049 0.048 0.049 0.049 0.051 0.052 0.055 0.057 0.061 0.065 
30 0.067 0.064 0.061 0.058 0.056 0.055 0.054 0.053 0.053 0.053 0.054 0.055 0.057 0.059 0.062 0.066 0.07 
35 0.072 0.069 0.066 0.063 0.061 0.06 0.058 0.058 0.058 0.058 0.059 0.06 0.062 0.064 0.067 0.071 0.075 
40 0.077 0.074 0.071 0.068 0.066 0.065 0.064 0.063 0.063 0.063 0.064 0.065 0.067 0.07 0.073 0.077 0.081 
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Table 49 NPI-NH at baseline – unadjusted scores 
 
Baseline  
Mean (SD) Missing 
 
Number experiencing the behaviour 
N (%) completed 
Frequency 
score 
Severity 
score 
Caregiver 
distress score 
Total domain 
score 
 
Control        
(n = 308) 
DCMTM 
Intervention 
(n = 418) 
Total (n = 
726) Control  DCMTM  Total Control  DCMTM Total  Control  DCMTM  Total  Control  DCMTM  Total  
Total score: 308 (100%) 417 (99.8%) 725 (99.9%)       3.4 (4.72) 0 3.2 (4.37) 0 3.3 (4.52) 0 13 (13.95) 0 11.7 (12.35) 
0 
12.2 (13.06) 
0 
Subscales:                
Delusions 59 
(19.2%)308 
69 
(16.5%)417 
128 
(17.7%)725 
2.7 (1.12) 0 2.7 (1.13) 2 2.7 (1.12) 2 1.8 (0.71) 0 1.8 (0.68) 2 1.8 (0.69) 2 1.9 (1.28) 1 1.5 (1.41) 3 1.7 (1.35) 4 5.3 (3.41) 0 4.9 (3.04) 2 5.1 (3.21) 2 
Hallucinations 47 
(15.3%)307 
59 
(14.2%)416 
106 
(14.7%)723 
2.6 (1.04) 0 2.6 (1.04) 1 2.6 (1.04) 1 1.4 (0.58) 0 1.5 (0.63) 1 1.5 (0.61) 1 0.8 (0.91) 0 1.2 (1.25) 1 1 (1.13) 1 3.8 (2.46) 0 4.2 (2.83) 1 4 (2.66) 1 
Agitation/ 
Aggression 
145 
(47.1%)308 
192 (46%)417 337 
(46.5%)725 
3 (0.95) 1 2.9 (0.94) 0 2.9 (0.95) 1 1.6 (0.67) 1 1.6 (0.69) 0 1.6 (0.68) 1 1.7 (1.23) 0 1.8 (1.28) 1 1.7 (1.25) 1 5 (2.85) 2 4.7 (2.86) 0 4.8 (2.85) 2 
Depression/ 
Dysphoria 
92    
(30%)307 
129 
(30.9%)418 
221 
(30.5%)725 
2.6 (0.94) 0 2.3 (1.01) 1 2.4 (0.98) 1 1.5 (0.67) 0 1.4 (0.6) 2 1.5 (0.63) 2 1.3 (1.04) 0 1.1 (1.14) 1 1.2 (1.1) 1 4.1 (2.77) 0 3.6 (2.63) 2 3.8 (2.7) 2 
Anxiety 80 (26%)308 98 
(23.5%)417 
178 
(24.6%)725 
2.8 (0.94) 2 2.6 (0.96) 3 2.7 (0.96) 5 1.7 (0.71) 2 1.5 (0.6) 3 1.6 (0.66) 5 1.6 (1.19) 2 1.5 (1.25) 3 1.6 (1.23) 5 5.2 (3.16) 2 3.9 (2.32) 3 4.5 (2.8) 5 
Elation/Euphoria 25 (8.1%)308 34 (8.2%)416 59 (8.1%)724 2.6 (0.96) 0 2.8 (1.07) 0 2.7 (1.02) 0 1.3 (0.44) 1 1.5 (0.62) 0 1.4 (0.56) 1 0.4 (1) 0 0.7 (1.04) 0 0.6 (1.02) 0 3.4 (2.16) 1 4.4 (2.81) 0 4 (2.59) 1 
Apathy/Indifference 91 
(29.5%)308 
130 
(31.2%)417 
221 
(30.5%)725 
3.1 (0.89) 1 3.1 (0.9) 1 3.1 (0.89) 2 1.6 (0.69) 1 1.6 (0.67) 1 1.6 (0.67) 2 0.8 (1.03) 1 0.8 (0.99) 1 0.8 (1.01) 2 5.4 (3.3) 1 5.2 (3.07) 1 5.3 (3.16) 2 
Disinhibition 51 
(16.6%)308 
65 
(15.6%)416 
116  
(16%)724 
2.8 (1.05) 0 2.6 (0.94) 0 2.7 (0.99) 0 1.7 (0.71) 0 1.4 (0.61) 0 1.5 (0.67) 0 1.5 (1.3) 1 1.2 (1.15) 0 1.3 (1.22) 1 5 (3.29) 0 3.8 (2.62) 0 4.3 (2.97) 0 
Irritability/Lability 117  
(38%)308 
153 
(36.7%)417 
270 
(37.2%)725 
2.9 (1.04) 3 2.7 (0.92) 0 2.8 (0.98) 3 1.7 (0.67) 3 1.5 (0.65) 0 1.6 (0.66) 3 1.7 (1.21) 4 1.3 (1.23) 0 1.5 (1.23) 4 5.3 (3.16) 3 4.4 (2.85) 0 4.8 (3.01) 3 
Aberrant motor 
behaviour 
94 
(30.5%)308 
135 
(32.5%)416 
229 
(31.6%)724 
3.6 (0.73) 0 3.4 (0.77) 0 3.5 (0.76) 0 1.6 (0.68) 0 1.6 (0.7) 0 1.6 (0.69) 0 1.1 (1.21) 0 1.1 (1.31) 0 1.1 (1.27) 0 5.9 (3) 0 5.7 (3.04) 0 5.8 (3.02) 0 
Sleep and night time 
behaviour disorders 
48 
(15.6%)307 
77 
(18.4%)418 
125 
(17.2%)725 
3.1 (0.78) 0 2.9 (0.95) 5 3 (0.89) 5 1.5 (0.65) 0 1.7 (0.74) 5 1.6 (0.71) 5 1.8 (1.39) 0 2 (1.43) 5 1.9 (1.42) 5 4.9 (2.64) 0 5 (2.73) 5 5 (2.68) 5 
Appetite and eating 
changes 
57 
(18.5%)308 
98 
(23.6%)415 
155 
(21.4%)723 
3.3 (0.85) 3 3.3 (0.79) 4 3.3 (0.81) 7 1.9 (0.63) 2 1.8 (0.72) 4 1.8 (0.69) 6 1.3 (1.18) 2 1.3 (1.19) 4 1.3 (1.18) 6 6.4 (2.92) 3 6.1 (3.26) 4 6.2 (3.13) 7 
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Table 50 NPI-NH at 6-months – unadjusted scores 
 
6-months 
Mean (SD) Missing 
 
Number experiencing 
the behaviour 
N (%) completed 
Frequency 
score 
Severity 
score 
Caregiver 
distress score 
Total domain 
score 
 
Control      
(n = 308) 
DCMTM 
Intervention 
(n = 418) Total (n = 726) Control  DCMTM  Total Control  DCMTM  Total  Control  DCMTM  Total  Control  DCMTM  Total  
*Total score: 244 (79.2%) 320 (76.6%) 564 (77.7%)       3 (4.03) 0 2.4 (3.26) 0 2.6 (3.62) 0 11.3 (12.35) 
0 
9.7 (10.14) 
0 
10.4 (11.17) 
0 
Subscales:                
Delusions 33 
(13.5%)245 
42  
(13.2%)319 
75    
(13.3%)564 
2.5 (1) 2 2.4 (1.01) 0 2.4 (1) 2 1.7 (0.68) 2 1.7 (0.67) 
0 
1.7 (0.67) 
2 
1.7 (1.19) 
2 
1.6 (1.19) 0 1.6 (1.19) 2 4.7 (3.07) 2 4.3 (2.99) 0 4.4 (3.01) 2 
Hallucinations 26 
(10.6%)245 
29    
(9.1%)319 
55      
(9.8%)564 
2.8 (0.88) 0 2.6 (0.98) 0 2.7 (0.94) 0 1.5 (0.71) 0 1.4 (0.57) 
0 
1.5 (0.63) 
0 
1.2 (1.12) 
0 
0.7 (0.84) 0 0.9 (1) 0 4.5 (2.72) 0 3.7 (1.91) 0 4.1 (2.34) 0 
Agitation/Aggression 120 
(49%)245 
125 
(39.2%)319 
245 (43.4%)564 2.9 (0.89) 0 2.6 (0.94) 0 2.8 (0.93) 0 1.8 (0.71) 0 1.6 (0.66) 
0 
1.7 (0.69) 
0 
1.8 (1.17) 
0 
1.7 (1.2) 0 1.7 (1.18) 0 5.4 (3.24) 0 4.4 (2.62) 0 4.9 (2.98) 0 
Depression/Dysphoria 63   
(26%)242 
101 
(31.6%)320 
164  
(29.2%)562 
2.4 (1.01) 0 2.4 (0.97) 1 2.4 (0.98) 1 1.4 (0.59) 0 1.4 (0.57) 
1 
1.4 (0.57) 
1 
1.2 (1.17) 
0 
0.9 (0.9) 1 1 (1.02) 1 3.7 (2.66) 0 3.5 (2.35) 1 3.6 (2.47) 1 
Anxiety 47 
(19.3%)244 
57  
(17.9%)319 
104  
(18.5%)563 
2.7 (0.99) 2 2.5 (0.87) 1 2.6 (0.93) 3 1.6 (0.74) 2 1.5 (0.66) 
1 
1.6 (0.7) 3 1.6  (1.2) 
2 
1.2 (1.06) 1 1.4 (1.13) 3 4.6 (2.92) 2 4 (2.71) 1 4.3 (2.81) 3 
Elation/Euphoria 15  
(6.1%)244 
19       
(6%)319 
34          
(6%)563 
2.8 (1.01) 0 2.4 (0.9) 0 2.6 (0.96) 0 1.4 (0.63) 0 1.3 (0.67) 
0 
1.4 (0.65) 
0 
0.3  (0.8) 
0 
0.3 (0.58) 0 0.3 (0.68) 0 4.3 (3.27) 0 3.4 (2.81) 0 3.8 (3.01) 0 
Apathy/Indifference 73 
(29.9%)244 
116 
(36.3%)320 
189   
(33.5%)564 
3.1 (0.87) 1 2.8 (0.98) 1 2.9 (0.95) 2 1.7 (0.77) 1 1.5 (0.62) 
1 
1.6  (0.7) 
2 
0.7 (0.93) 
1 
0.7 (0.91) 1 0.7 (0.91) 2 5.7 (3.39) 1 4.3 (2.91) 1 4.9 (3.16) 2 
Disinhibition 35 
(14.3%)244 
30    
(9.4%)320 
65    
(11.5%)564 
2.7 (1.07) 0 2.9 (0.88) 0 2.8 (0.99) 0 1.7 (0.67) 0 1.7 (0.83) 
0 
1.7 (0.74) 
0 
1.7 (1.39) 
0 
1.6 (1.45) 0 1.6 (1.41) 0 4.9 (3.08) 0 5.3 (3.44) 0 5.1 (3.23) 0 
Irritability/Lability 83 
(33.9%)245 
99  
(30.9%)320 
182  
(32.2%)565 
2.6 (0.92) 0 2.7 (0.88) 0 2.7 (0.9) 0 1.6 (0.66) 0 1.6 (0.69) 
0 
1.6 (0.68) 
0 
1.5 (1.14) 
0 
1.3 (1.18) 1 1.4 (1.17) 1 4.5 (3.12) 0 4.4 (2.89) 0 4.5 (2.99) 0 
Aberrant motor 
behaviour 
71 
(29.1%)244 
90  
(28.2%)319 
161  
(28.6%)563 
3.4 (0.73) 0 3.4 (0.69) 0 3.4 (0.7) 0 1.6 (0.62) 0 1.7 (0.67) 
0 
1.7 (0.65) 
0 
1.1 (0.98) 
0 
1.1 (1.12) 0 1.1 (1.06) 0 5.6 (2.58) 0 6 (2.98) 0 5.8 (2.81) 0 
Sleep and night time 
behaviour disorders 
39 
(15.9%)245 
51     
(16%)319 
90       
(16%)564 
3 (1) 0 2.9 (0.97) 0 3 (0.98) 0 1.5 (0.79) 0 1.6 (0.66) 
0 
1.6 (0.72) 
0 
1.7 (1.28) 
0 
2 (1.26) 0 1.8 (1.27) 0 4.9 (3.55) 0 5 (3.01) 0 5 (3.24) 0 
Appetite and eating 
changes 
48 
(19.6%)245 
46   
(14.4%)319 
94    
(16.7%)564 
3.3 (0.7) 1 3.2 (0.88) 1 3.3 (0.79) 2 1.9 (0.62) 1 1.8 (0.63) 
1 
1.8 (0.62) 
2 
1.4 (1.21) 
1 
1.6 (1.3) 1 1.5 (1.25) 2 6.3 (2.87) 1 5.8 (2.71) 1 6 (2.79) 2 
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Table 51 NPI-NH at 16-months original cohort – unadjusted scores 
 16-months original cohort 
 
Number experiencing 
the behaviour 
N (%) completed 
Frequency 
score 
Severity 
score 
Caregiver 
distress score 
Total domain 
score 
Mean (SD) Missing 
Control       
(n = 308) 
DCMTM 
Intervention 
(n = 418) Total (n = 726) Control  DCMTM  Total Control  DCMTM  Total  Control  DCMTM  Total  Control  DCMTM  Total  
Total score: 185 (60.1%) 222 (53.1%) 407 (56.1%)       1.8 (3.12) 
0 
1.6 (2.79)     
0 
1.7 (2.94) 
0 
10.4 (9.25) 
0 
7.7 (9.36)    
0 
8.9 (9.4)   
0 
Subscales:                
Delusions 18      
(9.7%)185 
20     
(9%)222 
38     
(9.3%)407 
2.8 (1.26) 
0 
2.6 (1.1) 0 2.7 (1.16) 
0 
1.7 (0.57) 
0 
1.5 (0.51) 0 1.6 (0.55) 
0 
0.9 (1.16) 
0 
1.5 (1.07) 1 1.2 (1.13) 
1 
5.2 (3.03) 0 3.9 (2.28) 0 4.5 (2.71) 
0 
Hallucinations 15      
(8.1%)185 
20     
(9%)222 
35     
(8.6%)407 
2.3 (1.18) 
0 
3 (1.08) 0 2.7 (1.15) 
0 
1.4 (0.63) 
0 
1.3 (0.44) 0 1.3 (0.53) 
0 
0.2 (0.41) 
0 
0.6 (0.82) 0 0.4 (0.7)  
0 
3.3 (2.32) 0 3.8 (1.99) 0 3.6 (2.12) 
0 
Agitation/ 
Aggression 
82     
(44.3%)185 
76 
(34.2%)222 
158 
(38.8%)407 
3   (0.92) 
0 
2.8 (1.02) 0 2.9 (0.97) 
0 
1.5 (0.55) 
0 
1.5 (0.64) 0 1.5 (0.59) 
0 
1.4 (1.17) 
0 
1.6 (1.17) 0 1.4 (1.17) 
0 
4.5 (2.3) 0 4.5 (3) 0 4.5 (2.65) 
0 
Depression/ 
Dysphoria 
63    
(34.1%)185 
55 
(24.8%)222 
118    
(29%)407 
2.6 (0.9) 1 2.5 (0.95) 1 2.5 (0.92) 
2 
1.3 (0.49) 
1 
1.2 (0.49) 1 1.3 (0.49) 
2 
0.6  (0.94) 
1 
0.6 (0.77) 1 0.6 (0.86) 
2 
3.5 (2.09) 1 3.1 (1.87) 1 3.3 (1.99) 
2 
Anxiety 29    
(15.7%)185 
34 
(15.3%)222 
63    
(15.5%)407 
2.9 (0.84) 
0 
2.7 (0.94) 1 2.8  (0.9) 
1 
1.5 (0.51) 
0 
1.5 (0.67) 1 1.5 (0.59) 
1 
1 (0.98)   
0 
1 (1.16) 1 1 (1.07)   
1 
4.5 (2.28) 0 4.4 (2.83) 1 4.4 (2.56) 
1 
Elation/Euphoria 7        
(3.8%)185 
14  
(6.3%)222 
21     
(5.2%)407 
3.1  (0.9) 
0 
2.6 (1.02) 0 2.8     (1) 
0 
1.3 (0.49) 
0 
1.2 (0.43) 0 1.2 (0.44) 
0 
0 (0)        
0 
0.2 (0.58) 0 0.1 (0.48) 
0 
4.1 (2.19) 0 3.3 (2.09) 0 3.6 (2.11) 
0 
Apathy/Indifference 73    
(39.5%)185 
62 
(27.9%)222 
135 
(33.2%)407 
3.3 (1.01) 
0 
3 (1) 0 3.2 (1.01) 
0 
1.6 (0.69) 
0 
1.6 (0.73) 0 1.6 (0.71) 
0 
0.4 (0.63) 
0 
0.5 (0.88) 0 0.4 (0.76) 
0 
5.5 (3.33) 0 5.2 (3.4) 0 5.3 (3.36) 
0 
Disinhibition 24       
(13%)185 
24 
(10.8%)222 
48    
(11.8%)407 
2.5 (1.04) 
1 
2.5 (1.14) 0 2.5 (1.08) 
1 
1.3 (0.47) 
1 
1.3 (0.56) 0 1.3 (0.52) 
1 
0.8 (1.03) 
1 
1.3 (1.3) 0 1.1 (1.19) 
1 
3.6 (2.43) 1 3.6 (2.59) 0 3.6 (2.48) 
1 
Irritability/Lability 65     
(35.1%)185 
66 
(29.7%)222 
131 
(32.2%)407 
3   (0.76) 
0 
2.6 (1.04) 0 2.8 (0.92) 
0 
1.5 (0.56) 
0 
1.4 (0.61) 0 1.5 (0.59) 
0 
1.2 (1.09) 
0 
1 (1.1) 0 1.1 (1.1)  
0 
4.5 (2.3) 0 4 (2.83) 0 4.2 (2.58) 
0 
Aberrant motor 
behaviour 
54    
(29.2%)185 
38 
(17.1%)222 
92    
(22.6%)407 
3.4 (0.74) 
0 
3.5 (0.73) 1 3.4 (0.73) 
1 
1.4 (0.56) 
0 
1.5 (0.56) 2 1.4 (0.56) 
2 
0.5 (0.84) 
0 
0.9 (1.15) 2 0.7 (0.98) 
2 
4.7 (2.41) 0 5.2 (2.35) 2 4.9 (2.38) 
2 
Sleep and night time 
behaviour disorders 
22    
(11.9%)185 
27 
(12.2%)222 
49      
(12%)407 
2.7 (1.08) 
0 
2.8 (1.03) 4 2.8 (1.04) 
4 
1.1 (0.35) 
0 
1.4 (0.59) 4 1.3 (0.51) 
4 
0.8 (1.01) 
0 
1.7 (1.47) 4 1.2 (1.32) 
4 
3.1 (1.58) 0 4 (2.1) 4 3.6 (1.9) 4 
Appetite and eating 
changes 
30    
(16.2%)185 
25 
(11.3%)222 
55    
(13.5%)407 
3 (0.96) 4 3.2 (0.77) 4 3.1 (0.88) 
8 
1.8 (0.61) 
4 
1.7 (0.78) 4 1.8 (0.69) 
8 
1.2 (1.23) 
4 
1.5 (0.93) 4 1.3 (1.11) 
8 
5.9 (2.96) 4 5.8 (3.22) 4 5.8 (3.05) 
8 
 
  
 203 
 
Table 52 NPI-NH at 16-months cross-sectional cohort – unadjusted scores 
 16-months cross-sectional cohort 
 
Number experiencing 
the behaviour 
N (%) completed 
Frequency 
score 
Severity 
score 
Caregiver 
distress score 
Total domain 
score 
Mean (SD) Missing 
Control          
(n = 287) 
Intervention  
(n = 388) Total (n = 675) Control  Intervention  Total Control  Intervention  Total  Control  Intervention  Total  Control  Intervention  Total  
Total score: 284 (99%) 384 (99%) 668 (99%)       1.6 (2.86) 0 2 (3.77) 0 1.9 (3.41) 0 10 (10.46) 
0 
8.4 (10.25) 0 9.1 (10.36) 0 
Subscales:                
Delusions 24 (8.5%)284 50 (13%)384 74 (11.1%)668 2.9 (1.26) 0 2.6 (1.13) 1 2.7 (1.17) 1 1.7 (0.62) 0 1.5 (0.62) 
1 
1.6 (0.62)   
1 
0.8 (1.1) 0 1.5 (1.15) 2 1.3 (1.17) 2 5.3 (3.28) 0 4 (2.66) 1 4.5 (2.92) 1 
Hallucinations 29 (10.2%)284 37 (9.6%)384 66 (9.9%)668 2.5 (1.09) 0 2.8 (1.12) 0 2.7 (1.11) 0 1.5 (0.69) 0 1.3 (0.53) 
0 
1.4 (0.6)     
0 
0.4 (0.78) 0 0.8 (0.95) 0 0.6 (0.89) 0 3.9 (3) 0 3.8 (2.38) 0 3.8 (2.65) 0 
Agitation/ 
Aggression 
116 (40.8%)284 141 (36.7%)384 257 (38.5%)668 3 (0.92) 0 2.9 (0.95) 2 2.9 (0.94) 2 1.5 (0.57) 0 1.5 (0.58) 
1 
1.5 (0.57)    
1 
1.3 (1.14) 0 1.6 (1.22) 2 1.4 (1.19) 2 4.7 (2.48) 0 4.7 (2.67) 2 4.7 (2.58) 2 
Depression/ 
Dysphoria 
95 (33.5%)284 105 (27.3%)384 200 (29.9%)668 2.5 (0.94) 2 2.4 (0.96) 1 2.5 (0.95) 3 1.3 (0.53) 2 1.3 (0.52) 
1 
1.3 (0.52)   
3 
0.6 (0.92) 2 0.8 (1) 1 0.7 (0.96) 3 3.5 (2.35) 2 3.2 (2.03) 1 3.3 (2.19) 3 
Anxiety 48 (17%)283 72 (18.8%)384 120 (18%)667 2.6 (0.98) 0 2.6 (0.95) 2 2.6 (0.96) 2 1.5 (0.62) 0 1.5 (0.61) 
2 
1.5 (0.61)   
2 
0.7 (0.96) 0 1.1 (1.22) 2 1 (1.14) 2 4 (2.45) 0 4 (2.57) 2 4 (2.51) 2 
Elation/Euphoria 13 (4.6%)283 22 (5.7%)384 35 (5.2%)667 2.8 (0.93) 0 2.6 (0.9) 0 2.7 (0.9) 0 1.4 (0.51) 0 1.3 (0.55) 
0 
1.3 (0.53)   
0 
0 (0) 0 0.2 (0.5) 0 0.1 (0.4) 0 3.8 (1.88) 0 3.6 (2.61) 0 3.7 (2.34) 0 
Apathy/Indifference 95 (33.5%)284 108 (28.1%)384 203 (30.4%)668 3.3 (1) 0 2.9 (1) 0 3.1 (1.01) 0 1.6 (0.71) 0 1.5 (0.65) 
0 
1.5 (0.68)   
0 
0.3 (0.63) 0 0.5 (0.85) 0 0.4 (0.76) 0 5.5 (3.41) 0 4.6 (3.06) 0 5 (3.25) 0 
Disinhibition 35 (12.3%)284 42 (10.9%)384 77 (11.5%)668 2.7 (1.09) 1 2.6 (1.03) 0 2.6 (1.05) 1 1.3 (0.53) 1 1.5 (0.71) 
0 
1.4 (0.64)   
1 
0.7 (0.93) 1 1.5 (1.38) 0 1.2 (1.26) 1 3.8 (2.7) 1 4.4 (3.22) 0 4.1 (2.99) 1 
Irritability/Lability 94 (33.1%)284 127 (33.1%)384 221 (33.1%)668 3 (0.84) 0 2.6 (0.96) 1 2.8 (0.93) 1 1.5 (0.58) 0 1.4 (0.57) 
1 
1.5 (0.58)   
1 
1.1 (1.05) 0 1.1 (1.13) 1 1.1 (1.09) 1 4.5 (2.44) 0 4 (2.66) 1 4.2 (2.58) 1 
Aberrant motor 
behaviour 
83 (29.2%)284 74 (19.3%)384 157 (23.5%)668 3.4 (0.8) 0 3.4 (0.72) 1 3.4 (0.76) 1 1.4 (0.59) 0 1.5 (0.58) 
2 
1.5 (0.58)   
2 
0.5 (0.85) 0 0.9 (1.15) 2 0.7 (1.01) 2 4.9 (2.53) 0 5.2 (2.54) 2 5.1 (2.53) 2 
Sleep and night time 
behaviour disorders 
28 (9.9%)284 49 (12.8%)384 77 (11.5%)668 2.9 (1.07) 1 2.8 (0.94) 5 2.9 (0.98) 6 1.2 (0.42) 1 1.5 (0.59) 
5 
1.4 (0.55)   
6 
0.8 (0.97) 1 1.7 (1.49) 5 1.4 (1.38) 6 3.7 (2.11) 1 4.3 (2.14) 5 4 (2.13) 6 
Appetite and eating 
changes 
41 (14.4%)284 44 (11.5%)384 85 (12.7%)668 3.1 (1.01) 7 3.3 (0.74) 4 3.2 (0.88) 11 1.9 (0.69) 7 1.6 (0.67) 
4 
1.7 (0.69) 
11 
1.1 (1.23) 7 1.4 (1.03) 4 1.3 (1.12) 11 6.1 (3.39) 7 5.3 (2.75) 4 5.7 (3.07) 11 
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Table 53 Behaviours staff find challenging, medications and mood (based on NPI domains) at 6-months 
Closed-cohort – behaviours staff find challenging, medications, mood at 6-months 
 
 
 
Logistic regression models 
Treatm
ent 
odds 
ratio 
(treated 
control) 
Lower 
95% 
confide
nce 
limit 
Upper 
95% 
confide
nce 
limit p-value N 
Behaviours staff find challenging  
 
Complete cases only 0.941 0.598 1.479 0.7921 558 
Missing data imputed assuming MAR 0.95 0.612 1.476 0.8196 726 
Cluster specific - complete cases only 0.939 0.561 1.57 0.8088 558 
Cluster specific - missing data imputed assuming 
MAR 
0.951 0.584 1.547 0.8381 726 
PRN antipsychotic medication  
 
Complete cases only 0.454 0.114 1.815 0.2640 581 
Missing data imputed assuming MAR 0.455 0.093 2.236 0.3314 726 
 Complete cases only without hub  0.494 0.093 2.629 0.4084 581 
 Missing data imputed assuming MAR without hub  0.533 0.095 2.997 0.4743 726 
Mood       
Depression/dysphoria 
 
Complete cases only 1.34 0.862 2.082 0.1932 558 
Missing data imputed assuming MAR 1.32 0.872 1.999 0.1895 726 
Anxiety  
 
Complete cases only 1.023 0.59 1.774 0.9343 558 
Missing data imputed assuming MAR 1.011 0.617 1.656 0.9668 726 
Apathy/indifference 
 
Complete cases only 1.319 0.79 2.2 0.2897 559 
Missing data imputed assuming MAR 1.33 0.853 2.073 0.2075 726 
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Table 54 Behaviours staff find challenging, medications and mood (based on NPI domains) at 16-months 
 Closed cohort – behaviours staff find challenging, medications, mood at 16-months  
 
Logistic regression models Treatment 
odds ratio 
(treated 
control) 
Lower 95% 
confidence 
limit 
Upper 95% 
confidence 
limit p-value N 
Behaviours staff find 
challenging  
 
Complete cases only  0.605 0.339 1.079 0.0886 403 
Missing data imputed assuming MAR 0.57 0.343 0.948 0.0305 726 
Cluster specific - complete cases only 0.591 0.308 1.133 0.1131 403 
Cluster specific - missing data imputed assuming 
MAR 
0.577 0.334 0.996 0.0484 726 
PRN antipsychotic medication  Complete cases only without hub  0.766 0.132 4.457 0.7666 406 
 Missing data imputed assuming MAR without hub  0.783 0.114 5.368 0.8019 726 
Mood       
Depression/dysphoria Complete cases only 0.614 0.345 1.094 0.0980 404 
 Missing data imputed assuming MAR 0.592 0.369 0.95 0.0298 726 
Anxiety  Complete cases only 1.027 0.51 2.069 0.9395 403 
 Missing data imputed assuming MAR 1.037 0.588 1.83 0.9004 726 
Apathy/indifference Complete cases only 0.601 0.322 1.124 0.1109 403 
 Missing data imputed assuming MAR 0.601 0.38 0.952 0.0302 726 
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Table 55 Behaviours staff find challenging, medications and mood (based on NPI domains) at 16-months 
Cross-sectional sample – behaviours staff find challenging, medications, mood at 16-months 
 
 
 
Logistic regression models 
Treatment 
odds ratio 
(treated 
control) 
Lower 95% 
confidence 
limit 
Upper 95% 
confidence 
limit p-value N 
Behaviours staff find challenging  
 
Complete cases only 0.723 0.481 1.088 0.1198 668 
Missing data imputed assuming MAR 0.720 0.479 1.083 0.1146 675 
Cluster specific - complete cases only 0.683 0.4 1.166 0.1619 668 
Cluster specific - missing data imputed assuming 
MAR 
0.681 0.4 1.158 0.1561 675 
Antipsychotic medication  Complete cases only 1.166 0.127 10.688 0.892 413 
 Missing data imputed assuming MAR 1.28 0.153 10.685 0.8189 675 
Mood       
Depression/dysphoria Complete cases only 0.757 0.51 1.123 0.1666 668 
 Missing data imputed assuming MAR 0.757 0.511 1.123 0.1672 675 
Anxiety  Complete cases only 1.134 0.667 1.928 0.6422 667 
 Missing data imputed assuming MAR 1.133 0.67 1.916 0.6423 675 
Apathy/indifference Complete cases only 0.81 0.525 1.249 0.3402 668 
 Missing data imputed assuming MAR 0.81 0.525 1.249 0.3403 675 
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Table 56 Quality of life analysis – QUALID (relative/ friend and staff) 
Quality of life analysis – closed-cohort QUALID (relative/ friend and staff) 
Analysis 
Estimated 
Mean 
Difference 
Lower 95% 
Confidence 
Limit 
Upper 95% 
Confidence 
Limit p-value 
Unadjusted 
ICC for 
Intervention  
Unadjusted 
ICC for 
Control  
Adjusted ICC 
for 
Intervention  
Adjusted 
ICC for 
Control  N 
6-months          
QUALID (staff) - complete cases only  -0.62 -1.91 0.67 0.334 0.1357 0.0173 0.0627 0.0001 560 
QUALID (staff) - missing data imputed assuming MAR -0.74 -1.91 0.43 0.214 0.129 0.005 0.035 0.001 726 
16-months          
QUALID (staff) - complete cases only -0.04 -1.24 1.16 0.948 0.0838 0.0064 0 0 404 
QUALID (staff) - missing data imputed assuming MAR -0.07 -1.26 1.11 0.902 0.07 0.004 0.004 0 726 
 
Table 57 Quality of life analysis – cross-sectional sample QUALID (relative/ friend and staff) 
Quality of life analysis – cross-sectional cohort QUALID (relative/ friend and staff) 
Analysis at 16-months 
Estimated 
Mean 
Difference 
Lower 95% 
Confidence 
Limit 
Upper 95% 
Confidence 
Limit p-value 
Unadjusted 
ICC for 
Intervention  
Unadjusted 
ICC for 
Control  
Adjusted 
ICC for 
Intervention  
Adjusted 
ICC for 
Control  N 
QUALID (staff) - complete cases only -0.06 -1.14 1.02 0.910 0.0788 0.0089 0.0119 0.0015 668 
QUALID (staff) - missing data imputed assuming MAR -0.05 -1.12 1.02 0.922 0.082 0.01 0.015 0.002 675 
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Table 58 Prescription of regular medications – closed-cohort at baseline and 6-months 
Prescription of regular medications – closed-cohort at baseline and 6-months 
 Baseline 6-months 
N prescribed (% sample) 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n = 726) 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n = 726) 
Antipsychotic  44 (14.3%) 51 (12.2%) 95 (13.1%) 35 (11.4%) 37 (8.9%) 72 (9.9%) 
Benzodiazepine  20 (6.5%) 21 (5.0%) 41 (5.6%) 14 (4.5%) 14 (3.3%) 28 (3.9%) 
Non-benzodiazepine 
anxiolytic 
 0 (0%) 4 (1.0%) 4 (0.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Non-benzodiazepine 
hypnotic 
 22 (7.1%) 14 (3.3%) 37 (5.1%) 20 (6.5%) 15 (3.6%) 35 (4.8%) 
Memantine  26 (8.4%) 28 (6.7%) 54 (7.4%) 21 (6.8%) 27 (6.5%) 48 (6.6%) 
Antidepressant  127 (41.2%) 135 (32.3%) 262 (36.1%) 107 (34.7%) 113 (27.0%) 220 (30.3%) 
Cholinesterase inhibitor  47 (15.3%) 61 (14.6%) 108 (14.9%) 40 (13.0%) 54 (12.9%) 94 (12.9%) 
Anticonvulsant  14 (4.5%) 20 (4.8%) 34 (4.6%) 13 (4.2%) 17 (4.1%) 30 (4.1%) 
Mood stabiliser  1 (0.3%) 2 (0.5%) 3 (0.4%) 1 (0.3%) 4 (1.0%) 5 (0.7%) 
Pain relief  143 (46.4%) 213 (51.0%) 356 (49.0%) 105 (34.1%) 160 (38.3%) 265 (36.5%) 
Total number of 
medications prescribed on 
the MAR over the reporting 
period 
Mean (SD) N 
taken/ month 
8.7 (4.3) 304 8.7 (4.01) 414 8.7 (4.13) 718 8.5 (3.73) 240 9.2 (4.4) 336 8.9 (4.15) 576 
Median (Q1, 
Q3) 
8 (6, 11) 8 (6, 11) 8 (6, 11) 8.5 (6, 11) 9 (6, 12) 9 (6, 12) 
Frequencies are given out of those in the respective samples, assuming the missing data reflects no prescriptions. 
Table 59 Number of closed-cohort and cross-sectional cohort residents prescribed regular medications at 16-months 
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Frequencies are given out of those in the respective samples, assuming the missing data reflects no prescriptions. 
  
 Prescription of regular medications - 16-months only 
 
16-months 
original cohort 
16-months 
cross-sectional cohort 
N (% sample) 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n = 726) 
Control 
(n = 287) 
Intervention 
(n = 388) 
Total 
(n = 675) 
Antipsychotic  29 (9.4%) 27 (6.5%) 56 (7.7%) 41 (14.3%) 46 (11.9%) 87 (12.9%) 
Benzodiazepine  11 (3.6%) 9 (2.2%) 20 (2.8%) 18 (6.3%) 14 (3.6%) 32 (4.7%) 
Non-benzodiazepine anxiolytic  0 (0.0%) 1 (0.2%) 1 (0.1%) 0 (0.0%) 1 (0.3%) 1 (0.1%) 
Non-benzodiazepine hypnotic  14 (4.5%) 12 (2.9%) 26 (3.6%) 21 (7.3%) 22 (5.7%) 43 (6.4%) 
Memantine  17 (5.5%) 21 (5.0%) 38 (5.2%) 31 (10.8%) 44 (11.3%) 75 (11.1%) 
Antidepressant  80 (26.0%) 68 (16.3%) 148 (20.4%) 119 (41.5%) 131 (33.8%) 250 (37.0%) 
Cholinesterase inhibitor  28 (9.1%) 33 (7.9%) 61 (8.4%) 50 (17.4%) 71 (18.3%) 121 (17.9%) 
Anticonvulsant  9 (2.9%) 10 (2.4%) 19 (2.6%) 9 (3.1%) 15 (3.9%) 24 (3.6%) 
Mood stabiliser  1 (0.3%) 0 (0.0%) 1 (0.1%) 2 (0.7%) 0 (0.0%) 2 (0.3%) 
Pain relief  84 (27.3%) 121 (28.9%) 205 (28.2%) 140 (48.8%) 201 (51.8%) 341 (50.5%) 
Total number of medications 
prescribed 
on the MAR over the reporting 
period 
Mean (SD) N 
taken/ month 
8.9 (3.82) 165 8.9 (4.61) 214 8.9 (4.28) 379 8.7 (3.71) 260 8.8 (4.74) 368 8.7 (4.34) 628 
Median (Q1, 
Q3) 
9 (6, 11) 8 (6, 12) 9 (6, 12) 9 (6, 11) 8 (5, 11) 8 (6, 11) 
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Table 60 Administration of PRN medications by cohort and time point 
 Baseline 6 months 
16 months 
original cohort 
16 months 
cross-sectional cohort 
N (% sample) 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n=726) 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n=726) 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n=726) 
Control 
(n = 287) 
Intervention 
(n = 388) 
Total          
(n = 675) 
Antipsychotic medication 1 (0.3%) 1 (0.2%) 2 (0.3%)    2 (0.6%) 1 (0.2%) 3 (0.4%)  1 (0.3%) 0 (0.0%) 1 (0.1%) 1 (0.3%) 1 (0.3%) 2 (0.3%) 
Benzodiazepine medication 9 (2.9%) 8 (1.9%) 17 (2.3%)  9 (2.9%) 9 (2.2%) 18 (2.5%) 4 (1.3%) 2 (0.5%) 6 (0.8%) 10 (3.5%) 6 (1.5%) 16 (2.4%) 
Non-benzodiazepine anxiolytic medication 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Non-benzodiazepine hypnotic medication 2 (0.6%) 3 (0.7%) 5 (0.7%)  1 (0.3%) 1 (0.2%) 2 (0.3%) 4 (1.3%) 1 (0.2%) 5 (0.7%) 6 (2.1%) 1 (0.3%) 7 (1.0%) 
Anticonvulsant medications 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Mood stabiliser medications 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Pain relief medications  67 (21.8%) 69 (16.5%) 136 (18.7%)  74 (24%) 93 (22.2%) 167 (23.0%) 48 (15.6%) 40 (9.6%) 88 (12.1%) 71 (24.7%) 67 (17.3%) 138 (20.4%) 
Frequencies are given out of those in the respective samples, assuming the missing data reflects no administrations. 
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Care homes 
Table 61 QUIS summaries - unadjusted 
QUIS summaries 
 Baseline 6-months 16-months 
All interactions (% 
positive) missing 
Control 
(n = 19) 
Intervention 
(n = 31) 
Total 
(n = 50) 
Control 
(n = 19) 
Intervention 
(n = 31) 
Total 
(n = 50) 
Control 
(n = 19) 
Intervention 
(n = 31) 
Total 
(n = 50) 
AM 0-15 min interval 255 (75.3%) 0 297 (83.8%) 2 552 (79.9%) 2 268 (89.2%) 0 283 (91.9%) 0 551 (90.6%) 0 180 (86.7%) 0 376 (83.5%) 0 556 (84.5%) 0 
 15-30 min interval 288 (71.9%) 0 334 (88.9%) 2 622 (81%) 2 250 (84%) 0 271 (89.7%) 0 521 (86.9%) 0 165 (86.1%) 0 254 (85.4%) 0 419 (85.7%) 0 
 30-45 min interval 213 (68.5%) 0 296 (85.1%) 1 509 (78.2%) 1 224 (88.4%) 0 280 (88.6%) 0 504 (88.5%) 0 204 (86.3%) 0 285 (81.8%) 1 489 (83.6%) 1 
 45-60 min interval 264 (83.7%) 0 303 (87.1%) 1 567 (85.5%) 1 258 (85.7%) 0 226 (81.9%) 0 484 (83.9%) 0 231 (84%) 0 276 (81.2%) 1 507 (82.4%) 1 
PM 0-15 min interval 298 (81.2%) 0 317 (79.5%) 2 615 (80.3%) 2 217 (78.3%) 0 341 (90%) 0 558 (85.5%) 0 211 (80.6%) 0 324 (83%) 0 535 (82.1%) 0 
 15-30 min interval 264 (75.4%) 0 312 (76.9%) 2 576 (76.2%) 2 168 (81.5%) 0 272 (86.8%) 0 440 (84.8%) 0 216 (80.6%) 0 316 (81%) 0 532 (80.8%) 0 
 30-45 min interval 246 (72.4%) 0 291 (74.9%) 1 537 (73.7%) 1 188 (69.7%) 0 319 (89.7%) 0 507 (82.2%) 0 200 (83%) 0 256 (86.3%) 0 456 (84.9%) 0 
 45-60 min interval 237 (67.9%) 0 255 (76.1%) 1 492 (72.2%) 1 193 (70.5%) 0 299 (88.6%) 0 492 (81.5%) 0 171 (83%) 0 233 (89.3%) 0 404 (86.6%) 0 
Both 
AM/PM 
0-15 min interval 553 (78.5%) 0 614 (81.6%) 4 1167 (80.1%) 4 485 (84.3%) 0 624 (90.9%) 0 1109 (88%) 0 391 (83.4%) 0 700 (83.3%) 0 1091 (83.3%) 0 
15-30 min interval 552 (73.6%) 0 646 (83.1%) 4 1198 (78.7%) 4 418 (83%) 0 543 (88.2%) 0 961 (86%) 0 381 (82.9%) 0 570 (83%) 0 951 (83%) 0 
 30-45 min interval 459 (70.6%) 0 587 (80.1%) 2 1046 (75.9%) 2 412 (79.9%) 0 599 (89.1%) 0 1011 (85.4%) 0 404 (84.7%) 0 541 (83.9%) 1 945 (84.2%) 1 
 45-60 min interval 501 (76.2%) 0 558 (82.1%) 2 1059 (79.3%) 2 451 (79.2%) 0 525 (85.7%) 0 976 (82.7%) 0 402 (83.6%) 0 509 (84.9%) 1 911 (84.3%) 1 
All interactions 2065 (74.9%) 0 2405 (81.7%) 1 4470 (78.6%) 1 1766 (81.7%) 0 2291 (88.6%) 0 4057 (85.6%) 0 1578 (83.7%) 0 2320 (83.7%) 0 3898 (83.7%) 0 
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Predictive and process measures 
Table 62 Care home CDR summaries 
 CDR summaries 
 Baseline 6-months 
16-months 
original 
16-months 
cross-sectional 
CDR 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n = 726) 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n = 726) 
Control 
(n = 308) 
Intervention 
(n = 418) 
Total 
(n = 726) 
Control 
(n = 287) 
Intervention 
(n = 388) 
Total 
(n = 675) 
Global CDR as categories 
N (%) 
            
0 1 (0.3%) 2 (0.5%) 3 (0.4%) 0 ( 0.0%) 1 (0.2%) 1 (0.1%) 0 ( 0.0%) 1 (0.2%) 1 (0.1%) 0 ( 0.0%) 1 (0.3%) 1 (0.1%) 
0.5 17 (5.5%) 23 (5.5%) 40 (5.5%) 6 (1.9%) 7 (1.7%) 13 (1.8%) 5 (1.6%) 0 ( 0.0%) 5 (0.7%) 11 (3.8%) 6 (1.5%) 17 (2.5%) 
1 79 (25.6%) 101 (24.2%) 180 
(24.8%) 
37 (12.0%) 77 (18.4%) 114 (15.7%) 27 (8.8%) 49 (11.7%) 76 (10.5%) 55 (19.2%) 101 (26.0%) 156 
(23.1%) 
2 111 
(36.0%) 
160 (38.3%) 271 
(37.3%) 
110 (35.7%) 145 (34.7%) 255 (35.1%) 54 (17.5%) 89 (21.3%) 143 (19.7%) 90 (31.4%) 151 (38.9%) 241 
(35.7%) 
3 98 (31.8%) 130 (31.1%) 228 
(31.4%) 
92 (29.9%) 92 (22.0%) 184 (25.3%) 99 (32.1%) 83 (19.9%) 182 (25.1%) 128 
(44.6%) 
125 (32.2%) 253 
(37.5%) 
Missing 2 (0.6%) 2 (0.5%) 4 (0.6%) 63 (20.5%) 96 (23.0%) 159 (21.9%) 123 (39.9%) 196 (46.9%) 319 (43.9%) 3 (1.0%) 4 (1.0%) 7 (1.0%) 
Global CDR score             
Mean (SD) missing 1.97 (0.85) 
2 
1.98 (0.84) 2 1.98 (0.84) 
4 
2.19 (0.74) 
63 
2.01 (0.77) 
96 
2.09 (0.76) 
159 
2.35 (0.79) 
123 
2.14 (0.77) 
196 
2.24 (0.79) 
319 
2.2 (0.83) 3 2.03 (0.8) 4 2.1 (0.82) 7 
Median (IQR) 2 (1, 3) 2 (1, 3) 2 (1, 3) 2 (2, 3) 2 (1, 3) 2 (2, 3) 3 (2, 3) 2 (2, 3) 2 (2, 3) 2 (2, 3) 2 (1, 3) 2 (1, 3) 
Subscales:             
Memory (primary category) 1.95 (0.81) 
2 
1.91 (0.84) 2 1.93 (0.83) 
4 
2.23 (0.73) 
63 
2.03 (0.75) 
96 
2.12 (0.75) 
159 
2.34 (0.7) 
123 
2.14 (0.76) 
196 
2.23 (0.74) 
319 
2.21 (0.78) 
3 
2.04 (0.79) 4 2.11 (0.79) 
7 
Orientation 1.98 (0.86) 
1 
1.87 (0.93) 3 1.92 (0.9) 4 2.17 (0.78) 
63 
1.96 (0.86) 
95 
2.05 (0.83) 
158 
2.32 (0.79) 
124 
2.12 (0.82) 
196 
2.21 (0.81) 
320 
2.2 (0.85) 4 2.02 (0.86) 4 2.1 (0.86) 8 
Judgement and problem 
solving 
1.85 (0.91) 
2 
1.89 (0.95) 3 1.88 (0.93) 
5 
2.12 (0.83) 
63 
1.95 (0.87) 
92 
2.03 (0.86) 
155 
2.29 (0.83) 
123 
2.12 (0.84) 
196 
2.2 (0.84) 
319 
2.14 (0.88) 
3 
1.98 (0.87) 4 2.05 (0.87) 
7 
Community affairs 1.86 (0.76) 
0 
1.9 (0.78) 2 1.88 (0.77) 
2 
2.04 (0.64) 
64 
1.95 (0.68) 
90 
1.99 (0.66) 
154 
2.17 (0.67) 
123 
2.09 (0.69) 
196 
2.13 (0.68) 
319 
2.07 (0.69) 
3 
2 (0.72) 4 2.03 (0.71) 
7 
Home and hobbies 1.79 (0.87) 
0 
1.86 (0.85) 3 1.83 (0.86) 
3 
2.09 (0.75) 
63 
1.94 (0.77) 
90 
2 (0.77) 153 2.15 (0.82) 
123 
2.04 (0.76) 
196 
2.09 (0.79) 
319 
2.02 (0.84) 
3 
1.92 (0.79) 4 1.96 (0.81) 
7 
Personal care 2.29 (0.86) 
2 
2.3 (0.83) 1 2.3 (0.84) 3 2.36 (0.8) 63 2.45 (0.72) 
90 
2.41 (0.76) 
153 
2.59 (0.74) 
123 
2.55 (0.68) 
196 
2.57 (0.71) 
319 
2.41 (0.9) 3 2.39 (0.82) 5 2.4 (0.85) 8 
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Table 63 Care home EAT summaries 
 EAT summaries 
 Baseline 6-months 16-months 
Mean % (SD) missing 
Control 
(n = 19) 
Intervention 
(n = 31) 
Total 
(n = 50) 
Control 
(n = 19) 
Intervention 
(n = 31) 
Total 
(n = 50) 
Control 
(n = 19) 
Intervention 
(n = 31) 
Total 
(n = 50) 
Total EAT score (%) 53.5 (9.17) 1 53 (10.26) 2 53.2 (9.76) 3 58.9 (6.04) 4 52.9 (8.57) 3 55 (8.22) 7 54.7 (9.28) 3 55.3 (8.52) 4 55.1 (8.7) 7 
Median (IQR) 53.2 (47.2, 62.3) 52.5 (46, 61) 52.9 (46.1, 62.3) 61.5 (56.5, 63.3) 52.1 (46.6, 61) 56.5 (48.2, 62.5) 55.2 (48.4, 62.3) 55.8 (51.3, 60.7) 55.8 (49.8, 60.7) 
Subscale scores (%)          
Safety 47.8 (13.83) 0 48.4 (16.08) 1 48.2 (15.1) 1 52.8 (16.68) 0 57.9 (13.56) 0 56 (14.86) 0 59.3 (14.58) 0 56.2 (16.28) 0 57.4 (15.57) 0 
Size 30.7 (23.74) 0 23.9 (24.64) 1 26.5 (24.28) 1 29.8 (21.93) 0 19.9 (26.67) 0 23.7 (25.22) 0 33.3 (27.78) 0 22.8 (27.85) 1 26.9 (28.02) 1 
Visual access features 23.1 (11.52) 0 25.4 (12.88) 1 24.5 (12.3) 1 19.6 (12.13) 1 21.2 (13.41) 1 20.6 (12.84) 2 17.6 (12.38) 0 24.1 (15.55) 0 21.6 (14.65) 0 
Highlighting useful stimuli 91.8 (13.65) 0 86.3 (13.59) 1 88.4 (13.74) 1 89.5 (13.97) 0 89.1 (11.52) 0 89.2 (12.37) 0 91.3 (10.8) 0 93 (9.02) 0 92.4 (9.66) 0 
Wandering 48.5 (35.95) 0 45.6 (38.08) 1 46.7 (36.92) 1 66 (32.27) 2 43.1 (38.02) 2 51.6 (37.34) 4 52.3 (33.05) 2 53.9 (30.81) 0 53.4 (31.27) 2 
Familiarity 71.1 (16.74) 0 74.4 (24.44) 1 73.2 (21.65) 1 73.5 (16.09) 0 80.2 (12.82) 0 77.7 (14.38) 0 70.4 (18.87) 0 79.6 (16.02) 1 76 (17.58) 1 
Privacy and community 76.6 (19.13) 0 81.5 (14.25) 1 79.6 (16.3) 1 77.1 (20) 0 75.8 (18.83) 0 76.3 (19.09) 0 76.8 (23.54) 0 72.2 (18.17) 0 73.9 (20.27) 0 
Community links 51.3 (48.93) 0 48.3 (49.97) 1 49.5 (49.08) 1 69.4 (42.49) 1 46.8 (49.89) 0 55.1 (48.14) 1 36.8 (46.67) 0 46.7 (50.74) 1 42.9 (48.95) 1 
Domestic activity 35 (9.36) 1 33.2 (11.43) 2 33.9 (10.62) 3 35.9 (11.62) 0 32.5 (11.46) 0 33.8 (11.52) 0 34.9 (10.22) 0 33.1 (10.19) 0 33.8 (10.14) 0 
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Table 64 Group living home characteristics 
 GLHC summaries 
 Baseline 6-months 16-months 
Mean (SD) missing 
Median (IQR) 
Control 
(n = 19) 
Intervention 
(n = 31) 
Total 
(n = 50) 
Control 
(n = 19) 
Intervention 
(n = 31) 
Total 
(n = 50) 
Control 
(n = 19) 
Intervention 
(n = 31) 
Total 
(n = 50) 
Total GLHC score 32.2 (4.09) 0 31.1 (4.19) 2 31.5 (4.14) 2 29.9 (5.13) 0 30.2 (5.25) 0 30.1 (5.15) 0 29.9 (3.91) 0 30.8 (4.29) 0 30.4 (4.13) 0 
 31 (28.5, 36) 31 (28, 33) 31 (28, 35.2) 29 (26, 34) 30 (27, 33) 29.5 (26.5, 33) 29 (27, 34) 31 (27, 34) 31 (27, 34) 
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Health economic analysis 
Table 65 Resource Use – complete case sample* 
    Intervention Control 
Health care resource item Month N Mean  SD Min Max N Mean  SD Min Max 
Primary care  
GP face to face visit 0 214 1.61 2.17 0 12 175 1.54 1.63 0 8 
  6 214 1.31 2.10 0 13 175 1.46 1.69 0 8 
  16 214 0.84 1.43 0 8 175 0.93 1.69 0 9 
GP telephone call 0 214 0.72 1.62 0 12 175 0.71 1.24 0 6 
  6 214 0.49 0.99 0 5 175 0.39 0.92 0 7 
  16 214 0.36 0.89 0 5 175 0.29 0.71 0 4 
District nurse visit 0 214 1.22 7.02 0 90 175 1.79 5.29 0 43 
  6 214 0.36 1.24 0 13 175 1.53 4.88 0 41 
  16 214 0.75 3.44 0 39 175 0.57 2.68 0 27 
District nurse telephone call 0 214 0.08 0.44 0 3 175 0.13 0.44 0 2 
  6 214 0.03 0.19 0 2 175 0.14 0.53 0 4 
  16 214 0.03 0.24 0 2 175 0.13 1.25 0 16 
Secondary care 
Nights spent in hospital 0 214 0.72 4.06 0 43 175 0.66 3.81 0 37 
  6 214 0.64 3.02 0 28 175 0.29 1.58 0 15 
  16 214 0.14 1.14 0 12 175 0.01 0.08 0 1 
Hospital day centre visit 0 214 0.01 0.10 0 1 175 0.02 0.13 0 1 
  6 214 0.00 0.07 0 1 175 0.00 0.00 0 0 
  16 214 0.00 0.07 0 1 175 0.03 0.20 0 2 
Hospital outpatient clinic visit 0 214 0.14 0.61 0 7 175 0.14 0.46 0 4 
  6 214 0.08 0.27 0 1 175 0.06 0.31 0 3 
  16 214 0.07 0.35 0 3 175 0.01 0.15 0 2 
Hospital A&E visit 0 214 0.15 0.83 0 11 175 0.10 0.39 0 2 
  6 214 0.07 0.27 0 2 175 0.06 0.29 0 2 
  16 214 0.01 0.12 0 1 175 0.01 0.08 0 1 
*Values represent resource use in the previous month only and are extrapolated for the whole trial period 
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Table 66: Main* Unit Costs  
Resource item Unit cost Assumptions and source 
Advanced nurse practitioner  £  77.24  NHS 2015-16 reference costs  
Advanced nurse practitioner (phone)  £  33.08  NHS 2015-16 reference costs  
Counsellor  £  62.03  PSSRU 2011/2 
 
District nurse  £  37.98  NHS 2015-16 reference costs 
DISTRICT NURSE (phone)  £  16.16  NHS 2015-16 reference costs 
GP   £132.69  PSSRU 2009/10  
 
GP phone   £  28.39  PSSRU2014/5 
 
Health visitor  £  64.81  NHS 2015-16 reference costs  
HEALTH VISITOR (phone)  £  26.38  NHS 2015-16 reference costs  
Hospital A&E  £137.74  NHS 2015-16 reference costs 
Hospital outpatient clinic  £136.79  NHS 2015-16 reference costs 
Hospital overnight stay  £464.83  NHS 2015-16 reference costs  
Member of community health team  £  43.00  PSSRU 2015/6 
 
Physiotherapist  £  48.94  NHS 2015-16 reference costs 
Psychiatrist or psychologist  £142.98  PSSRU 2011 
 
Social worker  £  39.50  PSSRU 2015/6  
 
Speech and language therapist  £  88.02  NHS 2015-16 reference costs 
*Main resource use items only. Unit costs for resources used less frequently are available on 
request. 
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Appendix 2: Summary of substantial amendments 
Summary of EPIC Substantial Amendments 
SA1 - Approved 10/01/2014 
Collection of data from medical records / Health and Social Care Information Centre 
(HSCIC) 
The proposed plan for collection of resource use data (prescription medication usage, repeat 
hospital attendances / admissions / safety data) was to obtain all required information from a 
review of the resident’s care home records. Having undertaken some consultation with other 
researchers doing care home research and collecting similar data, we have been informed that this 
data is often incomplete / ambiguous and further clarification has needed to be sought from the 
residents’ medical records.  
In order to minimise missing data and ensure a meaningful dataset is obtained, we therefore 
propose to amend section 13.5.5 of the protocol (see enclosed protocol with tracked changes) and 
the following participant information and consent / declaration forms (see enclosed documents with 
tracked changes) to include researcher consent to access the residents’ medical records (either 
via direct searching, or remotely via the HSCIC): 
- Resident Information  Sheet 
- Short form of Resident Information Sheet 
- Resident Consent Form 
- Personal Consultee Declaration Form 
- Personal Nominee Declaration Form 
Full NHS R&D permissions will be obtained from the relevant trusts and the study researchers will 
apply for research passports and approval to access these notes. 
SA2 - Approved 22/04/2014 
Changes to the Care Home Information Sheet 
The Care Home Information Sheet has been amended to incorporate comments following PPI 
review. The content has also been updated to amend inaccuracies and provide additional 
information and clarification regarding trial processes.  
Amendments to the approved document are highlighted using tracked changes. Below provides a 
brief summary of the key changes: 
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- Clarification of abbreviated title – The EPIC trial. 
- Addition of Trade Mark (DCMTM) throughout. 
- Clarification of “What will happen in the study” 
 Care Home Selection 
 Confirming Care Home Eligibility 
 Participant Consent 
 Care Home Allocation 
 DCM Training 
 Data Collection – Researcher Interview / Questionnaires 
- Clarification of “What do I do if I am Interested in taking part?” 
SA3 – Approved 26/06/2014 
Protocol amendments 
- Updated Care Home Selection process 
The proposed plan for care home selection has been revised during consultations with the 
statistical team and researchers experienced in recruitment in the care home setting to minimise 
the burden on care home staff. In order to maximise response rates whilst retaining a 
representative sample of care homes in an attempt to maximise generalisability of trial results we 
therefore propose to amend section 7.2 of the protocol (see enclosed version with tracked 
changes) to incorporate the following key changes; 
o Care Homes within Hub catchment area screened for eligibility and randomly 
ordered for subsequent contact. 
o Invitation information sent to ordered samples of eligible care homes. 
o Researchers contact all invited care homes (via telephone) to determine interest – 
care home reply slip no longer required. 
o If interested care homes will complete eligibility assessments via researcher 
interview, eligibility screening questionnaire no longer required. 
- Eligibility Criteria  
o English Proficiency 
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Following discussions with the Trial Management Group (TMG) and Trial Steering Committee 
(TSC) we intend to update the eligibility criteria for Residents, Staff (completing Staff Measures 
only), and Resident’s Relative / Friend to include the following; “Has sufficient proficiency in 
English to contribute to the data collection required for the research”.  
We propose this change for Staff completing Staff Measures as this questionnaire will be self-
completed by members of Staff with no assistance from trial researchers. Therefore to ensure that 
staff comprehend questions asked they would require sufficient proficiency in written English. 
Validated translations of assessments are also not available, therefore the TMG agreed it was not 
appropriate to use translated versions due to the potential impact on the validity of data collected. 
Consultation with care home managers and staff suggested that the majority of staff working within 
a UK care home should have sufficient English proficiency as required for employment. 
The proposed change has been suggested for Residents and their Relative / Friend (if applicable) 
as assessments are completed via Researcher Interview, therefore sufficient English proficiency is 
required to develop a meaningful dialog. Availability and accuracy of translated discussions was 
deemed to be infeasible by the TMG/TSC. 
o Proxy Informant 
As outlined in the protocol the primary outcome for analysis is based upon completion of the CMAI 
by a Proxy Informant (Staff). Therefore, we propose to update section 8 of the protocol to 
incorporate the following inclusion criteria for Residents; 
 Has an allocated member of staff willing to provide proxy data. 
o Screening Questionnaires 
Proxy Informants (Staff and Relative/Friend) were initially required to demonstrate their willingness 
to participate by completing and returning a screening questionnaire. However following a review 
of the process the TMG have confirmed that it would be more appropriate to collect Proxy 
Informant data via Researcher Interview. It is hoped that this will decrease the burden on Proxy 
Informants and increase response.  We therefore propose to amend the relevant section of the 
protocol (10.1-10.2).  
o Mutually exclusive roles 
The protocol outlines roles that staff members can undertake within the trial and highlights any that 
are mutually exclusive (e.g. Mapper cannot act as Proxy Informant). However to clarify further we 
propose to update exclusion criteria by role to ensure eligibility is assessed ahead of consent. This 
update will also clarify that a Staff Nominated Consultee cannot actively participate in the trial in 
any way (e.g. Providing Staff or Proxy Measures). 
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- Translation of trial documentation (information sheets/questionnaires) 
Following consultation with the TMG and suggested updates regarding sufficient English 
Proficiency the TMG agreed that Translation of trial documentation would no longer be required. 
Discussions regarding the variety of translations required by region (Hub) also suggested that this 
process would not be feasible. Therefore references to translation of materials have been removed 
from the protocol (please refer to tracked changes). 
- Data collection / assessments 
o Assessments 
We propose to amend data collection assessments used within the trial (please refer to tracked 
changes) following review with the TMG as summarised below; 
 DEMQOL replaced with QOL-AD: TMG agreed more appropriate to trial population. 
 CES replaced with SCIDS: TMG agreed more appropriate to trial population. 
 BADL removed: TMG agreed not appropriate to collect in trial population. 
The overall quantity, and therefore perceived participant burden remains the same. 
o Completion of Assessments (PAS / QUIS) 
The proposed plan for collection of independent assessments (PAS / QUIS) suggested that the 
PAS and QUIS would be completed on a random 25% of registered residents. However as these 
assessments are completed following observations made within communal areas the TMG agreed 
that it would not be appropriate to restrict observations to a random sample of residents, as if they 
were not available within communal areas at the time of observation, the data could not be 
completed, affecting the integrity of data for analysis. Thus it was agreed that PAS / QUIS data 
would be collected for all registered residents. The protocol has been updated (please refer to 
tracked changes) to incorporate these changes.    
- Monitoring – Recording Sessions 
o DCMTM Intervention – Feedback Sessions 
The protocol outlines planed recording of Dementia Care Mapping Feedback sessions within a 
sample (minimum of 10 Care Homes) of randomised Care Homes (n=30). Following discussions 
with DCMTM Experts it was agree that the feasibility and accuracy of standardised review would not 
be sufficiently robust therefore should not be undertaken. Therefore, we propose to update section 
12.7 of the protocol (please see tracked changes) to remove references to audio recording. 
- Withdrawal 
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o Proxy Informant – Relative / Friend 
We propose to amend the planed process for data collection following Relative / Friend withdrawal. 
The protocol currently suggests that in the event of a Relative / Friend withdrawal Researchers 
would encourage continuation of completion of a subset of assessments. However, following 
review with the statistical team, discussions concluded that this process would not be feasible and 
does not significantly impact upon the validity of data for analysis. Therefore, we propose to 
amend section 12.12 of the protocol (please refer to tracked changes) to outline that in the event of 
a Relative / Friend withdrawal a new Proxy Informant will be identified to complete all assessment 
measures. 
o Resident Safety 
Following consultation with the trial Data Monitoring Ethics Committee (DMEC) we propose 
changes to the protocol (please refer to tracked changes) to collect sufficient safety data for on-
going safety monitoring. Proposed changes include; 
 Proactive (monthly) reporting of Adverse Events that fulfil Serious (SAE) criteria 
(i.e. Hospitalisation). 
 Annual summary of hospitalisations for registered residents collected from 
Health and Social Care Information Centre (HSCIC). 
Suggested amendments to safety reporting have been reviewed by external experts (DMEC/TSC) 
to ensure reporting is commensurate with risk for this population in the context of this trial. 
- Data Monitoring Ethics Committee (DMEC) 
In accordance with guidance from the trial funder (NIHR HTA) a trial DMEC has been established 
and responsibilities agreed. We therefore propose changes to the protocol (please refer to tracked 
changes) to incorporate the DMEC. 
Patient Information Sheets and Informed Consent Document amendments 
- Study Title 
Following consultation with Patient and Public Involvement groups and Experts by Experience, the 
TMG have agreed to amend the study title in publicly available information to remove the acronym 
DCM (Dementia Care Mapping). We therefore include amended information sheets and consent 
documents with the title amended throughout. 
- Participant Consent 
o Mapper  
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We propose to add an additional statement to the Mapper consent form to reference the DCMTM 
Training Course schedule to make it clear to Mappers that we are asking them to be available for 
training; “I agree to attend the next scheduled DCMTM training course if my care home is randomly 
allocated to DCMTM + UC. <Insert course date>”. As the DCMTM Training Course is a publicly 
available course, dates are scheduled in advance and cannot be changed, so we need to be sure 
that mappers are able to attend on specified dates.  This will reflect the implementation of the 
intervention in practice.  
o Staff Proxy 
The proposed plan for Staff Proxy Informant consent was vague in the protocol, with no previous 
Staff Proxy Informant Consent form being submitted for REC approval. Therefore, in accordance 
with the proposed protocol update which removes references to the screening questionnaire 
(implied consent following return of data) a Staff Proxy Informant Consent Form has been 
produced and is submitted for approval. This document will be version 4.0 (dated 30.05.2014) to 
match existing documentation following approval of this amendment. 
o Resident (including Nominated and Personal Consultee) 
As Resident and a Resident’s Relative / Friend data is not used as part of the primary analysis, the 
TMG have agreed that consent to obtain information from Residents and their Relative/Friend can 
be optional. We therefore propose to update the relevant information sheets to incorporate these 
optional statements (please refer to tracked changes version attached. 
- Short form of Participant Information 
Following consultation with Patient and Public Involvement groups and Experts by Experience we 
have developed shortened versions of the information sheets for Staff (Measures), Staff Proxy, 
Relative / Friend Proxy. These short versions summarise key information from existing information 
sheets in a simple to understand format. It is intended that these information sheets will be used in 
addition to existing participant information to ensure informed consent is obtained.  
The existing Short form of the Resident Information Sheet has also been amended to reflect the 
format of the new short form information sheets. Please refer to relevant attachments for additional 
information. These documents will be versioned 4.0 (dated 30.05.2014) to reflect existing 
documentation following approval of this amendment. 
SA 4 – Approved 10/09/2014 
Protocol amendments  
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- Submission of a new document for approval (Personal Consultee Introductory 
Letter) 
The protocol (version 4.0) states in section 8.3.2 – Consent for those (Residents) without capacity, 
that if an identified potential personal consultee is not present within the Care Home during 
participant (Resident) recruitment they may be posted information regarding taking part (acting as 
a personal consultee) by the Care Home. We therefore enclose a proposed introductory letter 
template to be sent by Care Homes with the relevant (REC approved) Information Sheets. As this 
letter is designed to be sent by the Care Home it will be used as a template, and added to where 
appropriate by the Care Home to personalise it for the person in question. 
- Submission of a new document for approval (Personal Consultee Reminder Letter) 
The protocol (version 4.0) states in section 8.3.2 – Consent for those (Residents) without capacity, 
that a reminder will be sent to a potential personal consultee within one week of being approached 
to complete the relevant (REC approved) declaration form. We therefore enclose a proposed 
reminder letter template for Researchers to send within one week of initial approach (if required). 
As this letter is designed to be sent after initial discussions with the Researcher it this letter will be 
used as a template and added to by the Researcher where appropriate.  
- Submission of a new document for approval (Relative/Friend Proxy Informant 
Introductory Letter) 
The protocol (version 4.0) states in section 10.1 – Relative/Friend and Informants, that if an 
identified potential Relative/Friend is not present within the Care Home during participant 
recruitment that information regarding taking part can be posted (by the Care Home) to them. We 
therefore enclose a proposed introductory letter template to be sent by the Care Home with the 
relevant (REC approved) Information Sheets. As this letter is designed to be sent by the Care 
Home it will be used as a template, and added to where appropriate by the Care Home to 
personalise it for the relative. 
SA5 – Approved 15/01/2015 
Patient Information Sheets and Informed Consent Document amendments 
- Submission of a new document for approval (GP Letter) 
The protocol (version 4.0) states in section 12.1 – Intervention Details – Usual Care, that all GPs 
that deliver care within a consenting Care Home will be provided with current best practice 
guidelines for managing BSC (Behaviours Staff find Challenging to support). We therefore enclose 
a proposed GP Letter template to be sent to GP practices with a copy of current antipsychotic 
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prescribing guidance (Alzheimer’s Society). Please note in accordance with the protocol this 
information will not detail Residents currently participating in the study. 
SA6 – Approved 15/01/2015 
Protocol amendments 
- Change of Sponsor 
Following acceptance of a Professorship role at Leeds Beckett University Claire Surr, DCM EPIC 
Chief Investigator will be transferring from the University of Bradford to Leeds Beckett from 
February 2015. Therefore, the study Sponsor will be transferred to reflect this move.  
The following documents have therefore been updated; 
o NHS R&D and REC Form  
 A3-1. Chief Investigator 
 A4. Sponsor contact 
 A64. Details of Research Sponsor 
 A76. Insurance and/or Indemnity 
o Protocol (v5.0) section 20.4 – Clinical Governance Issues 
o Protocol (v5.0) section 23 – Statement of Indemnity 
o Protocol (v5.0) section 24 – Trial Organisational Structure 
- Care Home Eligibility Criteria 
Based upon experience from “pilot” care home recruitment and consultation with the trial oversight 
committees (TMG/TSC) we propose to amend the Care Home Eligibility criteria to clarify 
requirements to have a sufficient population of permanent residents living with dementia to recruit 
(register) a minimum of 10 Residents. This wording will reduce exclusion of Care Homes that 
would otherwise be eligible but do not achieve the criteria as currently worded.  
The protocol has also been updated to clarify minimum and maximum resident recruitment limits. 
As previously stated a minimum of 10 registered (Eligible, Consented, and completed Data) 
residents is required per Care Home. Following experiences of Care Home recruitment to date the 
trial team have also investigated whether a maximum recruitment limit is required. However from 
review of impact of cluster size variability on the power calculations for analysis with the trial 
oversight committees (TMG/TSC) have confirmed that no maximum limit for resident recruitment is 
required.  
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Therefore, the protocol (v5.0) section 7.1 Care Home Eligibility has been updated to reflect the 
suggested changes summarised above. 
- Resident Eligibility Criteria 
During Care Home screening it has become apparent that the potential for co-enrolment to other 
studies is not only relevant to Care Homes, but Residents as well. For example, a trial may be 
recruiting a large number of homes within the DCM EPIC Hub catchment areas (London, Oxford, 
and West Yorkshire) but may only be recruiting a small proportion of Residents within the 
participating Care Home. Therefore it would not be appropriate to exclude the Care Home, due to 
the associated impact upon Care Home Recruitment, but it would be appropriate to exclude the 
Resident, due to the potential for confounding factors and associated participant burden and 
research fatigue. 
Therefore the protocol (v5.0 – section 8.1) has been updated to include “involvement in another 
trial that conflicts with DCMTM or with the data collection during the course of their involvement in 
the EPIC study“.  
- Randomisation 
Following randomisation of the first two “pilot” homes the team have reviewed the stratification 
factors (external factor (other than intervention) that could impact upon trial outcome) for Care 
Home Randomisation with the trial oversight committees (TMG/TSC). It was noted that the current 
4 stratification factors do not include stratification by Hub (London, Oxford, and West Yorkshire). 
However, it was noted that “previous use of DCMTM” could depict Hub, with Oxford Care Homes 
introducing DCMTM at a local level.  
Therefore, the team concluded, in consultation with the trial oversight committees that the Care 
Home Randomisation stratification factors should be updated to replace “previous use of DCMTM” 
with “Recruiting Hub”. Protocol v5.0, section 11.2 has been updated to reflect the suggested 
changes summarised above. 
SA7 – Approved 22/10/2015 
Protocol amendments 
- Witnessing Consent 
We have had a few recent instances where we have quite illegible resident signatures – some can 
pass for a signature; others are more of a mark. We have discussed this with the Chief Investigator 
who is happy that any form of signature stands as informed consent, and notes that we must 
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respect residents’ dignity by not asking for a witness counter signature just because their 
handwriting isn’t clear. In the current version of the protocol (section 8.3.1) we say: 
“Residents who are able to give informed consent will sign the trial consent form. Where a resident 
is unable to sign his/her name, s/he will be asked to make a mark on a consent form that will be 
witnessed by an independent observer (staff member, relative or friend).” 
However, on checking HRA guidance and the clinical trials toolkit it seems that any form of mark is 
acceptable and we would only expect a witness where a participant cannot write at all. 
Following verbal confirmation from the REC Manager that following the HRA guidance on this 
issue is acceptable, we have removed this statement from the protocol and clarified that the 
witness of an independent observer is only required where a resident is unable to make any kind 
of mark on the form. As such, section 8.3.1 has been updated as follows: 
‘Residents who are able to give informed consent will sign, or make a mark on the trial  consent 
form. Where a resident is unable to sign, or make a mark, s/he will be asked to  indicate his/her 
consent verbally. This will be witnessed by an independent observer  (staff member, relative 
or friend) and recorded on the trial consent form.’ 
- Text messages to mappers 
In order to assist the mappers in planning subsequent cycles, ahead of each of the three DCM™ 
mapping cycles, we will send a short text messages to each mapper. The standard wording for 
these text messages can be found in the attached document (Mapper Text 
Reminders_V1.0_28/09/2015  
The following statement has been added to section 12.2.3 to reflect this process: 
“Ahead of each mapping cycle the CTRU will contact each mapper via SMS to remind them of the 
upcoming cycle.” 
Patient Information Sheets and Informed Consent Document amendments 
The table below summarises Substantial amendments made to the Participant Information Sheets, 
consent forms and covering letters. All amendments can be reviewed in tracked changed versions 
of the relevant document. 
Document Amendment Details 
Relative/Friend 
Proxy Informant 
Introductory 
 NEW LETTER: We have drafted a new letter to be used in instances where the 
Personal Consultee is also invited to act as the Relative/Friend Proxy Informant 
for the resident. The current Relative/Friend Proxy Informant covering letters 
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Letter for 
Personal 
Consultees 
previously approved by the REC are aimed at Relative/Friends who have no prior 
knowledge of the EPIC study, so are not appropriate in these circumstances. 
Personal 
Consultee 
Reminder Letter 
– POSTAL 
TEMPLATE 
(approach by 
CH Manager) 
 NEW LETTER: The current Personal Consultee Reminder Letter previously 
approved by the REC is aimed at Personal Consultees who have previously 
spoken with the Researcher at the care home regarding the EPIC study. In some 
instances, the potential Personal Consultee is approached via post as opposed 
to face to face in the Care Home (ie. in cases where their visits don’t coincide 
with the researcher’s time in the care home), and therefore the wording of the 
current letter isn’t appropriate. This new letter is aimed at Personal Consultees 
who have had no prior contact with the Researcher and therefore the initial 
approach would be by the Care Home Manager / Research Lead.  
Personal 
Consultee 
Reminder Letter 
– POSTAL 
TEMPLATE 
(approach by 
Researcher) 
 NEW LETTER: This letter will be used for circumstances similar to the one 
outlined above, however this will be for cases where a potential Personal 
Consultee has already given consent to be contacted by the Researcher directly 
and therefore the letter is from the Researcher, rather than the CH Manager / 
Research Lead. 
Relative/Friend 
Proxy Consent 
form 
 Updated to include date of birth (for identification purposes). 
 Address and telephone number of relative/friend proxy added in and a sentence 
regarding why this is collected added to page 2. 
Personal 
Consultee 
Declaration 
Form 
 Optional consent questions amended from initials to ‘Y’ or ‘N’ to aid completion. 
 There had been some confusion highlighted by the Researchers over question 
12 therefore an additional question (Q12) has been added for clarification – The 
additional question confirms if the Personal Consultee is happy to be asked 
questions about their relative/friend (i.e. acting as a proxy) 
 Due to the addition of Q12, Q13 has been reworded to confirm that if the 
personal consultee is not willing to be a relative/friend proxy they are happy for 
other relatives/friends to take on this role.   
 Address and telephone number of personal consultee added in and a sentence 
regarding why this is collected added to page 2. 
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SA8 – Approved 04/02/2016 
Protocol amendments 
- Process Evaluation  
More detail added to protocol on how the process evaluation associated with the trial will work in 
practice. The design of the process evaluation remains the same (integrating data from the main 
trial dataset/documentation with qualitative data from interviews and focus groups) we have simply 
provided more detail on the patient information leaflets and consent forms, data collection 
methods, sampling and data analysis that will be used. 
Summaries of the extra detail provided are as follows: 
o Data collection 
More detail has been provided on the data that will be extracted from the main trial dataset and 
trial documentation. Topic guides have been developed to indicate the kinds of questions that will 
be asked of participants during the qualitative data collection. The topic guides are enclosed with 
this amendment application. 
o Sampling 
In order to explore implementation of the intervention with sufficient depth, we plan to conduct the 
qualitative data collection in a subset of homes. Homes will be primarily selected according to 
degree of intervention implementation so that the factors affecting implementation can be 
thoroughly explored. More details on the sampling strategy are included in the amended protocol. 
A more basic evaluation of implementation (utilising data from the main trial dataset and trial 
documentation) will still take place across all homes. 
o Data Analysis 
More detail is provided on the approach to the qualitative data analysis (Framework Analysis) and 
how the qualitative and quantitative analysis will be integrated. 
 
- Staff measure booklet 
There has been a poor return rate for the staff measures booklet, despite multiple efforts to 
increase compliance. Following consultation and discussion with the DMEC and the TSC it has 
been agreed that persistence with staff data is important because Dementia Care Mapping (the 
intervention) is designed to effect a ‘whole home’ change. To try and increase compliance the TSC 
have suggested reducing the length and identifiable nature of the staff booklet. To this end, we are 
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proposing to remove the GHQ12 questionnaire and the request for personal data from the booklet. 
We would also like to improve the aesthetics of the booklet to ensure it is as easy for staff to 
complete as possible.  
- Relative/Friend Informants 
There has been poor trial participation by relatives/friends despite efforts to encourage uptake. It 
has been agreed by the oversight committees that the low percentage of data received will not be 
sufficient for quantitative analyses. Therefore, new relative/friend informants will not be identified at 
any follow up time points as this would utilise significant researcher resources but be unlikely to 
result in much additional uptake or data. However, we will continue to request follow up data for 
relative/friends who provided data at baseline because data from different time points could still be 
usefully analysed (for example to allow analysis of agreement between staff, resident and 
relative/friend completed measures and to augment the process evaluation). Relatives/friends who 
completed these baseline measures also indicated that they valued the opportunity to share their 
experiences and so would be likely to continue to take part. It seems unethical to exclude their 
data due to poor participation from other relatives. 
Patient Information Sheets and Informed Consent Document amendments 
We have developed new participant information leaflets and consent forms for the three groups 
that will be asked to participate in the process evaluation - staff, residents and relatives. The 
information leaflets and consent forms have been developed with PPI input. 
 
SA9 – Approved 15/04/2016 
Protocol amendments 
- Design Change 
We are proposing a change to the design of the EPIC Trial, such that additional residents will be 
recruited at the 16-month follow-up time point from each care home to minimise bias (due to higher 
than anticipated loss to follow-up) and maintain power and validity of the trial. This impacts on the 
following elements of trial conduct: 
o Additional resident screening, recruitment and registration 
o Identification of new staff proxies 
o Additional data collection from staff proxies 
o Data management 
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o Statistical analyses 
Therefore, the relevant sections of the protocol have been updated and the following new 
supporting documents have been produced to support the recruitment process; 
o 16M Resident Information Sheet_SHORT_v1.0 18 March 2016 
o 16M Resident Information Sheet_v1.0 18 March 2016 
o 16M Resident Consent Form_v1.0 18 March 2016 
o 16M Personal Consultee Introductory Letter_v1.0 18 March 2016 
o 16M Personal Consultee Declaration Form_v1.0 18 March 2016 
 
- Staff Proxy Informant Consent 
We propose an alternative method of documenting staff agreement to provide data about the 
resident they know well. In a similar trial in care homes run by the CTRU, the REC have agreed 
that provision of information to staff proxies followed by verbal consent to take on the role is 
sufficient. Agreement to hold their name for follow-up purposes is documented by the researcher in 
the data collection booklets. It is felt that this process is fit for purpose given we are not collecting 
any other personal data relating to the staff member. 
We propose adoption of this process for involvement of all staff proxies recruited at 16-months in 
the EPIC trial, and will adjust the data collection booklets accordingly.  
- Care Home Indemnity 
We propose to remove the statement “Possession of the appropriate insurance will be checked at 
point of recruitment of the care home to the study.” This is in line with new guidance received 
following the change of study Sponsor. The Sponsor has advised removal of this statements as 
EPIC is a trial of a low risk intervention, with care home employees delivering the intervention. 
Therefore, it is appropriate to assume that standard care home insurance will cover activities of 
their employees and additional checks are not required. 
- Staff Measures data collection 
Following a review of data collection, we have amended the trial protocol (section 9 – Staff roles, 
eligibility, recruitment, and consent) to include collection of “current pattern of work”. This 
information will be used to determine the impact of shift patterns on staff training and exposure to 
the trial intervention. 
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- Process Evaluation – Relative Friend Recruitment 
We are proposing to introduce a new document “RF Introductory Letter – PE” to support postal 
invitations to Relative/Friends to participate in the Process Evaluation. This document would be 
sent with a copy of the relevant information sheet and consent form, to RFs currently participating 
in the main trial that are not available in the care home during researcher visits. EPIC Researchers 
would confirm that postal contact is appropriate with the Care Home Manager (or delegate) prior to 
contacting the Relative/Friend. 
In addition to the new introductory letter we also propose to amend the RF consent form so that 
those completing and returning by post can outline their availability for discussions. This 
information would be useful to help Researchers schedule their time and ensure availability for RF 
feedback. 
Following comments from the trial funder we also propose to amend the number of residents and 
staff members approached to participate in the PE. We had originally planned to include 2-3 
residents and 8 members of staff, however we now propose to recruit up to 5 residents and up to 
10 members of staff. This amendment will also allow for flexibility in homes that have limited 
numbers of residents, or the emergence of key themes from fewer interviews. 
- GP Information for residents recruited at 16M 
We propose to update the Protocol (section 12) to clarify that we will only be sending generic best 
practice guidance to GPs for residents recruited at BL and not those additional residents recruited 
at 16M (associated with design change summarised above). This is due to the timelines for 
circulation of information to GPs and the potential confusion regarding active care home 
participation in the project, which ceases after 16-month data collection. The guidance information 
would therefore also have limited impact upon trial outcomes at this stage (i.e. supporting person 
centred care). 
- Personal Consultee Capacity 
Following a review of trial processes, we are proposing to update the Protocol (section 8.1.2 
Consent for those without capacity) to clarify the process for confirming ongoing capacity of 
Personal Consultees (PC). As a PC is not required to visit a care home with any frequency, and 
has the ability to provide postal ascent for trial participation, trial Researchers may never have 
face-to-face contact with a PC. Therefore, it is not feasible to determine any changes in capacity 
overtime in accordance with the MCA. In these instances, it is essential to obtain input from care 
home staff that may have more frequent interactions with the PC and be best placed to identify 
changes in capacity over time.  
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SA10 – Approved 25/07/2016 
Protocol amendments 
- Process Evaluation – participant demographics 
We are proposing additional data collection of participant demographics (Age/Gender) for those 
consented to participate in the process evaluation to aide with summarising the population 
sampled at analysis. As participants in the Process Evaluation are not required to have taken part 
in the main trial (as the intervention impacts the entire Care Home irrespective of individual trial 
participation) we are not able to summarise demographics as a subset of the main trial population. 
Therefore, we have amended relevant sections of the EPIC Protocol (section 14 – Process 
Evaluation). 
We have also updated the topic guides to include prompts to confirm participant details (ID, Role) 
at the start of the interview to assist with identification of recordings as is best practice for 
qualitative interviews. Any personal identifiers (i.e. Name) will be removed from all transcriptions. 
- Text Messages to Mappers 
We propose to introduce an additional text message to Staff members acting as DCMTM Mappers 
to highlight the mutually exclusive roles in EPIC ahead of follow-up (6- and 16-months). In EPIC 
Researchers completing follow-up data collection (6- and 16-months post randomisation) are 
blinded to Care Home allocation and are therefore not aware of any changes to Staff members 
delivering the trial intervention (Researchers recruit Staff to act as Mappers at baseline in all home 
(n=50), however due to high staff turnover these often change during the course of the trial for 
those homes randomised to deliver the intervention (n=31)). This has therefore led to instances of 
inappropriate members of staff (i.e. Mappers – those delivering the trial intervention) providing data 
(Staff Proxy Informant) for participating residents. 
 
We would therefore like to circulate the following text message ahead of follow-up (6- and 16-
months) to staff acting currently consented as a Mapper; 
“EPIC Researchers will be visiting your home shortly to collect some more data. Please remember 
not to provide data on behalf of any residents during this visit. Do not tell the Researcher you are 
acting as a DCM Mapper. Regards, The EPIC team!” 
The following statement has been added to the Protocol (section 9 Staff roles, eligibility, 
recruitment and consent); 
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“A text message will be sent to trained DCMTM mappers ahead of data collection (6 and 16months 
post randomisation) to remind mappers not to provide proxy data relating to residents
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Appendix 3: Rationale for design change 
HTA extension application 11/13/15 The EPIC Trial 
(March 2016) 
Justification 
 
In our original sample size estimation, we anticipated a 25% loss to follow-up rate of 
residents at 16-months (our primary outcome) following care home randomisation, to detect 
a clinically important difference of 3 points (SD 7.5) in agitation using the CMAI 
questionnaire. If loss to follow-up was higher than anticipated (but no greater than 35%), our 
sample size of 750 residents was still intended to provide more than 85% power at a 2-sided 
5% significance level to detect the moderate effect size, equating to 0.4 SDs. 
 
By monitoring loss to follow-up within the trial, we are now confident that the rate will exceed 
our lower limit of 25%. Using data from care homes randomised into the trial up to the 27th 
November 2015, we predict that loss to follow-up at 16-months will be in the range of 32.4% 
to 48.1%. As such, continuation of the trial as currently planned is unlikely to provide 
sufficient power for statistical analysis of the primary endpoint and so an amendment is 
required to ensure the results of trial are robust and generalizable. Therefore, based on 
consideration of all the available options, we propose recruiting more residents at follow-up 
(i.e. move to an “open cohort” design). 
 
As of 27th November 2015, there were 42 care homes randomised, with 638 registered 
residents. Residents are registered before care home randomisation. Overall, there were 11 
residents lost before the care homes were randomised, so at the point of randomisation 627 
residents were included in the trial. None of the care homes had reached the 16-month 
follow-up time point, and there were two care homes currently at 13-months following 
randomisation.  
 
Loss-to-follow-up rates were estimated using the number of residents who died or moved 
care home between randomisation and 27th November 2015. The rate was then extrapolated 
to 16-months. Figure 10 summarises the actual and predicted loss-to-follow-up rates by 
number of months since randomisation. The same is displayed graphically in the Kaplan-
Meier curve in Figure . 
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Figure 10: Predicted loss to follow-up 
 
x-axis represents number of months care homes have been randomised, numbers lost to follow-up are grouped by care home and month 
Figure 11: Kaplan-Meier Survival Curve stratified by the length of care home in the trial 
 
Numbers at risk: at care home randomisation, 3, 6, 9 and 12-months. Note that 16-months is 487 days “survival”.  
 
In order to provide a robust evaluation of the trial, we propose to move to An open cohort 
design in which all eligible residents (i) residing in the care home for 3-months or more at 
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16-months after care home randomisation and (ii) who are not already taking part in the trial 
or who have not already declined to take part, will be approached to provide consent for trial 
participation at the 16-months follow-up visit. All those consenting to take part (residents 
already participating in the trial and consented at baseline, as well as additional residents 
consenting at 16-months), will provide data at 16-months.  
 
The key impact of this option will be an increase to the size of the cohort at follow-up to 
maintain the power of the trial and its ability to detect the effect size of 0.4 with 90% power.  
 
Sample size calculations 
With a current estimated 48.2% loss to follow up, we expect to lose 360 residents before 16-
month follow-up meaning we will have data at all three time points from 388 residents. All the 
other parameters – significance level, 2-sided test, ICC of 0.1 are the same. We have 
worked out sample size calculations for three different scenarios of additional recruitment 
and all provide sufficient power to detect the effect size of 0.4.  
 
If we recruit, on average, an additional three residents per care home at 16-month follow-up 
(from the remaining 48 care homes) the sample size will be 388+48*3=532 residents (that is 
10.64 residents/ care home). Design effect will be 1+(10.64-1)*0.1=1.964. We will achieve 
89% power to detect the effect size of 0.4. 
 
Replacing residents with 35% recruited residents (columns F and G), overall number of 
residents available for analysis would be 388+254 (additional recruits)=642. Mean number of 
residents/ CH (cluster size) would be 12.8. Design effect is now 1+(12.8-1)*0.1=2.18. And 
the power to detect effect size of 0.4 would be 91% (or with 90% power, we can detect 
smaller effect size of 0.39). 
 
Replacing residents with 25% recruited residents (columns H and I), overall number of 
residents available for analysis would be 388+182 (additional recruits)=570. The mean 
number of CH residents/ CH (cluster size) will be 11.4. Design effect is now 1+(11.4-
1)*0.1=2.04. And the power to detect 0.4 effect size would be 90%. 
 
All scenarios will achieve the desired effect size with sufficient power. The message to 
researchers should still be to recruit as many residents as possible in order to minimise bias. 
We will need to monitor recruitment to ensure we have at least 3 extra residents from each 
remaining care home.  
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Benefits of this design change are:  
a) we will be able to detect intervention effects at the care home level (as the 
intervention is aimed at the whole care home);  
b) our conclusions can be generalised to a broader population of residents (i.e. not 
just to those still residing in the care home 16-months following randomisation);  
c) we will be able to analyse based on both a cross-sectional (i.e. open cohort) and 
closed cohort (longitudinal) design;  
d) we will minimise selection bias by providing an objective criterion for inclusion (all 
eligible consenting residents);  
e) our recruitment process will be resource-effective since all eligible residents can 
be approached to participate at a single time-point;  
f) we will be less reliant on assumptions around missing data mechanisms. 
 
Consideration was given to recruiting only a proportion of eligible residents at each home at 
16-months (to increase resident numbers to 75% baseline recruits in line with originally 
predicted loss to follow-up rates). However the team and oversight committees (TSC and 
DMEC) agreed that such an option would be open to selection bias, that statistical power 
and the ability to generalise could be limited by including a ceiling of the number of residents 
recruited at baseline. Recruitment processes could also be protracted by virtue of allowing 
time for Personal Consultee response – i.e. should this be negative, further resident-
consultee dyads would then need to be approached, so considerably lengthening the 
recruitment process and adding to researcher workload (and thus cost). 
 
As well as maintaining power and increasing generalisability, this design change incurs 
minimal additional cost (see ‘justification of funding requested’ section below), compared for 
example to recruiting additional clusters. 
 
This application for extension and the included options have been discussed in detail at the 
DMEC and TSC meetings in November and December 2015, respectively, based on the 
figures presented here. Those committee members supported the open cohort design, with 
the DMEC recommending it provided we address the risk of selection bias. It should be 
noted that, as of the beginning of January 2016, we have met our target of randomising 50 
care homes but the patterns of loss to follow-up remain unchanged. 
 
We believe approaching all eligible residents best addresses the potential threat of selection 
bias. With additional recruitment of eligible residents we will be able to achieve power of over 
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90% even if loss to follow-up in the original sample of residents was 50%. Moving to an open 
cohort design will require additional funding and time to complete the trial – we are 
requesting an additional 3-months extension to the trial (to end Dec 2017) to allow for the 
additional analysis and write-up time that will be needed if the design change is approved. 
We are not requesting additional funding for all co-applicants and trial staff for this period 
(see reconciliation spreadsheet for details).  
 
Impact if approved 
The design change only involves recruiting additional residents from care homes that are 
already randomised and aware of the requirements of the trial. We envisage that additional 
trial processes will result in minimal additional burden on care homes. 
Researchers will be able to combine 16-month follow-up visits to existing care homes (to see 
existing residents) with recruitment and data collection for newly eligible residents. This 
reduces researcher burden (when compared to recruiting entirely new care homes), 
although it does involve additional time at each care home which is costed in a later section 
of this application. 
By implementing an open cohort design we will be able to generalise trial results to a 
broader group of dementia residents and complete the trial robustly with sufficient power.  
 
Impact if not approved 
If the request is not approved, high attrition rates may decrease the statistical power, 
introduce bias in trial reporting and pose a threat to the validity and generalizability of the 
trial. 
If we continue with the trial with its current design, based on current data the anticipated 
proportion of residents lost to follow-up (died or moved care home) would be at least 32%. 
However, only 17/42 (40.5%) care homes have been randomised for more than 6-months. If 
only those randomised for more than 6-months contributed to the estimation of overall loss 
to follow-up (as this allows more precise estimates), the predicted loss at 16-months would 
be 48%.  
Loss of entire cluster(s) is also a realistic scenario with small clusters being most likely to be 
lost. Loss of clusters in addition to loss of residents induces further bias, as loss of cluster as 
a unit of randomisation has greater influence in cluster randomised trial analysis than loss of 
individual residents.  
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Table 67: Effect size detected based on the number of residents at the end of 
recruitment (variable cluster size with incorporated loss to follow up) 
Number of registered residents at 
randomisation 750 
Loss to follow up 32% 48% 
Design effect 1.96 1.72 
Power 90% 80% 90% 80% 
Able to detect the effect size 0.41 0.36 0.45 0.39 
The design effect (due to clustering of resident outcomes within care homes) is lower with 
higher loss to follow-up because the available mean cluster size at follow-up is smaller. 
However, high losses to follow-up with loss of entire clusters threaten the validity of the trial, 
introduce bias and affect generalisability. 
 
